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Concept of gene therapy
Gene therapy is an emerging therapeutic tool to deliver functional genetic material to cells 
in order to correct a defective gene. By delivering a copy of a therapeutic gene to affected 
cells, the messenger RNA (mRNA) and/or proteins will be continuously synthesized within 
the cell, utilizing the cell’s own transcriptional and translational machinery1. The main 
advantage of this technology is that it offers a potentially life-long therapeutic effect 
without the need for repeated administration. Gene therapy can be used to correct 
defective genes by introducing a functional copy of a defective gene, by silencing 
a mutant allele using RNA interference (RNAi), by introducing a disease-modifying gene, 
or by using gene-editing technology.2–4
Gene therapy vectors can be either viral or non-viral. Different physical and chemical 
systems can be applied to deliver therapeutic genes to cells without the need of a viral 
vector. Non-viral vectors have no size limitation for the therapeutic gene, generally have 
a low immunogenicity risk and can be produced at relatively low costs.5 However, because 
high therapeutic doses are required when using non-viral technologies, and the resulting 
gene expression is generally transient, most gene therapies now rely on viral vectors. 
Numerous viral vector types have been tested in clinic, including vaccinia, measles, 
vesicular stomatitis virus (VSV), polio, reovirus, adenovirus, lentivirus, γ-retrovirus, herpes 
simplex virus (HSV) and adeno-associated virus (AAV).6 Vaccinia, measles, VSV, polio, 
reovirus, adenovirus and HSV vectors are currently mainly used in either vaccines or cancer 
therapeutics while lenti- and γ-retroviral vectors are predominantly used for transduction 
of transplantable cells.7 For in vivo gene delivery, AAV is currently the preferred vector. 
AAV belongs to the Parvoviridae family and is preferred for gene therapy because it is 
non-replicating (AAV requires a helper virus for replication), has a low immunogenicity 
profile and is not known to cause disease.8,9 In the absence of a helper virus, AAV may 
stably integrate into the host genome, but at relatively low frequency. The genome of 
wildtype AAV is about 4.7 kb and is flanked between two inverted terminal repeats 
(ITRs) (Figure 1a).10 The open reading frame between the ITRs contains a replication (Rep) 
gene and a capsid (Cap) gene. The ITRs are cis-acting elements and are required for 
genome replication, integration, and packaging into the capsid. The Rep gene encodes 
4 proteins (Rep78, Rep68, Rep52, and Rep40) that have important roles in replication 
and encapsidation of the viral DNA.11 The Cap gene encodes three capsid proteins (VP1, 
VP2, and VP3) and an assembly activating protein that promotes capsid formation.12 
There is a growing number of naturally occurring and engineered AAV serotypes with 
different viral capsids that have altered tissue tropism, transduction rate, or other features 
such as the ability to cross the blood-brain barrier13,14 Recombinant AAV (rAAV) can be 
produced by replacing the rep and cap genes with an expression cassette containing 
a therapeutic gene of interest (Figure 1b). Formation of wild type AAV is prevented by 
expressing the rep and cap genes on a separate plasmid (AAV packaging plasmid or AAV 
helper plasmid). The ITRs are the minimal region required to be retained in rAAV to allow 
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packaging of its genome. rAAV might still integrate randomly in the human genome at 
very low frequencies but most of its genome is maintained as episomal circular structures 
known as concatamers. rAAVs have been widely used in over 200 human clinical studies 
and have demonstrated to be safe.15 AAV-based gene therapies are highly attractive for 
the treatment of neurogenerative diseases due to the neuronal tropism and good safety 
profile demonstrated in clinical studies.  In addition, a single administration results in 
long-term, potentially life-long gene expression, which is a main advantage when in vivo 
AAV administration require invasive procedures. 
Neurodegenerative diseases
Neurodegenerative diseases are a heterogeneous group of multi-system disorders 
affecting the central nervous system, ultimately leading to neurodegeneration16. Examples 
of the most common neurodegenerative diseases are amyotrophic lateral sclerosis (ALS), 
frontotemporal dementia (FTD), spinocerebellar ataxias (SCAs), Huntington’s disease (HD), 
Alzheimer’s disease (AD) and Parkinson’s disease (PD).17 The prevalence of these age-
dependent disorders is increasing, partly due to the aging population, placing a major 
economic burden on health care services. Some neurogenerative diseases are caused 
by genetic mutations and/or cellular and circuit dysregulation. In some cases, different 
neurodegenerative diseases are linked to the same polymorphisms or mutations, thereby 
sharing similar pathological mechanisms. It seems that certain environmental or lifestyle 
factors combined with genetic factors increase the risk for certain neurodegenerative 
disease but aging is considered to be the most important risk factor for the sporadic 
cases.18 Although each neurodegenerative disease have a different pathophysiology, they 
all lead to damage to the nervous system due to features such as cell death, impaired/
failure of axonal regeneration, demyelination and/or neuronal structural/functional 
deficits.19 These pathological features occur in different combinations and their causes 
can be either genetic or unknown.19 Common underlying causes leading to these 
conditions can be due to abnormal accumulation of proteins such as amyloid in AD, 
misfolded proteins (typical for PolyQ diseases), aggregation of proteins such as  Tau (AD 
and traumatic brain injuries), synuclein (PD) or TDP-43 (ALS), RNA toxicity or translational 
products from repeats expansion within genes.19,20 Each of these features has unique 
mechanisms of toxicity which in large part are currently not well understood. Some 
mechanisms of pathogenesis in neurodegenerative diseases share key characteristics 
with prions suggesting that  progression  of certain neurodegenerative diseases may 
share similar mechanisms involved in prion diseases.21 For example, misfolded protein 
aggregates (such as Tau, α-synuclein, amyloid-ß, huntingtin) can spread via cell to cell 
interaction and invade healthy tissues. The misfolded proteins  can induce secondary 
misfolding of other  unrelated aggregation -prone proteins, impairing the entire 
proteostatic network.22  Ultimately, they lead to a decline or even complete loss of sensory, 
motor, and cognitive functions. Symptoms commonly associated with neurodegenerative 
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Figure 1. a) Schematic of wild type AAV. Its genome consists of the viral rep and cap genes flanked 
by two inverted terminal repeats (ITRs). b) Schematic of recombinant AAV (rAAV) generated by 
replacing the viral genes for a therapeutic gene, flanked by the ITRs. The rep and cap genes are 
expressed from a different plasmid or viral vector. The rAAV is generated by co-transfecting cells 
with the transgene cassette flanked by AAV ITRs, the rep and cap genes of a specific AAV serotype, 
and the adenovirus helper plasmid.
diseases include cognitive impairment, memory loss, apathy, anxiety, muscle weakness, 
paralyses, difficulties with speech or breath and death.
One great mystery for most neurodegenerative diseases is the onset of clinically 
manifest symptoms, as pathological alterations usually occur long before symptoms 
start to develop. Progressive accumulation of neuronal cell damage and the effects of 
aging are two common explanations and more recently, the role of neuroplasticity in 
the development and progression of neurodegeneration has also been implicated.23 
The adult brain generally shows less neuroplasticity in response to insults than 
the developing nervous system.23 However early-life events and insults such as perinatal 
infections, an unstructured/abusive environment, social isolation, stress, poor nutrition, 
exposure to chemicals or metals could possibly interfere with the neuroplastic development 
in children and adolescents.24–26 These may place an additional burden on the plastic 
capacity of the developing neuronal system leading to the disturbance of the structural 
brain self-organization. A second challenge later in life could trigger the final onset 
of neurodegeneration and this may be a critical factor determining the onset and course 
of neurodegeneration.23 
A major clinical challenge is early diagnosis of neurodegenerative diseases and due 
to overlapping symptoms, discrimination between the different diseases is difficult. 
Moreover, early symptoms are often dismissed or interpreted as normal consequences of 
aging. Apart from diagnostic delay, additional challenges for new therapeutic approaches 
reaching the stage of clinical development are the lack of druggable targets, the limited 
choice of delivery methods, and a lack of reliable biomarkers and clinical parameters that 
Chapter 1
12
1
predict therapeutic efficacy or the rate of disease progression. To date neurodegenerative 
diseases cannot be cured, and only palliative treatments are available. Because these 
diseases are devastating for patients and their families, and cause a vast burden on 
society, there is an enormous need to better understand their causes, pathology and 
clinical progression and to develop early detection methods and new therapeutic 
interventions. The current thesis presents the development of RNAi-based gene therapies 
for ALS and SCA3 and discusses the currently available options for delivery to the target 
cells. Additionally, the preclinical validation of an AAV-based mifepristone-inducible 
GeneSwitch system is reported as one of the first steps in the development of a small 
molecule-regulated gene therapy approach. 
Amyotrophic lateral sclerosis
ALS (or Lou Gehrig’s disease) is the most common adult onset motor neuron disease 
affecting the upper- and the lower motor neurons in the brain and spinal cord, but 
other neuroanatomical regions may also be affected.27,28 The upper motor neurons are 
found in the motor cortex of the brain, while the lower motor neurons are located along 
the brainstem, spinal cord and extend to the muscles.29 Degeneration of the upper 
motor neurons causes symptoms such as spasticity and hyperreflexia while the loss of 
lower motor neurons results in progressive muscle weakness, cramps, fasciculations, 
muscle wasting and paralysis.29,30 The prevalence of ALS is currently estimated at 5 in 
100.000 but the estimated lifetime risk to develop the disease is about 1:400-800.31,32 
The discordance between the low prevalence but high lifetime risk is explained by the fact 
that ALS patients have a very limited life span with a median survival ranging from two 
to five years from symptom onset.28 The understanding of the genetic causes of ALS is 
continually expanding, but our knowledge of other risk factors such as environmental 
factors, lifestyle or aging remains poor. Only ten percent of ALS cases are familial, and 
the causal genetic mutations are usually inherited in a mendelian autosomal dominant 
manner. Thus, most ALS cases are assumed to occur sporadically, and the main causes 
are still unknown.
Two drugs have been approved by the Food and Drug Administration for the treatment 
of ALS, but the efficacy of both drugs is modest. Riluzole, first approved in 1995, is 
a glutamate receptor antagonist which may increase survival by 2 to 3 months. More than 
two decades later in 2017, Edaravone, a free radical scavenger was approved but its efficacy 
is still unclear, and at best the drug has a moderate effect on disease progression.33 More 
than 30 genes have been linked to ALS and mutations in chromosome 9 open reading 
frame 72 (C9orf72), superoxide dismutase1 (SOD1), transactive response DNA-binding 
protein 43 (TDP-43), or fused in sarcoma (FUS) are responsible for most of the familial ALS 
cases. A hexanucleotide expansion consisting of GGGGCC (G4C2) nucleotides in the first 
intron of the C9orf72 gene is the most frequent genetic cause of ALS and is found in 
about 40-50% of familial ALS cases and 5-10% of sporadic ALS cases.34 The G4C2 repeat 
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is transcribed bidirectionally and affected patients usually carry more than 30 G4C2 copies. 
Interestingly, the same mutation also causes FTD, the second most common form of 
dementia after AD. C9orf72 is responsible for 25% of familial FTD cases and 5-7% of 
sporadic FTD cases. ALS and FTD are considered overlapping diseases as about 15% of 
ALS patients develop FTD and up to 50% of ALS patients show some degree of functional 
loss in the frontal lobe of the brain.32 The function of the C9orf72 encoded protein is 
poorly understood, but it may be a regulator of  the autophagy-lysosome pathway during 
nutrient stress responses. 35 There are at least three proposed pathogenic mechanisms in 
C9orf72 related ALS and/or FTD patients; 1) RNA-mediated toxicity, 2) RAN translation 
and 3) haploinsufficiency. It is also possible that a combination of the three mechanisms 
contributes to the disease pathogenesis (Figure 2).36,37
RNA-mediated toxicity
RNA-mediated toxicity was first described in myotonic dystrophy type 1 (DM1), which is 
caused by a CTG repeat expansion in the 3’UTR of the myotonic dystrophy protein kinase 
gene.38,39 It was shown that RNA consisting of CUG repeats folds into stable structures 
that colocalize with RNA-binding proteins and sequester their function. For example, 
an important protein that is sequestered by CUG-containing RNA foci is the splicing 
factor muscleblind-like 1 (MBNL1).40 The sequestration of MBNL1 leads to its inactivation 
which subsequently cause mis-splicing of several pre-mRNAs, such as muscle-specific 
chloride ion channel and insulin receptor.41,42 RNA foci are observed in several other 
neurodegenerative diseases caused by  repeat expansions including ALS and SCA3.43  In 
C9orf72-related ALS and FTD, accumulation of sense and antisense G4C2-containing RNA 
foci is detected in several brain-, spinal cord tissues, lymphocytes and fibroblasts. RNA 
foci are also detected in patient-derived Induced-pluripotent stem cell (iPSC) -neurons. 
Although RNA foci mainly accumulate in the nucleus of cells they are also observed at 
lower concentrations in the cytoplasm. Several RNA binding proteins interact with G4C2 
RNA repeats, such as ADARB2, hnRNPA1, hnRNPA1B2, Pur-α, FUS, Nucleolin and TDP-
43.36,44,45 However the contribution of these proteins to the neurodegeneration is only 
partially understood.
RAN translation
Another proposed mechanism of toxicity in C9orf72 related ALS and/or FTD is by repeat-
associated non-ATG (RAN) translation.36,46,47 It has been shown that the repeat-containing 
transcripts can be translated into dipeptide repeat proteins (DPRs) even in the absence of 
an ATG start codon and even though the mutation is in a non-coding region of C9orf72. 
These DPR proteins are toxic and they can form aggregates that accumulate in the brain 
and spinal cord of patients.48,49  Six DPR proteins can be produced via unconventional 
translation in all reading frames. Glycine-alanine (GA) and glycine-arginine (GR) are 
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produced from the sense repeat-containing transcripts, while proline-arginine (PR) and 
proline-alanine (PA) are produced from the antisense repeat-containing transcripts. Glycine-
proline (GP) is produced from both sense and antisense repeat-containing transcripts.50 
Ample evidence indicates that DPR proteins are toxic and cause neurodegeneration. 
For example, neurotoxicity, proteasome activity and endoplasmic reticulum stress was 
observed in primary neurons expressing GA proteins.51 Addition of recombinant GR 
and PR proteins to Hela cells and human astrocytes was toxic and caused alterations 
in RNA processing.50 Expressing GR and PR proteins in Drosophila caused toxicity and 
early lethality.52 Several recent publications demonstrated that DPR proteins can lead to 
impairment of nuclear transport, causing accumulation of several RNA-binding proteins 
including TDP-43 in the cytoplasm.53–55 Cytoplasmic TDP-43 aggregation is observed 
in ~97% of cases of ALS, including those associated with C9orf72 mutations. TDP-43 
protein is predominantly found in the nucleus but can shuttle between the nucleus 
and cytoplasm to regulate processes such as RNA processing, transcription, pre-mRNA 
splicing, transport and stabilization of mRNA.56–58 In patients, TDP-43 accumulates as 
cytosolic inclusions with a C-terminal fragment of 25 or 35 kDa. The aggregated TDP-43 
is also post-translationally modified, being heavily ubiquitinated, and phosphorylated at 
the C-terminal region.56 Notably, mutations in TARDBP, the gene that encodes the TDP-43 
protein, have also been linked to ALS, but it remains unclear whether it is depletion of 
nuclear TDP-43, gain of a toxic function of cytoplasmic TDP-43, or a combination of 
these processes that are neurotoxic. Recently it was demonstrated that expressing PR in 
mice also resulted in neurodegeneration and premature death.59 PR proteins localized 
to the heterochromatin caused abnormal histone H3 methylation and aberrations in 
nuclear lamins and heterochromatin protein 1α (HP1α). This resulted in down-regulation 
of numerous differentially expressed genes and upregulation of many repetitive elements 
which was accompanied by the accumulation of double-stranded RNA, ultimately leading 
to neuronal death. Thus, as RNA foci and DPRs both contribute to the pathogenesis of 
ALS, their inhibition could potentially reduce the disease burden in patients.
Haploinsufficiency
The thought that haploinsufficiency may contribute to C9orf72-related ALS originates 
from the finding that reduced C9orf72 RNA and protein levels have been reported in 
brain and spinal cord tissues and in iPSC-neurons derived from ALS patients. Several 
mechanisms may lead to reduced levels of C9orf72, including abortive transcription 
caused by G-quadruplexes and R-loop structures of the repeat-containing transcripts. In 
addition, the C9orf72 locus is hypermethylated in several mutation carriers, which can 
lead to epigenetic silencing and similar mechanisms of gene silencing are observed in 
other repeat expansion diseases such as Friedrich ataxia and fragile X mental retardation 
syndrome. However, haploinsufficiency alone does not explain the observed ALS 
pathology in patients. Several loss-of-function mutations in C9orf72 have been identified 
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and seemed to be non-pathogenic.60 Furthermore, complete C9orf72 knockout mice 
showed no neurodegeneration but rather splenomegaly, enlarged cervical lymph nodes, 
and autoimmune related premature death.61,62 Interestingly, this phenotype was rescued 
in mice hemizygous for C9orf72, suggesting that a partial knockdown of the gene would 
be well tolerated.62 A recent publication suggest a cooperative pathogenesis between 
gain- and loss-of function mechanisms.37 Reduced C9orf72 protein in cultured motor 
neurons caused accumulation of glutamate receptors and excitotoxicity in response to 
glutamate. In addition, these motor neurons showed impaired clearance of DPRs and 
were hypersensitive for these proteins.
As most evidence points towards a toxic gain of function resulting from this mutation, 
an RNAi-based gene therapy would be an attractive therapeutic approach to silence 
the mutated gene.
Spinocerebellar ataxia type 3
The spinocerebellar ataxias (SCAs) are a large group of neurodegenerative diseases 
that are characterized by progressive ataxia due to degeneration of the cerebellum and 
often adjacent regions. SCAs are inherited in an autosomal-dominant manner and have 
a prevalence of about 1-3 in 100.000, although this highly vary between geography and 
ethnicity.63,64 More than 40 different types of SCA have been identified and the most 
common ones (SCA1, SCA2, SCA3, SCA6, SCA7 and SCA17) are caused by a CAG 
nucleotide repeat expansion encoding polyglutamine (polyQ).65 SCA3 (also known as 
Machado-Joseph disease or MJD) is the second most common PolyQ disorder after HD 
and the most common among the SCAs. SCA3 patients experience progressive ataxia, 
affecting balance, gait and speech and frequently symptoms are pyramidal signs, 
progressive external ophthalmoplegia, dysarthria, dysphagia, rigidity, distal muscle 
atrophies and double vision.66 The pathogenic CAG repeat is in the penultimate exon of 
ATXN3 gene on chromosome 14q32.1 and the disease severity is related to the number of 
CAG repeats:67 Up to 44 CAG repeats are considered normal, between 45 to 51 repeats 
are associated with intermediate or low penetrance of the disease, while SCA3 patients 
usually have more than 51 repeats. The survival rate is variable and usually between 
10 to 21 years after symptom onset.68 Similar to ALS, there is no cure for SCA3 and 
current treatments are based on antispasmodic drugs to help reduce spasticity, speech 
therapy and physiotherapy. Several molecules such as sulfamethoxazole-trimethoprim, 
varenicline and lithium carbonate have been tested in clinical trials, but all failed to show 
clinical improvement.
The ATXN3 gene encodes a 42-kDa protein called ataxin-3 which consists of 
a N-terminal catalytic Josephin domain and two to three (dependent on the splice variant) 
C-terminal ubiquitin (Ub)-interacting motifs flanking the polyQ tract.65,66,69 The ataxin-3 
protein is widely expressed in different cell types of peripheral and neuronal tissues and 
present in both nucleus and cytoplasm.70 Ataxin-3 is believed to interact with up to 100 
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proteins involved in ubiquitin-dependent pathways and quality control. The protein has 
a role in various ubiquitin-dependent pathways that maintain protein homeostasis. By 
partnering with ubiquitin ligases, ataxin-3 may be able to regulate, or edit, the lengths 
and linkage types of ubiquitin chains on proteins and in this manner either rescue 
proteins from being degraded, or stimulate protein breakdown. 71,72 Additional roles in 
endoplasmic reticulum-associated degradation, aggresome (aggregates of misfolded 
proteins) production and DNA repair  have also been implicated.73–77  
Mechanisms of toxicity
The mutant ataxin-3 protein is neurotoxic but the exact pathways leading to 
neurodegeneration are not completely understood.  Two attractive hypotheses postulate 
a gain of toxicity and RNA-mediated toxicity (Figure 3). The expanded CAG repeat in 
the ATXN3 gene leads to formation of an ataxin-3 protein with an expanded polyQ tract 
at its C-terminal region with toxic gain of function properties. In addition, the mutated 
protein causes aggregate formation in neurons which is typical for polyQ diseases. 
Aggregates are found in different types of neurons in the brain stem (ventral pons), 
substantia nigra, globus pallidus, dorsal medulla and dentate nucleus.66,69 Although 
the aggregates are mainly detected in the nucleus, they are also found at low levels 
in cytoplasm of neurons in affected areas and in axons within fiber tracts known to 
undergo neurodegeneration in the disease.78 The aggregates consist of different types 
of proteins such as ataxin-3 (wildtype and mutant), heat-shock proteins, transcription 
factors and other polyQ disease-associated proteins. It is believed that sequestering of 
these functional proteins contributes to cellular dysfunction and neurodegeneration. 
Furthermore, proteolytic cleavage of the mutant ataxin-3 may lead to generation 
of shorter soluble PolyQ fragments that are also toxic. Another hypothesis is that 
the polyQ expansion induces conformational changes in ataxin-3 and alters its function 
in multiple ubiquitin-dependent pathways that can lead to altered binding properties, 
loss of protein function, disorganized subcellular localization, aggregation, and altered 
proteolytic cleavage.66,79 
In addition to the mechanisms described above, which are based on protein toxicity, 
RNA toxicity could also contribute to the disease. As mentioned before, RNA containing 
CUG repeats can sequester various transcription factors and undergo RAN translation. 
A crucial evidence for RNA toxicity was observed in nematodes. CAG repeats cloned into 
the 3’ UTR of a marker protein showed severe toxicity in a length-dependent manner in 
Caenorhabditis elegans (C. elegans). The CUG RNAs formed RNA foci and colocalized 
with C. elegans muscleblind protein. The highest CAG repeats were embryonically 
lethal while the shorter CAG repeats were tolerated.80,81 Since the mutated ATXN3 gene 
produces a protein with a toxic gain of function, it is an ideal target for an RNAi-based 
gene therapy approach.
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In vivo and in vitro models for ALS and SCA3
Model systems that recapitulate the different aspects of the diseases are essential to 
understand the pathology, and to predict clinical efficacy during early development of 
new therapeutic approaches. Development of animal models for neurodegenerative 
diseases is a major challenge as the diseases have complex pathologies and symptoms 
can take decades to unfold. As a result, most of the currently available animal models 
for neurodegenerative diseases are not exact phenotypes of the human diseases and 
therefore lack the ability to forecast clinical success of new therapeutic approaches. 
Moreover, studies performed in vitro and in vivo on cells and small animals are difficult 
to translate to larger animals, because factors such as delivery route, dosing, distribution 
and toxicity vary between the different model systems.82 
Animal models for C9orf72 ALS/FTD
Various mouse models have been generated for C9orf72 ALS/FTD that recapitulate 
distinct disease-related pathological, functional, and behavioral phenotypes. An overview 
of the currently available models is shown in Table 1. The first mouse model for C9orf72 
ALS was created in 2015 by somatic transduction of the C57BL/6J mouse CNS using an 
AAV carrying 66 G4C2 repeat.
83 Although this model did not develop the severe ALS/FTD 
Table 1. Overview of the currently available mouse models for C9orf72 related ALS and/or FTD.
ALS mouse model Mutation phenotype
AAV-G4C266
(Chew et al. 2015)
(G4C2)66 + 119 bp 5’ + 100 bp 
3’ region (expressed by  
CBA promotor)
Mild: Histopathological features, 
Anxiety, decreased sociability, reduced 
motor function, weight loss, loss of 
NeuN positive neurons in cortex, motor 
cortex, Purkinje cells.83
BAC-C9-500/300
(Peters et al. 2015)
Human C9orf72 (exon 1-6) + 
~500 G4C2 repeats + 141 Kb 
5’ region
Only histopathological features (no 
TDP-43 pathology), no behavioural.86
Tg(C9orf72_3) Line 112 
(BAC-C9-(100-1000))
(O’Rourke et al. 2015)
Human C9orf72 ( 1-11) + mix 
of 100-1000 G4C2 repeats + 
110 Kb 5’ + 20 Kb 3’ region
Only histopathological features (no 
TDP-43 pathology), no behavioural.84
BAC-C9-450
(Jiang et al. 2016)
Human C9orf72 (exon 1-5) + 
~450 G4C2 repeats + 140 Kb 
5’region
Mild: Histopathological features, spatial 
learning deficit, anxiety, ~ 10% loss of 
hippocampal neurons.62
BAC-C9-500
(Liu et al. 2016)
Human C9orf72 ( 1-11) + 
~500 G4C2 repeats + 52 Kb 5’ 
+ 19 Kb 3’ region
Severe: Histopathological features, 
impaired motor function, reduced 
grip strength, hindlimb paralysis, 
decreased survival, loss of Purkinje cells, 
interneurons, upper and lower motor 
neurons.85
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symptoms, some important features were observed that correlate with the pathology in 
patients. For example, sense RNA foci and DPRs produced from RAN translation were 
observed and TDP-43 inclusions were found in ~7-8% of neurons in the cortex and 
hippocampus.83 In addition, mild neurodegeneration but no motor neuron loss was 
observed.83 Four other transgenic mouse models were created expressing either full 
length or truncated human C9orf72 with the G4C2 expansion. The C9orf72 Exon 1–6 
BAC (G4C2)500 SJL/B6 mice expressed sense and antisense RNA foci and poly GP proteins 
but no motor and/or behavioral impairment was observed.47 The Tg(C9orf72_3) line 112 
mouse was created containing the full length human C9orf72 with multiple G4C2-repeat 
sizes ranging from 100 to 1000 repeats.84 This model showed sense and antisense RNA 
foci and mild accumulation of poly GP but despite some evidence for nuclear stress 
there was no neuronal loss observed. Similarly, the BAC-C9-450 model also produced 
sense and antisense RNA foci in some brain regions and in the spinal cord as well as 
DPR proteins with an age dependent increase of poly(GA).62 Despite a partial learning 
deficit and increased anxiety, no other motor or behavioral changes were observed. 
In contrast, the FVB/NJ-Tg(C9orf72)500Lpwr/J mouse model expressing the full length 
mutated human C9orf72 gene including the 52 Kb 5’upstream region and the 19 Kb 3’ 
downstream region of the gene did show progressive neurodegeneration and decreased 
survival which is also seen in ALS patients.85 Sense RNA foci were observed in almost all 
NeuN positive neurons in the cortex, hippocampus and cerebellum. Antisense RNA foci 
were predominantly found in the motor cortex, hippocampus, cerebellar Purkinje layer 
and interneurons in the lateral and posterior horn of the spinal cord. DPR proteins in this 
mouse model increased with age throughout the brain, and nuclear and cytoplasmic 
TDP-43 aggregates were mainly observed in degenerating brain regions. The severe 
phenotype was exclusively observed in about one third of the females, while most of 
the males and females developed a mild phenotype. Nevertheless, the observations made 
in this model strongly support the involvement of the G4C2 repeat-mediated gain of 
toxicity in the disease pathology. 
Despite the variable penetrance, these models could still be valuable tools for research 
as they all displayed some specific features such as RNA foci and DPR proteins that are key 
characteristics of C9orf72 related ALS/FTD patients.
Animal models for SCA3
More than ten transgenic models for SCA3 have been published, all with variable 
differences in pathology and phenotype and most of them showing a mild form of 
neurodegeneration.87 A summary of the most commonly used mouse models and their 
key characteristics is shown in Table 2. Three models showed a severe phenotype and 
will be discussed here in more detail. The first transgenic mouse model for SCA3 was 
created more than two decades ago expressing either full length or truncated ataxin-3 
with 79 CAG repeat (Q79). Surprisingly, a severe ataxic phenotype was observed only in 
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Table 2. Overview of the currently available mouse models for SCA3.
SCA3 mouse model Mutation phenotype
Q79
(Ikeda et al. 1998)
L7 promotor + Human Ataxin 
3 +79 CAG 
L7 promotor + truncated 
Human Ataxin 3 +79 CAG 
Severe when 79 CAG is expressed by 
itself: severe ataxia, gait disturbances, 
motor deficits.88
MJD84.2 
(Cemal et al. 2002) 
Human ataxin-3 (YAC) + 84 
CAG + 35 Kb 5’ + 150 kb 3’ 
Intermediate: gait abnormalities, 
hypoactivity, Limb clasping, atrophy of 
the cerebellar Purkinje and molecular 
cell layers.95
Homozygous Q71C
(Goti et al. 2004)
Mouse prion promotor + 
human ataxin-3 + 71 CAG 
Severe: progressive postural instability, 
gait and limb ataxia, weight loss, 
premature death, neuronal intranuclear 
inclusions, decreased TH-positive 
neurons in the substantia nigra. 92
70.61
(Bichelmeier et al. 2007)
Mouse prion promotor + 
Ataxin-3 + 70 or 184 CAG
Severe: intranuclear inclusions in 
cortex and cerebellum, Shrinkage of ~ 
50-80% of Purkinje cells,  
premature death96
Ataxin-3-Q79HA
(Chou et al. 2008)
Mouse prion promotor + 
Ataxin-3 + 79 CAG 
Intermediate: neuronal dysfunction, 
ataxia, downregulation and 
upregulation of several genes.97
PrP/MJD77-het/hom
(Boy et al. 2009)
Ataxin-3 + 77 CAG Mild: Cerebellar dysfunction, reduced 
anxiety, hyperactivity, impaired rotarod 
performance, weight loss.98
HDProm-MJD148
(Boy et al. 2010)
ataxin-3 +148 CAG 
(expressed by  
Huntingtin promotor)
Mild: Late onset symptoms, declined 
motor coordination after one year.99
Hemi-CMVMJD94
(Silva-Fernandes
et al. 2010)
ataxin-3 + 94 CAG (expressed 
by CMV promotor)
Mild: represents early disease 
symptoms, neuronal atrophy and 
astrogliosis in several brain regions.100
Lentiviral Atx3-72Q
(Nóbrega et al. 2013)
Ataxin-3 + CAG (expressed by 
PGK promotor)
Mild: reduced motor coordination, 
wide-based ataxic gait, and 
hyperactivity. accumulation 
of intranuclear inclusions, 
neurodegeneration.101
Humanized SCA3 
knockin (Ki91)
(Switonski et al. 2015)
Ataxin-3+91 CAG Mild: deficits in coordination, 
transcriptional changes in the brain, 
amyloid depositions, mild degeneration 
of Purkinje cells in older mice, increased 
GFAP-positive glia in cerebellar  
white matter.102
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the truncated model, with degeneration of the cerebellum and loss of Purkinje cells.88 Due 
to this observation, it was strongly suggested that the C-terminal fragment of ataxin-3 
containing the expanded polyQ could be more toxic by itself than when expressed as part 
of full length ataxin-3. Consistently, putative cleavage fragments of expanded ataxin-3 
were identified in cell models, in post-mortem brains tissues of a SCA3 mouse model, in 
a drosophila model and in patients.89-93 It is now well-accepted that the gain of toxicity 
is directly caused by the CAG repeat and that the affected neurons express a protease 
that cleaves the mutant ataxin-3 protein, releasing short soluble polyQ fragments that are 
highly neurotoxic and more prone to form aggregates.80,81 Besides proteolytic cleavage 
of the C-terminal of the mutant ataxin-3 protein, mis-splicing could also play a role. 
A crucial evidence of mis-splicing leading to production of toxic short polyQ proteins 
was observed in HD. It was shown that exon 1 of the huntingtin, gene which contains 
the CAG repeat does not always splice to exon 2 but generates small polyadenylated 
HTTexon1 mRNA that encodes a small, highly pathogenic exon 1-polyQ  HTT protein (also 
known as “exon-1 protein”).94 
The two other SCA3 mouse models (Q71C and 70.61) with a severe phenotype both 
express mutant ataxin-3 under control of the prion protein promotor. Within 1 to 8 
months, both models showed early onset and a rapidly progressive type of SCA3 with 
several abnormalities such as progressive neurodegeneration, weight loss, behavioral 
problems, neuronal inclusions and premature death. Taken together, all these models 
could be useful to further study the disease mechanism in SCA3 and serve as tools for 
preclinical studies targeting mutant ataxin-3. It should be noted that the models with 
a severe phenotype all use non-native promoters to drive expression of mutant ataxin-3, 
lack regulatory flanking sequences, and often contain an excessive number of transgene 
copies. Thus, these models do not exactly mimic the expression pattern of mutant ataxin-3 
in patients.
In vitro models for ALS and SCA3
Induced-pluripotent stem cell (iPSC) technology is revolutionizing the study of genetic 
diseases and is now pivotal for the development of targeted therapies. The use of iPSC 
technology was made possible when Professor Shinya Yamanaka showed that expression 
of four transcription factors (Myc, Oct3/4, Sox2 and Klf4) in fibroblasts reprograms 
the cells into pluripotent stem cells with the capability for indefinite self-renewal. For this 
discovery he was awarded the Noble prize in 2012.103 It was subsequently demonstrated 
that iPSCs can be generated from different human somatic cell types that can be easily 
obtained such as fibroblasts, white blood cells, renal epithelial cells, keratinocytes etc. 
What made this technology widely accepted was the fact that it bypasses the ethical 
concerns associated with the use of embryonic stem cells and depending on the type of 
study, it may even replace animal models. iPSC lines can be generated from patients and 
differentiated back toward the disease-specific cells. For ALS, iPSC- derived motor neurons 
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have been of particular interest to study toxicity caused by the G4C2 repeat and to test 
therapeutic compounds. Cortical neurons can also be generated from iPSCs representing 
the cells primarily affected in FTD. For SCA3, it is currently still challenging to model 
cerebellar diseases with iPSC technology and although generation of cerebellar neurons 
such as Purkinje cells from iPSCs has been reported, this seems difficult to reproduce.104 
Hence, modeling cerebellar neurons with iPSC technology is less commonly reported as 
compared to other neuronal cell types in the frontal brain, midbrain and spinal cord. iPSC 
technology makes it possible to generate cell models for an individual or a specific group 
of patients which is a big advantage when compared to the different types of animal 
models, that always display species-related differences. Human-derived iPSCs with a wide 
variety of genetic backgrounds can be differentiated into different types of cells. This 
makes iPSC technology a very useful tool to study disease mechanisms, to use in early 
drug discovery (e.g screening of new therapeutic compounds), for toxicology testing and 
for prediction of off-target effects of gene modulating compounds (e.g. RNAi) in humans.
A limitation of iPSC systems is that in vitro two-dimension (2D) monocultures fail 
to represent physiological cellular functions and signaling pathways due to the lack of 
cell-cell and cell-matrix interactions. Recently, it was discovered that iPSCs can also be 
cultured in three dimensions (3D) to generate organoids that could represent different 
types of tissues, including different brain regions.105,106 These 3D brain organoids allow 
cell-cell interactions and complex cyto-architectures to be modeled and studied in greater 
detail and in more physiological contexts. It is currently difficult to control the cell type 
organization and cell-cell or cell-matrix interactions and most organoid only represent 
single or partial components of a tissue. Efforts are being made to make organoids with 
multiple cell types in a more controlled fashion which may be promising in the future 
to replace animal models. While the use of animal models may be significantly reduced 
with the current advances on iPSC technology, at present, drug development and 
study of disease mechanisms still rely on a combination of different in vitro and in vivo 
model systems.
RNAi-based therapeutic strategies for 
neurogenerative diseases
As discussed, several neurodegenerative diseases are caused by mutations that lead to gain 
of toxic functions, and gene silencing technologies are attractive to lower the expression 
of disease-causing genes. A specific technology that can be applied for gene silencing is 
RNA interference (RNAi). 
The discovery of RNAi dates almost three decades (1990) back, when Napoli and 
Jorgensen reported that injection of an extra chimeric copy of chalcone synthase, a gene 
responsible for the purple pigment anthocyanin in petunias, unexpectedly resulted in 
white petunias.107 Thus, instead of complementing each other and producing extra purple 
flowers, the two copies of chalcone synthase seemed to interact with each other and 
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turned themselves off. The mechanism underlying this observation remained unclear 
until 1998, when Andrew Fire and Craig C. Mello provided an explanation of the RNAi 
mechanism. They discovered that a small non-coding RNA, miRNA (lin-4), binds to 
the 3’-UTR of the lin-14 mRNA in C. elegans, silencing its expression. For this work they 
were awarded the Nobel prize in Physiology or Medicine in 2006.108 It was subsequently 
demonstrated that miRNA-mediated silencing also occurs in mammalian cells and this 
mechanism became a popular new tool to study gene function.109
It is now known that RNAi is a naturally occurring process in eukaryotic cells where 
double stranded RNA molecules can knock down or suppress the expression of genes that 
contain a homologous RNAi target sequence. RNAi plays an important physiological role in 
gene regulation and also has a function in the innate immune response of cells by providing 
protection against foreign nucleic acids from pathogens such as viruses and bacteria.110 
One of the first discovered mediators of RNAi is the RNAi-induced silencing complex 
(RISC), which has a nuclease activity that can cleave mRNA and knock down its expression. 
RNAi can be triggered by both endogenous and exogeneous double stranded RNAs.111–113 
Three types of small non-coding RNAs use the RNAi pathway; microRNA (miRNAs), small 
interfering RNA (siRNA) and piwi-interacting RNAs (piRNAs). miRNAs and siRNAs have a role 
as negative regulators of gene expression, while the piRNAs defend organisms against 
transposable elements.114  miRNAs and siRNA are both widely being used as therapeutics 
in clinical trials and each system has its own merits. The focus of this thesis will be 
on miRNAs 
miRNAs and their processing
miRNAs are small non-coding RNAs that are thought to regulate about 30% of genes in 
humans. More than 2000 miRNAs (www.mirbase.org) have been identified in humans 
and these are known to regulate several important cellular processes. Dysregulation 
of miRNAs is associated with several types of metabolic and CNS diseases, and with 
cancer. Apart from regulating gene expression, miRNAs can act as signaling molecules 
for intercellular communication. For example, it has been shown that miRNAs can be 
packaged into exosomes or microvesicles that following secretion, can be endocytosed 
by secondary cells, and re-establish their function.115 
The biogenesis of a miRNA is tightly regulated in humans and involves 4 key enzymes; 
Drosha, exportin 5, Dicer and argonaute (AGO) proteins (Figure 4). The precursor of 
a miRNA is naturally encoded in the genome and is transcribed by RNA polymerase II 
or III into a long primary miRNA (pri-miRNA) with a cap and poly-A tail. The pri-miRNA 
transcript folds into a complex hairpin structure consisting of a double-stranded stem 
of about 30 base pairs, a terminal loop and two flanking unstructured single-stranded 
tails. The pri-miRNA is further processed in the cell nucleus by a ribonuclease called 
Drosha, resulting in a short 70-nt stem-loop structured precursor miRNA (pre-miRNA). 
The pre-miRNA is then transported to the cytoplasm by exportin 5 and is cleaved into 
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a short double stranded miRNA by a RNAse III enzyme called Dicer. The double stranded 
miRNA is recognized by AGO proteins and is loaded on RISC, usually preserving the guide 
strand and degrading the passenger strand.  The RISC-AGO complex guides the miRNA 
guide strand to its target mRNA and induce its degradation and/or inhibit its translation. 
The first seven nucleotides near the 5’end of the guide strand form the seed sequence 
and are critical for the target recognition. It is also worth to mention that not all miRNAs 
are processed as described above and miRNA processing in plants differs at several 
points from the above described pathway. Furthermore, several mammalian miRNAs 
can bypass Drosha and currently one miRNA is known to bypass Dicer processing.116 
This Dicer-independent miRNA is microRNA-451a (miR-451a or miR-451), which has 
a role in the regulation of erythroid development.117 Its recognition by Dicer seems to be 
perturbed due to its unusually short base paired stem and as a result, an active strand 
derived from the stem is produced, consisting of the single-stranded loop and part of 
the complementary stem region (figure 4).  The ability to design artificial miRNAs that 
specifically silence disease-related genes is the basis for therapeutics such as miRNA 
mimics, anti-miRs and artificial miRNAs. miRNA mimics are double stranded miRNAs made 
synthetically to match a corresponding miRNA, aiming to compensate the loss of miRNAs 
that are downregulated in diseases. Anti-miRs are artificially made single stranded miRNA 
to bind target miRNAs and inhibit their function. Artificial miRNAs are made by replacing 
the guide strand sequence of an endogenous miRNA precursor with the sequence of an 
mRNA of interest, enabling silencing of genes that are upregulated in diseases (figure 5). 
Recently, the miQURE™ Gene Silencing platform was introduced by uniQure. miQURE 
uses the advantages of the non-canonical processing of miR-451 to silence genes 
involved in diseases. miR-451 produces no passenger strand as the pre-miR-451 escapes 
Dicer cleavage and only a 5’ arm strand is active on the targets. Thus, there is no miRNA 
duplex formation that requires strand separation and selection for the RISC. Because 
of this efficient processing, off-target effects due to a passenger strand activity can be 
neglected. This technology was first applied in uniQure’s Huntington’s disease program 
and is now being investigated for application in other neurodegenerative diseases such 
as ALS and SCA3 and for liver indications.
Clinical applications for Therapeutic RNAi
Several RNAi-targeted therapeutics have reached clinical development.  For example, 
MRX34 (synthetic miR-34), a miRNA developed by Mirna Therapeutics was the first to enter 
a clinical trial to treat different types of cancer.118,119 Its mode of action was to decrease 
the expression of collagen and other proteins that are involved in fibrous scar formation. 
However, clinical development was terminated in 2016 due to several immune-related 
severe adverse events. An example of a successful anti-miR clinical trial is Miravirsen, 
an Locked Nucleic Acid (LNA) anti-miR-122 oligo developed by Santaris Pharma to treat 
Hepatitis C.120 The phase II trials demonstrated reduced Hepatitis C viral load, even at low 
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therapeutic concentrations and no adverse events was observed.121–123  Another phase 
I/II clinical trial to treat patients with Hepatitis C infection was based on shRNAs and 
was conducted by Benitec Biopharma. Their lead product was TT-034 which is based on 
intravenous AAV8 delivery of three independent shRNAs targeting three well-conserved 
21 
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Figure 4. Schematic of miRNA processing pathway. Most miRNAs are processed in the Dicer 
dependent (canonical) pathway shown in the left part of the figure. After being transcribed, 
the pri-miRNA transcripts are cropped by Drosha in the nucleus, resulting in a 60–70 nt pre-miRNA. 
The pre-miRNA is exported to the cytoplasm by Exportin 5 and the hairpin is then diced by Dicer 
into ~22-nt miRNA duplex, after which it is separated into a guide and passenger strand. The guide 
strand is usually loaded into Ago proteins to form RISC. There are four Ago proteins and all are 
capable to repress translation or promote mRNA degradation. Ago2 is the only Ago protein with 
a slicer activity which plays a critical role in Dicer independent processing of miR451 (right part of 
the figure). miR451 is also processed in the nucleus by Drosha, but results in a unusually short, 
41–42-nt pre-miRNA which is not recognized by Dicer and do not form a miRNA duplex. However, 
the further processing of miR-451 requires the slicer activity of Ago2. Ago2 cleaves the 3’ arm of 
pre-miRNA by its slicer activity and yields a 30-nt intermediate whose 3’ end is further trimmed by 
PARN to generate a mature, ~23-nt miRNA. This mature miRNA is loaded into Ago proteins to form 
the RISC.
General introduction
27
1
sequences located in the 5’ UTR and NS5B regions of the HCV genome.124 Overall, TT-034 
was well tolerated and safe in patients. Furthermore, liver biopsies revealed sustained 
transduction of hepatocytes and expression of the three anti-HCV shRNAs. However, 
Benitec Biopharma decided to discontinue this program due to decrease in commercial 
opportunities for TT-034 following the introduction of highly effective viral eradication 
strategies based on (combinations of) small molecules. Compared to miRNAs, siRNAs 
have been more widely tested in clinical trials for treatment of different types of diseases 
such as cancer, viral infections, age-related macular degeneration, diabetic macular, 
hypercholesterolemia and ocular hypertension.125 DNA constructs encoding therapeutic 
RNAi following delivery by lentiviral vectors have also been clinically tested. Benitec, Inc 
in collaboration with the City of Hope National Medical Center conducted a trial to treat 
HIV-1 infection in AIDS/lymphoma patients.126 This was executed by genetically modifying 
hematopoietic stem cells (hSC) ex vivo by transduction with a lentiviral vector expressing 
three small RNAs targeting HIV: An shRNA targeting an exon in HIV-1 tat/rev , a RNA 
decoy for the HIV TAT-reactive element, and a ribozyme targeting the host cell CCR5 
chemokine receptor. The transduced hSC were then infused into patients whose bone 
marrow has been ablated to treat their AIDS related lymphoma. Sustained expression of 
the anti-tat/rev shRNA  and ribozyme was observed for up to 24 months post-infusion.123 
Although this study demonstrated feasibility and safety of this approach, it failed to 
demonstrate clinical benefit because an insufficient number of hSCs was transduced.
In the neurodegenerative field, uniQure recently obtained Food and Drug 
Administration (FDA) clearance for AMT-130 and this will be the first AAV-miRNA-
based gene therapy for a neurodegenerative disease to start a Phase I/II clinical trial. 
AMT-130 is based on a miRNA designed to target both wild-type and mutant Huntingtin 
allele (AAV5-miHTT).127,128 Significant lowering of human mutant huntingtin mRNA and 
protein was achieved in the brain of a transgenic HD (tgHD) minipig model after a single 
Figure 5. Artificial miRNA design. Artificial miRNAs can be made by replacing the mature miRNA 
sequence of a natural pri-miRNA for a complementary sequence of a target mRNA of interest. 
The artificial pri-miRNA sequence can be cloned in an expression construct. Upon transfection with 
the artificial miRNA construct, the artificial miRNA is processed in the cell into a mature artificial 
miRNA which can bind and knockdown expression of a mRNA of interest.
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administration into the brain. 128 uniQure plans to start the first PhaseI/II clinical trial in 
early HD patients in the second half of 2019. A similar approach is being pursued by 
Voyager Therapeutics and promising results have been obtained with their lead candidate 
VY-HTT01 in preclinical models. miRNA mediated silencing is thought to be an attractive 
therapeutic modality in many other neurodegenerative diseases, including the SCAs, ALS, 
FTD, synucleopathies including Parkinson’s disease, tauopathies and AD.129–132 miRNAs may 
cause toxicity related to (passenger strand) off-target toxicity. Hence, during development 
these effects should be closely investigated and minimized, by selecting scaffolds with 
little to no passenger strand activity and by predicting the chances of binding to off-
target genes using computer-based bioinformatic tools. Another important limitation of 
miRNA-based therapeutics is the required efficacy in the nucleus of cells, because active 
mature miRNAs resulting from canonical Dicer processing in the cytoplasm are thought 
not to re-enter the nucleus. However, as many of these hurdles are being tackled, more 
miRNA therapeutics are expected to reach the clinic. 
Common alternative silencing strategies
Antisense oligonucleotides
Antisense oligonucleotides (ASOs) are short, synthetic, single-stranded nucleic acids of 
about 20-25 bases long that bind cellular RNA and reduce, restore, or modify protein 
expression via several distinct mechanisms. The silencing pathway of ASOs differs 
from siRNA and miRNAs and there is no known cellular mechanism to facilitate strand 
recognition. ASOs classically bind to complementary mRNA through Watson Crick base-
pairing leading to endonuclease-mediated transcriptional knockdown.133 Once bound to 
the mRNA, ASOs can form an RNA–DNA hybrid that becomes a substrate for the enzyme 
RNase H, which hydrolyzes the mRNA resulting in its degradation.134 The cleaved mRNA 
products are then processed by the normal cellular degradation pathways in the nucleus 
and cytoplasm.135 ASOs can be engineered to have enhanced pharmacological properties 
by introducing backbone modifications. For example, modified ASOs can knockdown 
gene expression by sterically blocking splicing factors and altering pre-mRNA splicing, 
or by preventing ribosome recruitment to block mRNA translation.136 Interestingly, ASOs 
can destabilize splicing sites and displace or recruit splicing factors when designed 
Table 3. clinical trials using ASOs for ALS by Ionis Pharmaceuticals
Disease Trial code Vector
Delivery 
route
Status  
(completion year) Sponsor
ALS137,138 NCT01041222 ASO (SOD1) Intrathecal Phase I (2012) Ionis Pharmaceuticals
ALS NCT02623699 ASO (SOD1) Intrathecal Phase I/II (2019) Biogen & Ionis 
Pharmaceuticals
ALS NCT03626012 ASO (C9orf72) Intrathecal Phase I (2022) Biogen & Ionis
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to bind within intron–exon junctions. This makes it possible to exclude (“skip”) or 
include exons of interest, which can be beneficial in genetic diseases.136 Through this 
mechanism normal gene function can be restored by re-establishing a normal reading 
frame following a pathogenic frame shift, or by excluding mutated segments of DNA.133 
ASOs have been used in preclinical studies since the 1970s and several programs have 
made it into clinical development. A phase I ALS trial using intrathecal administration of 
ASOs targeting SOD1 was completed in 2012 by Ionis Pharmaceuticals  (Table 3).137,138 
Unfortunately this study failed to show a reduction of SOD1 protein which was explained 
by the low target tissue ASO concentration but the treatment proved to be safe, and 
a follow up phaseI/II trial study is ongoing (BIIB067; IONIS-SOD1). Ionis Pharmaceuticals 
also initiated a phase I clinical trial in 2019 with ASOs targeting C9orf72-ALS patients 
(BIIB078). BIIB078 targets specifically the intronic region of C9orf72 to cause reduction of 
only the repeat-containing C9orf72 transcripts and is administered intrathecally to adult 
patients.  Ionis Pharmaceuticals has developed ASOs for many other diseases and have 
ongoing clinical trials for HD, DM1 and SMA. Furthermore, several preclinical studies have 
shown efficacy of ASOs in C9orf72-related ALS and SCA3 in vitro and in vivo but these 
programs have not yet reached clinical development. A clinical study (NCT03508947) 
with ASOs that has raised some concerns regarding toxicity was performed by WAVE 
life Sciences to treat patients with Duchenne muscular dystrophy (DMD). DMD is a fatal 
genetic disorder characterized by progressive muscle wasting and is caused by mutations 
in the DMD gene which encodes for dystrophin, an essential protein to maintain muscle 
integrity. The ASO  was administered intravenously and was designed to skip the mutated 
exon 51 in the DMD gene to restore normal function of dystophin.139 Adverse events 
such as headache, fever, vomiting and tachycardia occurred in the low and mid dose 
groups and these adverse events were even more severe in the high-dosed groups. 
WAVE life sciences reported to continue with the lower doses for Phase II/III trial which 
is expected to be initiated in 2019 but it is unclear if these adverse events will re-occur 
during re-administration and whether or not the lower doses are therapeutically effective. 
A major limitation of ASOs for clinical application is that they are degraded by endo- and 
exonucleases and re-administration is required.140 This is especially problematic in CNS 
disorders that require invasive delivery methods. However, the pharmacological profiles of 
ASOs can be enhanced by introducing chemical modifications and efforts are being made 
to improve ASOs delivery to for example cross the blood brain barrier (BBB) and to improve 
target engagement.141  
Gene Editing (CRISPR)
Gene editing is a relatively novel approach to remove, add or alter DNA in a sequence-
specific manner. The pivotal discovery that made gene editing possible was the discovery 
that the endogenous cellular repair machinery can be triggered by targeted DNA double 
strand breaks (DSBs) through homology-directed repair (HDR) or nonhomologous end-
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joining (NHEJ).  DNA DSBs can be introduced at a precise location by using engineered 
nucleases harboring a sequence-specific DNA-binding domain, fused to a DNA cleavage 
module. The most popular nucleases are zinc-finger nucleases (ZFNs), transcription 
activator-like effector nucleases (TALENs), and the RNA-guided clustered regulatory 
interspaced short palindromic repeats (CRISPR) and CRISPR-associated system 9 (Cas9) 
(CRISPR/Cas9).  ZFNs are currently the only gene editing technology that have made it to 
clinical trials. In 2018 Sangamo Therapeutics started a clinical trial using this technology 
in mucopolysaccharidosis II (MPS II). ZFNs consist of ~30 amino acids which folds into 
ββα “fingers” structures that recognize and bind a trinucleotide sequence of DNA.142–144 
The nuclease domain is based on a restriction endonuclease (FokI) that can cut DNA 
when following dimerization.142 Binding to DNA sequences longer than 3 and up to 18 
base pairs (in multiples of 3 base pairs) is possible by arranging a series of linked zinc-
fingers. However, this requires recoding of proteins for each new target site which is 
a very challenging and time-consuming process. Another limitation is the restricted target 
site selection as zinc-fingers can only target binding sites every ~50-200 base pairs in 
a random DNA sequence 142 Furthermore, all gene editing technologies including zinc-
fingers may have off-target effects, resulting in unwanted induction of DNA mutations 
or deletions. Like ZFNs, TALENs are based on a DNA-protein association but they use 
a different DNA binding domain termed (transcription activator-like effectors) TALE 
repeats.142 A TALE motif can recognize a single nucleotide and an array of TALEs can 
recognize and bind to a longer DNA sequence. Unlike ZFNs, the design of TALENs are 
less complicated and the TALE repeat array can be easily extended to whatever length 
is desired.142 Furthermore, as compared to ZFNs, site-specific targeting is easier because 
multiple TALEN pairs are available for each base pair of a random DNA sequence. Some 
major limitations for TALENs are off-target effects and compared to ZFNs, they are about 
3x larger in size (~3 Kb) which makes delivery by viral vectors more challenging.
CRISPR/Cas9 is the latest of the above-mentioned nuclease systems and is based on 
a naturally occurring process in the adaptive immune system of the bacteria Streptococcus 
pyogenes. CRISPR/Cas9 is distinct from ZFN and TALEN endonucleases in that it does not 
use a protein but an RNA-guided system to perform genome editing. Unlike the other 
nuclease systems, CRISPR/Cas9 does not require custom design of novel proteins for 
each DNA target site. Thus, the design of constructs is relatively easy and cost-effective. 
Bacteria use the RNA-guided Cas proteins to create DSBs in exogenous DNA derived from 
invading viruses (bacteriophages).It does so by creating CRISPR arrays from exogenous 
DNA by insertion of these DNA sequences between short palindromic repeats in 
the CRISPR locus of its own DNA. Upon a repeated viral attack, these “foreign” inserts 
can be transcribed from the virus specific CRISPR locus into CRISPR RNA fragments that 
match the invading viral DNA. CRISPR RNAs contain a tail transcribed from the CRISPR 
locus which facilitates incorporation into complexes to form hairpins-like structures that 
allow them to dock on a Cas protein. The Cas protein is then guided by the CRISPR 
RNA to hybridize to its parental exogeneous DNA and induce a DSB.145 This CRISPR/Cas9 
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system can be implemented in eukaryotes by designing sequences that target a specific 
DNA sequence and co-expressing Cas9. The Cas9 protein cuts the DNA at the target 
site, which is repaired by HDR or NHEJ. Several animal models have been created using 
the CRISPR/Cas9 system and a rapidly increasing number of preclinical studies show 
the promises of this technology in combination with gene therapy for the treatment 
of neurodegenerative diseases. For example, in AD, the defective (amyloid precursor 
protein) APP gene was successfully edited in human fibroblasts using a CRISPR/cas9 
construct and this resulted in reduction of Amyloid beta, a main component of plaques 
found in brain of AD patients.146 In ALS, the G4C2 repeat in the non-coding region of 
the C9orf72 gene was successfully deleted in transfected patient-derived iPSCs and this 
prevented RNA foci formation as well as the promoter hypermethylation that is typical 
for ALS.147 For HD, permanent suppression of mutant Huntingtin and it’s aggregates was 
achieved in the striatum of the HD140Q-knock-in mice by CRISPR/Cas9.148 For SCA3, 
CRISPR/Cas9-mediated deletion CAG repeat in ATXN3 gene was successfully performed 
in patient-derived iPSCs.149 Following the CAG deletion, the iPSCs retained pluripotency 
and neurons differentiated from these cells retained a normal ubiquitin-binding capacity 
of ATXN3. 
The CRISPR/Cas9 system has great potential for targeting pathogenic genes, but a major 
hurdle is the occurrence of off-target effects, Cas9 specificity, and potential mutagenesis. 
Not unexpectedly, continuous expression of Cas9 proteins at high concentrations has been 
linked to toxicity.150 The chances for off-target binding in the host genome using current 
systems are estimated to be relatively high (≥50%).151 Another limitation is the delivery 
method as the CRISPR/Cas9 components are about 8-10 kb long whereas AAV vectors 
have a packaging capacity limited to 4.8 kb. Thus, the CRISPR/Cas9 system has a huge 
potential to be developed in therapeutic approaches but major challenges need to be 
overcome to make this technology suitable to treat human diseases.
AAVs for gene transfer to the nervous system
A major difficulty to treat neurodegenerative diseases remains the method of administration. 
Due to existence of the BBB, many small molecules and most therapeutic nucleotides or 
gene therapy vectors that are administered systemically or orally fail to reach the brain or 
spinal cord at a therapeutically relevant dose. Different alternative routes of administration 
are being investigated for delivery to the CNS and their application is highly depended 
on the disease pathology. While some diseases require local targeting or transduction, 
others require widespread distribution throughout the CNS. Intracerebral administration, 
directly injected in the parenchyma of the brain can be safely and effectively done using 
convection-enhanced delivery (CED) in combination with precise positioning using 
magnetic resonance imaging-based guidance technologies (MRI).152 CED uses a pressure 
gradient to generate bulk flow within the brain parenchyma. Due to the low velocity of 
injection, potential structural damage is minimized, and a uniform distribution can be 
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obtained.153,154 The advantage of this injection route is that it bypasses the BBB and high 
local transduction can be obtained with a relatively low dose of AAV, with limited leakage 
to periphery organs. Further spread of AAV may occur via anterograde or retrograde 
transport along axons but this is highly dependent on the AAV serotype.9,155 A drawback 
of this delivery route is that the procedure itself is invasive and may lead to complications 
such as bleeding or leakage of the administered vector into the CSF. In addition, 
intracerebral administration is only suitable for diseases with pathology limited to specific 
brain areas. Alternative routes to cover larger areas of the CNS are systemic or intrathecal 
delivery. Systemic delivery by intravenous injection is a relatively simple procedure, less 
invasive and avoids costly neurosurgical procedures. However, systemic delivery of AAV 
gene therapy is currently less suitable for neurodegenerative disorders because the bulk 
of such vectors is taken up by peripheral organs and can cause systemic immunogenicity. 
Even though some vectors can cross the BBB, the target tissue concentration after 
systemic delivery is often not therapeutically relevant. Nevertheless, a successful clinical 
trial with systemic administration was performed by AveXis to treat children with SMA.156 
The vector used was a self-complementary AAV9 and following systemic administration 
a therapeutic effect in motor neurons of the spinal cord was observed. It remains 
questionable whether similar effects can be obtained in adults as the integrity of the BBB 
is known to be different. Despite the initial promising results, AveXis changed the delivery 
method in children to an intrathecal administration route in the follow up study. This 
amendment was based on a study in NHP showing improved transduction of the CNS 
with up to 10 times lower intrathecal dose as compared to intravenous administration.157 
Intrathecal administration can be done through lumbar puncture, direct administration 
into the cisterna magna or in the cerebral ventricle.158,159 Thus, the vector is delivered 
directly into the CNS bypassing the BBB. This approach is less invasive than intracerebral 
administration and usually show less leakage to the periphery organs as compared to 
systemic administration. One limitation of intrathecal administration is dilution of vector 
and the consequent transduction is usually lower when compared to intracerebral 
administration. Furthermore, transduction of the deeper brain structures is poor, possibly 
because the vector needs to pass the ependymal cell layer or the pia mater.160,161 
Gene therapy clinical trials for neurogenerative diseases
Several gene therapies for different types of neurodegenerative diseases have progressed 
into clinical development. For C9orf72 related ALS and SCA3, no gene therapy has been 
clinically investigated yet. An overview of the currently ongoing clinical trials published 
on https://clinicaltrials.gov is depicted in table 4 and will be further discussed in 
this paragraph. 
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Parkinson’s disease
PD is a neurodegenerative disorder caused by loss of dopaminergic neurons in 
the substantia nigra, leading to bradykinesia, rigidity, tremor, and gait dysfunction. 
Expressing neurotrophic factors such as GDNF delivered by AAV was tested in a single 
clinical trial and AAV-delivered neurturin (NTN) was investigated in three clinical trials for 
PD. The rationale for delivering these neurotrophic factors was not to target a causative 
pathological molecular pathway but to provide neurotrophic support to the degenerating 
neuronal population. Although these studies were well tolerated, their efficacies are 
unclear. However, these studies were important to demonstrate the feasibility and 
tolerability of intraparenchymal AAV delivery of gene therapy directly in the human brain.
Most gene therapy approaches for PD aim to restore dopamine production in neurons. 
Deliveryof 1-amino acid decarboxylase (AADC), a key enzyme for dopamine production 
showed to be more promising than neurotrophic factors. Proof of concept studies in NHP 
showed an increase in levels of dopamine which was sustained for up 7 years.154,162 The first 
AAV delivered AADC study in humans (NCT00229736) was in general well tolerated with 
some minor side effects.163,164 A significant improvement of Parkinson’s Disease Rating 
Scale (UPDRS) scores was reported at 6 months post-surgery which was sustained for 
up to 2 years. These promising results have triggered other AAV-based trials on AADC 
delivery and several studies are currently ongoing with higher doses and larger cohorts 
of patients. A clinical trial using a intrastriatal delivered lentivirus (ProSavin) expressing 
the three key tyrosine hydrolase, AADC, and GTP cyclohydrolase-1, with the aim of 
providing a continuous source of dopamine in the striatum has also demonstrated to be 
safe and well tolerated with no surgical complications (CT01856439 ).165,166 A significant 
improvement of motor function was observed, and a long-term analysis is ongoing. 
Another lentiviral gene therapy that is currently being tested in clinic and very similar to 
ProSavin also expresses tyrosine hydroxylase, AADC and GTP-cyclohydrolase. While there 
is no data available yet from this study, the preclinical results in human primary neuronal 
cultures and NHP showed higher dopamine production compared to ProSavin.167
Alzheimer’s disease
AD is the most common cause of age-related dementia affecting more than 40% of 
individuals of 85 years and older. More than 100 therapeutic compounds have been 
tested to date,  but all failed  to positively modify the course of the disease. Most gene 
therapy clinical trials for AD are based on intracerebral delivery of AAV-NGF. NGF encodes 
nerve growth factor and similar to GDNF and NTN, could provide neurotrophic support 
to neurons. Preclinical studies have shown that NGF can prevent degeneration of adult 
cholinergic neurons in the fore brain after injury.168,169 Although the surgical procedures and 
the treatments proved to be safe in humans, the efficacy of the studies was inconclusive. 
A more recent study for AD is based on intracisternal delivery of AAVrh.10hAPOE2 
(NCT03634007). It was shown that inherence of an extra allele of APOE4 gene, a variant 
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Table I. Gene therapy clinical trials for neurogenerative diseases
Disease Trial code Vector Delivery route Status (completion year) Sponsor
Parkinson184 NCT00252850 AAV2- Neurturin Intrastriatal Phase I (2007) Ceregene
Parkinson155 NCT00400634 AAV2-Neurturin Putamen Phase II (2008) Ceregene
Parkinson185 NCT00985517 AAV2-Neurturin Substantia nigra Phase II (2018) Sangamo Therapeutics
Parkinson186–188 NCT01621581 AAV2-GDNF Putamen Phase I (2027) National Institute of Neurological Disorders and  
Stroke (NINDS)
Parkinson163 NCT00229736 AAV-hAADC-2 Intrastriatal Phase I (2013) Genzyme
Parkinson NCT01973543 AAV2-hAADC Intrastriatal Phase I (2019) Voyager Therapeutics
Parkinson NCT03562494 AAV2-hAADC Intrastriatal Phase II (2020) Voyager Therapeutics
Parkinson NCT02418598 AAV-hAADC-2 Putamen Phase II  (2022) Jichi Medical University
Parkinson166 NCT01856439 ProSavin (LV-TH-GCH-AADC) Intrastriatal Phase I/II (2021) Oxford BioMedica
Parkinson NCT03720418   AXO-Lenti-PD(OXB-102-01) Intrastriatal Phase I/II (2020) Axovant Sciences Ltd
Parkinson189,190 NCT00643890 AAV-GAD Subthalamic nucleus Phase II (terminated) Neurologix, Inc
Alzeimer NCT00087789 AAV2-NGF Basal forebrain Phase 1 (2010) Ceregene
Alzeimer191 NCT00876863 AAV2-NGF Basal forebrain Phase II (2020) Sangamo Therapeutics
Alzeimer NCT03634007 AAVrh.10hAPOE2 Intracisternal Phase I (2020) Weill Medical College of Cornell University
Batten192–194 NCT03770572 AAV9-CLN3 Intrathecal Phase II (2022) Nationwide Children’s Hospital & Amicus Therapeutics
Batten195 NCT00151216 AAV2CUhCLN2 Intracranial Phase I (2019) Weill Medical College of Cornell University
Batten NCT01161576 AVRh.10CUhCLN2 Intracranial Phase I (2020) Weill Medical College of Cornell University
Batten NCT02725580 scAAV9.CB.CLN6 Intrathecal Phase II (2019) Nationwide Children’s Hospital
Mucopolysaccharidosis  Type IIIA173 NCT03612869 AAVrh10-h.SGSH Intracerebral Phase III (2022) LYSOGENE
X-Linked Myotubular Myopathy NCT03199469 AAV8-hMTM1 Intravenous Phase II (2025) Audentes Therapeutics
spinal muscular atrophy Type 1 NCT02122952 AAV9-SMN Intravenous Phase I (2019) AveXis, Inc
spinal muscular atrophy157,196 NCT03505099 AAV9-SMN Intravenous Phase I (2020) AveXis, Inc
spinal muscular atrophy157,196 NCT03306277 AAV9-SMN Intravenous Phase I (2020) AveXis, Inc
spinal muscular atrophy156,197 NCT03461289 AAV9-SMN Intravenous Phase III (2020) AveXis, Inc.
spinal muscular atrophy156,197 NCT03381729 AAV9-SMN Intrathecal Phase I (2020) AveXis, Inc.
Pompe disease198 NCT03533673 AAV2/8LSPhGAA Intravenous Phase II (2020) Actus Therapeutics, Inc
Pompe disease NCT02240407 rAAV9-DES-hGAA intramuscular Phase I (2019) University of Florida
Pompe disease199 NCT00976352 rAAV1-CMV-GAA intradiaphragmatic Phase II (2015) University of Florida
Canavan disease200 NA AAV2- hASPA Intraparenchymal Phase I (2002) National Institute of Neurological Disorders and Stroke
AADC deficiency NCT01395641 AAV2- hAADC Intraparenchymal 
(Putamen)
Phase I/II (2020) National Taiwan University Hospital
AADC deficiency NCT02926066 AAV2- hAADC Intraparenchymal 
(Putamen)
Phase II (2018) National Taiwan University Hospital
AADC deficiency NCT02852213 AAV2- hAADC Intraparenchymal Phase I (2020) National Taiwan University Hospital
MPS I201 NCT02702115 AAV6-ZFN Intravenous Phase I (2020) Sangamo Therapeutics
MPS II202 NTC03041324 AAV6-ZFN Intravenous Phase I (N.A) Sangamo Therapeutics
MPS IIIA NCT02716246 AAV9-hSGSH Intravenous Phase I/II (2019) Abeona Therapeutics
MPS IIIA173 NCT03612869 AAVrh.10- hSGSH Intracerebral Phase II/III (2022) LYSOGENE
Sanfilippo Disease Type A NCT02053064 AAVrh10- SGSH Intracerebral Phase II (2017) LYSOGENE
MPSIIIB174 NCT03300453 AAV5- hNAGLU Intracerebral Phase I/II (2019) UniQure Biopharma B.V.
MPSIIIB NCT03315182 AAV9- hNAGLU Intravenous Phase I/II (2020) Nationwide Children’s Hospital
Huntington’s disease NA AAV5-miHTT Intrastriatal Phase I/II (N.A) UniQure Biopharma B.V.
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Table I. Gene therapy clinical trials for neurogenerative diseases
Disease Trial code Vector Delivery route Status (completion year) Sponsor
Parkinson184 NCT00252850 AAV2- Neurturin Intrastriatal Phase I (2007) Ceregene
Parkinson155 NCT00400634 AAV2-Neurturin Putamen Phase II (2008) Ceregene
Parkinson185 NCT00985517 AAV2-Neurturin Substantia nigra Phase II (2018) Sangamo Therapeutics
Parkinson186–188 NCT01621581 AAV2-GDNF Putamen Phase I (2027) National Institute of Neurological Disorders and  
Stroke (NINDS)
Parkinson163 NCT00229736 AAV-hAADC-2 Intrastriatal Phase I (2013) Genzyme
Parkinson NCT01973543 AAV2-hAADC Intrastriatal Phase I (2019) Voyager Therapeutics
Parkinson NCT03562494 AAV2-hAADC Intrastriatal Phase II (2020) Voyager Therapeutics
Parkinson NCT02418598 AAV-hAADC-2 Putamen Phase II  (2022) Jichi Medical University
Parkinson166 NCT01856439 ProSavin (LV-TH-GCH-AADC) Intrastriatal Phase I/II (2021) Oxford BioMedica
Parkinson NCT03720418   AXO-Lenti-PD(OXB-102-01) Intrastriatal Phase I/II (2020) Axovant Sciences Ltd
Parkinson189,190 NCT00643890 AAV-GAD Subthalamic nucleus Phase II (terminated) Neurologix, Inc
Alzeimer NCT00087789 AAV2-NGF Basal forebrain Phase 1 (2010) Ceregene
Alzeimer191 NCT00876863 AAV2-NGF Basal forebrain Phase II (2020) Sangamo Therapeutics
Alzeimer NCT03634007 AAVrh.10hAPOE2 Intracisternal Phase I (2020) Weill Medical College of Cornell University
Batten192–194 NCT03770572 AAV9-CLN3 Intrathecal Phase II (2022) Nationwide Children’s Hospital & Amicus Therapeutics
Batten195 NCT00151216 AAV2CUhCLN2 Intracranial Phase I (2019) Weill Medical College of Cornell University
Batten NCT01161576 AVRh.10CUhCLN2 Intracranial Phase I (2020) Weill Medical College of Cornell University
Batten NCT02725580 scAAV9.CB.CLN6 Intrathecal Phase II (2019) Nationwide Children’s Hospital
Mucopolysaccharidosis  Type IIIA173 NCT03612869 AAVrh10-h.SGSH Intracerebral Phase III (2022) LYSOGENE
X-Linked Myotubular Myopathy NCT03199469 AAV8-hMTM1 Intravenous Phase II (2025) Audentes Therapeutics
spinal muscular atrophy Type 1 NCT02122952 AAV9-SMN Intravenous Phase I (2019) AveXis, Inc
spinal muscular atrophy157,196 NCT03505099 AAV9-SMN Intravenous Phase I (2020) AveXis, Inc
spinal muscular atrophy157,196 NCT03306277 AAV9-SMN Intravenous Phase I (2020) AveXis, Inc
spinal muscular atrophy156,197 NCT03461289 AAV9-SMN Intravenous Phase III (2020) AveXis, Inc.
spinal muscular atrophy156,197 NCT03381729 AAV9-SMN Intrathecal Phase I (2020) AveXis, Inc.
Pompe disease198 NCT03533673 AAV2/8LSPhGAA Intravenous Phase II (2020) Actus Therapeutics, Inc
Pompe disease NCT02240407 rAAV9-DES-hGAA intramuscular Phase I (2019) University of Florida
Pompe disease199 NCT00976352 rAAV1-CMV-GAA intradiaphragmatic Phase II (2015) University of Florida
Canavan disease200 NA AAV2- hASPA Intraparenchymal Phase I (2002) National Institute of Neurological Disorders and Stroke
AADC deficiency NCT01395641 AAV2- hAADC Intraparenchymal 
(Putamen)
Phase I/II (2020) National Taiwan University Hospital
AADC deficiency NCT02926066 AAV2- hAADC Intraparenchymal 
(Putamen)
Phase II (2018) National Taiwan University Hospital
AADC deficiency NCT02852213 AAV2- hAADC Intraparenchymal Phase I (2020) National Taiwan University Hospital
MPS I201 NCT02702115 AAV6-ZFN Intravenous Phase I (2020) Sangamo Therapeutics
MPS II202 NTC03041324 AAV6-ZFN Intravenous Phase I (N.A) Sangamo Therapeutics
MPS IIIA NCT02716246 AAV9-hSGSH Intravenous Phase I/II (2019) Abeona Therapeutics
MPS IIIA173 NCT03612869 AAVrh.10- hSGSH Intracerebral Phase II/III (2022) LYSOGENE
Sanfilippo Disease Type A NCT02053064 AAVrh10- SGSH Intracerebral Phase II (2017) LYSOGENE
MPSIIIB174 NCT03300453 AAV5- hNAGLU Intracerebral Phase I/II (2019) UniQure Biopharma B.V.
MPSIIIB NCT03315182 AAV9- hNAGLU Intravenous Phase I/II (2020) Nationwide Children’s Hospital
Huntington’s disease NA AAV5-miHTT Intrastriatal Phase I/II (N.A) UniQure Biopharma B.V.
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of apolipoprotein E (APOE) can significantly increase the risk for developing sporadic 
AD, while APOE2 homozygotes are protected against the disease. Thus, APOE2 delivery 
could potentially be beneficial in APOE4 homozygous patients.170 Whether this approach 
indeed modifies the course of the disease is yet to be demonstrated. 
Batten disease
Batten disease or neuronal ceroid lipofuscinosis (NCLs) is a rare group of neurodegenerative 
disorders that can manifest in infants, children and adults. Symptoms include epilepsy, 
loss of cognitive and motor function, degeneration of the retina leading to blindness, and 
early death. More than a dozen CLN genes and more than 430 loss of function mutations 
have been linked to the diseases.171 AAV-based clinical trials for Batten disease have 
mainly focused on delivery of AAV-CLN2 and AAV-CLN3. The first study (NCT00151216), 
using intracranial delivery of AAV2CUhCLN2 showed little therapeutic benefit. A follow 
up study is still ongoing and used a different vector (AAVRh.10CUhCLN2) but abnormal 
T2 hyperintensities was observed in first dosed patient and led to a lowering of the dose 
for the following patient. For CLN3, one study (NCT03770572) is still recruiting and is 
based on AAV9-CLN3 delivery. For CLN6, an study with intrathecally delivered scAAV9.
CB.CLN6 is ongoing. A press release announcement from the preliminary data from 
the first two dosed patients stated no further progression of the disease (according to 
the Hamburg motor and language score) during the first two years after dosing.
Mucopolysaccharidoses (MPSs) 
Mucopolysaccharidoses (MPSs) are rare metabolic diseases that are caused by impaired 
degradation of mucopolysaccharides, leading to accumulation of glycosaminoglycans in 
the lysosome. Symptoms can be detected as early as during the prenatal period but can also 
occur in adulthood. The symptoms in adults include difficulty of speech, ataxia, weakness, 
and dyskinesia, while children usually show neurological impairment, developmental 
delay and premature death.172 Several gene therapy clinical trials are currently in progress 
for the treatment of MPS I (Hurler infantile syndrome or Hurler-Scheie and Scheie for 
the juvenile and adult forms), MPS II (Hunter syndrome), MPS IIIA and MPS IIIB (Sanfilippo 
syndromes A and B). For MPS I and MPS II, the trials are based on intravenous AAV delivery 
of ZFN therapeutic agents to insert a functional copy of alpha- L-Iduronidase (IDUA) or 
iduronate 2-sulfatase (IDS) into the albumin locus of patient hepatocytes. These trials are 
currently being tested in adult patients aiming to improve the peripheral symptoms of 
these diseases. For MPS IIIA, the main goal is to deliver a functional copy of the human 
N-sulfoglucosamine sulfohydrolase (h.SGSH) directly into the brain of young children. 
Thus far, h.SGSH delivery seems to be safe, but the therapeutic benefit was limited with 
cognitive improvement observed in only one patient.173 For the treatment of MPS IIIB, 
the goal is to deliver N-sulfoglucosamine sulfohydrolase (NAGLU) to restore its expression 
in patients. Both intracerebral and intravenous delivery of AAV-NAGLU have shown to be 
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promising in preclinical studies in rodent and dog models but whether this translates to 
therapeutic benefit in patients is yet to be demonstrated.174,175
Pompe disease
Pompe disease is a progressive neuromuscular disorder and is caused by a mutation in 
the acid alpha-glucosidase (GAA) gene, which encodes an enzyme required to degrade 
lysosomal glycogen.176 Accumulation of glycogen in multiple tissues results in cardiac, 
respiratory, and skeletal muscle dysfunction. Preclinical studies in GAA knockout mouse 
models showed rescue of glycogen accumulation in muscle and the central nervous 
system and increased survival upon delivery of GAA by AAV.177 Delivery of GAA by AAV is 
currently being tested in three different clinical trials. 
Spinal muscular atrophy 
SMA is caused by the loss of function of the gene encoding the survival motor neuron 
1 (SMN1) protein and is characterized by progressive loss of the lower motor neurons. 
The most severe form is type 1 SMA which affect infants. The patients usually die before 
the age of 20 months. Several clinical trials are run by AveXis based on AAV9-SMN 
delivery. Thus far, remarkable clinical benefit was observed including increased motor 
functions, head control, sitting, rolling over and speaking. The high dose of intravenous 
injected AAV9-SMN led to an increase in serum aminotransferase, a sign of liver toxicity, 
which was managed by oral prednisolone. Intrathecal delivery of AAV9-SMN is also 
being investigated by AveXis as improved transduction of the CNS was observed in 
lower dose as compared to intravenous administration in NHP. This program is currently 
also being investigated in clinic for other types of SMA (NCT03306277, NCT03505099, 
NCT03461289, and NCT03381729), results of which are pending (Table 1). A Biological 
License Application was submitted to the US FDA in November 2018 by Novartis, which 
acquired AveXis. In March 2019, Novartis announced the FDA approval of AAV9-SMN 
(Zolgensma®) for the treatment of pediatric SMA type 1 patients.
Huntington’s disease
HD is the most common autosomal dominant neurodegenerative disorder worldwide.178,179 
The genetic cause is an expansion of  39 CAG triplets or more in  first exon of the huntingtin 
(HTT) gene.180 The mutated gene produces a  mutant HTT protein that contain a long 
polyglutamine (polyQ) tract and results in a toxic gain of function. The mutant HTT 
protein causes neuropathology affecting the entire brain, with medium spiny neurons 
of the striatum being particularly vulnerable at early stages.181,182 The clinical symptoms 
include progressive motor, cognitive, and psychiatric disturbances. Currently there is no 
treatment available that would halt or delay disease progression.  Artificial DNA or RNA 
molecules to achieve lowering of HTT translation as a potential therapy for HD have been 
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broadly investigated in preclinical studies but few have made it to clinical trials. IONIS was 
the first to initiate a Phase I/II clinical trial (NCT02519036) in 2015 based on HTT lowering 
with an intrathecally administered antisense oligonucleotide targeting both wildtype and 
mutant HTT. This trial was safe and a reduction of HTT protein was detected in the CSF.183 
Roche is continuing this study with a large  phase III trial (NCT03761849) that was launch 
in 2018 and will be conducted at around 80-90 sites in about 15 countries. It remains 
unknown whether this intrathecally delivered ASO will reach the deeper brain structures 
to achieve sufficient lowering of the mutant HTT in the striatum. Concerningly, the latest 
published data using this approach showed a dose- and time-dependent increase of 
the ventricular volume, which suggests that the treatment cause more CNS atrophy, 
instead of the desired prevention of CNS atrophy. 
UniQure will launch the first AAV-based RNAi therapy for HD in the second half 
of 2019. The therapeutic candidate is AAV5-miHTT (AMT-130), which is based on an 
anti-HTT miRNA targeting a region close to the repeat in exon 1 of the HTT gene to silence 
both wildtype and mutant HTT. AMT-130 will be injected directly in the striatum and 
should provide a long-lasting production of miHTT with no re-administration required. 
Due to the close proximity of the miHTT target site to the CAG repeat, it is expected that 
AMT-130 also targets the short HTTexon1 fragments which are highly toxic.
Controlled gene therapy using inducible systems
One potential issue with current gene therapies is the irreversible state as transgene 
expression cannot be stopped. Thus, if continued expression of a therapeutic gene causes 
unwanted effects, these side effects would most likely persist in the patient without 
the possibility to terminate the treatment or control the dose. For example, the expression 
of recombinant GDNF showed side effects associated with cerebellar Purkinje cell loss 
in non-human primate models.203 In this case, inducible systems that could provide 
a more controlled expression of the transgene would be highly beneficial and would add 
considerably to the safety profile of the gene therapy.
Most classical inducible systems are based on two elements: the first is a chimeric 
transactivator protein capable of modulating gene expression in a drug-dependent 
(inducer) manner and the second is an inducible promoter which is often a minimal 
pol II promoter linked to sequences recognized by the chimeric transactivator protein.204 
These two elements can also be combined in a single expression system to express both 
transgene and the transactivator protein in a single plasmid or expression vector.205 
Additionally, two mechanisms of gene regulation can be distinguished, called On-switch 
and Off-switch. In the On-switch mechanism, the chimeric transactivator protein 
binds specifically to its DNA recognition sequence within the inducible promoter in 
the presence of the inducer, which in consequence activates gene expression. In the Off-
switch mechanism, the chimeric protein-repressor is constantly bound to its recognition 
sequences and dissociates upon induction allowing transcription. An inducible gene 
General introduction
39
1
expression system should fulfil several requirements for safe and long-term gene therapy 
application, including low basal expression in absence of the inducer and a high induction 
ratio. Another important safety requirement is that the chimeric proteins used in inducible 
systems, in active or inactive form, do not interfere with endogenous gene expression, 
because chimeric proteins are formed from potent transcription factors that can lead to 
unspecific activation of endogenous promoters and thus interfere with cellular processes. 
The safety aspects should also be determined for all inducible system components within 
the context of immune system activation. 
Regulated gene expression should ideally exhibit a wide dynamic range of induction 
with dose-response over a broad range of inducer concentrations, as opposed to acting 
merely as an on-off switch. For therapeutic applications, additional safety measures are 
required to minimize potential immune responses or other unwanted effects. For example, 
the regulatory proteins should be built from human proteins and should respond to an 
inducer that is safe, physiologically inert at the doses used, and with pharmacokinetics 
that permit a clinically tractable dosing regimen.
Several inducible gene expression systems have been developed including tetracycline, 
rapamycine, Isopropyl β-D-1-thiogalactopyranoside (IPTG), ecdysone and mifepristone 
dependent technologies.206–208 In this paragraph the GeneSwitch and tetracycline-
dependent (tet) system are discussed as they are currently the most widely used 
inducible systems.
GeneSwitch
GeneSwitch is one of the best  characterized inducible systems for regulation of gene 
expression.207,209 It exploits a chimeric transactivator GeneSwitch protein which consists of 
a DNA binding domain from the yeast Gal4 protein (Gal4 BD), a truncated ligand binding 
domain from human progesterone receptor (PR) and a p65 transcriptional activation 
domain of the human NF-kappa B transcription factor (p65) (Figure 6). The second 
component is the GeneSwitch inducible promoter, which consists of a minimal pol II 
promoter with upstream activation sequences (Gal4) that can be recognized by Gal4 
BD of the GeneSwitch protein. This hybrid system can be activated by the antiprogestin 
mifepristone (MFP), a clinically approved synthetic steroid that binds to the PR domain 
of the GeneSwitch protein. MFP induces GeneSwitch conformational changes and 
dimerization, resulting in binding of the GeneSwitch dimer to the Gal4 sites placed 
upstream of a promoter to activate transcription of a transgene. In absence of mifepristone, 
the transgene will remain silent. The GeneSwitch system is highly attractive for clinical 
application as it does not contain any bacterial or viral components and is considered to 
be less immunogenic than most other inducible systems. The classical GeneSwitch system 
has been optimized to be delivered in a single vector, with low background levels and 
a high transgene expression after induction. Furthermore, GeneSwitch proved promising 
in combination with AAV-based gene therapy in preclinical studies for neurodegenerative 
Chapter 1
40
1
diseases.205 For example, GDNF expression was successfully induced up to three hundred-
fold in rat brains and the expression was reversible with no background expression. It was 
also possible to re-activate GDNF expression after long-term off-status, and therapeutic 
benefits of induced GDNF was demonstrated in a PD rat model by restoring motor 
pathology.205,210 The major advantage of the GeneSwitch system is that it lacks virally- or 
bacterially derived components thus limiting a potential immune reaction to GeneSwitch 
expression. Another advantage of the system is its inducer MFP, which is a marketed drug 
with well characterized pharmacokinetics and the induction occurs at sub-therapeutic 
MFP concentrations.211 One concern is that expression of GeneSwitch for one month 
resulted in transcriptional changes in the murine liver.209 Although these alterations 
were not associated with any biochemical or morphological changes, this aspect needs 
more attention.
Figure 6. A schematic of the GeneSwitch system and its mechanism of action. The classical 
GeneSwitch system consists of two expression cassettes on two separate vectors; one containing 
the GeneSwitch gene and one containing the transgene. The expression of GeneSwitch is driven 
by a promoter, which can be tissue specific. Expression of the transgene is driven by a minimal pol 
II promoter with Gal4 binding sites. The GeneSwitch protein comprises yeast Gal4 DNA-binding 
domain, a human p65 activation domain and a Mifepristone (MFP) controlled domain derived 
from the human progesterone receptor. The GeneSwitch protein (monomer) can be activated by 
the steroid inducer MFP. And active dimer is formed that can attach to the Gal4-binding sites 
in the inducible promoter of the transgene. Hence only in the presence of MFP the transgene 
is transcribed.
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(tet) system 
Another inducible system is the tetracycline-dependent (tet) system which is currently 
the most widely used regulatable system.212 There are two versions, namely a tetOFF and 
a tetON system. TetOFF is based on a fusion between the wild-type tet repressor and 
the activation domain of the HSV VP16 transcription factor.213 In the tetON system, the tet 
repressor sequence has been replaced by a mutant which reverses the tet-repressor to 
a tet-inducer system.214 Compared to tetOFF, tetON seems more suitable for further 
development to use in clinic as repeated punctual treatments using an inducible system 
is more favorable than a repressible system.214 TetON consists of a transactivator-protein 
(rtTA) that can be activated by the antibiotic doxycycline and bind to a Tet promoter 
upstream of a transgene of interest. The TetON system was also successfully used in 
combination with AAV gene therapy in rodents and showed controlled expression of 
GDNF in brain of rats.213 However, some major concerns are the side effects that may be 
caused by the inducer (an antibiotic) and the immunogenicity caused by the rtTA protein. 
Long-term exposure to antibiotics is undesirable and the rtTA protein of this system which 
is derived from bacteria showed to be highly immunogenic in non-human primates.215,216 
Therefore, the GeneSwitch system is currently preferable for further development into an 
applicable system in humans.
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Scope of this thesis
During the past decades, several discoveries have highlighted the potential of AAV-based 
gene therapy for the treatment of inherited diseases. By means of gene replacement 
or RNAi, gene therapy has emerged as an attractive and clinically viable option to treat 
neurodegenerative diseases. In the current thesis we developed and characterized 
RNAi-based gene therapy for ALS and SCA3 aiming to silence two single genes that 
are the root cause of the diseases. These diseases have a very high unmet medical need 
with a progressive decline in the quality of life and no effective treatments available. 
Additionally, different delivery methods of AAV-based gene therapy were investigated for 
the CNS, as well as methods to regulate the transgene expression.
Chapter 1 introduces the concept of gene silencing using miRNAs and provides an 
overview of the pathogenesis of neurodegenerative diseases that are the subject of this 
thesis. The challenges for developing novel therapies for neurodegenerative diseases are 
discussed with an emphasis on ALS and SCA3.  Chapter 2 describes the design of a novel 
miRNA-based gene silencing technology for ALS. miRNAs targeting different regions 
of C9orf72 were designed and tested in vitro for silencing efficacy. For a long time, 
the functionality of miRNAs was thought to be restricted to the cytoplasm but some 
diseases, including C9orf72-related ALS require intranuclear silencing of the pathogenic 
repeat-containing transcripts. We demonstrated that nuclear silencing is possible with 
our miRNAs. We also report on feasibility of different targeting strategies to silence 
the sense- and/or antisense transcripts. Targeting exons within the C9orf72 gene resulted 
in lowering of the healthy and mutated sense transcript, but not the antisense transcripts. 
Targeting both sense and antisense transcript can be achieved by expressing two 
miRNAs in a concatenated fashion in a single expression vector. An approach to target 
only the mutated transcripts is also possible by developing miRNAs close to the repeat 
region, but targeting the repeat region directly was not successful as this region consisted 
solely from GC nucleotides and has a highly complicated tertiary structure. In chapter 3, 
the therapeutic potential of C9orf72-targeting miRNAs was tested on patient-derived 
iPSC-neurons and in an C9orf72 ALS mouse model. We confirmed the presence and 
activity of the therapeutic miRNAs in the nucleus of cells and showed reduction of 
the repeat-containing transcripts as well as nuclear RNA foci formation in the brain of an 
ALS mouse model. In chapter 4, the miQURE technology was applied to further develop 
a miRNA gene therapy for SCA3. Several miRNAs were tested in vitro, and three lead 
candidates were incorporated into AAV5. The therapeutic potential of these constructs 
was tested in human iPSC-neurons and in an SCA3 knock-in mouse model using different 
routes of delivery. We demonstrated strong reduction of ATXN3 mRNA in both model 
systems. Further support for this approach was provided by the finding that mutant 
ataxin-3 protein was reduced in the brain stem and cerebellum of treated mice. Targeting 
the affected brain regions is critical for AAV-based silencing technologies. In chapter 5 
we studied the biodistribution of AAV5 in the rat brain using different delivery routes. We 
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found that each delivery route has its own merits and should be carefully investigated for 
each type of disease. In many cases it may be useful to be able to regulate the expression 
of therapeutic constructs in the brain following delivery. In chapter 6, a proof on concept 
study was performed to investigate the ability to regulate expression of a therapeutic 
transgene using the mifepristone regulated GeneSwitch system. Using a novel design 
that can fit both the GeneSwitch system and the transgene in a single vector, we showed 
that this system is safe and that it is possible to regulate expression of the transgene in 
vitro and in vivo using. In chapter 7, we discussed our main findings and compare our 
therapeutic strategies with others. We further discussed the future perspectives for gene 
therapies for neurodegenerative diseases. Overall, we provided evidence that our RNAi-
technology has the potential to be further developed in effective therapies for a group of 
severe diseases with no medical cure and a high demand for novel treatments. 
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Abstract
The most common pathogenic mutation in amyotrophic lateral sclerosis (ALS) and 
frontotemporal dementia (FTD) is an intronic GGGGCC (G4C2) repeat in the chromosome 
9 open reading frame 72 (C9orf72) gene. Cellular toxicity due to RNA foci and dipeptide 
repeat (DPR) proteins produced by the sense and antisense repeat-containing transcripts 
is thought to underlie the pathogenesis of both diseases. 
RNA-seq data of C9orf72-ALS patients and controls were analyzed to better 
understand the sequence conservation of C9orf72 in patients. MicroRNAs were 
developed in conserved regions to silence C9orf72 (miC) and the feasibility of different 
silencing approaches was demonstrated in reporter overexpression systems. In addition, 
we demonstrated the feasibility of a bidirectional targeting approach by expressing two 
concatenated miC hairpins.
The efficacy of miC was confirmed by the reduction of endogenously expressed 
C9orf72 mRNA in both nucleus and cytoplasm and ~50% reduction of nuclear RNA foci 
in (G4C2)44 expressing cells. Ultimately, two miC candidates were incorporated in adeno-
associated viral vector serotype 5 (AAV5) and silencing of C9orf72 was demonstrated 
in HEK293T cells and Induced pluripotent stem cell (iPSC)-derived neurons. These data 
support the feasibility of miRNA-based and AAV-delivered gene therapy that could 
alleviate the gain of toxicity seen in ALS and FTD patients.
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Introduction
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease 
characterized by progressive degeneration of the upper and lower motor neurons leading 
to muscle atrophy and paralysis. There is no disease-modifying therapy for ALS and most 
patients die with respiratory failure within 3-5 years after the onset of symptoms.1–3 
An significant number of ALS patients also develop frontotemporal dementia (FTD), 
a presenile dementia caused by progressive degeneration of the frontal and temporal 
lobes.3,4 The most common genetic cause of familial and sporadic ALS and FTD is an 
expanded GGGGCC (G4C2) repeat in the first intron of the chromosome 9 open reading 
frame 72 (C9orf72) gene.2,5 The G4C2 repeat in patients can be several hundred of 
repeats long and is transcribed bidirectionally.2,6 Generally, less than 30 repeats are 
considered nonpathogenic.2,6,7 
The G4C2 repeat is found in approximately 40% of familial ALS cases and 9% 
of sporadic ALS.8,9 The mechanisms underlying the involvement of C9orf72 in 
neurodegeneration have been a debate for several years, with loss of function, gain of 
toxicity, or a combination of both being implicated.10,11 A reduction of C9orf72 transcripts 
is detected in a significant number of C9orf72-ALS (C9-ALS) patients, supporting loss 
of function.9,12 However, complete elimination of C9orf72 in mice causes immune 
system related pathology but no motor deficits. These conditions were rescued in mice 
hemizygous for C9orf72 that express 50% of C9orf72 mRNA.13,14 In humans, a few loss-
of-function mutations in C9orf72 were identified and all seemed to be non-pathogenic, 
thus C9orf72 reduction in humans is likely to be tolerable.15 Most evidences suggest that 
C9orf72-related pathogenicity is a result of  gain of toxicity by accumulation of sense 
and antisense RNA foci in the nucleus, and deposition of dipeptide repeat (DPR) proteins 
in the cytoplasm.8,16–21 RNA foci can bind and sequester the function of RNA binding 
proteins leading to RNA-mediated toxicity.20,22 DPR proteins are a linked to a variety of 
toxic effects.10,20,22 Thus, lowering the accumulation of RNA foci and DPR proteins is an 
attractive therapeutic strategy in ALS and FTD.
Directly targeting the G4C2 repeat to exclusively silence the repeat containing transcripts 
is preferable, but challenging due to the high GC content, bidirectional transcription, 
intronic position and nuclear localization.23 The repeat-containing transcripts are also 
poorly characterized and  sequence variations downstream of the G4C2 repeat region 
suggest that the area close to the repeat may not be well conserved between patients.24 
Fully complementary anti-GGGGCC or anti-CCCCGG single-stranded silencing RNAs 
(ss-siRNAs) reduced C9orf72 sense and antisense foci.25 Antisense oligonucleotides (ASOs) 
against C9orf72 intron 1 near the G4C2 repeat also resulted in reduction of sense RNA foci 
and DPR proteins, while the overall C9orf72 levels were not affected.18,26,27 Interestingly, 
RNA foci and DPR proteins were also reduced by ASOs against exonic regions to target 
all C9orf72 transcripts. Thus, both mutant specific or total C9orf72 silencing approaches 
can lower RNA foci and DPR proteins.
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Administration of synthetic siRNAs and ASOs are promising but require repeated 
administration. We and others have reported that siRNAs derived from short hairpin 
RNA (shRNA) or microRNA (miRNA) scaffolds delivered with adeno-associated viral (AAV) 
vectors have the advantage to provide long lasting therapeutic effects in different disease 
models of the central nervous system (CNS).28–31 High concentrations of shRNAs can 
bypass the nuclear RNase III Drosha processing and overload the cytoplasm with double 
stranded RNA, leading to toxicity.32 miRNAs are safer, as their precursors are encoded 
in the genome, thus mimicking the natural processing pathway. Moreover, the miRNA-
expression cassette can be driven by polymerase (pol) II or pol III promoters allowing for 
tissue- or cell-specific expression. 
We here report on the development of therapeutic miRNAs (miC) as proof of concept 
to silence C9orf72 mRNA. We used a recently published RNA-seq library from C9-ALS 
patients to investigate C9orf72 expression and sequence composition for identification of 
potential miC target sites in intron 1 and exonic regions.33 miC constructs were designed 
to target the sense, antisense or both strands of C9orf72. The natural cellular primary (pri)-
miR-101-1 and pri-miR-451 scaffold were selected to embed the miC sequences based on 
our previous findings that both scaffolds produced guide strands that were highly active.31 
Pri-miRNAs are produced by RNA pol I or RNA pol II transcription and fold into hairpin-
like scaffold which determine their further processing by the microprocessor complex.34 
The tail of pri-miRNAs is cleaved by Drosha in the nucleus generating a precursor miRNA 
(pre-miRNA) that is subsequently exported to the cytoplasm for further processing into 
a mature miRNA.35–37 The silencing efficacy of the miC-101 and miC-451 candidates were 
tested on luciferase (luc) reporters and confirmed with knockdown of the endogenously 
expressed C9orf72 mRNA. The processing pattern was determined by next generation 
sequencing (NGS). 
One major challenge for an effective RNAi approach is the nuclear localization of 
the repeat containing transcripts, as the mature miC is produced in the cytoplasm. 
Therefore, the expression and silencing efficacy of the miC candidates in both nucleus 
and cytoplasm was investigated, and we studied the ability of these constructs to silence 
nuclear RNA foci formation caused by G4C2 repeats. Finally, two candidates were selected 
and incorporated into AAV5 vector to test their efficacy in vitro on Human embryonic 
kidney (HEK)293T cells and in frontal brain-like neurons generated from Induced 
pluripotent stem cells (iPSCs) from an FTD patient. The expression of total C9orf72 (all 
C9orf72 sense transcripts) was significantly reduced in both cell lines. Hence, our data 
provide evidence on the efficacy of artificial miRNAs against C9orf72 as a promising 
AAV-based gene therapy for ALS and FTD.
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Results
Reduced C9orf72 levels detected by RNA-seq in C9-ALS patients
The human C9orf72 gene  consists of 12 exons that can be transcribed in three different 
transcript variants (V1, V2, V3) (figure 1a). The G4C2 repeat in intron 1 is in the promoter 
region of V2 and the first intron of V1 and V3. We used a publically available RNA-seq 
library to determine the expression of C9orf72 in cerebellar and cortical tissues of 8 C9-ALS 
patients and 7 healthy controls.33 Notably, we found that C9orf72 is higher expressed 
(~ 2-fold) in the cerebellum compared to cortex in both C9-ALS patients and controls 
(figure 1b). It was also found that C9orf72 mRNA expression is consistently reduced in 
both cerebellum and cortex of C9-ALS patients. To determine if the reduction seen in 
C9-ALS patients is variant specific, we investigated the relative expression of V1, V2 and 
V3 in patients and controls (figure 1c). Expression of V1, V2 and V3 was determined in 
percentage, relative to total (100%) C9orf72 expression. In both cerebellum and cortex, 
the proportion of the variants in patients and controls were similar, suggesting that 
the reduction of C9orf72 mRNA levels in C9-ALS patients is not variant specific. 
Intronic inclusions due to G4C2 repeat are detected in C9-ALS patients by 
RNA-seq
C9orf72 Intron 1 should be spliced out and degraded but defective splicing may result in 
accumulation of repeat containing transcripts in the cell nucleus.38 These repeat-containing 
transcripts are poorly characterized and there is little information on the conservation of 
this region in C9-ALS patients. To address this question, read alignments from C9-ALS 
patients and controls were compared to investigate the sequence conservation of intronic 
and exonic regions of C9orf72 transcripts (figure 1d). The read depth in exon 1a, exon 1b, 
intron 1, exon 2 and exon 11 was estimated by correcting the total number of reads by 
the area size. We found a complete coverage of exon 2 to exon 11, though read depth in 
exon 1a, exon 1b and intronic regions was very low in both C9-ALS and control groups. 
Exonic regions from exon 2 to exon 11 were less covered in patients while read depth for 
intron 1 in the patients was comparable with controls. To estimate the relative coverage 
of the exons and introns, the ratio between the number of reads in C9-ALS patients 
and controls was determined (figure 1e). All C9orf72 exonic regions were about twofold 
lower expressed in C9-ALS patients. Intron 1 had the same number of reads in patient 
samples compared to controls, while intron 2-4 was 1.4 times higher in C9-ALS patients 
than controls. Introns 5, 6 and 7 were excluded as these could potentially be 3’UTR of 
the short C9orf72 variant and coverage of intron 8, 9 and 10 was not increased in C9-ALS 
patients. Similarly, in the frontal cortex samples of C9-ALS patients the coverage ratio 
between intronic and exonic regions were increased (supplementary figure S1). Thus, 
although exonic regions were expressed twofold lower in C9-ALS patients, this was not 
the case for intron 1-4, suggesting that intronic C9orf72 reads are relatively overexpressed 
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Figure 1. C9orf72 expression and target regions. a) Schematic of C9orf72 gene and transcript 
variants. The G4C2 repeat is in intron 1 of transcript variants V1 and V3 and in the promotor 
region of V2. b) C9orf72 expression in C9-ALS patients and controls. C9orf72 gene expression was 
determined from RNA-seq libraries in cerebellum and frontal cortex from 8 C9-ALS patients and 
7 control donors. The mean expression values are shown in Fragments Per Kilobase of transcript 
per Million mapped reads (FPKM). c) Relative expression of predicted C9orf72 variants. The mRNA 
variants in C9-ALS and controls were predicted from the mapped and aligned RNA-seq data. 
Isoform V1 is predicted from reads alignment from exon 1a to exon 5 (1950bp), isoform V2 from 
exon 1b to exon 11 (3243bp) and isoform V3 from exon 1a to exon 11 (3338bp). Expression of 
C9orf72 isoforms is presented in percentage of the total (100%) C9orf72 expression. T-tests were 
performed between groups and n.s. indicates no significant differences in the levels of all isoforms. 
d) Estimation of the read depth per region in C9orf72. Read depth was estimated for exon 1a, intron 
1, exon 1b, exon 2 and exon 11 in cerebellum from C9-ALS patient and controls. The total amount 
of reads per region were counted and corrected for the area size. Each dot or triangle represents 
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in C9-ALS patients. Our data confirm previous findings that the higher amount of intronic 
sequences in the C9orf72 mRNA could be due to aberrant splicing.38,39 
Design of miRNAs targeting conserved C9orf72 regions
We selected the well conserved exon 2 and exon 11 as target sites for a total silencing 
approach. Due to the poor coverage of intron 1, we selected regions that have been 
successfully targeted before by ASOs.26 For the antisense strand, a region that has 
been identified before by PCR was selected.40 We designed miC expression constructs 
miC1-miC11 and miC22-miC31 in intron 1 to target only the sense intronic transcripts 
(figure 2a). miC32-miC50 were designed in exon 2 and exon 11 to target all sense 
C9orf72 transcripts. miC12*- miC22* were designed on the antisense strand to target 
only the antisense transcripts and are indicated with an asterisk (*). The miC sequences 
were embedded in the pri-miR-101 and pri-miR-451 scaffold because of previous findings 
by us that both scaffolds produce high amount of active guide strands.31 The pri-miC-101 
and pri-miC-451 structures were predicted to produce mature miC lengths of 21nt and 
22nt respectively (figure 2b). The miC constructs were expressed by the synthetic CMV 
early enhancer and chicken β actin (CAG) promotor (figure 2c). This promoter is known 
to drive stable and high expression of a transgene and is highly active in the CNS.41
In vitro testing of miC-101 and miC-451 constructs on reporter systems
To test the efficacy of the miC candidates, we designed Luc reporters bearing 
complementary C9orf72 target regions fused to the renilla luciferase (RL) gene 
(figure 2d). As targets, intron 1, exon 2, exon 11 and the antisense strand sequences were 
used. Independently from RL, firefly luciferase (FL) was expressed from the reporter vector 
to correct for transfection efficiency. 
We first performed a prescreening for all the miC expression constructs by co-
transfection with the corresponding Luc reporters in a 1:1 ratio. Of the miC variants 
designed to target the sense intronic transcripts, miC2_101 and miC4_101 showed 
a moderate knockdown (~50%) and miC31_101 showed a strong knockdown (~80%) 
(figure 3a). These were selected for further optimization. Amongst candidates predicted 
to target total C9orf72, miC32_101, miC33_101, miC38_451, miC39_451, miC40_451 
and miC43_451 targeting exon 2 showed a strong knockdown of >80% (figure 3b). 
Similarly, miC46_101, miC49_451 and miC50_451 targeting exon 11 induced a strong 
knockdown (>80%) (figure 3c). Dilution of the selected miC candidates demonstrated that 
a single sample e) Ratio of reads between C9-ALS patients and controls in cerebellum. The total 
amount of reads counted in different intronic and exonic regions from C9-ALS patients were 
divided by the total amount of reads from the same region of control donors. Data were evaluated 
using two-way ANOVA with Tukey’s multiple comparison: *p < 0.05; **p < 0.01; ***p < 0.001; 
****p < 0.0001.
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Figure 2. Design of artificial miC expression constructs targeting sense and antisense C9orf72. 
a) Schematic representation of the human C9orf72 gene consisting show of 12 exons including 
the alternatively spliced exon 1a and 1b and the intronic G4C2 repeat. The positions of the miC 
target sites are indicated with numbers. Numbers in green shows position of ASO’s described by 
Lagier-Tourenne et al.18 In grey are the sense targeting miC candidates embedded in miR-101 
scaffold, in blue are sense targeting miC candidates embedded in miR-451 scaffold, in red are 
antisense targeting miC candidates embedded in miR-451 scaffold. b) Schematic of the miC-101 
and miC-451 secondary structures. The scaffolds were selected from miRBase database (www.
mirbase.org). The guide strand was replaced by the mature miC sequence and the passenger strand 
was corrected in order to preserve pri-miC scaffolding. miR-101 can be processed into active guide 
strands (red) and in some cases passenger strands (grey). miR-451 produces only guide strands. 
c) Schematic of the pri-miC-451 and pri-miC-101 constructs consisting of the CAG promoter, 
pri-miC sequence and human growth hormone polyadenylation (hGH polyA) signal. d) Schematic 
of the reporter genes. To represent the C9orf72 sense transcripts, sequences from C9orf72 intron 
1 (int 1a and int 1b), exon 2 (ex2) and exon 11 (ex11) were cloned downstream of the RL gene. In 
addition, FL was co-expressed from the vector as an internal control. For the antisense reporter (AS), 
the intronic antisense sequence was cloned. 
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Figure 3. Silencing efficacy of miC candidates on luc reporters. a) knockdown by miC1 to miC11 and 
miC22 to miC31 targeting intron 1 either between exon 1a and the G4C2 repeat or between exon 
1b and exon 2. HEK293T cells were co-transfected in a 1:1 ratio with luc reporters and the different 
miC variants embedded in miR-101 (grey bars) or miR-451 (blue bars) scaffold. RL and FL were 
measured 2 days post-transfection and RL was normalized to FL expression. Scrambled miRNA 
(miScr) served as a negative control and was set at 100%. Candidates selected for further testing 
are underlined. b-c) Knockdown of exon 2 reporter by miC32 to miC45 and exon 11 reporter by 
miC46 to miC50. d) knockdown of the antisense reporter by miC12_451* to miC21_451*. c). e-h) 
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the most effective candidates were miC31_101 against intron 1 (figure 3e), miC32_101 
against exon 2 (figure 3f) and miC46_101 against exon 11 (figure 3g).  
For the antisense C9orf72 transcript, miC15_451* and miC21_451* were selected 
as the most effective candidates with a knockdown efficiency of ~70% (figure 3d). Both 
miC15_451* and miC21_451* showed an equal dose dependent knockdown (figure 3h). 
Our data demonstrate that intron 1 remains a difficult target region as all miC 
candidates in the highly structured repeat region between exon 1a and 1b failed to induce 
a strong knockdown. The most effective miC candidates were downstream of exon 1b 
or in exonic regions 2 and 11. Yet, if a moderate knockdown of the G4C2 repeat would 
be sufficient for a therapeutic effect, miC2_101 and miC4_101 could still be promising 
candidates to target the repeat containing transcripts in C9-ALS patients. 
Bidirectional targeting of C9orf72 is possible by introduction of  
a second miC concatenate
The region around the G4C2 repeat of C9orf72 is transcribed in both sense and 
antisense transcripts and both strands have been linked to toxicity. Therefore, a therapy 
simultaneously targeting both strands could potentially add to therapeutic benefit. To 
investigate the feasibility for this approach using miRNAs we made concatenated constructs 
expressing two hairpins predicted to target both transcripts under control of the CAG-
promotor (fig, 4a). The first hairpin from the concatenated hairpin miRNA construct was 
in a miR-451 scaffold and targets the antisense transcript. The second hairpin was in 
a miR-101 scaffold against the sense transcripts. The most effective candidates on luc 
reporters for intron 1 sense and antisense were selected. The miC15*+31 construct was 
designed to express miC15_451* and miC31_101 and was tested on the intron 1 and 
antisense reporters (figure 4b-c). A silencing of up to 60% was observed on the intron 1 
sense and on the antisense reporter. Similarly, miC21*+31 expressing miC21_451* and 
miC31_101 was made and tested and up to 60% knockdown was observed on both 
reporter constructs (figure 4d-e).  Both constructs showed a dose dependent reduction 
of the intron 1 sense and antisense reporters containing Luc. Our data demonstrates 
that two different miC can be properly processed and are active when expressed from 
a single promotor. Hence, a bidirectional miRNA-based approach to simultaneously 
target the sense and antisense transcripts of C9orf72 is feasible, using two miC variants 
expressed in a concatenated fashion.
Dose dependent effect of the selected miC candidates on luc reporters. HEK293T cells were co-
transfected with 10ng of the Luc reporters and 1, 5, 10 and 25 ng of the selected miC constructs 
for intron 1 (e), exon 2 (f) and exon 11 (g) and the antisense transcript (f). RL and FL luciferases were 
measured as described above. Data were analyzed using a multiple comparison one-way ANOVA 
to determine statistically significances cells treated with scrambled and miC. The p values of miC 
candidates selected for further testing are listed in the graph by asterisks: ****p < 0.0001. Each bar 
represents the average and standard deviation of 3 independent experiments.
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Figure 4. Efficacy of double hairpin constructs for bidirectional knockdown. a) Schematic of 
the concatenated pri-miC-451 and pri-miC-101 construct consisting of the CAG promoter, two 
pri-miC sequences in miR-451 and miR-101 scaffold, and human growth hormone polyadenylation 
(hGH polyA) signal. b) optimization of miC15*+31 on luc-intron 1b reporter. HEK293T cells were 
co-transfected with 10ng Luc-intron 1b reporter and 1, 5, 10 or 25 ng of miC15*+31 construct 
designed to simultaneously target both sense and antisense C9orf72 transcripts. miC31_101 
(targeting only sense) was used as positive control and miC15_451* served as negative control. 
RL and FL were measured as described in figure 3. c) Optimization of miC15*+31 on the antisense 
reporter. miC15*_451 was tested as positive control for the antisense reporter and miC31_101 
as negative control. d) Knockdown of luc-intron 1b reporter by miC21*+31 with miC31_101 as 
positive and miC21_451* and negative controls. e) Dose dependent knockdown of the antisense 
reporter by miC21*+31. miC21_451* served as positive control and miC31_101 as negative control. 
Endogenous knockdown of C9orf72 expression in HEK293T cells by miC 
variants 
We next investigated whether the selected miC candidates reduce the endogenous levels 
of C9orf72 in HEK293T cells. Cells were transfected with the selected miC candidates 
and endogenous levels of C9orf72 mRNA were determined 2 days post-transfection by 
RT-qPCR. As HEK293T cells lack the G4C2 expansion linked to the C9orf72 pathology 
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Figure 5. Lowering of endogenous C9orf72 mRNA. a) Total and sense intronic C9orf72 expression 
in HEK293T cells. RNA was isolated, and RT-qPCR was performed for total and sense intronic 
C9orf72 transcripts. mRNA input levels were normalized to GAPDH and set relative to total C9orf72 
b-c) Endogenous knockdown of total C9orf72 and sense intronic C9orf72 by the selected miC 
candidates. RT-qPCR for total and sense C9orf72 was performed on RNA from HEK293T cells that 
were transfected with 250 ng of different miC plasmids. mRNA input levels were normalized to 
GAPDH mRNA. miScr served as a negative control and was set at 100%. d) Processing of miC-101 
candidates. HEK293T cells were transfected with 250 ng of the constructs, 48 hours post-
transfection RNA was isolated and small RNA NGS was performed to determine the length and ratio 
of guide and passenger strands.  e) Processing of miC-451 candidates. Performed as described in 
(d).  f) Cytoplasmic and nuclear expression of miC candidates in miR_101 scaffold. RNA was isolated 
from cytoplasm and nucleus of HEK293T cells transfected with 250 ng of miC plasmid. miC levels 
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we first determined the expression of total C9orf72 and intronic C9orf72 mRNA. We 
found good expression of total C9orf72, while the intronic C9orf72 was detectable but 
at very low levels (figure 5a). For miC candidates in miR-101 scaffold, total C9orf72 
mRNA was reduced up to 50% by miC32_101, miC33_101 and miC46_101 (figure 5b). 
The intronic C9orf72 transcripts were also decreased by ~25% (figure 5c). miC2_101 and 
miC4_101 targeting intron 1 were less effective in lowering total C9orf72 but the efficacy 
on intronic C9orf72 was comparable to miC candidates targeting total C9orf72. Thus, 
both candidates may be targeting the repeat containing transcripts without significantly 
changing the total C9orf72 expression. miC31_101 targeting intron 1 showed the best 
efficacy for the intronic C9orf72 (40%) but despite its intronic localization, the total 
C9orf72 RNA levels were also reduced by ~40% (figure 5b-c). Reduction of C9orf72 was 
also observed by the selected miC candidates in miR-451 scaffold but their efficacy were 
slightly lower. Altogether, we demonstrated reduction of endogenous levels of C9orf72 
in HEK293T cells, confirming that the miC candidates are functional in cells.
Different processing pattern from miR-101 and miR-451 scaffolds
To assess the processing of the miC candidates, we analyzed the mature miC lengths 
and sequence composition of the guide and passenger strands by next-generation 
sequencing (NGS) for small transcriptome analysis (figure 5d-e). NGS was performed on 
small RNAs isolated from HEK293T cells that were transfected with the selected miC 
constructs. For each sample, we obtained between 15–30 million small RNA reads that 
were subsequently adaptor-trimmed and aligned against the corresponding reference 
sequence. All reads shorter than 10 nucleotide (nt), longer than 45 nt, or represented less 
than 10 times were excluded from the analysis. 
miR-101 is processed into a miRNA duplex, first by Drosha cleavage and then by 
Dicer cleavage at the hairpin structure (supplementary figure S2). The miRNA duplex 
is then separated, and the guide strand is usually incorporated into the RNA-induced 
silencing complex (RISC) while in most cases the passenger strand is degraded.42–44 
The miC-101 candidates were processed into a 20-23 nt long mature miRNA, (figure 5d). 
The most frequently found length of guide strands was 22nt which is 1 nt longer than 
were measured by small RNA TaqMan and mRNA input levels was normalized to u6 small nuclear 
RNA and set relative to untreated (BL) cells. g) Expression of miC candidates in miR-451 in cytoplasm 
and nucleus. Performed as described in (f). h) Reduction of total C9orf72 by miC-101 in cytoplasm 
and nucleus. RT-qPCR for total C9orf72 was performed on cytoplasmic and nuclear fractions of 
transfected cells. mRNA input levels were corrected for GAPDH and BL was set at 100%. i) Total 
C9orf72 reduction in nucleus and cytoplasm by miC-451. Performed as described in (h). Data were 
analyzed using a multiple comparison one-way ANOVA to determine statistically significances cells 
treated with scrambled or BL and miC. The p values are listed in the graph by asterisks: *p < 0.05; 
**p < 0.01; ***p < 0.001; ****p < 0.0001. Each graph represents the mean values with standard 
deviation of 2 independent experiment.
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the cleavage pattern predicted by miRBase (http://www.mirbase.org/) (supplementary 
table S1). The length of the passenger strands ranged between 19-23 nt. In most cases, 
Drosha cleavage sites of the mature miC-101 at 3’ end of the pre-miC-101 candidates 
were precise and consistent with the prediction from miRBase except for miC33_101 
and miC49_101. Following cleavage by Drosha, the hairpin of the pre-miC_101 is being 
cleaved by Dicer. Dicer cleavage in the hairpin generated more variability for almost all 
the miC variants. Processing of miC2_101, miC4_101, miC32_101 and miC33_101 
yielded a high frequency of guide strands with very low percentage of the passenger 
strand. miC46_101 processing yielded more passenger strand, while miC49_101 and 
miC50_101 produced a relatively equal amount of guide and passenger strand. 
The processing of the miC-451 candidates did not produce passenger strands but 
often generated longer guide strands than the predicted 22nt obtained from miRbase 
(figure 5e, supplementary table S2). Drosha cleavage sites at 5’ end of the mature 
miC-451 were precise but the trimming of the 3’ ends of the mature miC-451 by PARN 
were different for most candidates leading to a variety of mature lengths. miC39_451, 
miC43_451 and miC49_451 processing generated most often mature lengths between 
21-26 nt long and processing of miC38_451 and miC50_451 often resulted in mature 
length longer than 27 nt. 
Overall, we demonstrated that expressing different C9orf72 target sequences from 
miR-101 scaffold yields a differential processing of mature guide and passenger strands. 
Using the miC-451, no passenger strands were detected, but this scaffold often generated 
longer mature guide strands. 
miC-101 and miC-451 are active in the nucleus
pre-miRNAs are transported from the nucleus to cytoplasm for further processing 
and incorporation into the RISC.42–44 However, because C9orf72 related ALS and FTD 
are characterized by accumulation of the G4C2 containing transcripts in the nucleus, 
mature miC should be active in the cell nucleus to achieve therapeutic effect. Based 
on the efficacy in vitro, we selected miC2_101 and miC4_101 as the most promising 
candidates to target only the intronic transcripts. Similarly, miC32_101, miC46_101, 
miC49_451 and miC50_451 were selected for a total silencing approach based on 
their strong silencing efficacy in vitro. HEK293T cells were transfected with the different 
miC candidates, nuclear and cytoplasmic fractions were separated and expression of 
the mature miC2, miC4, miC32, miC46, miC49 and miC50 in nucleus and cytoplasm was 
evaluated. We detected mature miC in both nucleus and cytoplasmic fractions for all miC 
candidates but the expression levels in nucleus were consistently ~5 fold lower compared 
to cytoplasm (figure 5f-g). Next, we evaluated the silencing efficacy of the miC candidates 
in nucleus and cytoplasm by measuring the endogenous levels of total C9orf72 mRNA. 
miC32_101, miC46_101 and miC49_451 caused a reduction of total C9orf72 mRNA 
in both nucleus and cytoplasm (fig 5h, i). However, the silencing efficacy in the nucleus 
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was lower compared to cytoplasm, consistent with the lower miC levels detected in 
the nucleus. As expected, miC2_101 and miC4_101 which target the intronic C9orf72 
transcripts had limited to no effect on the total C9orf72 expression. Thus, our data 
suggest that the mature miC-101 and miC-451 can both shuttle from the cytoplasm to 
the cell nucleus and can actively induce knockdown. Reduction of C9orf72 was observed 
in both the nucleus and cytoplasm suggesting that both scaffolds can be used for further 
development into gene therapy for ALS and/or FTD.
Reduction of nuclear RNA foci by miC variants in (G4C2)44 expressing cells
A hallmark of the RNA mediated toxicity in ALS and/or FTD is the formation of toxic 
RNA foci by the repeat-containing transcripts. We generated a cell model that develops 
nuclear RNA foci using methods similar to those described previously.45,46 We expressed 
constructs consisting of (G4C2)44 or (G4C2)3 including 150 nt 5’ and 50 nt 3’ flanking 
regions linked to C9orf72 exon 2 in HEK293T cells. Nuclear RNA foci were visualized by 
fluorescence in situ hybridization (FISH) using a TYE563-(C4G2)3 locked nucleic acid (LNA) 
probe. However, we were not able to detect DPR proteins in these cells as the assay is 
technically challenging. Using a green fluorescence protein (GFP) construct the transfection 
efficiency was determined to be ~95-100% (data not shown). We observed sense RNA 
foci at 2 days post-transfection in ~40% of (G4C2)44 cells (figure 6a) but antisense RNA 
foci were not detected (data not shown). RNA foci were primarily present in the nucleus. 
Control cells expressing a shorter (G4C2)3 repeat did not accumulate RNA foci. To evaluate 
whether the foci were RNA specific, transfected cells were treated with RNAse or DNase 
(figure 6a). Almost all observed foci were degraded by RNAse but not DNAse, confirming 
that the observed foci are primarily composed of RNA. 
miC4_101 and miC32_101 were evaluated for efficacy on RNA foci formation by 
co-transfection. Both miC candidates significantly decreased the percentage of (G4C2)44 
foci-positive cells by ~ 50% after 24 hours (figure 6b-c). miScr served as control and did 
not reduce the amount of foci in the cells. This confirms that our miC candidates are 
functional in reducing RNA foci in the cell nucleus.
Reduction of endogenous C9orf72 in cells by AAV5-miC
To further investigate the silencing of C9orf72 in context of a gene therapy for ALS and 
FTD, we selected miC32_101 as the best candidate to target total C9orf72 based on 
the strong efficacy and low frequency of passenger strand formation. miC46_101 was 
selected as the most effective candidate based on silencing efficacy, but its high amount 
of passenger strand could make it less suitable to treat patients. Both candidates were 
incorporated in AAV5. Increasing doses of AAV5-miC32_101 and AAV5-miC46_101 were 
used to transduce HEK293T cells and iPSC derived frontal brain-like neurons from an FTD 
patient. Expression of the mature miC32 and miC46 was verified using TaqMan.  Cells 
transduced with AAV5-GFP served as control for the transduction efficiency. At 3 days 
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Figure 6. miC variants inhibit RNA foci formation in (G4C2)44 expressing cells. a) RNA foci detected 
in HEK293T cells expressing (G4C2)44. Cells were transfected with 250 ng of (G4C2)44 and (G4C2)3 
plasmid and fixed 2 days post-transfection after treatment with DNAse or RNAse. RNA FISH was 
performed using a TYE563-(CCCCGG)3 LNA probe (red) and nuclei were stained with DAPI (blue). 
Nuclear foci were resistant to DNAse but degraded by RNAse indicating RNA foci. b) Reduction of 
RNA foci by miC4_101 and miC32_101. Cells were co-transfected with 250 ng of (G4C2)44 and 100 
ng miC4_101, miC32_101 or miScr plasmid. Cells were fixed 2 days post- transfection and RNA 
FISH was performed as described in (a).  c) Quantification of RNA foci in miC4_101 and miC32_101 
transfected cells. A series of five images were made using a 10x magnification to quantify the number 
of cells containing nuclear foci using image J (mean ± standard deviation, one-way ANOVA, multiple 
comparison test, ***p < 0.001).
post-transduction, AAV5-GFP transduced ~80% of HEK293T cells (figure 7a). The mature 
guide strand expression of miC32 and miC46 was expressed at a dose-dependent manner 
and resulted in a dose dependent reduction of total C9orf72 expression at a maximum 
of ~40-50% (figure 7b-c). The levels of mature miC32_101 and miC46_101 produced 
in transduced cells correlated well with C9orf72 silencing (figure 7d-e). Similarly, miC 
expression and up to 50% lowering of C9orf72 was observed in transduced frontal brain-
like neurons (figure 7f-g). Hence, these data provide a strong rationale for further proof 
of concept studies in animal models of C9orf72-ALS leading towards a miRNA-based 
gene therapy to treat ALS and FTD.
Our results indicate that miRNAs could be used as therapeutics to reduce the gain of 
toxicity caused by the G4C2 expanded repeat of C9orf72. We demonstrated the feasibility 
of different targeting approaches by miC to silence the sense, antisense or both transcripts 
of C9orf72.  In addition, the processing of miC in the miR-101 and miR-451 was 
demonstrated and both scaffolds produced mature miC that were functional in the cell 
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Figure 7. Silencing of endogenous C9orf72 by AAV5-miC. a) Transduction efficiency by AAV5 in 
HEK293T cells. Cells were transduced with 1e12 genomic copies (gc) of AAV5-GFP and visualized 
3 days post-transduction. b) Levels of mature miC32_101 and miC46_101 guide strands in 
transduced cells. Cells were transduced with 2e10, 2e11 and 2e12 gc of AAV5-miC32_101 
and AAV5-miC46_101. RNA was isolated 3 days post-transduction to determine expression of 
the mature miC32_101 and miC46_101 by TaqMan. MicroRNA input levels were normalized to 
U6 small nuclear RNA and set relative to PBS treated cells. c) Silencing of C9orf72 in transduced 
HEK293T cells. Performed as described in (b). Total C9orf72 was determined by RT-qPCR. mRNA 
input was normalized to GAPDH and set relative to PBS treated cells. d) Correlation of miC32_101 
expression levels and C9orf72 knockdown in cells upon transduction with AAV5-miC32_101. 
Pearson correlation (r) = -0,925. e) Correlation of miC46_101 expression levels and C9orf72 
knockdown in cells transduced with AAV5-miC46_101 (r= -0,808). f) Levels of mature miC32_101 
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nucleus and cytoplasm. Silencing of C9orf72 by AAV5-miC was demonstrated in patient 
derived frontal brain-like neurons, proving promising results for further development of 
a miRNA-based gene therapy for ALS and FTD.
Discussion
A G4C2 repeat expansion in intron 1 of C9orf72 is the most frequent cause of ALS and 
FTD, leading to accumulation of sense and antisense RNA foci in the cell nucleus and 
DPR proteins in the cytoplasm. Here we report on the design and characterization of 
an AAV-delivered miRNA-based approach to target C9orf72 transcripts with potentially 
a long-lived therapeutic effect following a single administration. We analyzed RNA-seq 
data from C9-ALS patients to investigate C9orf72 expression and sequence conservation 
to predict potential target regions for a miRNA-based targeting approach. We observed 
reduced levels of C9orf72 in cortex and cerebellum from C9-ALS patients. This finding is 
consistent with other studies where significant reduction of C9orf72 was also reported 
in brain and spinal cord tissues and in iPSC-derived neurons from patients.2,39,47–49 Some 
studies reported that the V2 variant from C9orf72 was the most affected transcript 
variant.47,50 We did not find evidence that the reduction seen in patients was variant-
specific. Reduced transcription of C9orf72 in ALS patients could be a result of epigenetic 
silencing due to CpG hypermethylation of the G4C2 repeat and this raises the question 
whether haploinsufficiency also contributes to the pathology of the disease.50 However, 
a significant body of evidences also support a G4C2-mediated toxicity.
49–52 
In order to identify potential miC target sites, we investigated the sequence 
conservation of C9orf72. Whereas exonic regions from exon 2 to exon 11 were completely 
covered, intronic regions were poorly represented and not much can be concluded about 
the conservation of intron 1 containing transcripts in patients. Despite the low coverage, 
read alignment for intronic regions was found in both patient and controls. Interestingly, 
the coverage of the introns 1-4 was relatively higher in C9-ALS patients than in controls, 
supporting findings that the impairment of full length C9orf72 transcription in patients 
could be a result of accumulation of aberrant or unspliced C9orf72 transcripts.38,39 
Directly targeting intron 1 is a challenging therapeutic strategy due to the low expression 
and miC46_101 guide strands in transduced iPSC-derived frontal brain-like neurons from an FTD 
patient. Cells were transduced with 2e11 and 2e12 gc of AAV5-miC32_101 and AAV5-miC46_101. 
RNA was isolated 7 days post-transduction to determine expression of the mature miC32_101 
and miC46_101 by TaqMan. MicroRNA input levels were normalized to U6 small nuclear RNA 
and set relative to AAV5-GFP treated cells. g) Reduction of C9orf72 in iPSC-derived frontal 
brain-like neurons from. Performed as described in (f) Total C9orf72 levels were determined by 
RT-qPCR. mRNA input was normalized to GAPDH and set relative to cells treated with AAV5-GFP. 
Data were evaluated using two-way ANOVA multiple comparison test: *p < 0.05; **p < 0.01; 
***p < 0.001; ****p < 0.0001. Each graph represents the mean values with standard deviation of 
2 independent experiment.
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and difficulty to detect intron 1 containing transcripts, as well as its high GC content. 
Moreover, GC rich regions are common in the genome and therapeutics targeting such 
region should be carefully investigated for off target effects. The coverage of the antisense 
transcript was very poor and limited coverage were found only in the 5’UTR of C9orf72. In 
contrast, exonic regions had complete coverage and therefore are much easier to target. 
We designed miC candidates with intron 1 binding sites to target only the sense 
intronic transcripts and candidates binding within exon 2 and exon 11 to target all 
sense transcripts. miC candidates were also designed to specifically target the antisense 
transcripts of C9orf72. 
In line with our difficulties to detect the repeat-containing transcripts with RNA-seq, 
the repeat region could also be less accessible for the mature miC due to its highly 
structured nature. Only two miC candidates targeting the G4C2 region showed 
a moderate knockdown of the intron 1 reporter. It is also possible that the high GC 
content of the mature miC itself interferes with strand loading and target recognition. 
miC candidates further downstream of the G4C2 repeat in intron 1, or in exon 2 and exon 
11 showed a much stronger knockdown of the luc reporters and two miC candidates 
were also effective on the antisense reporter. 
One challenge for our miC approach is simultaneous targeting of sense and antisense 
transcripts. To test the feasibility of such an approach, we designed a construct that 
expresses two miC molecules in a concatenated fashion against both sense and antisense 
transcripts. Silencing of both the intron 1 reporter and the antisense reporter constructs 
was achieved, demonstrating the feasibility for a bidirectional silencing of C9orf72 by 
miC. Combining two or more miRNA hairpins in a single construct has been successfully 
performed previously and one study showed increased silencing efficacy by miRNAs in 
a polycistron setting.53,54 Thus, expressing different miC in concatenated fashion could be 
promising to target both sense and antisense transcripts of C9orf72.  
In the current study we used two differentially processed miRNA scaffolds, miR-101 
and miR-451. The pre-miR-101 follows the canonical processing pathway as the further 
downstream processing in the cytoplasm involved Dicer cleavage of the hairpin 
to generate 5’ arm strands and 3’ arm strands. The 5’ arm strand, which become 
the passenger strand, is usually degraded. Though, both strands could be incorporated 
into the RISC and loaded onto Argonaute (Ago), producing active guide- and passenger 
strands that cleaves the complimentary mRNA (supplementary figure S2). The pre-miR-
451 follows the non-canonical pathway as it escapes Dicer cleavage producing only a 5’ 
arm that is subsequently cleaved by Ago and trimmed by poly(a)-specific ribonuclease 
(PARN) into 22-24 nt guide strands that are incorporated into the RISC (supplementary 
figure S3). However, trimming of miR-451 can result into functional guide strands that are 
longer than the mature length.31,55 Thus, both miR-101 and miR-451 are promising but 
simultaneous guide and passenger strand expression or mature miC much longer than 
the predicted length may increase the chance of hitting non-target genes due to miRNA-
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like effects.  Hence, it is important to determine the processing of miC candidates in both 
scaffolds and assess target similarity with other genes to minimize off-target effects.
The processing of the miC candidates was determined by NGS analysis. We confirmed 
a differential processing of the various miC-101 candidates, resulting in different ratios 
of guide and passenger strands. miC2_101, miC4_101, miC32_101 and miC33_101 
produced low amounts of passenger strand and are predicted to have little off target 
effects. miC46_101, miC49_101 and miC50_101 may have an increased risk for off 
targets due to the high amount of passenger strands. The finding that the miC-101 
candidates were differently processed, even in the same miRNA scaffold, support 
previous observations that not only the pri-miRNA scaffold, but also the miRNA sequence 
is critical for choosing which sequences of the duplex enters the RISC.31,56–59 This strand 
selection has been extensively studied and seems to be also dependent on the difference 
in stability of the miRNA duplex at the 5’ ends of each strand.31,57–62 miC-451 candidates 
did not show any passenger strand activity. However, miC38_451 and miC50_451 
produced mature guide strands longer than 27nt and could also have increased risk 
for off targets. The different miC processing pattern suggest that selection of C9orf72 
silencing candidates should be based on a balanced assessment of silencing efficacy and 
NGS processing data. 
The efficacy of the best miC candidates was further confirmed by their ability to 
reduce endogenously expressed C9orf72 mRNA. We found up to ~50% reduction of total 
C9orf72 mRNA and ~25% reduction of intronic transcripts by miC candidates targeting 
exon 2 or exon 11. The silencing efficacy of miC-451 was slightly lower compared to 
miC-101, consistent with the lower levels of mature miC-451 detected by NGS. Two miC 
candidates targeting the repeat region had limited effect on the total C9orf72 mRNA 
expression but the reduction of the intronic transcripts was comparable with candidates 
targeting the total C9orf72 mRNA. Thus, a total silencing approach and a mutant-specific 
approach can both result in lowering G4C2 repeat containing C9orf72 transcripts.
Another challenge for therapeutic miC is the nuclear localization of the toxic transcripts. 
Thus, recognition of the transcripts by the miC candidates within the nucleus is required 
whereas the mature miC is produced in the cytoplasm. Nuclear RNA foci have been found 
in different neuronal cells of patients including spinal motor neurons, cerebellar Purkinje 
cells, cerebellar granule cells, hippocampal neurons and pyramidal cells in the motor 
cortex.18 We report that the mature miC-101 and miC-451 candidates are detected in 
both nucleus and cytoplasm, and they lower C9orf72 mRNA in both cellular structures. 
There is increasing evidence that miRNA-RISC components such as Ago and Dicer are 
present in the cell nucleus and retain their catalytic activity in the nucleus.63,64 The current 
assumption is that miRNA-AGO complexes that are formed in the cytoplasm can travel 
back into the nucleus.64 Indeed, we detected a reduction of nuclear RNA foci after 
treatment with miC candidates targeting intronic C9orf72 or total C9orf72 transcripts. 
A critical factor determining the success of a gene therapy is the selected delivery 
system to the target cells or tissues. It is likely that a widespread transduction of neurons 
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in the whole brain and spinal cord including glia cells will be required to achieve disease 
modifying therapeutic effect in ALS and/or FTD patients. AAV vectors exhibit important 
advantages including a high transgene expression, long term stability and positive safety 
profile due to the non-pathogenic nature of the wild type form.65 We demonstrated 
high expression of miC levels and up to 50% reduction of total C9orf72 by AAV5-miC 
candidates in iPSC-derived frontal brain-like neurons from an FTD patient. It remains 
questionable how much reduction is required to achieve a rescue effect on the disease 
phenotype. However, previous findings using ASOs in an ALS mouse model without 
a clear clinical phenotype showed between 40-60% reduction of C9orf72, which appears 
to be sufficient to reduce RNA foci formation by ~50% and DPR proteins by ~80%.26
The delivery of RNAi-based AAV treatment strategies in ALS have predominantly 
been explored in preclinical studies to treat SOD1-ALS and have demonstrated to be 
promising.66–69 AAV9 resulted in effective transduction of spinal cord and motor neurons, 
but sufficient widespread distribution in the adult CNS upon systemic injection remain 
challenging.69–71  in children with spinal muscular atrophy type 1, a single intravenous 
infusion of AAV9 for gene replacement therapy resulted in widespread transduction of 
neurons within the spinal cord and significant clinical improvement.72  However, for an RNAi 
based approach in adult with ALS and FTD patients, the blood–brain barrier (BBB) could still 
be a major obstacle for sufficient transduction of the CNS after systemic delivery. We have 
previously demonstrated strong transduction of the striatum and cortex, and lowering of 
mutant huntingtin protein in a Huntington’s disease minipig model after direct injection 
of AAV5 into the striatum.73 Furthermore, intrastriatal injection of AAV5 have shown to 
distribute via axons trough anterograde and/or retrograde transport and resulted into 
transduction of different type of neurons, astrocytes, microglia and oligodendrocytes.73,74 
Thus, a local delivery to the brain parenchyma is promising in patients with FTD for 
treatment of the symptoms associated with cortical degeneration. Parenchymal delivery 
of AAV also resulted in transduction of motor neurons along the corticospinal tract in 
non-human primates.75  However, it needs to be assessed whether the transduction of 
motor neuron is sufficient to achieve therapeutic concentrations of AAV. An alternative 
approach could be intrathecal administration but further studies in large animals are 
required to predict the efficacy in the brain and spinal cord. Ultimately, intrathecal 
administration combined with parenchymal administration to the brain may be required 
to obtain sufficient transduction of the affected areas in ALS and/or FTD patients. 
In summary, following an RNA sequence analysis of C9orf72 in ALS patients and 
controls, we rationally designed miC candidates using the miR-101 and miR-451 scaffolds 
to target total, intronic and antisense C9orf72 transcripts. We demonstrated that 
specifically targeting the G4C2 repeat by miC is possible but challenging. The feasibility 
of a bidirectional approach was also demonstrated by expressing two miC hairpins 
targeting the sense and antisense C9orf72 in a concatenated fashion.  The efficacy of 
the miC candidates was evaluated based on their ability to lower C9orf72 mRNA and 
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the processing was determined by NGS. In addition, we also provided evidence that miC 
can be active in the nucleus by reduction of nuclear C9orf72 mRNA and RNA foci.
Material and methods
RNA-seq and C9orf72 target sequences
An RNA-seq library published by Prudencio et al was downloaded.33 The data was analyzed 
by BaseClear B.V. In brief, we downloaded RNA-seq samples from the sequence reads 
archive(SRA) from NCBI Gene Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) 
database under accession number GSE67196.33 These samples were individually mapped 
to the human reference genome (GRCh38.p10) with Tophat version 2.1.1.76 The mapped 
reads from Tophat are fragment per kilobase of transcript per million fragments mapped 
(FPKM) values. Differential gene and isoform expression was estimated on their relative 
abundance by Cufflinks 2.2.1.77  With the CummeRbund 2.16 R package we visualized 
gene and isoform expression of C9orf72.78 The alignment (.bam) and junctions file(.bed) 
generated by Tophat were used by the Integrative Genomics Viewer (IGV) 2.3.94.79
DNA constructs
To generate the miC vectors, we searched for sequences in intron 1, exon 2 and exon 
11 of C9orf72 that were mostly conserved between human, non-human primates and 
mouse. The miC sequences were incorporated into the cellular pri-miRNA miR-101-1 
or miR-451 scaffold of the human. 200 nt 5’ and 3’ flanking regions were included 
with EcoRV and BamHI restriction sites and the mfold program (http://unafold.rna.albany.
edu/?q=mfold) was used to determine if the miC candidates are folded correctly into 
their secondary structures. The complete sequences were ordered from GeneArt gene 
synthesis (Invitrogen). These constructs were subsequently cloned into an expression 
vector containing the CMV immediate-early enhancer fused to chicken β-actin (CAG) 
promoter (Inovio, Plymouth Meeting, PA) using the EcoRV and BamHI sites. For 
generation of the Luc reporters, sequences from C9orf72 intron 1 (sense and antisense), 
exon 2 or exon 11 were synthesized at GeneArt gene synthesis and cloned in the 3’UTR 
of the renilla luciferase (RL) gene of the psiCHECK-2 vector (Promega, Madison, WI). 
The firefly luciferase (FL) gene was also expressed in this vector and served as internal 
control (figure 2d). 
Culture and transfections of HEK293T cells
HEK293T were maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Invitrogen) 
containing 10% fetal calf serum (Greiner, Kremsmünster, Austria), 100U/ml penicillin 
and 100U/ml streptomycin (Thermo Fisher, Waltham, MA), at 37 °C and 5% CO2. 
Transfections. For all assays, cells were seeded in 24-wells plates at a density of 
0.1*106 cells per well in DMEM. Transfections in HEK293T cells were performed 
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1-day post plating with Lipofectamine 2000 reagent (Invitrogen) according to 
the manufacturer’s instructions.
Culture of iPSC-neurons
Frontotemporal Dementia (ND42765) iPSCs derived from fibroblast were ordered from 
Coriell Biorepository (https://www.coriell.org/) and was cultured on Matrigel (corning) 
-coated 6 wells plates in mTeSR1 (STEMCELL). For embryoid body-based neural induction, 
iPSCs were seeded on AggreWell800 plates and cultured in STEMdiff Neural Induction 
Medium (STEMCELL) for 5 days with daily medium changes. Embryoid bodies were 
harvested and plated on 6 wells plates coated with poly-D-lysine (Sigma-Aldrich) and 
laminin (Sigma-Aldrich) in STEMdiff Neural Induction Medium for 7 days with daily 
medium changes.  Rosettes were selected with rosette selection medium and plated on 
poly-D-lysine and laminin coated 6-wells plates in STEMdiff Neural Induction Medium for 
24 hours. For differentiation into frontal brain-like neurons, STEMdiff Neural Induction 
Medium was replaced for STEMdiff Neuron Differentiation Medium (STEMCELL) and 
neuroprogenitor cells were differentiated for 5 days. The neuroprogenitor cells were 
then plated on poly-D-lysine and laminin coated plates in STEMdiff Neuron Maturation 
Medium (STEMCELL) for one week. The mature frontal brain-like neurons were stored in 
liquid nitrogen in Neuroprogenitor Freezing Medium (STEMCELL).
Luciferase assays
HEK293T cells co-transfected with the miC expression constructs and Luc reporters were 
assayed at 48 hours post-transfection in 100 µl 1x passive lysis buffer (Promega) by gentle 
rocking for 15 minutes at room temperature. The cell lysates were centrifuged for 5 
minutes at 4,000 rpm to get rid of cell debris and 10 µl of the supernatant was used to 
measure FL and RL activities with the Dual-Luciferase Reporter Assay System (Promega). 
Relative luciferase activity was calculated as the ratio between RL and FL activities. 
RNA isolation
For all RNA isolation, cells were lysed in 200 ul Tryzol and RNA isolation was performed 
using the Direct-zol kit (R2061, ZYMO Research) according to the manufacturer protocol.
RT-qPCR, and miRNA TaqMan assay
To determine C9orf72 mRNA knockdown, HEK293T cells were transfected with different 
concentrations of the miC variants. total RNA was isolated from the cells at 2 days post-
transfection. Genomic DNA contamination was removed by DNAse treatment using 
recombinant shrimp DNase (ThemoFisher Scientific). First-strand complementary DNA was 
reverse transcribed using random hexamer primers with the Dynamo kit (Finnzymes, Espoo, 
Finland). Real-time PCR amplification was performed with primers targeting total C9orf72 
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(forward CGGAAAGGAAGAATATGGATGC, reverse CCATTACAGGAATCACTTCTCCA, 
probe AGCATTGGAATAATACTCTGACCCTGATCTTC) or sense intronic C9orf72 (forward 
ACGCCTGCACAATTTCAGCCCAA, reverse CAAGTCTGTGTCATCTCGGAGCTG, probe 
TGAGGGCAGCAATGCAAGTCGGTGTG).80 The assays were performed on ABI 7000 
or ABI 7500 (Applied Biosystems, Foster City, CA, USA). The mRNA expression levels 
were normalized to human GAPDH (forward GAAGGTGAAGGTCGGAGTC, reverse 
GAAGATGGTGATGGGATTTC, probe CAAGCTTCCCGTTCTCAGCC) as an internal 
control, and the level of gene expression was calculated relative to cells transfected with 
a scrambled plasmid. To determine the expression of miC, a Custom TaqMan Small RNA 
Assay Design Tool (ThemoFisher Scientific) was used to design miC2 (assay ID CTEPR3R), 
miC4 (Assay ID: CTFVKNN), miC32 (assay ID CSGJPRB) and miC46, (assay ID CSHSNXJ) 
miC49 (Assay ID: CTGZE9K), miC50 (Assay ID: CTH49UH). All RT reaction and TaqMan for 
small RNAs were performed according to the manufacturer protocol.
RNA isolation from nucleus and cytoplasm separation
Nucleus and cytoplasm were isolated 2 days post transfections. Cells were washed with 
cold 1x PBS and 100 ul cold Nuclei EZ Lysis Buffer was added. Cells were incubated on 
a shaker on ice for 5 minutes and nucleus was collected by centrifugation at 500g for 5 
minutes. The supernatant contains cytoplasmic components and was stored. The pellets 
were washed twice in 300 ul cold Nuclei EZ Lysis Buffer and the pellets containing nuclei 
components were stored. 200 ul Tryzol was added to both cytoplasmic and nuclei lysates 
and RNA was isolated as described in the previous section.
Next-generation sequencing (NGS) and data analysis
Small RNA sequencing libraries for the Illumina sequencing platform were generated 
using high-quality total RNA as input and the NEXTflex Small RNA Sequencing kit (Bioo 
Scientific, Austin, TX) as described before.31 Briefly, the small RNA species were subjected 
to ligation with 3’ and 5’ RNA adapters, first strand reverse transcription, and polymerase 
chain reaction (PCR) amplification. Sample-specific barcodes were introduced in the PCR 
step. The PCR products were separated on TBE-PAGE electrophoresis and the expected 
band around 30bp was recovered for each sample. The resulting sequencing libraries were 
quantified on a BioAnalyzer (Agilent, Santa Clara, CA). The libraries were multiplexed, 
clustered, and sequenced on an Illumina HiSeq 2000 (TruSeq v3 chemistry) with a single-
read 36 cycles sequencing protocol and indexing. The sequencing run was analyzed with 
the Illumina CASAVA pipeline (v1.8.2), with demultiplexing based on sample-specific 
barcodes. The raw sequencing data produced was processed removing the sequence 
reads which were of too low quality (only “passing filter” reads were selected). In total, 
between 15–35 million reads per sample were generated. NGS small RNA raw data sets 
were analyzed using the CLC Genomics Workbench 8 (Qiagen). The obtained reads were 
adaptor-trimmed, which decreased the average read size from ~50bp to ~25bp. All reads 
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containing ambiguity N symbols, reads shorter than 10 nt, longer than 45 nt, and reads 
represented less than 10 times were discarded. Next, the obtained unique small RNA 
reads were aligned to the reference sequences of the pre-miC constructs with a max. of 
3 nt mismatches allowed. The percentages of reads based on the total number of reads 
matching the reference sequence were calculated (Table S1).
Cloning of (G4C2)44-exon2 and (G4C2)3-exon2 expression vectors
To generate (G4C2)44 and (G4C2)3 expression vectors we designed a sequence consisting 
of the intronic C9orf72 repeat region. The sequence contained either 44 or 3 repeats 
of the G4C2 hexanucleotide and 150 nt of 5’ and 50 nt’ of 3’ flanking regions was 
added. A restriction site ApaI was included at the 3’ end to serve as cloning site. These 
sequences were synthesized and ordered from GeneArt gene synthesis (Invitrogen). In 
order to link the (G4C2)44 and (G4C2)3 vectors to exon 2, the C9orf72 exon 2 sequence was 
ordered at GeneArt gene synthesis and cloned in in the (G4C2)44 and (G4C2)3 vectors using 
the ApaI site. 
RNA foci fluorescence in situ hybridization (FISH)
RNA FISH was performed as described previously with some adjustments.45 In brief, 
HEK293T cells were grown on poly-D-lysine coated 8 wells Nunc™ Lab-Tek™ Chamber 
Slide System at a density of 80k cells per well. The cells were transfected on day 2 with 
200 ng (G4C2)44 or (G4C2)3 plasmid. On day 4, cells were fixed in 4% paraformaldehyde 
for 20 min, permeabilized in ice-cold methanol for 10 min, and washed 3 times with 
DEPC-treated PBS (DEPC-PBS). Optionally, cells were treated for 30min with 5mg/ml 
RNAse A (Qiagen) or 100 U RNAse free DNAse (Invitrogen). The cells were incubated 
for 1 hour in hybridization buffer (50% formamide, 10% dextran sulfate, 0.1 mg/mL 
yeast tRNA,2xSSC, 50 mM sodium phosphate) at 37°C and hybridize overnight with 
40nm TYE563-(C4G2)3 LNA probe in hybridization buffer at 37°C. Cells were then washed 
once with 40% formamide/1xSSC for 30 min at 37°C and 3x with DEPC-PBS at room 
temperature for 5 min. The slides were mounted with ProLong® Gold Antifade Mountant 
with DAPI (Invitrogen) and visualized using a LEICA DM2500 fluorescence microscope.
To determine the effect of miC4 and miC32 on foci formation, HEK293T cells co-
transfected with 200 ng of (G4C2)44 and 400ng of miC4, miC32 or miScr plasmid. Two 
days post-transfection, cells were fixed and subjected to FISH as described above. To 
quantify foci-bearing cells, ten fields were randomly selected under 10× magnification. 
For each field, the number of foci-positive nuclei and the total number of nuclei were 
counted using image J software. These counts were used to determine the average 
percentage of foci-positive cells for each condition.
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AAV5 vector production and transductions
AAV5 encoding miC32_101 and miC46_101 were produced by a baculovirus-based AAV 
production system as described previously.31 Briefly, the miC cassettes were obtained 
by digestion with restriction enzymes HindIII and PvuI and cloned in a uniQure transfer 
plasmid named pVD789 in order to generate an entry plasmid. The presence of the two 
inverted terminal repeats (ITRs) was confirmed by restriction digestion with SmaI. The ITR-
CAG-miC cassettes were inserted in a recombinant baculovirus vector by homologous 
recombination in Spodoptera frugiperda Sf9 cells and clones were selected and screened 
by plague purification and PCR. The recombinant baculovirus containing the ITR-CAG-miC 
cassettes were further amplified till P6 in Sf+ cells and screened for the best production 
and stability by PCR and RT-qPCR. To generate AAV5, Sf+ cells were triple infected with 
three different recombinant baculoviruses expressing the ITRs-CAG-miC, the replicon 
enzyme and the capsid protein. The cells were lysed 72 hours after the triple infection 
and the crude lysate was treated with 50U/ml Benzonase (Merck, Darmstadt, Germany) 
for 1 hour at 37 °C. AAV5 was purified on an AVB Sepharose column (GE Healthcare, 
Little Chalfont, UK) using an AKTA purification system (GE Healthcare). The final titer 
concentration was determined by RT-qPCR with primers amplifying a 95bp fragment from 
the CAG promoter region. 
For transductions with AAV, HEK293T cells were plated in 24-wells plates at 0.1x106 
cells per well in DMEM and transduced with AAV after 24 hours. Mature frontal brain-like 
neurons were plated at 0.3x106 cells per well and transduced with AAV after one week. 
RNA isolation, and TaqMan for miC32_101, miC46_101 and total C9orf72 Rt-qPCR was 
performed as described previously.
Statistical Analysis
Data were analyzed using the one-way ANOVA or Student’s t-test to determine statistically 
significances between control and treated cells. A two-way ANOVA was used to 
determine statistically significances between multiple treated groups. The p values were 
either listed or represented by the following number of asterisks: *p < 0.05; **p < 0.01; 
***p < 0.001; ****p < 0.0001. 
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Supplementary material
Figure S1. Ratio of reads between C9-ALS patients and controls in cortex. The total amount of reads 
counted in different intronic and exonic regions from C9-ALS patients were divided by the total 
amount of reads from the same region of control donors. 
Figure S2. Processing of miC-101 in the cell. In the canonical pathway, miC-101 is transcribed by 
RNA pol II and produces a primary miRNA (pri-miC) hairpin, which is processed by Drosha to generate 
a precursor miRNA (pre-miC). The pre-miC is transported by exportin 5 (exp 5) into the cytoplasm 
for further processing by Dicer to produce a miC duplex of ~20-22 basepairs. An Argonaute (Ago2) 
protein binds the duplex and incorporates the mature miC-101 guide strand in the RNA-induced 
silencing complex (RISC) to suppress downstream target gene expression. The passenger strand of 
the miC-101 duplex is usually discarded but can also be functional.1
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Figure S3. Processing of miC-451 in the cell. In the non-canonical pathway, miC-451 follows 
the same Drosha dependent processing in the nucleus into a pre-miC. The pre-miC-451 is too 
short to be cleaved by dicer and is directly loaded into Ago proteins. Ago2 cleaves the 3’ arm of 
pre-miR-451 by its slicer activity and yields a ~30-nt intermediate that is further trimmed by PARN 
to generate a mature miC of ~23nt. The trimming of the miC-451 is not essential for efficiency and 
miC-451 can be functional with mature guide strands longer than the mature length.2
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Table S2. miC-451 processing by NGS. Sequence distribution (%) of guide strands of reads mapping 
to miC38_451, miC39_451, miC43_451, miC49_451 and miC 50_451. Performed as described in 
table S1.
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Summary
A hexanucleotide GGGGCC expansion in intron 1 of chromosome 9 open reading frame 
72 (C9orf72) gene is the most frequent cause of amyotrophic lateral sclerosis (ALS) and 
frontotemporal dementia (FTD). The corresponding repeat-containing sense and antisense 
transcripts cause a gain of toxicity through accumulation of RNA foci in the nucleus 
and deposition of dipeptide-repeat (DPR) proteins in the cytoplasm of the affected cells. 
We have previously reported on the potential of engineered artificial miRNAs (miC) 
targeting C9orf72 to reduce gain of toxicity caused by the repeat-containing transcripts. 
In the current study, we tested the silencing efficacy of AAV5-miC in human-derived 
iPSC-neurons and in an ALS mouse model. We demonstrated that AAV5-miC transduces 
different types of neuronal cells and can reduce the accumulation of repeat-containing 
C9orf72 transcripts. Additionally, we demonstrated silencing of C9orf72 in both nucleus 
and cytoplasm which has an added value for treatment of ALS/FTD patients. A proof 
of concept in an ALS mouse model demonstrated significant reduction of the repeat-
containing C9orf72 transcripts and RNA foci after treatment. Taken together, these 
findings support the feasibility of a gene therapy for ALS and FTD based on reduction of 
toxicity caused by the repeat-containing C9orf72 transcripts.
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Introduction
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are two severe 
neurodegenerative diseases with overlapping pathologic and genetic features, but distinct 
clinical features. ALS is the most common adult onset motor neuron degenerative disorder 
that affects mainly the upper and lower motor neurons in the brain and corticospinal 
tract.1,2 FTD is a presenile dementia characterized by degeneration of neurons in the frontal 
and temporal lobes of the brain.2,3 A significant number of patients develop both diseases 
(ALS-FTD).4  
The most common genetic mutation in both ALS and FTD is a hexanucleotide 
GGGGCC (G4C2) repeat expansion in the first intron of the chromosome 9 open reading 
frame 72 (C9orf72) gene.4–6 ALS and FTD patients display hundreds to a few thousand 
copies of the G4C2 repeat in the C9orf72 gene.
5 The contribution of this mutation to 
the pathogenesis of both diseases has been debated for several years, with loss of 
C9orf72 function (haploinsufficiency), gain of toxicity or a combination of both being 
implicated.7,8 Reduced C9orf72 mRNA levels in patients due to hypermethylation of 
the G4C2 repeat supports haploinsufficiency.
6,9 On the other hand, a causal role for RNA-
mediated toxicity is supported by accumulation of the repeat-containing transcripts 
that fold into stable structures forming RNA foci enriched with RNA binding proteins 
in the nucleus.5,10–13 RNA foci are detected in several repeat expansion diseases and can 
sequester RNA binding proteins. RNA foci produced from both the sense (G4C2) and 
antisense (G2C4) repeat transcripts are detected in tissues and in induced pluripotent stem 
cell (iPSC)-derived neurons from ALS and FTD patients, proving that the repeat region is 
bidirectionally transcribed.14,15 
Gain of toxicity is also supported by repeat-associated non-AUG-dependent (RAN) 
translation of the sense and antisense repeat transcripts resulting in accumulation of five 
aberrant dipeptide-repeat (DPR) proteins (poly(GA), poly(GR), poly(GP), poly(PA), poly(PR)) 
in the cytoplasm, all with different toxicity profiles shown in vitro and in vivo.12,16,17 In 
addition, DPRs disrupt the nucleocytoplasmic transport system of cells.18,19 Furthermore, 
autopsy studies revealed that ~90% of C9orf72 ALS and ~50% of FTD patients have 
cytoplasmic aggregation of the transactive response DNA-binding protein of 43 kDa 
(TDP-43; encoded by TARDBP).8,20 Abnormal aggregation of P62 and ubiquitin have 
also been described in C9orf72 related ALS and FTD patients.21–23 A recently developed 
BAC transgenic mouse model expressing the human C9orf72 including the expanded 
G4C2 repeat showed gain of toxicity features such as RNA foci, DPRs, TDP43 and p62 
inclusions.24  These mice also develop neurodegeneration and ALS/FTD-like phenotypes, 
suggesting that these inclusions result into gain of toxicity and contribute to the pathology 
observed in ALS and FTD.24
Regardless of the contribution of either RNA mediated toxicity or haploinsufficiency, 
a therapy reducing the repeat-containing transcripts could potentially translate into 
reduction of RNA foci and DPR proteins, slowing down the disease progression. Silencing 
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of C9orf72 transcripts by RNA interference (RNAi) strategies such as duplex and single-
stranded siRNAs or by the RNAse H mediated antisense oligonucleotides (ASOs) indeed 
resulted in reduction of RNA foci and DPR proteins in patient-derived iPSC-neurons and in 
mouse models.15,25–28 Interestingly, targeting only the sense strand of C9orf72 with ASOs 
not only reduced RNA foci but also rescued the disrupted nucleocytoplasmic transport in 
patient-derived iPSC-neurons.19 Another promising strategy to achieve similar outcomes 
is by adeno-associated virus (AAV) delivered artificial microRNAs (miRNAs) engineered to 
target C9orf72. miRNAs are short non-coding RNAs that bind to a complementary mRNA 
through specific base pairing, inducing its degradation and/or translational repression. 
As AAVs express stable extrachromosomal nuclear episomes, the primary miRNA 
transcripts can be continually produced resulting in a longer-lasting therapeutic effect. 
The primary miRNA transcripts are processed into precursor miRNAs that are transported 
to the cytoplasm for further processing and incorporation into the RNA-induced silencing 
complex (RISC).29 Thus, one mayor challenge to overcome for a miRNA-based gene therapy 
approach is targeting of the repeat-containing C9orf72 transcripts within the cell nucleus. 
In one study, siRNAs which are also processed by RISC demonstrated silencing of C9orf72 
mRNA in patient derived iPSC neurons but the nuclear repeat-containing transcripts and 
RNA foci were unaffected, indicating a predominant efficacy in the cytoplasm.15 We 
previously reported on miRNAs sequences (miC) that target the sense, antisense or both 
transcripts of C9orf72 and demonstrated in vitro using luciferase reporter systems that 
all three approaches are feasible.30 In addition, we used cell models and showed crucial 
evidence that miC can be functional in the cell nucleus, where the repeat-containing 
transcripts accumulates and form RNA foci.
In the current study, we investigated the efficacy of AAV-delivered miC on lowering 
of C9orf72 in human derived iPSCs-neurons and in the Tg(C9orf72_3) line 112 mice as 
a proof of concept for an AAV-based gene therapy.31 Different human neuronal cell types 
were transduced and the C9orf72 lowering efficacy in the nucleus and cytoplasm was 
investigated. In addition, we showed evidence that miC targeting C9orf72 in the mouse 
brain causes reduction of nuclear RNA foci. Our study provides strong evidence that AAV 
delivered miC can target C9orf72 in the cell nucleus and may be promising to alleviate 
the RNA mediated toxicity in ALS and FTD patients.
Results
AAV5 can efficiently transduce neuronal and non-neuronal cells
The neuronal cells affected in ALS and FTD deviate. The main affected cells in ALS patients 
are motor neurons in the brain and spinal cord, whereas neurons in the frontal and 
temporal lobes of the brain are mainly affected in patients with FTD. About 15% of 
patients develop both ALS and FTD, where different types of neurons in the brain and 
spinal cord are affected.32 Besides motor neurons, other CNS cell types such as astrocytes, 
microglia, and oligodendrocytes may contribute to the progression of the diseases.33–36 
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For example, it has been shown that astrocytes carrying the C9orf72 hexanucleotide 
expansion are toxic to motor neurons.33,35 Although the underlying mechanisms remain 
unclear, intercellular seeding and transmission of DPRs between the two cell types could be 
a contributing factor.33,37 Thus, ideally a therapeutic drug for ALS and/or FTD should target 
a large variety of neuronal and non-neuronal cell types. We generated and characterized 
different human derived iPSC-neurons and astrocytes to validate the transduction of AAV5 
in different CNS cell types (Figure 1). iPSCs were induced into a neural progenitor state 
and differentiated into frontal brain like neurons (FBN) or astrocytes (Supplementary Figure 
S1). In addition, commercially available mature dopaminergic neurons and motor neurons 
from a healthy person were obtained. Immunohistochemistry was performed and about 
60% of FBN were ß-tubulin III positive and glial fibrillary acidic protein (GFAP) negative, 
implicating a successful differentiation rate of iPSCs into mature neurons.  Similarly, 
mature astrocytes were ~90% GFAP positive, confirming a successful differentiation of 
iPSCs into astrocytes. Mature dopaminergic neurons were ~90% tyroxine hydroxylase 
(TH) positive, confirming successful differentiation. Mature motor neurons were also 
successfully differentiated as ~85% were choline acetyltransferase (CHAT) positive. 
Following transduction with AAV5-GFP, ~90% of all the different cell types expressed GFP 
(Figure 1a). Immunohistochemistry for GFP combined with either ß-tubulin III, TH, GFAP 
or CHAT antibodies confirmed that all four cell types were transduced by AAV5 (Figure 
1b). To compare the AAV transduction tropism of the different cell types, we isolated DNA 
and RNA of transduced cells and quantitated vector copies and GFP mRNA expression in 
the cells (Figure 1c-d). A similar dose-dependent transduction efficiency was observed 
in all cell types and transduction correlated with GFP expression. Thus, AAV5 efficiently 
transduces different human CNS specific cell types including FBN, dopaminergic neurons, 
motor neurons and astrocytes and hence is a promising vector to deliver therapeutic 
genes to the CNS to treat neurogenerative diseases such as ALS and FTD.
C9orf72 expression is reduced in neuronal cells derived from an FTD 
patient
iPSCs from an FTD patient (ND42765) and a healthy non-diseased person (ND42245) were 
differentiated into FBN (FTD-FBN) and astrocytes to compare the levels of C9orf72 mRNA 
and repeat-containing transcripts (Supplementary Figure S1). RT-qPCR was performed 2 
weeks after maturation for total C9orf72 mRNA (detecting all transcript variants), and 
the sense intronic transcripts (detecting sense transcripts containing G4C2 repeat) to 
compare the expression levels in these cells. Primers amplifying a region spanning exon 
2 to exon 4 were used to detect total C9orf72 mRNA (Figure 2a).10 The sense intronic 
transcripts were detected with primers amplifying a region in intron 1.10 The levels of total 
C9orf72 mRNA were significantly reduced in the FTD-patient derived cells: A reduction of 
~60% was observed in FBN and ~25% in astrocytes from the FTD patient as compared 
to healthy cells (Figure 2b). Interestingly, although at a low level, sense intronic transcript 
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Figure 1. Transduction of different iPSC-derived cells by AAV5. a) Human iPSCs were differentiated 
into mature frontal brain like neurons (FBN), dopaminergic neurons (DPN), astrocytes (Astr) and 
motor neurons (MN). The cells were transduced with 5e12 genomic copies (GC) of AAV5-CAG-GFP 
and live cell imaging was performed at 2 weeks post transduction. b) Characterization of iPSC-
derived cells. FBN, DPN, Astr and MN were transduced with AAV5-CAG-GFP and fixed at 2 weeks 
post transduction.  Immunohistochemistry was performed with antibodies detecting β-tubulin III 
(β tub III) for mature FBN, tyrosine hydroxylase (TH) for mature DPN, glial fibrillary acidic protein 
(GFAP) for mature astrocytes and choline acetyltransferase (ChAT) for mature MN. c-d) Transduction 
efficiency of AAV5 in iPSC-derived neurons. FBN, DPN, Astr and MN were transduced with increasing 
doses of AAV5-CAG-GFP. The vector copy distribution and GFP mRNA expression were evaluated 
at 2 weeks post transduction. Vector copies were calculated using a standard curve. For GFP mRNA 
expression, the input of RNA was corrected for GAPDH and expression was calculated relative to 
cells treated with the formulation buffer (mock).
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Figure 2. Silencing of C9orf72 in iPSC-neurons by AAV5-miC. a) Schematic of C9orf72 gene and 
location of the miC binding sites. The C9orf72 gene consists of 12 exons, including two alternatively 
spliced exon 1a and exon 1b. The G4C2 expansion is in the first intron between exon 1a and 1b. 
the gene produces three sense transcripts (V1, V2 and V3) and an antisense transcript. miC candidates 
were designed with binding sites in intron 1 (miC2 and miC4), exon 2 (miC32) and exon 11 (miC46). 
Primersets in intron 1 were used to detect the sense intronic transcripts of C9orf72 (SFP-SRP). Total 
C9orf72 mRNA was detected with primers spanning exon 2 and exon 4 (mFP-mRP) as described 
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levels were increased by ~ 30% in FBN and ~20% in astrocytes of the FTD patient 
cells as compared to healthy cells (Figure 2c). Thus, while total C9orf72 mRNA levels 
were reduced, sense intronic transcripts seems to accumulate in iPSC-derived FBNs and 
astrocytes from the FTD patient.
AAV5-miC can lower the repeat-containing transcripts of C9orf72 in 
iPSC-neurons
Sequences on the human C9orf72 were previously selected to design artificial anti-
C9orf72-targeting miRNAs (miC).30 The miC sequences were embedded in the primary 
miR-101 and/or miR-451 scaffold by replacing the naturally expressed guide strand 
sequences.  Four lead miC candidates were selected in the miR-101 scaffold based on 
their efficacy on reporter genes and their ability to reduce the endogenously expressed 
C9orf72 mRNA and sense intronic transcripts in cells.30 miC32 and miC46 were designed 
to target C9orf72 exon 2 and exon 11 respectively, targeting all sense C9orf72 transcripts 
(Figure 2a). miC2 and miC4 were designed in intron 1 to selectively silence the sense G4C2 
sense intronic transcripts. 
To determine whether miC delivered by AAV5 is functional in patient-derived cells, 
FTD-FBNs were transduced with AAV5-miC2, AAV5-miC4, AAV5-miC32 and AAV5-
by others.10 b-c) Expression of C9orf72 mRNA and sense intronic transcripts in FBN and Astrocytes. 
iPSCs were differentiated into FBN and astrocytes. RNA was isolated from cells after 2 weeks of 
maturation and RT-qPCR was performed to detect the endogenous expressed total C9orf72 mRNA 
and sense intronic transcripts (intronic C9orf72). The RNA input levels were corrected to GAPDH and 
calculated relative to the cell line with the highest expression of C9orf72 (FBN). Error bars indicate 
the mean of two independent experiments. Data were evaluated using Student’s t test: (*p < 0.05; 
**p < 0.01). d) Expression of the mature miC guide strands in FBN after transduction with AAV5. 
Mature FTD FBNs were transduced with 2e12 gc of AAV5-miC2, AAV5-miC4, AAV5-miC32 and 
AAV5-miC46. Cells treated with the formulation buffer (mock) or AAV5-GFP served as controls. 
RNA was isolated 7 days post-transduction and expression of the mature miC2, miC4, miC32 and 
miC46 were determined by TaqMan. MicroRNA input levels were normalized to U6 small nuclear 
RNA and set relative to cells treated with AAV5-GFP. e) Silencing of C9orf72 mRNA and sense 
intronic transcripts in iPSC derived FBNs. Mature FTD FBNs were transduced with 2e12 gc of AAV5-
miC2, AAV5-miC4, AAV5-miC32 and AAV5-miC46. RNA was isolated 7 days post-transduction. 
The levels of total C9orf72 mRNA and the sense intronic transcripts were determined by RT-qPCR. 
mRNA input was normalized to GAPDH and set relative to cells treated with AAV5-GFP. Data were 
evaluated using a one-way ANOVA with Dunnett’s multiple comparison test (*p < 0.05) to compare 
cells treated with AAV5-miC to AAV5-GFP. f)  miC32 and miC46 expression in transduced motor 
neurons. Healthy motor neurons differentiated from human iPSCs were transduced with AAV5-GFP, 
AAV5-miC32 and AAV5-miC46 for two weeks. Total RNA was isolated and small RNA TaqMan was 
performed to detect the mature miC32 and miC46 as described in (d). g-h) C9orf72 reduction in 
motor neurons by AAV5-miC. RNA was isolated from transduced motor neurons two weeks post 
transduction and RT-qPCR was performed to detect the total C9orf72 mRNA (g) and sense intronic 
transcripts (h) as described in (e). Error bars represent the mean of two independent experiments. 
Data were evaluated using a one-way ANOVA with Dunnett’s multiple comparison test (*p < 0.05; 
**p < 0.01) to compare cells treated with AAV5-miC to AAV5-GFP.
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miC46. Two weeks following transduction, all four mature miC were expressed, suggesting 
a successful transduction by AAV5-miC and efficient processing into a mature miC (Figure 
2d). Sense intronic transcript levels were reduced by ~40% in FBNs transduced with miC2 
and miC4, while the C9orf72 mRNA levels were not affected (Figure 2e). Thus, both 
candidates exclusively target the sense intronic transcripts while preserving normal levels 
of C9orf72 mRNA. Of the candidates targeting the total C9orf72 mRNA, both miC32 
and miC46 reduced the levels of C9orf72 mRNA (~50%) and the sense intronic transcript 
(~40%). Thus, the sense intronic transcripts could be also targeted by silencing total 
C9orf72 mRNA. 
Additionally, we investigated silencing of C9orf72 in a healthy motor neuron cell 
line, as motor neurons are highly affected in ALS. The expression of C9orf72 was 
first evaluated in control (non-transduced) motor neurons and both total and intronic 
C9orf72 was detected. However, the intronic C9orf72 expression in this cell line, that 
lacks the G4C2 expansion, was very low and slightly above the detection limit (data not 
shown). Having established that C9orf72 can be detected in healthy motor neurons, 
the cells were transduced with AAV5-miC32 and AAV5-miC46 for 2 weeks. We found 
expression of miC32 and miC46, confirming that AAV5 efficiently transduces human 
motor neurons (Figure 2f). Consistently, we observed a ~40% reduction of total C9orf72 
mRNA by both miC candidates and a mild reduction of the intronic C9orf72 (~20%) 
(Figure 2g-h). Altogether, we demonstrated reduction of total and intronic C9orf72 levels 
in FBNs and motor neurons, confirming that both neuronal cell types are transduced, and 
that the miC candidates are effective in lowering C9orf72 these cells.
Efficient silencing of C9orf72 in the nucleus of iPSC derived neurons by 
AAV-miC
Accumulation of the G4C2 repeat-containing transcripts in the cell nucleus seems to highly 
contribute to the progression of both ALS and FTD. These transcripts form RNA foci 
in the cell nucleus that sequester RNA binding proteins and inhibit their function, or 
are transported to the cytoplasm for repeat-associated non-ATG (RAN) translation into 
toxic DPRs.14,17,38,39 Thus, for a therapeutic approach, efficacy within the cell nucleus is 
required to effectively target the RNA-mediated toxicity in ALS and FTD. The processing of 
miRNAs occurs through a multi-step process involving a nuclear and cytoplasmic phase, 
but the mature miRNA product is produced in the cytoplasm.29,40–42 Therefore, miRNAs 
were initially thought to be predominantly expressed and active in the cytoplasm. We 
previously demonstrated that active mature miC is also detected in the nucleus of cells 
transfected with miC constructs, but at lower levels than in the cytoplasm.30 Here we 
evaluated whether transduction of iPSC neurons by AAV5-miC is sufficient to express 
the mature miC and reduce C9orf72 levels in nucleus (Figure 3). 
FTD-FBNs were transduced with AAV5-miC32 and AAV5-miC46 and after a week RNA 
was isolated from nuclear and cytoplasmic fractions to calculate the percentage of RNA 
transcripts in both cellular compartments. In control FBN, ~80% of total C9orf72 mRNA 
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Figure 3. Reduction of C9orf72 in the nucleus by miC. a) Nuclear and cytoplasmic expression of 
C9orf72 in FTD FBN. RNA was isolated from nuclear and cytoplasmic fractions of mature FTD FBN 
and RT-qPCR was performed to detect the total C9orf72 mRNA (total C9orf72) and sense intronic 
transcripts (intronic C9orf72). Total and intronic C9orf72 mRNA levels were normalized to GAPDH 
(n=4). The sum of nuclear and cytoplasmic C9orf72 expression values were set at 100%. (2^-∆ct 
nuclear C9orf72 RNA + 2^-∆ct cytoplasmic C9orf72 RNA = 100%). b)  Mature miC expression in 
nucleus and cytoplasm. FTD FBNs were transduced with mock, AAV5-GFP, AAV5-miC31 and AAV5-
miC46 for 7 days (n=4). RNA was isolated from nucleus and cytoplasm and expression of mature 
miC31 and miC46 were determined by small RNA TaqMan. mRNA input levels were normalized to 
GAPDH.  The sum of nuclear and cytoplasmic miC expression values was set at 100%. c-d) Silencing 
of total C9orf72 in nucleus and cytoplasm.  RNA was isolated from nucleus (c) and cytoplasm (d) of 
FTD FBN transduced for 7 days with mock, AAV5-GFP, AAV5-miC31 and AAV5-miC46. mRNA levels 
were normalized to GAPDH and total C9orf72 expression was determined relative to AAV5-GFP 
treated cells. e) Reduction of intronic C9orf72 in nucleus of FTD FBN. Performed as described in 
(c-d) intronic C9orf72 expression was determined relative to AAV5-GFP treated cells. Data were 
evaluated using a one-way ANOVA with Dunnett’s multiple comparison test (*p < 0.05; **p < 0.01; 
***p < 0.001; ****p < 0.0001) to compare cells treated with AAV5-miC to AAV5-GFP (n=4).
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was detected in the nucleus and ~20% was measured in the cytoplasm, whereas, sense 
intronic transcripts were predominately (~95%) found in nucleus of FTD-FBNs (Figure 3a). 
Thus, both C9orf72 mRNA and sense intronic transcript levels were significantly higher 
in the nucleus of FTD-FBNs. Next, the percentage of the mature miC and the silencing 
of C9orf72 was determined in nucleus and cytoplasm after transducing FTD-FBNs with 
AAV5-miC32 and AAV5-miC46. About 20% of the mature miC32 was detected in 
the nucleus while ~80% was measured in the cytoplasm (Figure 3b). In cells treated 
with AAV5-miC46, ~10% of the mature miC was expressed in the nucleus and ~90% 
in the cytoplasm. Interestingly, both AAV5-miC32 and AAV5-miC46 resulted in ~30% 
reduction of C9orf72 mRNA in the nucleus and ~40% reduction in the cytoplasm 
(Figure 3c-d). Consistently, ~25% reduction of the sense intronic transcripts was observed 
in the nucleus (Figure 3e). Our data show that the mature miC32 and miC46 can both 
shuttle from the cytoplasm to the cell nucleus and can reduce levels of both C9orf72 
mRNA and the sense intronic transcripts in the nucleus as well as in the cytoplasm. 
AAV5-miC32 and AAV5-miC46 can both reduce C9orf72 in 
Tg(C9orf72_3) line 112 mice
Having established the efficacy of AAV5-miC in different human neuronal cell types we 
next evaluated their efficacy in vivo in Tg(C9orf72_3) line 112 mice.31 This mouse model 
is based on several tandem copies of the human C9orf72 with repeat sizes ranging from 
100-1000 repeats. Although the progressive neurodegeneration seen in ALS and FTD 
patients is not observed in these mice, they do exhibit some of the pathological features 
seen in patients such as RNA foci (starting at ~3 months of age) and poly GP protein 
(starting at ~6-20 months of age). Three months old mice were injected bilaterally in 
the striatum with AAV5-GFP, AAV5-miC32 and AAV5-miC46. Mice were sacrificed 6 
weeks post injection to determine distribution of AAV5, mature miC expression, C9orf72 
lowering, and the effect of miC on RNA foci formation. A widespread distribution 
of AAV5 to the cortex, striatum and midbrain was observed after administration in 
the striatum (Figure 4a). A weak transduction of the cerebellum was observed while 
the spinal cord was not transduced. Consistent with the AAV5 distribution, small RNA 
TaqMan showed high expression of miC32 and miC46 in the cortex and striatum which 
resulted in a 20-40% lowering of C9orf72 mRNA and the sense intronic transcripts (Figure 
4b-d). Both AAV5-miC32 and AAV5-miC46 also target the mouse C9orf72 ortholog 
(3110043O21 Rik) and indeed lowered the target 3110043O21 Rik. No behavioral and/
or phenotypic changes were observed in mice treated with AAV5-miC32 or AAV5-miC46 
(Supplementary Figure S3).
AAV5-miC32 and AAV5-miC46 are processed differently in mice brain
We further investigated the fidelity of miC processing in the mouse brain. Following 
transcription of the miC construct, the primary miR-101 is processed by Drosha cleavage 
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Figure 4. Reduction of C9orf72 in C9BAC mice. a) Vector copy distribution of AAV5 upon intrastriatal 
injection. Three months old Tg(C9orf72_3) line 112 mice were injected with AAV5-GFP (5e10gc), 
AAV5-miC32 (5e10gc) and AAV5-miC46 (1e10gc) bilaterally in the striatum. All mice were sacrificed 
6 weeks after surgeries and frontal cortex, striatum, mid brain, cerebellum and spinal cord were 
collected. DNA was isolated from the tissues and qPCR was performed with primers amplifying 
a 95bp fragment from the CAG promoter region. The GC per tissue was calculated using a standard 
curve. b) Expression of mature miC32 an miC46 guide strands cortex and striatum of Tg(C9orf72_3) 
line 112 mice. Performed as described in (a). Total RNA was isolated from the cortex and striatum for 
small RNA TaqMan. MicroRNA input levels was normalized to U6 small nuclear RNA and set relative 
to AAV-GFP treated mice. c-d) Lowering of total and intronic C9orf72 by miC in Tg(C9orf72_3) 
line 112 mice. Performed as described in (a). Total RNA was isolated from the cortex and striatum 
and RT-qPCR was performed using primers for total C9orf72 mRNA and sense intronic transcripts. 
RNA input levels were normalized to GAPDH and set relative to AAV-GFP mice. e) Processing of 
miC32 and miC46 in mice. Small RNA NGS was performed on RNA isolated from the striatum 
Targeting RNA-mediated toxicity in C9ORF72 ALS/FTD by RNAi-based gene therapy
109
3
to determine the length and ratio of guide and passenger strands. f) detection of RNA foci in 
cortex of Tg(C9orf72_3) line 112 mice. Mice brain was frozen and sectioned in OCT. RNA FISH 
was performed using a TYE563-(CCCCGG)3 LNA probe to detect the sense foci. Sense foci (shown 
as white spots) was detected in Tg(C9orf72_3) line 112 mice (C9+) but not in control littermates 
(C9-) g-h) Reduction of RNA foci in frontal cortex. Cells with 0, 1-5 or >5 foci were counted in 
control (AAV5-GFP) and treated groups (AAV5-miC32 and AAV5-miC46). The percentage of cells 
containing 0, 1-5 or >5 foci were calculated from 6 different images per treatment group (N=3). 
Red arrows show the cells that contain RNA foci. Data were evaluated using a one-way ANOVA 
with Dunnett’s multiple comparison test (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
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and then by Dicer cleavage into a miRNA duplex. The miRNA duplex is then separated, 
and the guide strand is usually incorporated into the RNA-induced silencing complex 
(RISC) while in most cases the passenger strand is degraded. The processing of the miC32 
and miC46 was analyzed by small RNA sequencing to determine the ratio of guide and 
passenger strands that are produced. Small transcriptome analysis was performed on 
RNA isolated from the striatum of four mice that were injected with AAV5-miC32 or 
AAV5-miC46. For each sample, we obtained between 15–30 million small RNA reads 
that were subsequently adaptor-trimmed and aligned against the corresponding 
reference sequence. All reads shorter than 10 nucleotides, longer than 45 nucleotides, 
or represented less than 10 times were excluded from the analysis. miC32 was processed 
into predominantly guide strands (~87%) of 19-20 nucleotides long with low percentage 
of the passenger strand (~13%). However, miC46 processing yielded more passenger 
strands (~82%) of between 19-22 nucleotides long and low amounts (~18%) of guide 
strands (Figure 4e, Supplementary Table S1). 
AAV5-miC reduces RNA foci in Tg(C9orf72_3) line 112 mice
RNA foci formation by the repeat-containing transcripts is considered a hallmark of 
the RNA mediated toxicity in ALS/FTD.4,11,13,14 Fluorescence in situ hybridization (FISH) 
using a TYE563-(C4G2)3 locked nucleic acid (LNA) probe showed that ~60-80% of cells 
in cortex, hippocampus and cerebellum of the Tg(C9orf72_3) line 112 mice contained 
RNA foci (fig. 4f).31 After confirming the presence of sense and antisense RNA foci in 
the cortex, hippocampus and cerebellum, the efficacy of AAV5-miC32 and AAV5-miC46 
to reduce RNA foci was determined. Both miC candidates caused a significant drop of 
sense RNA foci in cortex and hippocampus and the number of cells containing RNA foci, 
as well in as the total amount of RNA foci per cell (Figure 4g-h, Supplementary Figure 
S2). AAV5-miC32 resulted in a 20% drop of cells containing RNA foci and the number of 
cells containing 1-5 RNA foci and >5 RNA foci were reduced by 11% and 9% respectively. 
Similarly, AAV5-miC46 treatment resulted in 14% reduction of foci-containing cells, 
3% reduction in cells containing 1-5 foci and 11% reduction in cell containing >5 
RNA foci. Hence, these data confirm that AAV5 delivered miC candidates against total 
C9orf72 mRNA are functional in reducing nuclear sense RNA foci in brain tissues of 
the Tg(C9orf72_3) line 112 mice.
Overall, we demonstrated that AAV5 can transduce different CNS cell types relevant for 
ALS/FTD treatment and that miC candidates targeting C9orf72 are successfully delivered 
and are functional in mice brain. Furthermore, we showed that total C9orf72 mRNA and 
sense intronic C9orf72 transcripts can be lowered in both nucleus and cytoplasm of cells, 
increasing the potential for achieving therapeutic benefit in patients.
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Discussion
The intronic G4C2 repeat of C9orf72 produces repeat-containing transcripts that cause 
RNA foci and DPR proteins which contribute to ALS/FTD pathology. Thus, a therapy 
reducing these gain of toxicity features could slow down disease progression in ALS/FTD 
patients. In the current study we provide evidence that AAV5-delivered miRNAs targeting 
C9orf72 reduce gain of toxicity features caused by the G4C2 repeat in a murine model. 
Initially described as a pure motor neuron disease, it is now thought that other cell 
types, including resident glial cells, are involved in ALS.43,44 Abnormal neuropsychological 
testing is observed in ~50% of ALS patients, indicating that besides motor neurons, other 
neuronal cell types in the brain are affected.32 In addition, some patients develop both 
ALS and FTD, affecting different types of neurons in the brain and spinal cord. Delivery 
of therapeutics to the affected cell types is a mayor challenge for ALS/FTD therapy. We 
demonstrated that AAV5 can transduce various cell types of the CNS that are relevant to 
both diseases. 
We observed a reduction of C9orf72 mRNA in astrocytes and FBN derived from an FTD 
patient compared to healthy cells. This finding was consistent with several other studies 
that reported a  reduction of C9orf72 mRNA and protein in iPSC neurons, and in brain and 
spinal cord tissues from C9orf72 related ALS/FTD patients.6,9,45–48 This reduction is caused 
by methylation of the repeat region of C9orf72 which is located in or near the promotor 
region, leading to transcription inhibition.49–51 However, C9orf72 haploinsufficiency alone 
is most likely not sufficient to cause neurodegeneration. Reduction of C9orf72 in mice 
was tolerable while complete elimination of C9orf72 caused splenomegaly and enlarged 
lymph nodes but not neurodegeneration or mis-localization of TDP-43.52–54 
Compared to C9orf72 mRNA levels, the expression of sense intronic transcripts were 
low in FTD and control cells. Yet, sense intronic transcripts were increased in FTD cells 
as compared to healthy cells, consistent with what have been reported by others.10 
The elevated sense intronic transcript levels detected in the FTD cells seems to be caused 
by defective splicing of intron 1 due to presence of the G4C2 repeat.
5,55 The corresponding 
transcripts containing the G4C2 repeat may be protected from degradation which allow 
them to accumulate in the cell.46,55–57 Despite a relatively low abundance as compared 
to C9orf72 mRNA, the intronic transcripts could still be sufficient to accumulate into 
RNA foci over time.30,49,55 Furthermore, it has been estimated that hundreds of protein 
products could be produced by a single mRNA, suggesting that even low levels of intronic 
transcripts are sufficient to cause accumulation of toxic DPR proteins in the cell.9,58
Several approaches such as antisense oligonucleotides, duplex and single-stranded 
siRNAs and small compounds have been tested and proved promising to reduce gain of 
toxicity features caused by the G4C2 repeat.
27,39,59 In the current study we investigated 
the feasibility for a miRNA-based gene therapy to obtain long-term silencing of 
the repeat-containing transcripts of C9orf72. Four AAV5-miC candidates were tested on 
human derived iPSC neurons and all four resulted in sufficient transduction to express 
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therapeutically relevant levels of the corresponding mature miC. Selective reduction of 
the sense intronic transcripts was achieved with miC targeting intron 1, without affecting 
normal C9orf72 mRNA levels. This approach could prevent RNA-mediated toxicity 
without further reducing C9orf72 protein. However, as sequence variations within intron 
1 have been observed, genomic screening of patients for selection could be necessary 
when targeting this region.60 Thus, sequence conservation of miC2 and miC4 targets 
should be determined in larger cohort studies. We previously used a publicly available 
RNAseq data of  patients to investigate the conservation of miC2 and miC4 target sites 
in intron 1, but the intronic transcript levels detected were too low to determine their 
conservation.30,61 The target sequences of miC32 and miC46, targeting either exon 2 or 
exon 11, were well conserved between the patients and both candidates also reduced 
levels of the sense intronic transcripts in iPSC-neurons. The reduction of sense intronic 
transcripts by miC32 and miC46 supports previous findings that intron 1 is still present in 
the mature C9orf72 mRNA, suggesting defective splicing.55 Although miC32 and miC46 
also reduced the levels of normal C9orf72 mRNA, its expression was not completely 
eliminated. Additionally, we observed transduction, mature miC expression and reduction 
of C9orf72 mRNA in a healthy motor neuron cell line. As expected, the expression of 
the sense intronic transcripts in this cell line was very low as the repeat expansion is 
absent in healthy individuals. 
Having established that miC delivered by AAV5 are effective in human derived iPSC 
neurons, we specifically studied their efficacy in the cell nucleus where C9orf72 mRNA 
and intronic transcripts are predominantly expressed. Although the primary and precursor 
miRNAs originate from the cell nucleus, their transport to the cytoplasm to exert post 
transcriptional gene silencing via the RISC have been well described.29,40,41,62 Indeed, 
most studies have initially focused on post transcriptional gene silencing of miRNAs in 
the cytoplasm. However, the discovery of several mature miRNA and RISC components 
enriched in the nucleus indicate that nuclear miRNAs do exists.63 Additionally, several 
proteins mediating nucleus – cytoplasm shuttling of small RNAs have been identified.63,64 
We found ~5 times lower levels of mature miC in the nucleus compared to cytoplasm 
of transduced iPSC-neurons, but the nuclear miC levels were still sufficient to reduce 
the levels of C9orf72 mRNA and the sense intronic transcripts in the nucleus. Thus, AAV-
delivered miC can lower the repeat-containing transcripts that accumulate in the nucleus 
of ALS/FTD patients.
Moving forward to an in vivo proof of concept study, we tested the delivery and 
efficacy of AAV5-miC in the BAC transgenic Tg(C9orf72_3) line 112 mouse model.31 
These mice exhibit pathologic features such as sense and antisense RNA foci and poly 
GP protein but no TDP-43 or P62 inclusions. These mice also do not develop ALS and/or 
FTD-like phenotype in their lifespan, possibly due to lack of 5’ and 3’ regulatory elements 
needed to control sufficient expression of sense and antisense transcripts.24,31 Intrastriatal 
injection of AAV5 resulted in a strong localized transduction on the injection site and 
surrounding areas including frontal cortex and midbrain area but was not sufficient to 
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transduce the spinal cord. Thus, further studies in larger animals are required to predict 
the best routes of injection into the CSF to transduce the brain and spinal cord of 
patients. Intrastriatal delivery of AAV5-miC caused high expression of mature miC and 
significant lowering of C9orf72 mRNA and the sense intronic transcripts in the transduced 
areas. The efficacy of AAV5-miC in the nucleus was further confirmed by the finding 
of a significant reduction of nuclear sense RNA foci in the cortex and hippocampus, 
suggesting that the mature miC is functional in the nucleus of transduced neurons in 
vivo. Moreover, reduction of the mice C9orf72 ortholog was also observed and was well 
tolerated in mice (3110043O21Rik). The processing of the miC in the mice brain revealed 
that miC32 has a low amount of passenger strand decreasing the risk for off target 
effects in comparison to miC46. In the present study all mice were sacrificed at 5 months 
of age and future studies in older mice that have more accumulation of poly GP proteins 
would be needed to investigate the effect of miC on the DPR protein accumulation. 
However, based on the observed reduction of the sense intronic transcripts, a reduction 
of poly GP protein would be expected as fewer repeat-containing transcripts are available 
to undergo RAN translation. 
Taken together, these studies provide proof of concept for silencing of C9orf72 
by AAV5-miC in relevant cell types as a potential treatment approach for ALS/FTD. 
miC32 offers the superior profile as a candidate to reduce gain of toxicity in ALS/FTD 
due to the sense intronic transcripts. We showed nuclear and cytoplasmic silencing, 
increasing the potential for a therapeutic effect of a miC32-based gene therapy that 
silences C9orf72. 
Material and methods
Cell culture
Human control (ND42245) and Frontotemporal Dementia (ND42765) iPSC cells derived 
from fibroblast were ordered from Coriell Biorepository and was cultured on Matrigel 
(corning) -coated 6 wells plates in mTeSR1 (STEMCELL). For embryoid body-based neural 
induction, iPS cells were seeded on AggreWell800 plates and cultured in STEMdiff Neural 
Induction Medium (STEMCELL) for 5 days with daily medium changes. Embryoid bodies 
were harvested and plated on 6 wells plates coated with poly-D-lysine (Sigma-Aldrich) 
and laminin (Sigm-Aldrich) in STEMdiff  Neural Induction Medium for 7 days with daily 
medium changes.  Rosettes were harvested with STEMdiff Neural Rosette Selection 
Reagent (STEMCELL) and plated on poly-D-lysine and laminin coated 6-wells plates in 
STEMdiff Neural Induction Medium for 24 hours. For differentiation into FBN, STEMdiff 
Neural Induction Medium was replaced for STEMdiff Neuron Differentiation Medium 
(STEMCELL) and neuroprogenitor cells were differentiated for 5 days. For differentiation into 
astrocytes, neuroprogenitor cells were differentiated in STEMdiff Astrocyte Differentiation 
Medium (STEMCELL). The neuroprogenitor cells were then plated on poly-D-lysine and 
laminin coated plates in STEMdiff Neuron Maturation Medium (STEMCELL) for one week 
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or STEMdiff Astrocytes Maturation Medium for 3 weeks. The mature FBN and astrocytes 
were stored in liquid nitrogen in Neuroprogenitor Freezing Medium (STEMCELL). 
Cryopreserved non- diseased mature dopaminergic neurons (iCELL Dopaneurons, 
01279, Cat# C1028, Lot# 102477) were ordered at FUJIFILM Cellular Dynamics, Inc. 
Cryopreserved non-diseased mature motor neurons (cat# 40HU-005, lot#400089) were 
ordered at iXCells Biotechnologies.
Generation of AAV5-miC vectors and transductions
The design and cloning of the miC constructs was performed as described previously.30,65 
The miC constructs were all expressed by the synthetic CMV early enhancer/chicken β 
actin (CAG) promotor. To produce AAV5, the CAG-miC2, CAG-miC4, CAG-miC32 and 
CAG-miC46 cassettes were obtained by digestion with restriction enzymes HindIII and 
PvuI and cloned in a uniQure transfer plasmid in order to generate an entry plasmid. 
The presence of the two inverted terminal repeats (ITRs) was confirmed by restriction 
digestion with SmaI. The ITR-CAG-miC cassettes were inserted in a recombinant 
baculovirus vector by homologous recombination in Spodoptera frugiperda Sf9 cells and 
clones were selected by plague purification and insert PCR. The recombinant baculovirus 
containing the ITR-CAG-miC were further amplified till P6 in Sf+ cells and screened for 
the best production and stability by PCR and RT-qPCR. To generate AAV5, Sf+ cells were 
triple infected with three different recombinant baculoviruses expressing the ITRs-CAG-
miC, the replicon enzyme and the capsid protein. The cells were lysed 72 hours after 
the triple infection and the crude lysate was treated with 50U/ml Benzonase (Merck, 
Darmstadt, Germany) for 1 hour at 37 °C. AAV5 was purified on an AVB Sepharose 
column (GE Healthcare, Little Chalfont, UK) and eluted in a formulation buffer consisting 
of 1x PBS and 4% sucrose.  the final titer was determined by RT-qPCR with primers 
amplifying a 95bp fragment from the CAG promoter region. 
For transductions with AAV, FBN, DPN and MN were plated in 24-wells plates at 
0.3*106 cells per well. Astrocytes were plated at 0.1*106 cells per well in STEMdiff 
Astrocyte Maturation Medium (STEMCELL) on matrigel coated plates. FBN were plated in 
STEMdiff Neuron Maturation Medium (STEMCELL) on poly-D-lysine and laminin coated 
plates. Dopaminergic neurons were plated in iCell Neural Base Medium (FUJIFILM Cellular 
Dynamics, Inc) according to the manufacturer’s description on poly-D-lysine and laminin 
coated plates.  Motor neurons were plated in Motor Neuron Maintenance Medium 
according to the manufacturer’s description on matrigel coated plates. After 1 week of 
acclimation, cells were transduced with AAV5 for 1-2 weeks. 
RNA and DNA isolation
For RNA, plated cells and tissues were lysed in 300ul TRizol. RNA was isolated from 
TRizol using the DIRECT-ZOL miniprep kit (cat# R2050, ZYMO Research). DNA was 
isolated using the DNeasy Blood & Tissue Kit (cat# 69506, Qiagen) according to 
the manufacturer’s protocol.
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Next-generation sequencing (NGS)
Small RNA sequencing libraries for the Illumina sequencing platform were generated 
using high-quality total RNA as input and the NEXTflex Small RNA Sequencing kit (Bioo 
Scientific, Austin, TX). Briefly, the small RNA species were subjected to ligation with 3’ 
and 5’ RNA adapters, first strand reverse transcription, and polymerase chain reaction 
(PCR) amplification. Sample-specific barcodes were introduced in the PCR step. The PCR 
products were separated on TBE-PAGE electrophoresis and the expected band around 
30bp was recovered for each sample. The resulting sequencing libraries were quantified 
on a BioAnalyzer (Agilent, Santa Clara, CA). The libraries were multiplexed, clustered, and 
sequenced on an Illumina HiSeq 2000 (TruSeq v3 chemistry) with a single-read 36 cycles 
sequencing protocol and indexing. The sequencing run was analyzed with the Illumina 
CASAVA pipeline (v1.8.2), with demultiplexing based on sample-specific barcodes. 
The raw sequencing data produced was processed removing the sequence reads which 
were of too low quality (only “passing filter” reads were selected). In total, we generated 
between 15–35 mln reads per sample.
NGS data analysis
NGS small RNA raw data sets were analyzed using the CLC Genomics Workbench 8 
(Qiagen). The obtained reads were adaptor-trimmed, which decreased the average read 
size from ~50bp to ~25bp. All reads containing ambiguity N symbols, reads shorter than 
10 nt, longer than 45 nt, and reads represented less than 10 times were discarded. 
Next, the obtained unique small RNA reads were aligned to the reference sequences 
of the pre-miC9 constructs with a max. of 3 nt mismatches allowed. The percentages 
of reads based on the total number of reads matching the reference sequence were 
calculated (Supplementary Table S1).
RT-qPCR, and miRNA TaqMan assay
To determine C9orf72 mRNA knockdown in cells, RNA was isolated, and first-
strand complementary DNA was reverse transcribed using random hexamer primers 
with the Dynamo kit (Finnzymes, Espoo, Finland). Real-time PCR amplification 
was performed with primers to detect total C9orf72 mRNA and the sense intronic 
transcripts of human. Total C9orf72 mRNA was detected with primers: mFP 
5’-CGGAAAGGAAGAATATGGATGC-3’, mRP 5’-CCATTACAGGAATCACTTCTCCA-3’ 
and probe mPRB 5’-AGCATTGGAATAATACTCTGACCCTGATCTTC-3’. The sense intronic 
transcripts was detected with primers SFP 5’-ACGCCTGCACAATTTCAGCCCAA-3’, 
SRP 5’-CAAGTCTGTGTCATCTCGGAGCTG-3’ and probe SPRB 
5’-TGAGGGCAGCAATGCAAGTCGGTGTG-3’.  The mRNA expression levels were 
normalized to human GAPDH (forward GAAGGTGAAGGTCGGAGTC, reverse 
GAAGATGGTGATGGGATTTC, probe CAAGCTTCCCGTTCTCAGCC) as an internal 
control. PCR reaction conditions were: 95 °C for 10 min, followed by 40 cycles of 15 
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s at 95 °C and 1 min at 60 °C. The assays were performed on ABI 7000 or ABI 7500 
(Applied Biosystems, Foster City, CA, USA). Gene expression levels were normalized to 
GAPDH as an internal control, and the level of gene expression was calculated relative 
to control cells. To determine the expression of miC2, miC5, miC32 and miC46, Custom 
TaqMan® Small RNA Assay (ThemoFisher Scientific) was used; miC2 (assay ID CTEPR3R), 
miC4 (Assay ID: CTFVKNN), miC32 (assay ID CSGJPRB) and miC46 (assay ID CSHSNXJ). 
The RT reaction and TaqMan was performed according to the manufacturer’s protocol.
Animals
Two breeding couples were ordered at the Jacksons Laboratory (stock number: 023099) and 
were kept and bred at the Neurosciences Division, Center for Applied Medical Research, 
CIMA, University of Navarra, Pamplona, Spain.  The animals were housed 4–5 per cage 
with ad libitum access to food and water and maintained in a temperature controlled. 
environment on a 12-h dark/light cycle. All procedures were carried out in accordance 
with the current European and Spanish regulations (86/609/EEC; RD1201/2005). This 
study was approved by the Ethical Committee of the University of Navarra (no. 137/010).
Intrastriatal injection in Tg(C9orf72_3) line 112 mice
Surgeries were performed as described previously.66 In brief, 3 months old mice were 
anesthetized with ketamine/xylazine (80/10 mg/kg, i.p.) and placed in a stereotactic 
frame. The scalp was shaved, and a longitudinal incision was made along the midline 
of the skull. The dorsal surface of the skull was then exposed, and two burr holes were 
drilled above the infusion sites. 2 or 5 μL of virus suspension or PBS solution (sham 
mice) was infused bilaterally to striatum (+0.8 mm AP, +/- 2 mm ML, -4.0 mm DV to 
bregma) according to the Paxinos and Watson mouse brain atlas (1998). A 5 μL Hamilton 
syringe (or 10 for ventricle surgeries) was used for the infusion (Hamilton Co., Reno, 
NV). The infusion rate was 0.2 μL/min and the needle remained in place for 5 min after 
the infusion for vector absorption. Finally, the site was stitched closed.
RNA foci fluorescence in situ hybridization (FISH)
RNA FISH was performed as described previously with some adjustments.24,31,59 In brief, 
whole mice brain were fixed in 4% PFA for 1 week at 4°C. Brains were transferred into 
15 ml tubes containing 10 ml of 30% PBS/sucrose andleft at 4°C until brains sinks to 
the bottom. The brains were then frozen in OCT and 25 µM thick cryostat sections 
were prepared.  Brain sections were permeabilize in 0.2% Triton/1x PBS for 10 min and 
incubated for 1 hour in hybridization buffer (50% formamide, 10% dextran sulfate, 
0.1 mg/mL yeast tRNA,2xSSC, 50 mM sodium phosphate) at 55°C. Hybridization was 
performed overnight with 40nm TYE563-(C4G2)3 LNA probe in hybridization buffer 
at 55°C. Brain sections were then washed once with 40% formamide/1xSSC for 30 
min at 55°C, 2x in 2x SSC/0.1% Tween-20 at room temperature for 5 min and 3x in 
Targeting RNA-mediated toxicity in C9ORF72 ALS/FTD by RNAi-based gene therapy
117
3
0.1x SSC for 10 min at room temperature. The slides were mounted with ProLong® 
Gold Antifade Mountant with DAPI (Invitrogen) and visualized using a LEICA DM2500 
fluorescence microscope.
Statistical Analysis
Data were analyzed using Student’s t test or ordinary one-way ANOVA to determine 
statistically significances. The p values are represented by the following number of 
asterisks: *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. 
Acknowledgments
The authors would like to thank Ellen Broug and Eileen Sawyer for reviewing 
the manuscript.
Author contributions 
Conceptualization: P.K and R.M. Investigation: R.M., J.M.L., A.O., J.M., Recourses: A.O, 
M.C, M.E, S.U.. Supervision, formal analysis, visualization and writing - initial draft: P.K, 
R.M., M.E., S.D Project Administration and Writing – review and editing: P.K., S.D., H.P. 
Funding acquisition: P.K.
Chapter 3
118
3
References
1. Geser, F, Lee, VMY and Trojanowski, JQ 
(2010). Amyotrophic lateral sclerosis 
and frontotemporal lobar degeneration: 
A spectrum of TDP-43 proteinopathies. 
Neuropathology 30: 103–112.
2. Ferrari, R, Kapogiannis, D, Huey, ED and 
Momeni, P (2011). FTD and ALS: a tale of 
two diseases. Curr. Alzheimer Res. 8: 273–94.
3. Liscic, RM, Grinberg, LT, Zidar, J, Gitcho, 
MA and Cairns, NJ (2008). ALS and FTLD: 
Two faces of TDP-43 proteinopathy. Eur. J. 
Neurol. 15: 772–780.
4. Renton, AE, Majounie, E, Waite, A, 
Sim??n-S??nchez, J, Rollinson, S, Gibbs, 
JR, et al. (2011). A hexanucleotide 
repeat expansion in C9orf72 is the cause 
of chromosome 9p21-linked ALS-FTD. 
Neuron 72: 257–268.
5. DeJesus-Hernandez, M, Mackenzie, IR, 
Boeve, BF, Boxer, AL, Baker, M, Rutherford, 
NJ, et al. (2011). Expanded GGGGCC 
Hexanucleotide Repeat in Noncoding Region 
of C9orf72 Causes Chromosome 9p-Linked 
FTD and ALS. Neuron 72: 245–256.
6. Heutink, P, Jansen, IE and Lynes, EM (2014). 
C9orf72; abnormal RNA expression is 
the key. Exp. Neurol. 262: 102–110.
7. Gendron, TF, Belzil, V V., Zhang, YJ and 
Petrucelli, L (2014). Mechanisms of toxicity in 
C9FTLD/ALS. Acta Neuropathol. 127: 359–376.
8. Ling, SC, Polymenidou, M and Cleveland, 
DW (2013). Converging mechanisms in 
als and FTD: Disrupted RNA and protein 
homeostasis. Neuron 79: 416–438.
9. Shi, Y, Lin, S, Staats, KA, Li, Y, Chang, W-H, 
Hung, S-T, et al. (2018). Haploinsufficiency 
leads to neurodegeneration in C9orf72 
ALS/FTD human induced motor neurons. 
Nat. Med.doi:10.1038/nm.4490.
10. Liu, J, Hu, J, Ludlow, AT, Pham, JT, Shay, 
JW, Rothstein, JD, et al. (2017). c9orf72 
Disease-Related Foci Are Each Composed 
of One Mutant Expanded Repeat RNA. 
Cell Chem. Biol. 24: 141–148.
11. Cooper-Knock, J, Walsh, MJ, 
Higginbottom, A, Highley, JR, Dickman, MJ, 
Edbauer, D, et al. (2014). Sequestration of 
multiple RNA recognition motif-containing 
proteins by C9orf72 repeat expansions. 
Brain 137: 2040–2051.
12. Zu, T, Liu, Y, Banez-Coronel, M, Reid, 
T, Pletnikova, O, Lewis, J, et al. (2013). 
RAN proteins and RNA foci from 
antisense transcripts in C9orf72 ALS and 
frontotemporal dementia. Proc. Natl. 
Acad. Sci. 110: E4968–E4977.
13. Wojciechowska, M and Krzyzosiak, WJ 
(2011). Cellular toxicity of expanded RNA 
repeats: Focus on RNA foci. Hum. Mol. 
Genet. 20: 3811–3821.
14. Zu, T, Liu, Y, Banez-Coronel, M, Reid, 
T, Pletnikova, O, Lewis, J, et al. (2013). 
RAN proteins and RNA foci from 
antisense transcripts in C9orf72 ALS and 
frontotemporal dementia. Proc. Natl. 
Acad. Sci. 110: E4968–E4977.
15. Lagier-Tourenne, C, Baughn, M, Rigo, F, 
Sun, S, Liu, P, Li, H-R, et al. (2013). Targeted 
degradation of sense and antisense 
C9orf72 RNA foci as therapy for ALS and 
frontotemporal degeneration. Proc. Natl. 
Acad. Sci. U. S. A. 110: E4530-9.
16. Freibaum, BD and Taylor, JP (2017). 
The Role of Dipeptide Repeats in C9orf72-
Related ALS-FTD. Front. Mol. Neurosci. 10.
17. Ash, PEA, Bieniek, KF, Gendron, TF, 
Caulfield, T, Lin, WL, DeJesus-Hernandez, 
M, et al. (2013). Unconventional Translation 
of C9orf72 GGGGCC Expansion Generates 
Insoluble Polypeptides Specific to c9FTD/
ALS. Neuron 77: 639–646.
18. Jovičič, A, Mertens, J, Boeynaems, S, 
Bogaert, E, Chai, N, Yamada, SB, et al. 
(2015). Modifiers of C9orf72 dipeptide 
repeat toxicity connect nucleocytoplasmic 
transport defects to FTD/ALS. Nat. 
Neurosci. 19: 1226–1229.
19. Zhang, K, Donnelly, CJ, Haeusler, AR, 
Grima, JC, Machamer, JB, Steinwald, P, et 
al. (2015). The C9orf72 repeat expansion 
disrupts nucleocytoplasmic transport. 
Nature 525: 56–61.
20. Scaber, J and Talbot, K (2016). What is the role 
of TDP-43 in C9orf72-related amyotrophic 
Targeting RNA-mediated toxicity in C9ORF72 ALS/FTD by RNAi-based gene therapy
119
3
lateral sclerosis and frontemporal dementia? 
Brain 139: 3057–3059.
21. Gijselinck, I, Van Langenhove, T, van der 
Zee, J, Sleegers, K, Philtjens, S, Kleinberger, 
G, et al. (2012). A C9orf72 promoter repeat 
expansion in a Flanders-Belgian cohort 
with disorders of the frontotemporal lobar 
degeneration-amyotrophic lateral sclerosis 
spectrum: A gene identification study. 
Lancet Neurol. 11: 54–65.
22. Al-Sarraj, S, King, A, Troakes, C, Smith, 
B, Maekawa, S, Bodi, I, et al. (2011). 
P62 positive, TDP-43 negative, neuronal 
cytoplasmic and intranuclear inclusions in 
the cerebellum and hippocampus define 
the pathology of C9orf72-linked FTLD and 
MND/ALS. Acta Neuropathol. 122: 691–702.
23. Brettschneider, J, Van Deerlin, VM, 
Robinson, JL, Kwong, L, Lee, EB, Ali, YO, et 
al. (2012). Pattern of ubiquilin pathology 
in ALS and FTLD indicates presence of 
C9orf72 hexanucleotide expansion. Acta 
Neuropathol. 123: 825–839.
24. Liu, Y, Pattamatta, A, Zu, T, Reid, T, Bardhi, 
O, Borchelt, DR, et al. (2016). C9orf72 
BAC Mouse Model with Motor Deficits 
and Neurodegenerative Features of ALS/
FTD. Neuron 90: 521–534.
25. Jiang, J, Zhu, Q, Gendron, TF, Saberi, S, 
McAlonis-Downes, M, Seelman, A, et al. 
(2016). Gain of Toxicity from ALS/FTD-
Linked Repeat Expansions in C9orf72 Is 
Alleviated by Antisense Oligonucleotides 
Targeting GGGGCC-Containing RNAs. 
Neuron 90: 535–550.
26. Gendron, TF, Chew, J, Stankowski, JN, 
Hayes, LR, Zhang, YJ, Prudencio, M, et 
al. (2017). Poly(GP) proteins are a useful 
pharmacodynamic marker for C9orf72-
associated amyotrophic lateral sclerosis. 
Sci. Transl. Med. 9.
27. Hu, J, Rigo, F, Prakash, TP and Corey, DR 
(2017). Recognition of c9orf72 Mutant 
RNA by Single-Stranded Silencing RNAs. 
Nucleic Acid Ther. 27: 87–94.
28. Hu, J, Liu, J, Li, L, Gagnon, KT and Corey, 
DR (2015). Engineering Duplex RNAs 
for Challenging Targets: Recognition of 
GGGGCC/CCCCGG Repeats at the ALS/FTD 
C9orf72 Locus. Chem. Biol. 22: 1505–1511.
29. Graves, P and Zeng, Y (2012). 
Biogenesis of Mammalian MicroRNAs: 
A Global View. Genomics, Proteomics 
Bioinforma. 10: 239–245.
30. Martier R, Liefhebber J, Miniarikova J, 
van der Zon T, Snapper J, Kolder I, Petry 
H, van Deventer S, Evers M, KP. Artificial 
microRNAs targeting C9orf72 have 
the potential to reduce accumulation of 
the intra-nuclear transcripts in ALS and 
FTD patients. Mol. Ther. - Nucleic Acids.
31. O’Rourke, JG, Bogdanik, L, Muhammad, 
AKMG, Gendron, TF, Kim, KJ, Austin, A, et 
al. (2015). C9orf72 BAC Transgenic Mice 
Display Typical Pathologic Features of ALS/
FTD. Neuron 88: 892–901.
32. Lee, S and Huang, EJ (2017). Modeling 
ALS and FTD with iPSC-derived neurons. 
Brain Res. 1656: 88–97.
33. Meyer, K, Ferraiuolo, L, Miranda, CJ, 
Likhite, S, McElroy, S, Renusch, S, et 
al. (2014). Direct conversion of patient 
fibroblasts demonstrates non-cell 
autonomous toxicity of astrocytes to 
motor neurons in familial and sporadic 
ALS. Proc. Natl. Acad. Sci. 111: 829–832.
34. Di Giorgio, FP, Boulting, GL, Bobrowicz, S 
and Eggan, KC (2008). Human Embryonic 
Stem Cell-Derived Motor Neurons Are 
Sensitive to the Toxic Effect of Glial Cells 
Carrying an ALS-Causing Mutation. Cell 
Stem Cell 3: 637–648.
35. Haidet-Phillips, AM, Hester, ME, Miranda, 
CJ, Meyer, K, Braun, L, Frakes, A, et al. 
(2011). Astrocytes from familial and 
sporadic ALS patients are toxic to motor 
neurons. Nat. Biotechnol. 29: 824–828.
36. Ilieva, H, Polymenidou, M and Cleveland, 
DW (2009). Non-cell autonomous toxicity 
in neurodegenerative disorders: ALS and 
beyond. J. Cell Biol. 187: 761–772.
37. Selvaraj, BT, Livesey, MR and Chandran, S 
(2017). Modeling the C9orf72 repeat expansion 
mutation using human induced pluripotent 
stem cells. Brain Pathol. 27: 518–524.
38. Peters, OM, Cabrera, GT, Tran, H, Gendron, 
TF, McKeon, JE, Metterville, J, et al. 
Chapter 3
120
3
(2015). Human C9orf72 Hexanucleotide 
Expansion Reproduces RNA Foci and 
Dipeptide Repeat Proteins but Not 
Neurodegeneration in BAC Transgenic 
Mice. Neuron 88: 902–909.
39. Jiang, J, Zhu, Q, Gendron, TF, Saberi, S, 
McAlonis-Downes, M, Seelman, A, et al. 
(2016). Gain of Toxicity from ALS/FTD-
Linked Repeat Expansions in C9orf72 Is 
Alleviated by Antisense Oligonucleotides 
Targeting GGGGCC-Containing RNAs. 
Neuron 90: 535–550.
40. Lee, Y, Kim, M, Han, J, Yeom, K-H, Lee, S, 
Baek, SH, et al. (2004). MicroRNA genes 
are transcribed by RNA polymerase II. 
EMBO J. 23: 4051–4060.
41. Kim, VN and Nam, JW (2006). Genomics 
of microRNA. Trends Genet. 22: 165–173.
42. Winter, J, Jung, S, Keller, S, Gregory, RI and 
Diederichs, S (2009). Many roads to maturity: 
microRNA biogenesis pathways and their 
regulation. Nat. Cell Biol. 11: 228–234.
43. Tyzack, G, Lakatos, A and Patani, R 
(2016). Human Stem Cell-Derived 
Astrocytes: Specification and Relevance 
for Neurological Disorders. Curr. Stem Cell 
Reports 2: 236–247.
44. Madill, M, McDonagh, K, Ma, J, Vajda, A, 
McLoughlin, P, O’Brien, T, et al. (2017). 
Amyotrophic lateral sclerosis patient iPSC-
derived astrocytes impair autophagy via 
non-cell autonomous mechanisms. Mol. 
Brain 10.
45. Xu, Z, Poidevin, M, Li, X, Li, Y, Shu, L, Nelson, 
DL, et al. (2013). Expanded GGGGCC 
repeat RNA associated with amyotrophic 
lateral sclerosis and frontotemporal 
dementia causes neurodegeneration. 
Proc. … 110: pp 7778–7783.
46. Haeusler, AR, Donnelly, CJ, Periz, G, Simko, 
EAJ, Shaw, PG, Kim, MS, et al. (2014). 
C9orf72 nucleotide repeat structures 
initiate molecular cascades of disease. 
Nature 507: 195–200.
47. van Blitterswijk, M, Gendron, TF, Baker, 
MC, DeJesus-Hernandez, M, Finch, 
NCA, Brown, PH, et al. (2015). Novel 
clinical associations with specific C9orf72 
transcripts in patients with repeat 
expansions in C9orf72. Acta Neuropathol. 
130: 863–876.
48. Donnelly, CJ, Zhang, PW, Pham, JT, Heusler, 
AR, Mistry, NA, Vidensky, S, et al. (2013). 
RNA Toxicity from the ALS/FTD C9orf72 
Expansion Is Mitigated by Antisense 
Intervention. Neuron 80: 415–428.
49. Rizzu, P, Blauwendraat, C, Heetveld, S, 
Lynes, EM, Castillo-Lizardo, M, Dhingra, 
A, et al. (2016). C9orf72 is differentially 
expressed in the central nervous system and 
myeloid cells and consistently reduced in 
C9orf72, MAPT and GRN mutation carriers. 
Acta Neuropathol. Commun. 4: 37.
50. Dodge, JC, Treleaven, CM, Fidler, JA, Hester, 
M, Haidet, A, Handy, C, et al. (2010). AAV4-
mediated expression of IGF-1 and VEGF 
within cellular components of the ventricular 
system improves survival outcome in familial 
ALS mice. Mol. Ther. 18: 2075–84.
51. Rizzu, P, Blauwendraat, C, Heetveld, S, 
Lynes, EM, Castillo-Lizardo, M, Dhingra, 
A, et al. (2016). C9orf72 is differentially 
expressed in the central nervous system and 
myeloid cells and consistently reduced in 
C9orf72, MAPT and GRN mutation carriers. 
Acta Neuropathol. Commun. 4: 37.
52. Koppers, M, Blokhuis, AM, Westeneng, 
HJ, Terpstra, ML, Zundel, CAC, Vieira 
De Sá, R, et al. (2015). C9orf72 ablation 
in mice does not cause motor neuron 
degeneration or motor deficits. Ann. 
Neurol. 78: 426–438.
53. Sudria-Lopez, E, Koppers, M, de Wit, M, van 
der Meer, C, Westeneng, HJ, Zundel, CAC, 
et al. (2016). Full ablation of C9orf72 in mice 
causes immune system-related pathology 
and neoplastic events but no motor neuron 
defects. Acta Neuropathol. 132: 145–147.
54. O’Rourke, JG, Bogdanik, L, Yáñez, A, Lall, 
D, Wolf, AJ, Muhammad, AKMG, et al. 
(2016). C9orf72 is required for proper 
macrophage and microglial function in 
mice. Science (80-. ). 351: 1324–1329.
55. Niblock, M, Smith, BN, Lee, Y-B, Sardone, 
V, Topp, S, Troakes, C, et al. (2016). 
Retention of hexanucleotide repeat-
containing intron in C9orf72 mRNA: 
implications for the pathogenesis of ALS/
FTD. Acta Neuropathol. Commun. 4: 18.
Targeting RNA-mediated toxicity in C9ORF72 ALS/FTD by RNAi-based gene therapy
121
3
56. Fratta, P, Mizielinska, S, Nicoll, AJ, Zloh, M, 
Fisher, EMC, Parkinson, G, et al. (2012). 
C9orf72 hexanucleotide repeat associated 
with amyotrophic lateral sclerosis and 
frontotemporal dementia forms RNA 
G-quadruplexes. Sci. Rep. 2: 1016.
57. Reddy, K, Zamiri, B, Stanley, SYR, 
Macgregor, RB and Pearson, CE (2013). 
The disease-associated r(GGGGCC)
nrepeat from the C9orf72 gene forms tract 
length-dependent uni- and multimolecular 
RNA G-quadruplex structures. J. Biol. 
Chem. 18: 9860–9866.
58. Schwanhüusser, B, Busse, D, Li, N, Dittmar, 
G, Schuchhardt, J, Wolf, J, et al. (2011). 
Global quantification of mammalian gene 
expression control. Nature 473: 337–342.
59. Su, Z, Zhang, Y, Gendron, TF, Bauer, PO, 
Chew, J, Yang, WY, et al. (2014). Discovery 
of a Biomarker and Lead Small Molecules 
to Target r(GGGGCC)-Associated Defects 
in c9FTD/ALS. Neuron 83: 1043–1050.
60. Nordin, A, Akimoto, C, Wuolikainen, A, 
Alstermark, H, Forsberg, K, Baumann, P, et 
al. (2017). Sequence variations in C9orf72 
downstream of the hexanucleotide repeat 
region and its effect on repeat-primed 
PCR interpretation: a large multinational 
screening study. Amyotroph. Lateral Scler. 
Front. Degener. 18: 256–264.
61. Prudencio, M, Belzil, V V., Batra, R, Ross, 
CA, Gendron, TF, Pregent, LJ, et al. (2015). 
Distinct brain transcriptome profiles in 
C9orf72-associated and sporadic ALS. 
Nat. Neurosci. 18: 1175–1182.
62. Han, J, Lee, Y, Yeom, KH, Kim, YK, Jin, H 
and Kim, VN (2004). The Drosha-DGCR8 
complex in primary microRNA processing. 
Genes Dev. 18: 3016–3027.
63. Liu, H, Lei, C, He, Q, Pan, Z, Xiao, D and Tao, 
Y (2018). Nuclear functions of mammalian 
MicroRNAs in gene regulation, immunity 
and cancer. Mol. Cancer 17.
64. Schraivogel, D and Meister, G (2014). 
Import routes and nuclear functions of 
Argonaute and other small RNA-silencing 
proteins. Trends Biochem. Sci. 39: 420–431.
65. Miniarikova, J, Zanella, I, Huseinovic, A, 
van der Zon, T, Hanemaaijer, E, Martier, 
R, et al. (2016). Design, Characterization, 
and Lead Selection of Therapeutic miRNAs 
Targeting Huntingtin for Development of 
Gene Therapy for Huntington’s Disease. 
Mol. Ther. Nucleic Acids 5: e297.
66. Pascual-Lucas, M, Viana da Silva, S, Di 
Scala, M, Garcia-Barroso, C, Gonzalez-
Aseguinolaza, G, Mulle, C, et al. (2014). 
Insulin-like growth factor 2 reverses memory 
and synaptic deficits in APP transgenic 
mice. EMBO Mol. Med. 6: 1246–1262.
Chapter 3
122
3
Supplementary material
Figure S1. Differentiation and characterization of iPSC neurons. a) iPSC cells were seeded on 
AggreWell800 plates and cultured in STEMdiff Neural Induction Medium until day 5 to induce 
embryoid bodies formation.  Embryoid bodies were harvested and replated in STEMdiff Neural 
Induction Medium for 7 days.  At day 12, Rosettes were selected with rosette selection medium 
and differentiated in STEMdiff  Neuron Differentiation medium or STEMdiff astrocyte Differentiation 
medium (STEMCELL) for 5 days. The cells were then maturated into mature FBN or astrocytes for 
one week. 
Figure S2. Reduction of RNA foci in hippocampus of Tg(C9orf72_3) line 112 mice.
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Figure S3. Reduction of the mouse C9orf72 in striatum and cortex of C9BAC mice. Total RNA was 
isolated from the striatum and cortex of mice treated with AAV5-miC32 and AAV5-miC46. RT-qPCR 
was performed using primers to detect the mouse C9orf72 ortholog (3110043O21Rik). RNA input 
levels were normalized to GAPDH and set relative to AAV-GFP treated mice.
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Abstract
Spinocerebellar ataxia type 3 (SCA3) or Machado-Joseph disease (MJD) is a progressive 
neurodegenerative disorder caused by a CAG expansion in the ATXN3 gene. The expanded 
CAG repeat is translated into a prolonged polyglutamine repeat in the ataxin-3 protein and 
accumulates within inclusions, acquiring toxic properties, which results in degeneration 
of the cerebellum and brain stem. 
In the current study, a non-allele specific ATXN3 silencing approach was investigated 
using artificial microRNAs engineered to target various regions of the ATXN3 gene 
(miATXN3). The miATXN3 candidates were screened in vitro based on their silencing 
efficacy on a luciferase reporter co-expressing ATXN3. The three best miATXN3 candidates 
were further tested for target engagement and potential off-target activity in induced-
pluripotent stem cells (iPSC) differentiated into frontal brain-like neurons and in a SCA3 
knock-in mouse model. Besides a strong reduction of ATXN3 mRNA and protein, small 
RNA sequencing revealed efficient guide strand processing without passenger strands 
being produced. We used different methods to predict alteration of off-target genes 
upon AAV5-miATXN3 treatment and found no evidence for unwanted effect. 
Furthermore, we demonstrated in a large animal model, the minipig, that intrathecal 
delivery of AAV5 can transduce the main areas affected in SCA3 patients. These results 
proved a strong basis to move forward to investigate distribution, efficacy and safety of 
AAV5-miATXN3 in large animals.
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Introduction
Spinocerebellar ataxia type 3 (SCA3), or Machado-Joseph disease (MJD), is the most 
common spinocerebellar ataxia worldwide and the second most common polyglutamine 
(polyQ) disease after Huntington disease (HD)1–5. Similar to the other polyQ disorders, SCA3 
is inherited in an autosomal dominant manner, which is progressively neurodegenerative 
and ultimately fatal. SCA3 is caused by an expanded stretch of CAG triplets in the coding 
region of the ATXN3 gene6. Healthy individuals have up to 44 CAG repeats, whilst affected 
individuals have between 52 and 86 glutamine repeats6–8. Repeat ranges from 45 to 51 
are associated with incomplete penetrance of the disease. There is a clear correlation 
between CAG repeat size and age of onset, though CAG repeat length only accounts for 
approximately 50% of the total variability in age of onset9. Age at onset of SCA3 is highly 
variable but most commonly in the second to fifth decade, with an average age at onset 
of 40 years10. The CAG expansion has full penetration as patients harboring the mutation 
will inevitably develop the disease and have 50% chance to pass it on to their offspring.
The ATXN3 transcript is alternatively spliced and produces different isoforms of 
the ataxin-3 protein10,11. The most abundant protein isoform contains an N-terminal 
Josephin domain which has a deubiquitinase activity and a C-terminal region that has 
three ubiquitin-interacting motifs (UIM), implicating a role of ataxin-3 in the ubiquitin-
proteasome pathway1,12. The expanded CAG repeat in the ATXN3 gene leads to 
formation of an expanded polyQ tract in the C-terminal region of the ataxin-3 protein. 
This mutated ataxin-3 protein causes toxic gain of function and leads to formation of 
neuronal aggregates which is a hallmark of polyQ diseases13. Despite extensive research 
the mechanisms leading to the observed neurodegeneration in SCA3 patients have not 
been completely elucidated. Ataxin-3 is normally ubiquitously found throughout the cell 
and can translocate from the cytoplasm to the nucleus and vice versa14. In neurons, 
ataxin-3 is predominantly expressed in the cytoplasm while the mutated protein mainly 
accumulates in the nucleus and acquires toxic properties 13–17. Formation of neuronal 
aggregates comprising the mutated ataxin-3 protein is a typical neuropathological 
hallmark of the disease. Besides protein toxicity, RNA toxicity may also contribute to 
pathogenicity of the disease18, as the expanded CAG repeat, and CUG-containing RNA 
molecules can form RNA foci, which colocalize with RNA binding proteins and sequester 
their functions. For example, colocalization of CAG and CUG-containing RNA foci with 
the muscleblind-like 1 (MBNL1) splicing factor in nuclei of both muscle cells and neurons 
resulted in inactivation of MBNL1, leading to dysregulation of alternative splicing18–22. 
Neuropathological studies have detected widespread neuronal loss in the cerebellum, 
thalamus, midbrain and spinal cord of SCA3 patients17. Although widespread pathology 
is reported in later disease stage of SCA3 patients, the general consensus is that 
the main neuropathology in SCA3 patients is located in the cerebellum and brain stem23. 
The main clinical symptom observed in SCA3 patients is progressive ataxia, affecting 
balance, gait and speech18. Other frequently described symptoms include pyramidal 
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signs, progressive external ophthalmoplegia, dysarthria, dysphagia, rigidity, distal muscle 
atrophies and double vision2. Most of the patients die due to pulmonary complications, 
usually within 6 to 29 years after onset, and up to now there is no disease modifying 
treatment available.2425
From a therapeutic standpoint, an advantage of monogenetic disorders such as 
SCA3 is that reducing expression of the responsible gene should result in alleviation 
of mutant RNA and protein toxicity18. Silencing approaches by RNA interference (RNAi) 
or antisense oligonucleotides (ASOs) are attractive to achieve silencing of the mutant 
ataxin-3. The silencing can be allele-specific; silencing only the mutant ataxin-3, or non-
allele specific; silencing both wildtype and mutant allele. Both approaches demonstrated 
that neuropathology in SCA3 rodents can be improved26–28. 
In the current study, we investigated a non-allele specific RNAi based gene therapy 
for SCA3 patients with a potentially long-lived therapeutic effect. The therapeutic 
product is an adeno-associated virus (AAV) vector expressing a microRNA that binds 
ATXN3 mRNA leading to its degradation via the RNA-induced silencing complex (RISC). 
Non-allele specific silencing of ataxin-3 by RNAi have been tested in wildtype and SCA3 
rodent models and demonstrated improvement of the observed neuropathology27. This 
approach was well tolerated despite the concomitant reduction of the wildtype ataxin-3. 
We engineered artificial microRNAs (miATXN3) to target various exons within the ATXN3 
mRNA. The miATXN3 candidates were incorporated in the primary-miR451 scaffold 
which has been extensively studied by us and proved to be safe in rodents, pigs and 
non-human primates29–31. By targeting both wildtype and mutant ataxin-3 and using 
a scaffold that is known to produce no passenger strands, we are aiming for a therapy to 
treat the whole SCA3 patient population while significantly reduce the risk for off-target 
effect. Since miR451 has not passenger activity, the effects of the passenger strand is 
completely eliminated. A preselection for the most efficient miATXN3 candidates was 
performed in vitro on a luciferase (Luc) reporter. The best candidates were incorporated 
in AAV serotype 5 (AAV5) and their efficacies were tested in human-derived induced-
pluripotent stem cells (iPSC)-neurons and in a knock-in SCA3 mouse model. We observed 
strong reduction of ATXN3 mRNA and mutant ataxin-3 protein, suggesting that our AAV-
microRNA-based approach could have therapeutic benefits in SCA3 human patients. In 
addition, we investigated the intrathecal delivery of AAV5 in a minipig and confirmed 
that the main areas affected in SCA3 patients are transduced at a therapeutically relevant 
dose. These data demonstrate that AAV-based RNAi gene therapy has potential for use in 
SCA3 treatment by lowering of the mutant ataxin-3 protein in the central nervous system.
Results
Design of artificial miATXN3 constructs and prescreening on Luc reporter
Silencing of mutant ATXN3 mRNA should result in alleviation of toxicity caused by 
the mutant ataxin-3 protein. Using this rationale, we engineered artificial microRNAs 
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complementary to various regions of the ATXN3 gene aiming at a knockdown of ATXN3 
mRNA. Different regions of the human ATXN3 gene were selected to design anti-ATXN3 
microRNAs (miATXN3) constructs (Figure 1a). All miATXN3 constructs were designed 
to specifically target the human ATXN3 transcripts with high to full conservation for 
non-human primates, mouse and rat ATXN3. The miATXN3 sequences were embedded 
in the engineered pre-miR-451 scaffold and expressed by the ubiquitous CAG promoter 
that consists of the cytomegalovirus immediate-early enhancer fused to chicken β-actin 
promoter (Figure 1b). This promoter has been broadly used in central nervous system (CNS) 
indications, showing stable and high transgene expression32. To test the silencing efficacy 
of the miATXN3 constructs, we designed a Luc reporter bearing complementary ATXN3 
target mRNA fused to the renilla luciferase (RL) gene (Figure 1c). The firefly luciferase 
(FL) gene was independently expressed from RL in the same reporter to correct for 
transfection efficiency. We co-transfected the miATXN3 constructs with the Luc reporter 
and prescreened for the best candidates. miATXN3_7, miATXN3_9 and miATXN3_11 
were selected for further testing as these candidates showed knockdown on the Luc 
reporter at lower concentrations and reached up to 80-90% knockdown efficiencies at 
higher concentrations (Figure 1D).
Strong silencing of endogenous ATXN3 and ataxin-3 protein by miATXN3
We next investigated whether the selected miATXN3 candidates were capable of reducing 
the endogenous levels of total ATXN3 mRNA and protein in HEK293T cells. Cells were 
transfected with the miATXN3_7, miATXN3_9 or miATXN3_11 and the endogenous 
levels of ATXN3 mRNA was determined 2 days post-transfection by quantitative reverse 
transcription PCR (RT-qPCR). A significant reduction was observed by all three miATXN3 
constructs (Figure 2a). The most effective candidate was miATXN3_9 with a silencing 
efficacy of 52%. Consistently, silencing of the ATXN3 mRNA also resulted in significant 
reduction of ataxin-3 protein with up to 75% reduction achieved with miATXN3_9 
(Figure 2b). Thus, all three selected candidates can reduce ATXN3 mRNA and protein in 
transfected cells, miATXN3_9 being the most potent. 
AAV5-miATXN3 is highly effective in human iPSC-neurons
To further confirm the silencing of ATXN3 in the context of a gene therapy for SCA3, 
we incorporated all three candidates in AAV5. Subsequently, increasing doses of AAV5-
miATXN3 were tested in iPSC-neurons. Human iPSCs were differentiated into frontal 
brain-like neurons which represent mainly neurons of the frontal cortex. About 90% of 
these neurons expressed beta tubulin III indicating a successful differentiation.33 The cells 
were transduced with AAV5-miATXN3_7, AAV5-miATXN3_9 or AAV5-miATXN3_11 for 
two weeks. As shown previously, at this time point, about 80% of cells are GFP positive.33 
Following miATXN3 transductions, the silencing efficacy of ATXN3 mRNA was determined. 
ATXN3 mRNA were reduced up to 65% in a dose dependent manner by all three miATXN3 
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Figure 1. Design and screening of engineered miATXN3 constructs. a) Schematic representation of 
the human ATXN3 gene and miATXN3 binding sites. The ATXN3 gene (NG_008198.2) consists 
of 11 exons shown by the numbered black boxes. The white boxes represent the 5’ and 3’ 
UTR’s. The CAG expansion in exon 10 is depicted by a red triangle. The position of the miATXN3 
candidates are shown on top of the exons and indicated with numbers 1 till 11. miATXN3_3, 
miATXN3_8 and miATXN3_9 are exon spanning. b) Schematic representation of the miATXN3 
constructs. Each construct was expressed by the CAG promotor, followed by the primary miATXN3 
sequence in the miR-451 scaffold, and a human growth hormone polyadenylation (hGH polyA) 
signal. c) Schematic representation of the Luc reporter. The whole sequence of the ATXN3 mRNA 
(NM_004993.5) was cloned downstream of the RL gene. In addition, FL was co-expressed from 
the vector as an internal control. d) Dose dependent knockdown of ATXN3 Luc reporter by miATXN3 
constructs. HEK293T cells were co-transfected with 50 ng of the Luc reporter and 0.1, 1, 10 and 
100 ng of the miATXN3 constructs. RL and FL were measured 2 days post-transfection and RL was 
normalized to FL expression. Scrambled microRNA (miScr) served as a negative control and was 
set at 100%.
candidates (Figure 3a). Consistent with the knockdown of the Luc reporter, AAV5-
miATXN3_9 had the strongest silencing efficacy in iPSC-neurons. The mature miATXN3 
guide strands levels were also determined by a small RNA TaqMan assay. All three mature 
miATXN3 were expressed in the cell in a dose dependent manner, suggesting a successful 
transduction by AAV5-miATXN3 and processing into a mature microRNA (Figure 3b). 
No Saturation of endogenous RNAi machinery by miATXN3
As microRNA overexpression can lead to toxicity, we determined the overall expression 
of the miATXN3 candidates in human transduced iPSC-neurons relative to other 
endogenous microRNAs. Small transcriptome analysis was performed on total RNAs 
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Figure 2. Silencing of ATXN3 mRNA and protein in HEK293T cells. a) Endogenous knockdown ATXN3 
mRNA by the selected miATXN3 candidates. RT-qPCR ATXN3 mRNA was performed on RNA from 
HEK293T cells that were transfected with 250 ng of miATXN3_7, miATXN3_9 or miATXN3_11 
for 3 days. mRNA input levels were normalized to GAPDH mRNA. Cells transfected with a GFP 
construct served as negative control and was set at 100%. b) Silencing of total ataxin-3 protein. 
HEK293T cells were transfected as describe in A and protein expression was determined by 
western blot. α tubulin was included as internal control. Western blot intensity bands of ataxin-3 
was quantitated and the knockdown was calculated relative to GFP. Data were analyzed using 
a multiple comparison one-way ANOVA to determine statistically significances of cells treated 
the miATXN3 constructs. The p-values are listed in the graph by asterisks: *p < 0.05; **p < 
0.01; ***p < 0.001; ****p < 0.0001. Each graph represents the mean values with standard 
deviation (n=3).
isolated from frontal brain-like neurons that were transduced with AAV5-miATXN3_7, 
AAV5-miATXN3_9 or AAV5-miATXN3_11 for two weeks. We then compared the total 
amount of reads corresponding to the mature guide strand sequences of miATXN3_7, 
miATXN3_9 and miATXN3_11 to the total amount of reads of other natural expressed 
microRNAs found in the cell (Figure 3c). All three miATXN3 candidates were expressed 
at normal levels and within the expression range of other natural microRNAs in the cell, 
thus the microRNA biogenesis system was not overloaded. miATXN3_9 had the highest 
expression, consistent with its strong silencing efficacy. 
miATXN3 is processed into exclusively guide strands in human iPSC-
neurons
The miATXN3 candidates were incorporated in the natural human precursor miR-451 
scaffold. miR-451 is processed in the non-canonical pathway, first by Drosha to generate 
a precursor microRNA (pre-miATXN3). The pre-miATXN3 is then transported by exportin 
5 (EXP5) into the cytoplasm for further processing by Argonaute 2 (AGO2) and poly(A)-
specific ribonuclease (PARN)34–38. Ago2 cleaves the 3′ arm of pre-miR-451 by its slicer 
activity and generates a ~30-nt intermediate that is further trimmed by PARN to generate 
Chapter 4
134
4
Figure 3. Silencing of ATXN3 mRNA by AAV5-miC in human iPSC-neurons. a) Dose dependent 
silencing of ATXN3 in transduced iPSC-neurons. Frontal brain-like neurons were transduced with 
2.4e12, 2.4e11 and 2.4e10 gc of miATXN3_7, miATXN3_9 or miATXN3_11 incorporated into 
AAV5. RNA was isolated 2 weeks post-transduction and ATXN3 mRNA levels was determined by 
RT-qPCR. mRNA input was normalized to GAPDH and set relative to PBS treated cells. b) Levels of 
mature miATXN3 guide strands in transduced cells. Performed as described in (a). Expression of 
the mature miATXN3_7, miATXN3_9 and miATXN3_11 were determined by small RNA TaqMan. 
MicroRNA input levels were normalized to U6 small nuclear RNA and set relative to PBS treated 
cells. c) Relative miATXN3 expression levels in transduced cells by small RNA sequencing. Frontal 
brain-like neurons were transduced with 2.4e12 gc miATXN3_7, miATXN3_9 or miATXN3_11 
incorporated in AAV5. Small RNA sequencing was performed 2 weeks post-transduction. The total 
amount of small RNA reads corresponding the three lead miATXN3 candidates shown by the black 
arrows. The total amount of reads from other natural expressed endogenous microRNAs are shown 
in grey. d) Processing of miATXN3 in iPSC-neurons by small RNA sequencing. Frontal brain-like 
neurons were transduced as described in (c). The secondary miATXN3 structure based on miRbase 
prediction are shown on the first row, including their predicted 22 nucleotide guide strands shown 
in red. The sequence distribution of the different guide strand length (nt) mapping to miATXN3_7, 
miATXN3_9 and miATXN3_11 pre-microRNA sequences in miR451 scaffold were calculated in 
percentage (% reads). 
a mature miATXN3 of ~22 nucleotides. The trimming is not essential for efficiency and 
mature guide strands longer than the mature length can still be functional39. However, 
mature microRNAs that are too long could increase the risk of binding to off-target genes. 
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Figure 3. (continued)
The processing was investigated by small transcriptome analysis and all three miATXN3 
candidates resulted into exclusively guide strands between 19 to 30 nucleotides long, 
with no passenger strands detected (Figure 3d). However, the individual length of mature 
guide strands that were generated varied between the three miATXN3 candidates. 
The majority of miATXN3_7 guide strands were between 2 to 7 nucleotides longer at 
the 3’ end than the in silico 22-nucleotide prediction. miATXN3_9 was processed into 
primarily 22 nucleotides guide strands, as was predicted on mfold. The processing of 
miATXN3_11 mainly generated guide strands between 1 to 4 extra nucleotides at the 3’ 
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end than predicted. Thus, Drosha cleavage sites at 5’ end of the mature guide strand 
was precise for all the miATXN3 candidates but the trimming at the 3’ ends by PARN was 
different and resulted to a variety of mature lengths. 
Overall, no passenger strands were detected by the miATXN3 candidates, and 
the processing of miATXN3_9 was the closest to our prediction. 
Diffused AAV5 transduction of cerebellum and brain stem upon 
administration in the cisterna magna or DCN of SCA3 knock-in mice
The primary pathology in SCA3 is degeneration of the cerebellum and brain stem. 
Thus, for an AAV-based gene therapy for SCA3, diffused transduction of both brain 
structures is required in order to prevent neuronal dysfunction caused by mutant ataxin-3 
protein. To determine the most effective delivery route needed for transduction of 
the cerebellum and brain stem, a study was conducted in a SCA3 knock-in mouse model. 
The SCA3 knock-in mouse model was generated using Zinc Finger technology by cutting 
the murine (CAG)6 and subsequent homologous recombination with a (CAACAGCAG)48 
donor vector with interrupted repeat. This mouse model was characterized to express 
a mutant ataxin-3 protein with a 304 glutamine repeat. Three routes of injection were 
explored; (1) intracerebroventricular (ICV), (2) intracisterna magna, or (3) bilateral into 
the deep cerebellar nuclei (DCN) (Figure 4a). Injections were performed with AAV5-
miATXN3_7, AAV5-miATXN3_9 or AAV5-miATXN3_11, whereas AAV5-GFP was taken 
along as control: The animals were sacrificed 6 weeks post-surgery and qPCR of 
the transgene was performed on the miATXN3 or GFP to determine the biodistribution 
in the cortex, cerebellum and brain stem. ICV administration resulted in a relative low 
vector copy distribution to all three analyzed tissues. Some transduction was observed 
only in the cortex (Figure 4b). Administration into the cisterna magna resulted in low 
transduction of the cortex but strong transduction of the brain stem and cerebellum 
(Figure 4c). The highest transduction was detected in the brain stem with up to 2.9 
x107 genome copies (gc)/µg tissue DNA. One mouse that received AAV5-miATXN3_9 in 
the cisterna magna was excluded because no genomic copies were detected, suggesting 
that the injection failed. Direct injection into the DCN also resulted in relatively high 
transduction of the cerebellum and the brain stem. Compared to cisterna magna 
administration, DCN injection resulted in better transduction of the cerebellum and less 
transduction of the brain stem (Figure 4d). Up to 4.6 x106 gc/µg tissue DNA was detected 
in the cerebellum. Based on the current observation, we concluded that administration 
into the cisterna magna resulted in the highest combined transduction of both cerebellum 
and brain stem of mice.
Significant reduction of ATXN3 mRNA in SCA3 knock-in mice brain
Having established distribution of AAV5 upon different routes of injection, we further 
investigated the efficacy of the AAV5-miATXN3 candidates to reduce the total ATXN3 
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mRNA in the transduced tissues. Direct injection into the DCN showed highest expression 
of mature miATXN3 in the cerebellum (Figure 5a). miATXN3_9 had the highest microRNA 
expression, consistent with the observation in vitro. The microRNA expression correlated 
well with a mild (~15-20%) but significant reduction of ATXN3 mRNA by miATXN3_9 
and miATXN3_11 in the cerebellum (Figure 5b). Administration to the cisterna magna 
resulted into lower mature microRNA expression in the cerebellum as compared to 
DCN injection (Figure 5c). Nevertheless, miATXN3_9 was best expressed and resulted in 
significant lowering (~15%) of ATXN3 mRNA in the cerebellum (Figure 5d). The highest 
microRNA expression and silencing efficacy from all three delivery routes was observed 
in the brain stem after administration in the cisterna magna (Figure 5e-f). Expression of 
the miATXN3 candidates were high in the brain stem and all led to a strong reduction 
of ATXN3 mRNA of about 40%. Both AAV5-miATXN3_9 and AAV5-miATXN3_11 had 
comparable efficacies in the brain stem although the significance of AAV5-miATXN3_9 
was smaller because one mouse was excluded. Overall, we concluded that administration 
of AAV5-miATXN3_9 to the cisterna magna resulted in ATXN3 mRNA reduction in both 
cerebellum and brain stem, which are the main areas affected in SCA3 patients.
Reduction of mutant ataxin-3 protein in brain stem and cerebellum of 
mice
Heterozygous SCA3 knock-in mice showed reduced body weight in male mice with 48 
weeks in life. Additionally, male and female SCA3 knock-in mice developed an ataxic 
gait with 18 months of age. Neuropathologically, accumulation of mutant ataxin-3 and 
protein aggregates were found in cerebellum, DCNs and pons of heterozygous SCA3 
knock-in mice starting at the age of three months with higher amounts at later age.
Figure 5. Silencing of mutant ataxin-3 in SCA3 knock-in mice. a) Expression of mature miATXN3 guide 
strands in the cerebellum after DCN administration. Total RNA was isolated from the cerebellum 
for small RNA TaqMan. MicroRNA input levels was normalized to U6 small nuclear RNA and set 
relative to AAV-GFP treated mice. b) Lowering of total ATXN3 mRNA in cerebellum of DCN injected 
mice. Total RNA was isolated from cerebellum and RT-qPCR was performed to detect the mouse 
wildtype ATXN3 mRNA. RNA input levels were normalized to GAPDH and set relative to AAV-GFP 
treated mice. c) Expression of mature miATXN3 guide strands in the brain stem after cisterna magna 
administration. Performed as described in (a). d) Lowering of total ATXN3 mRNA in cerebellum of 
cisterna magna injected mice. Performed as described in (b). e) Expression of mature miATXN3 
guide strands in the brain stem after cisterna magna administration. Performed as described in 
(a). f) Lowering of total ATXN3 mRNA in brain stem of cisterna magna injected mice. Performed 
as described in (b). g) Reduction of mutant ataxin-3 protein in the brain stem after cisterna 
magna delivery. TR-FRET immuno-assay was performed on tissue homogenates to specifically 
detect the mutant ataxin-3 protein containing more than 37 glutamine repeats (no detection of 
wildtype mouse ataxin-3). H) Reduction of mutant ataxin-3 protein in the cerebellum after cisterna 
magna delivery.
Chapter 4
140
4
The polyQ expansion within the mutant ataxin-3 protein causes toxic gain-of-function, 
leading to the formation of neuronal intranuclear inclusions, neuronal dysfunction and 
degeneration15,26. Decreasing the levels of the mutant proteins leads to therapeutic 
benefit in several preclinical models18,26–28,40. We used a time-resolved fluorescence energy 
transfer (TR-FRET) immuno-assay to measure the levels of mutant ataxin-3 in cerebellum 
and brain stem homogenates of treated mice41. We found a strong lowering of up to 
64% of the mutant ataxin-3 protein in the cerebellum and brain stem homogenates of 
mice receiving AAV5-miATXN3_9 and AAV5-miATXN3_11 in the cisterna magna (Figure 
5g-h). The reduction of the mutant ataxin-3 protein in the cerebellum and brain stem of 
mice confirmed the feasibility of an RNAi based gene therapy approach for lowering of 
mutated ataxin-3 protein in the affected brain regions of patients.
Prediction of off-target genes due to miATXN3 treatment
We next investigated whether miATXN3 treatment results in major alterations in RNA 
expression profile in SCA3 knock-in mouse brain and human-derived iPSC-neurons. 
Although the miATXN3 candidates were designed to specifically target ATXN3 mRNA 
transcript, complementarity with other transcripts might result in off-target lowering 
of other genes. The off-target activity of AAV5-miATXN3_7, AAV5-miATXN3_9 and 
AAV5-miATXN3_11 was predicted using BLAST to search for transcripts with (partial) 
complementarity with the guide strand using the homo sapiens reference RNA sequence 
database (refseq_rna [taxid 9606]). The BLAST results were subsequently compared to 
RNA sequencing expression values that were performed on total RNA from human-
derived frontal brain-like neurons transduced with the three AAV5-miATXN3 candidates 
and the formulation buffer (control). As expected, all three candidates showed a 100% 
coverage to ATXN3 mRNA and RNA sequencing data revealed a significant downregulation 
of ATXN3 mRNA (Table S2). Some other genes showed partial coverage to ATXN3 mRNA 
and minor alterations (<1.5-fold) were found in those genes by RNA sequencing. 
microRNAs can act by binding along the entire mRNA, but studies have shown that 
the 3’ untranslated region (3’ UTR) of transcripts is the most frequently target site for 
microRNAs.42 Further analysis was performed on all three miATXN3 candidates using 
siSPOTR to predict the binding of their predicted seed sequences to the 3’ UTR of human 
target transcripts.43 The transcript Probability of off-Target Score (tPOTS) were calculated 
by siSPOTR based on the number and type of seed matches (8mer, 7mer-M8, 7mer-1A 
and 6mer) found in each transcript.43 The top 20 genes with the highest tPOTS were 
compared to the gene expression values obtained by RNA sequencing in human-derived 
frontal brain-like neurons treated with AAV5-miATXN3_7, AAV5-miATXN3_9, AAV5-
miATXN3_11 or control (Table S3-S5). We did not find a correlation between tPOTS and 
gene expression. In the most cases, only minor changes in gene expression (<1.5-fold) 
were accompanied with the miATXN3-mediated reduction of ATXN3. In frontal brain-like 
neurons treated with AAV5-miATXN3_7, expression of all 20 genes were smaller than 
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1.5-fold. For AAV5-miATXN3_9 treated cells, only two genes showed a higher alteration 
in expression. Prostaglandin-endoperoxide synthase 1(PTGS1) was found downregulated 
(-3.4 fold change) and Formin 1 (FMN1) was upregulated (2.1 fold change). In AAV5-
miATXN3_11 treated cells, Tudor Domain Containing 6 (TDRD6) was found downregulated 
(-1.6 fold change) and Lysyl oxidase (LOX) was upregulated (1.8 fold change).
The 3’ UTR off-target analysis was also performed on RNA derived from brain stem of 
SCA3 knock-in mice. We selected mice injected with AAV5-miATXN3_9 in the cisterna 
magna, as we observed the strongest knockdown using this route of administration. 
Consistent with the human cells, no correlation was found between tPOTS values and 
the expression of two genes was slightly over the 1.5 -fold threshold (table S6). Overall, 
we found no major alterations in gene expression after treatment with the three miATXN3 
candidates, suggesting that the risks for off-target effects are limited.
Widespread AAV5-GFP transduction in minipig brain after intrathecal 
administration
The translation of preclinical studies performed in rodent models to the clinic is 
a challenging process, particularly due to the relatively small brain and spinal cord sizes 
of rodents. Successful delivery of AAV to reach the target tissues in humans is likely 
dependent on brain size and structure. Therefore, we further investigated the delivery 
of AAV5 in a minipig CNS in order to predict the biodistribution of AAV5 more precisely. 
The brain stem and cerebellum are the primary affected regions in SCA3 patients and 
transduction of these brain region is required for an ATXN3-based lowering gene therapy. 
Because cisterna magna injection in minipig was not feasible due the relatively thick neck, 
we investigated the biodistribution of AAV5 upon intrathecal injection in the lumbar 
region of the spinal cord. The biodistribution of AAV5 was determined by vector DNA 
genome copies and immunohistochemistry for the transgene (GFP). We found a relatively 
equal distribution of the vector DNA across the whole brain, including the cerebellum 
and brain stem (Figure 6a). The cerebellar cortex, DCN and brain stem were transduced 
at therapeutically relevant doses of ~105 genomic copies per µg DNA. To visualize 
AAV5 distribution in the brain, GFP immunohistochemical analysis was performed and 
the widespread GFP expression in the minipig brain confirmed an equally distribution 
of AAV5 (Figure 6b). Overall, the current data suggest that intrathecal administration of 
AAV5 could be sufficient for an AAV-based ATXN3-lowering gene therapy.
Discussion
In the current study we focused on the development of a microRNA-based gene therapy 
that could benefit the entire human SCA3 patient population. We aimed for a non-allele 
selective reduction of human ATXN3 mRNA as this approach has been tested in several 
rodent preclinical models and showed no overt symptoms or toxicity27,44. Furthermore, 
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ataxin-3 knock-out mice have no major abnormalities suggesting that lowering of ataxin-3 
in the context of SCA3 is safe and effective44. An additional advantage of this approach 
is that the entire human patient population can be treated. Allele-specific approaches for 
downregulation of only the mutant ataxin-3 have also been tested. For example, allele 
specific silencing was achieved using short hairpin (sh)RNAs directed against a single 
nucleotide polymorphisms (SNP) unique to the mutant ataxin-3 transcript which seems to 
be present in over 70% of SCA3 patients. The SNP-specific shRNA was able to specifically 
silence mutant ataxin-3 and was found to be neuroprotective in SCA3 mouse and rat 
models45. Single-stranded silencing RNAs (ssRNAs), ASO and peptide nucleic acids (PNAs) 
directly targeting the expanded CAG repeat also resulted in translational blockage of 
only the mutant ataxin-346–49. The latter approach is very interesting because it may be 
used to treat multiple polyQ diseases but knockdown of several other endogenous CAG 
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repeat-containing transcripts, like huntingtin (HTT), TATA-binding protein (TBP) and other 
ATXNs might be detrimental.
Several miATXN3 were designed in the natural human miR-451 scaffold to target 
different regions within exons of ATXN3 mRNA by using the knowledge and technologies 
developed for a Huntington’s disease RNAi gene therapy29–31. A pre-screening of 
the miATXN3 candidates were performed on a Luc reporter construct and miATXN3_7, 
miATXN3_9 and miATXN3_11 showed the highest silencing efficacy. All three candidates 
also successfully reduced the endogenous ATXN3 mRNA and protein levels in cells and 
the strongest efficacy was consistently obtained with miATXN3_9.
For clinical development, it is important to establish the fidelity of cellular processing 
of the microRNA in the target human tissue and select the candidates with the least 
probability for off-target effects. For this reason, we analyzed the microRNA processing 
patterns in iPSC-neurons transduced with the three selected AAV5-miATXN3 candidates by 
small RNA sequencing. We found high expression of all three miATXN3 in transduced iPSC-
neurons, but they were not overexpressed, even after transducing the cells with very high 
concentration of AAV-miATXN3. Furthermore, no dysregulation in microRNA molecules 
was observed, strongly limiting the possibility of off-target effects due to the saturation 
Figure 6. AAV5 biodistribution in brain of minipig upon intrathecal administration. A) Vector copy 
distribution in brain of a 7 months old Gottingen minipig. The minipig was injected with 5 mL of 
AAV5-GFP (4 x 1013 gc/ml) into the lumbar region. The minipig was sacrificed 4 weeks post injection 
and DNA was isolated from several punches of the brain. RT-qPCR was performed to determine 
the vector copy distribution. The genomic copies per µg DNA were calculated for each brain region 
using a standard curve. B) Widespread GFP expression in minipig brain transduced with AAV5-GFP. 
Brains were fixed in paraformaldehyde, embedded in paraffin and serially cut in 5 µm sections. GFP 
staining was performed to visualize GFP expression throughout the brain. Different area of the brain 
was numbered according to Atlas of the Gottingen minipig brain (Cense): 1) PFC lateral, 2) PFC 
lateral, 3) PFC ventral, 4) Motor cortex M1, 5) Motor cortex M1, 6) Cingulate cortex, 7) PFC lateral, 
8) PFC medial, 9) PFC ventral, 10) Motor cortex, 11) Somatosensory S1 dorsal,12) Frontal lobe WM, 
13) Cingulate cortex, 14) Centrum semioval WM , 15) Somatosensory S1 ventral, 16) Insular cortex, 
17) PFC medial, 18) Olfactory cortex 19) M1/S1 cortex, 20) M1 cortex, 21) M1 cortex, 22) Cingulate 
cortex, 23) Somatosensory S1dorsal, 24) Insular cortex, 25) Nuc Caudate (frontal), 26) Putamen 
(F), 27) Nucleus Accumbens, 28) Motor cortex M1, 29) Cingulate cortex, 30) Occipital lobe (Visual 
cortex), 31) Occipital lobe (Visual cortex), 32) Somatosensory S1 ventral , 33) Centrum semioval WM 
34) Insular lobe , 35) Caudate, 36) Caudate, 37) Putamen, 38) Putamen 39) Nucleus Accumbens, 
40) Occipital lobe (Visual cortex), 41) Cingulate cortex, 42) Cingulate cortex, 43) Somatosensory S1 
ventral, 44) Caudate, 45) Insular cortex, 46) Insular cortex, 47) Putamen, 48) Globus pallidus, 49) 
Visual cortex, 50) Cingulate cortex, 51) Visual cortex, 52) Centrum semiovale WM, 53) Temporal 
cortex, 54) Temporal lobe WM, 55) Insular cortex, 56) Caudate, 57) Thalamus anterior, 58) Thalamus 
ventral, 59) Putamen, 60) Globus pallidus, 61) Visual cortex, 62) Visual cortex, 63) Visual cortex, 64) 
Occipital lobe, 65)Temporal cortex, 66) Insular cortex, 67) Hippocampus, 68) Thalamus (Medial), 69) 
Thalamus (lateral), 70) Thalamus (ventral), 71) Temporal cortex, 72) Occipital cortex (Visual cortex), 
73) Cerebellum lobe, 74) Cerebellum lobe, 75) Reticular formation (pons), 76) Cerebellum lobe, 
77) Cerebellum lobe, 78) Cerebellar nuclei, 79) Medulla oblongata, 80) Cerebellar peduncle, 81) 
Reticular formation (pons).
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of the endogenous RNAi pathway. We detected a typical variability in the read length 
(19-30 nucleotides) occurring when the miR-451 precursor is intracellularly processed. 
This observation is consistent with expected processing mechanism of miR-451 which 
escapes Dicer cleavage in the cytoplasm and is instead processed by Ago2. Ago2 cleavage 
generates a 30-nucleotide guide strand which is further trimmed by PARN leading to 
the observed variability in length. The processing and expression varied per miATXN3, and 
miATXN3_9 was the most efficiently processed and the highest expressed of the three 
tested miATXN3s. The higher expression could be a result of a more efficient processing 
because the thermodynamic stability at the loop of miATXN3_9 is lower, compared to 
miATXN3_7 and miATXN3_11. miATXN3_9 has a A-U nucleotide at the loop, thus less 
energy may be needed to break this A-U bond by PARN. miATXN3_7 and miATXN3_11 
both have a G-C nucleotide. The efficient processing and high expression of miATXN3_9 
is likely to be responsible for its strong silencing efficacy. For miATXN3_9 the most 
abundant reads were, as predicted in silico, 22 nucleotides long and showed the exact 
miATNX3 guide strand sequence. The second most abundant reads had either 1 or 2 
extra nucleotides at the 3’ end and no passenger strands were detected, indicating that 
off-target effects due to microRNA-like effect of the passenger strand can be excluded. 
The absence of a passenger strand associated with the miR-451 precursor also confirms 
our previous findings in the human neuronal cells and animal models, that this scaffold 
does not produce a passenger strand.30,50 
The success of a RNAi-based gene therapy for SCA3 is also dependent on the delivery 
method to reach the affected brain regions. AAV vectors are of particular interest due to 
their high safety profile and different AAV serotypes have proven to be stable and safe, 
each with different tropism for a wide range of tissues51–54. AAVs can be delivered to 
the CNS either by systemic administration, direct intraparenchymal administration or in 
the cerebrospinal fluid (CSF). Systemic AAV infusion has been used in preclinical models 
and in clinical studies and some serotypes were identified that can cross the blood brain 
barrier55,56. Based on our own experience we anticipate that intravenous (IV) infusion of 
AAV would not be sufficient to achieve silencing of ATXN3 in the cerebellum and brain 
stem with the current technology. Direct injection of AAV in the parenchyma of brain is 
more invasive but studies in rodents, minipig and non-human primates consistently showed 
very strong transduction of the deeper brain structures and vector spread to the adjacent 
brain areas29,57. The target regions in SCA3 patients are the cerebellum and brain stem 
and they are the primary affected areas in the early stages of the disease. Therefore, direct 
intraparenchymal administration would not result in spread of the vector to those areas 
and a CSF-mediated delivery would be necessary. In SCA3 mouse models, ICV injection of 
ASOs resulted into sufficient reduction of the mutant ataxin-3 in the cerebellum and brain 
stem58. microRNAs delivered by AAV directly in the cerebellum (DCN) also reduced mutant 
ataxin-3 in the cerebellum, while the effect was not evaluated in the brain stem28,59. We 
investigated the transduction of cerebellum and brain stem of mice injected with AAV5-
miATXN3 in the CSF via ICV injection or cisterna magna, or directly to the cerebellum via 
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DCN injection. Upon ICV injection, the transduction of the cerebellum and brain stem of 
mice was low and not sufficient to expect a therapeutic benefit. In contrast, intracisterna 
magna administration resulted in transduction of the brain stem and cerebellum, with 
the highest transduction in the brain stem. DCN injection also transduced both brain 
regions but transduction was the highest in the cerebellum. However, a single delivery 
to the cisterna magna resulted in the most optimal transduction of cerebellum and brain 
stem combined. Consistently, lowering of ATXN3 mRNA and the mutant ataxin-3 protein 
were observed in both cerebellum and brain stem of SCA3 knock-in mice injected with 
AAV5-miATXN3_9 and AAV5-miATXN3_11 in the cisterna magna. The efficacy of both 
miATXN3 candidates were comparable, despite the fact that AAV5-miATXN3_9 was 
the most effective candidate in our in vitro screening. A logical explanation is that while 
the miATXN3_11 target sequence had 100% homology with the human and mouse 
ATXN3 gene, miATXN3_9 had one nucleotide mismatch with the mouse ATXN3. This 
means that the efficacy of miATXN3_9 seen could be underestimated in the mouse model 
used in this study as mismatches interferes with the binding efficacy of a microRNA. 
Nevertheless, we showed that miATXN3_9 and miATXN3_11 are highly effective by 
mediating a strong knock-down of the mutant ataxin-3 protein in the cerebellum and 
brain stem after a single administration in the cisterna magna. Previous studies using 
RNAi and ASO’s showed that reduction of about 37 up to 80% of the mutant ataxin 3 
protein is sufficient to reverse molecular phenotypes associated with mutant ataxin-3 
gain of toxicity  in SCA3. We are aiming for a 40-50% reduction of the mRNA and 
showed that we can reach more that 50% knockdown of ATXN3 mRNA and mutant 
ataxin-3 protein lowering of 53.1% in the cerebellum and 64% in the brain stem which is 
within the therapeutic range. To further predict potential off-target genes, we examined 
the impact of AAV5-miATXN3 treatment on the overall gene expression profile. In-silico 
analysis was performed using BLAST to search for off-target genes with partial guide-
strand complementarity to human and mice microRNA and siSPOTR tool was used to 
predict potential off-target effects related to the miATXN3 seed sequence. The data 
obtain by BLAST and siSPOTR was compared to an unbiased RNA sequencing to look 
at differential changes in gene expression upon treatment. We selected an exclusion 
criterion of -1.5 – 1.5-fold change, based on observations from previous studies in large 
animals that most of the genes within this range do not show significant changes when 
this data is revalidated with other applications such as qPCR.  Two genes (PTGS1 and 
FMN) were differentially expressed upon AAV5-miATXN3_9 treatment. PTGS1 encodes 
the enzyme Cyclooxygenase (COX) which is involved in conversion of arachinodate to 
prostaglandin. PTGS1 is also downregulated by nonsteroidal anti-inflammatory drugs 
such as aspirin and ibuprofen  suggesting its downregulation is tolerable in humans.60 
Interestingly, ibropufen was found to have neuroprotective properties in SCA3 mouse 
model by increasing levels of neural progenitors proliferation and synaptic markers.61 
Whether PTGS1 downregulation by ibropufen may have play a role is unclear and may be 
worth investigating. If this is the case, a combination therapy based on PTGS1 lowering 
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and ATXN3 downregulation could add to therapeutic benefit.  FMN belongs to the formin 
family of proteins and is involved in actin nucleation.62 Upregulation of FMN has not been 
linked to diseases. Similarly, two genes (TDRD6 and LOX1) were slightly modulated upon 
AAV5-miATXN3-11 treatment. TDRD6 encodes a protein that is specific to the male germ 
line and essential for chromatoid body structure.63 TDRD6 is usually only expressed in 
mid prophase I spermatocytes. Thus, its downregulation in the brain is not expected to 
be relevant. LOX1 is a member of the lysyl oxidase family and has a role in crosslinking 
of collagens and elastin.64 Its role in disease is unclear as it has been reported to enhance 
metastasis of certain cancers, but it was also shown to have tumor suppressor function.65–68 
Overall, dysregulation in one of these genes were not directly linked to any known 
diseases, increasing our confidence that AAV5-miATXN3 mediated silencing of ATXN3 
mRNA may have limited risk for off-target effects. However, further investigation will be 
needed across multiple human cellular systems and larger animal models transduced with 
therapeutically relevant doses of AAV5-miATXN3 to better predict gene dysregulation 
and their effects after treatment with AAV5-miATXN3 in humans.
We demonstrated thus far that AAV5-miATXN3 can successfully lower the mutant 
ATXN3 mRNA and protein in iPSC-neurons and SCA3 knock-in mice. One major challenge 
remains the translation of AAV5 delivery results acquired from the mouse model to 
humans. Multiple neuronal systems are affected in SCA3 patients and degeneration of 
neurons is especially observed in the cerebellum, brainstem, basal ganglia, some cranial 
nerves and the spinal cord.1,17,69 In the cerebellum, neurodegeneration is observed in 
dentate nucleus. The cerebellar cortex seems less affected but loss of granule and 
Purkinje cells has been reported in the cerebellar vermis.1,70–73 Main areas affected in 
the brainstem include the vestibular, pontine and motor nuclei.1,71,74 Other regions such 
as the cerebral cortex, autonomic ganglia, striatum,  substantia nigra, nerve motor nuclei, 
Clarke’s column nuclei, the anterior horn of the spinal cord are also affected1,45,72,75 .  We 
investigated AAV5 delivery and distribution in a larger minipig model with a brain and 
spinal cord size that closely resemble the situation in humans. Because administration 
into the cisterna magna was not feasible, AAV5-GFP was administered intrathecally. 
Next to widespread vector distribution and transgene expression, successful transduction 
of the structures mostly affected in SCA3 patients was observed. The current data 
increase of our confidence that mutant ataxin-3 protein can be modulated in these brain 
regions.  Moving forward, further studies in large animal models is needed to determine 
the silencing efficacy and tolerability AAV5-miATXN3. 
In summary, we presented the development of a gene therapy for SCA3 patients 
based on non-allele specific lowering of ATXN3 mRNA and protein by AAV5-miATXN3. 
We demonstrated the efficacy in cellular models and in a SCA3 knock-in mouse model. 
In addition, we demonstrated that administration of AAV5 to the cisterna magna of mice 
can be successfully translated to intrathecal administration of a minipig to simultaneously 
transduce the cerebellum and brain stem, and potentially lower ATXN3 mRNA and mutant 
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ataxin-3 protein in these brain regions. The current preclinical data support the feasibility 
for an AAV-based microRNA gene therapy and further studies in animals with a larger 
brain would be required to investigate the translation of the current observations in 
the small mouse brain to a larger brain size closer to humans. 
Material and methods
DNA constructs
To generate the miATXN3 vectors, we searched for sequences on ATXN3 gene that were 
mostly conserved between human, non-human primates and rodents. The sequences 
were incorporated into the cellular miR-451 scaffold of humans. 200 nt 5’ and 3’ flanking 
regions were included with EcoRV and BamHI restriction sites and the mfold program (http://
unafold.rna.albany.edu/?q=mfold) was used to determine if the miATXN3 candidates are 
folded correctly into their secondary structures. The complete sequences were ordered 
from GeneArt gene synthesis (Invitrogen). These constructs were subsequently cloned 
into an expression vector containing the CMV immediate-early enhancer fused to chicken 
β-actin (CAG) promoter (Inovio, Plymouth Meeting, PA) using the EcoRV and BamHI sites. 
For generation of the Luc reporter, the complete ATXN3 mRNA (NM_004993.5) sequence 
was synthesized at GeneArt gene synthesis and cloned in the 3’UTR of the renilla luciferase 
(RL) gene of the psiCHECK-2 vector (Promega, Madison, WI). The firefly luciferase (FL) 
gene was also expressed in this vector and served as internal control.
Culture and transfections of HEK293T cells
Human embryonic kidney (HEK)293T were maintained in Dulbecco’s modified Eagle’s 
medium (DMEM) (Invitrogen) containing 10% fetal calf serum (Greiner, Kremsmünster, 
Austria), 100U/ml penicillin and 100U/ml streptomycin (Thermo Fisher, Waltham, MA), 
at 37 °C and 5% CO2. Transfections: For all assays, cells were seeded in 24-wells plates 
at a density of 0.1*106 cells per well in DMEM. Transfections in HEK293T cells were 
performed 1 day post-plating with Lipofectamine 2000 reagent (Invitrogen) according to 
the manufacturer’s instructions.
Luciferase assays
HEK293T cells were co-transfected with the miATXN3 expression constructs and the Luc 
reporter. The cells were lysed at 48 hours post-transfection in 100 µl 1x passive lysis 
buffer (Promega) by gentle rocking for 15 minutes at room temperature. The cell 
lysates were centrifuged for 5 minutes at 4,000 rpm to get rid of cell debris and 10 µl 
of the supernatant was used to measure FL and RL activities with the Dual-Luciferase 
Reporter Assay System (Promega). Relative luciferase activity was calculated as the ratio 
between RL and FL activities. 
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Culture of iPSC-neurons
Frontal brain-like neurons were generated as described previously.33 Control iPSC cells 
(ND42245) derived from fibroblast were ordered from Coriell biorepository and were 
cultured on Matrigel (corning) -coated 6 wells plates in mTeSR1 (STEMCELL). For embryoid 
body-based neural induction, iPSC cells were seeded on AggreWell800 plates and cultured 
in STEMdiff Neural Induction Medium (STEMCELL) for 5 days with daily medium changes. 
Embryoid bodies were harvested and plated on 6 wells plates coated with poly-D-lysine 
(Sigma-Aldrich) and laminin (Sigm-Aldrich) in STEMdiff Neural Induction Medium for 7 
days with daily medium changes. Rosettes were selected with rosette selection medium 
and plated on poly-D-lysine and laminin coated 6-wells plates in STEMdiff Neural Induction 
Medium for 24 hours. For differentiation into frontal brain-like neurons, STEMdiff Neural 
Induction Medium was replaced for STEMdiff Neuron Differentiation medium (STEMCELL) 
and neuroprogenitor cells were differentiated for 5 days. The neuroprogenitor cells were 
then plated on poly-D-lysine and laminin coated plates in STEMdiff Neuron Maturation 
medium (STEMCELL) for one week. The mature frontal brain-like neurons were stored in 
liquid nitrogen in neuroprogenitor freezing medium (STEMCELL).
Western blot
Western blot was performed to detect wildtype ataxin-3 protein expression in transfected 
HEK293T cells. In brief, cells were lysed using RIPA lysis buffer solution, containing Tris-HCL 
(pH 8,0), NaCl, 1% IGEPAL CA-630, 0,5% DOC and cOmplete protease inhibitor and 
extracted by centrifugation. Equal amounts of tissue (30°g) were loaded through a 10% 
SDS-PAGE gel. The gel was transferred to a bio-rad nitrocellulose membrane using bio-rad 
turbo transfer system, running for 30 minutes at 90V. Membranes were blocked for one 
hour in 3% milk in TBS, containing 0,1% Tween-20 (TBST), and incubated overnight with 
primary antibody mouse anti-ATXN3 (Abcam ab61392 1:1000) and mouse anti-α tubulin 
(Abcam ab13533 1:1000) at 4°C. Secondary antibody incubation was with horseradish 
peroxidase (HRP) conjugated rabbit anti-mouse (DAKO 1:5000) for one hour at 
room temperature. 
AAV5 vector production
AAV5 encoding miATXN3_7, miATXN3_9 and miATXN3_11 were produced by 
a baculovirus-based AAV production system as described previously30. Briefly, the miATXN3 
cassettes were obtained by digestion with restriction enzymes HindIII and PvuI and cloned 
in an uniQure transfer plasmid in order to generate an entry plasmid. The presence of 
the two inverted terminal repeats (ITRs) was confirmed by restriction digestion with 
SmaI. The ITR-CAG-miC cassettes were inserted in a recombinant baculovirus vector by 
homologous recombination in Spodoptera frugiperda Sf9 cells and clones were selected 
and screened by plague purification and PCR. The recombinant baculovirus containing 
the ITR-CAG-miC casettes were further amplified till P6 in Sf+ cells and screened for 
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the best production and stability by PCR and RT-qPCR. To generate AAV5, Sf+ cells were 
triple infected with three different recombinant baculoviruses expressing the ITRs-CAG-
miATXN3, the replicon enzyme and the capsid protein. The cells were lysed 72 hours 
after the triple infection and the crude lysate was treated with 50U/ml Benzonase (Merck, 
Darmstadt, Germany) for 1 hour at 37 °C. AAV5 was purified on an AVB Sepharose column 
(GE Healthcare, Little Chalfont, UK) using an AKTA purification system (GE Healthcare). 
The final titer concentration was determined by RT-qPCR with primers amplifying a 95bp 
fragment from the CAG promoter region. 
Transduction of iPSC-neurons
Mature frontal brain-like neurons were plated in 500µL STEMdiff Neuron Maturation 
medium (STEMCELL) at 0.3*106 cells per well in 24-wells plates. 1 week after plating, 
the cells were transduced with the 100µL, 10µL or 1µL of 2. 42x1013 gc/mL of AAV5-
miATXN3_7, AAV5-miATXN3_9, AAV5-miATXN3_11 or AAV5-GFP. The cells were 
incubated with AAV for 2 weeks and medium were changed twice a week. 
SCA3 mice and treatment groups
All procedures were approved by the local ethics committee at the Regierungspraesidium 
Tuebingen and performed in accordance with the German Animal Welfare Act and 
the guidelines of the Federation of European Laboratory Animal Science Associations 
based on the European Union legislation (Directive 2010/63/EU). All efforts were made to 
minimize the suffering and the number of animals used. 
Heterozygous SCA3 knock-in animals expressing 304 glutamines within the murine 
ataxin-3 polyQ locus were used in this study and maintained in a controlled facility in 
a 12-hour light/dark cycle with free access to food and water. 3 animals (2 males and 1 
female) were recruited to each treatment group (Table S1).
Viral delivery by stereotaxic injections and tissue collection in mice
Animals were injected at 3 months of age. For each injection, the animal was initially 
anaesthetized with 5 % isoflurane in an oxygen-air mixture in the induction box. After 
induction, the animal was injected intraperitoneally with a combination of fentanyl 
0.05 mg/kg, midazolam 5 mg/kg and medetomidine 0.5 mg/kg and transferred to 
the stereotaxic frame. Isoflurane was then delivered via the facemask and reduced to 
1.5-2.0 % depending on the weight and responses of the animal. Eye ointment was 
given to the animal to prevent the eyes from drying during surgery. The body temperature 
of the animal was monitored and maintained at 37 ± 0.5 °C through a rectal probe 
and a negative feedback controlled heat pad (Harvard Apparatus, US). The depth of 
anesthesia was checked by the lack of pedal withdrawal to a firmly pinched hind toe or 
foot. The head was shaved and disinfected, and local anesthetic agent (2% lidocaine, 5 
mg/kg) was injected subcutaneously. For ICV and DCN injections, bregma and lambda 
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were used for alignments and locating the injection sites after midline skin incision. Small 
skull hole was drilled to expose the dura over the injection site. Craniotomy (0.5-0.8 mm 
in diameter) was performed using a microscope or magnifying glass and a pneumatic 
drill. In the case of cisterna magna injections, skin incision was performed at the neck 
region. Dura mater was exposed by blunt dissection of the subcutaneous neck muscles. 
The animal received bilateral DCN (AP-6.5, ML±1, DV-2.8), ICV (AP+0.3, ML+1, DV-3) 
or cisterna magna injection according to the assigned treatment group. 2.0 µl per 
hemisphere (bilateral DCN) or 10 µl (ICV and cisterna magna) of AAV5-miATXN3_7, AAV5-
miATXN3_9, AAV5-miATXN3_11 or AAV5-GFP was delivered at a rate of 0.25 µl/min 
using a microinjection pump (UMP3-1, WPI) with a 10 µl Hamilton syringe and a 32-gauge 
needle. The AAVs were titer matched at 2,42x1013 gc/mL. After the injection, the needle 
remained at the injection site for 5 mins before withdrawal. The animal was then sutured 
and given carprofen (5 mg/kg) subcutaneously as analgesics post-surgery. For recovery 
from anesthesia, the animal was given a mixture of naloxone (1.2 mg/kg), flumazenil (0.5 
mg/kg) und atipamezole (2.5mg/kg) subcutaneously and transferred to a warm (37°C) 
environment with access to food and water. The operated animal was returned to its 
home cage after recovery from anesthesia. All animals were given carprofen (5 mg/kg) 
subcutaneously every 24 hours and provided with antibiotics (enrofloxacin, 10mg/kg)-
containing water until the 3rd and 7th day post-surgery respectively. Health and other 
conditions of all animals were closely monitored throughout the project duration using 
score sheets.
All treated animals were euthanized 6 weeks after viral delivery. For the untreated 
group, animals were sacrificed at 4.5 months of age. The animals were given saturated 
carbon dioxide in the home cage until death. Tissues were dissected and snap frozen in 
liquid nitrogen and stored at -80°C for subsequent analyses.
RNA isolation
For all RNA isolation, cells and tissues were lysed in 300 µl Tryzol and RNA isolation 
was performed using the Direct-zol kit (R2061, ZYMO Research) according to 
the manufacturer protocol.
RT-qPCR, and microRNA TaqMan assay
To determine ATXN3 mRNA knockdown, total RNA was isolated as described above. 
Genomic DNA contamination was removed by DNAse treatment using recombinant 
shrimp ds DNase (ThemoFisher Scientific). First-strand complementary DNA was reverse 
transcribed using random hexamer primers with the Dynamo kit (Finnzymes, Espoo, 
Finland). Real-time PCR amplification was performed with a customizes TaqMan for 
human ATXN3 (assay ID Hs01026440_g1) or mouse ATXN3 (assay ID Mm00804702_m1) 
on ABI 7000 or ABI 7500 (Applied Biosystems, Foster City, CA, USA). The mRNA expression 
levels were normalized to human GAPDH (assay ID Hs02758991_g1) or mouse GAPDH 
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(assay ID Mm99999915_g10 as an internal control. A custom TaqMan Small RNA Assay 
Design Tool (ThemoFisher Scientific) was used to design microRNA TaqMan for the mature 
miATXN3_7 (assay ID CTCE3VJ), miATXN3_9 (Assay ID CTEPRZE) and miATXN3_11 
(assay ID CTFVKKC). The microRNA expression levels were normalized to U6 snRNA (assay 
ID 001973) as an internal control. All reverse transcription reaction and TaqMan for small 
RNAs were performed according to the manufacturer protocol.
Next-generation sequencing (NGS) and data analysis (small RNAs)
Mature frontal brain-like neurons were plated in 500µL STEMdiff Neuron Maturation 
medium (STEMCELL) at 0.3*106 cells per well in 24-wells plates. 1 week after plating, 
the cells were transduced with the 100µL of 2. 42x1013 gc/mL of AAV5-miATXN3_7, 
AAV5-miATXN3_9 or AAV5-miATXN3_11. Small RNA sequencing libraries for the Illumina 
sequencing platform were generated using high-quality total RNA as input and the NEXTflex 
Small RNA Sequencing kit (Bioo Scientific, Austin, TX). Briefly, the small RNA species were 
subjected to ligation with 3’ and 5’ RNA adapters, first strand reverse transcription, and 
polymerase chain reaction (PCR) amplification. Sample-specific barcodes were introduced 
in the PCR step. The PCR products were separated on TBE-PAGE electrophoresis and 
the expected band around 30bp was recovered for each sample. The resulting sequencing 
libraries were quantified on a BioAnalyzer (Agilent, Santa Clara, CA). The libraries were 
multiplexed, clustered, and sequenced on an Illumina HiSeq 2000 (TruSeq v3 chemistry) 
with a single-read 36 cycles sequencing protocol and indexing. The sequencing run was 
analyzed with the Illumina CASAVA pipeline (v1.8.2), with demultiplexing based on 
sample-specific barcodes. The raw sequencing data produced was processed removing 
the sequence reads which were of too low quality (only “passing filter” reads were 
selected). In total, between 15–35 million reads per sample were generated. NGS small RNA 
raw data sets were analyzed using the CLC Genomics Workbench 8 (Qiagen). The reads 
were adaptor-trimmed and aligned against the corresponding reference sequence. Reads 
that were shorter than 10 nucleotide (nt), longer than 45 nt, or represented less than 10 
times were excluded from the analysis. The custom adapter sequenced used for trimming 
all the bases extending 5’ was: GTGACTGGAGTTCCTTGGCACCCGAGAATTCCA. Next, 
the obtained unique small RNA reads were aligned to the reference sequences of the pre-
miATXN3 constructs with a max. of 3 nt mismatches allowed. The percentages of reads 
based on the total number of reads matching the reference sequence were calculated.
RNA sequencing and transcriptome analysis
For human transcriptome-related off-target analysis, total RNA from healthy human-
derived frontal brain-like neurons treated with the AAV5-miATXN3 candidates or 
formulation buffer as control. For analysis in mice, total RNA was isolated from brain stem 
of SCA3 knock-in mice transduced with miATXN3_9 or the formulation buffer. Total RNA 
was reverse transcribed and single-end sequence reads were generated using the Illumina 
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HiSeq2500 system (BaseClear B.V., Leiden, The Netherlands). FASTQ sequence files were 
generated using the Illumina Casava pipeline version 1.8.3. Initial quality assessment 
was based on data passing the Illumina Chastity filtering. Subsequently, reads containing 
PhiX control signal were removed using an in-house filtering protocol. In addition, 
reads containing (partial) adapters were clipped (up to minimum read length of 50bp). 
The second quality assessment was based on the remaining reads using the FASTQC 
quality control tool version 0.10.0. The analysis of the weighted proportions fold change 
and p-value scores between the conditions were calculated using the Baggerley’s Beta-
binomial test. The fold change in gene expression was calculated for each comparison 
(AAV5-miATXN3_7 versus control, AAV5-miATXN3_9 versus control and AAV5-
miATXN3_11 versus control).
TR-FRET assay
TR-FRET assay was performed as described before.41 Brain tissues were lysed by sonication 
in 10x v/w of ice-cold lysis buffer (PBS +1% TritonX100+1X protease inhibitor cocktail 
(Roche)). Anti-ataxin-3 clone 1H9 (MAB5360, Millipore) was labeled with donor Lumi4-Tb-
fluorophore (Cisbio). Anti-ployglutamine expansion marker clone 5TF1-1C2 (MAB1574, 
Millipore) was labeled with D2 acceptor fluorophore (Cisbio). The combination of 1H9 
and 5TF1-1C allow detection of more than 37 glutamine repeats. After optimization of 
antibody titers and incubation conditions, quantification of mutant ataxin-3 levels was 
performed in low volume polystyrene 384 microtiter plates (Greiner Bio-One) with 5 µl 
sample volume and addition of 1 µl antibody solution (50 mM NaHPO4+400 mM NaF 
+0.1% BSA +0.05% Tween-20 +1 ng/ml 1H9-Tb +10 ng/ml 1C2-D2). Plates were then 
incubated at 4°C for 20 h and analyzed by time-resolved fluorescence at 620 nm and 665 
nm on an Envision Multilabel reader (Perkin Elmer).
AAV5 injection in minipigs
A male 7 month old Gottingen minipig was selected at the Institute of Animal Physiology 
and Genetics in Libechov (Czech Republic). General anaesthesia was induced by 
intramuscular application of tiletamine (4 mg/kg), zolazepam (4 mg/kg Zoletil 100; Virbac), 
ketamine (5 mg/kg Narketan 10: Chassot), and xylazine (1 mg/kg (Rometar 2%; Spofa) 
mixture followed by intravenous ear cannulation and intubation. Artificial ventilation 
and isoflurane/nitrous oxide anaesthesia was used during the rest of the procedure. 
For intrathecal administration, a spinal needle (Yale; 121884; 1.2x90 mm) attached 
to a 5-mL syringe was used. 5 mL of AAV5-GFP (4 x 1013 gc/ml) was delivered slowly 
(over approximately 5 min) by hand injection into the lumbar region of the minipig. 4 
weeks after treatment the minipig was sacrificed using pentobarbital sodium intravenous 
injection (100 mg/kg) followed by a bilateral thoracotomy. The animal was transcardially 
perfused with 500-1,000 mL of heparinized PBS. Once removed from the skull, the brain 
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was coronally sliced into 3-4 mm blocks from frontal to occipital. The left hemisphere was 
used for biomolecular analyses, where 102 brain punches were taken and stored at -80 °C. 
The right hemisphere was fixed by paraformaldehyde (PFA) for immunostaining of GFP 
protein (at Libechov, Czech Republic). 
DNA isolation from minipig brain tissue
DNA isolation from brain tissue punches was performed using the DNeasy Blood and 
Tissue kit (QIAGEN, Germany). Primers specific for the CAG promoter sequence were 
used to measure the vector genome copies (gc) by SYBR Green Fast qPCR (Thermo Fisher 
Scientific). The amount of vector DNA was calculated based on a plasmid standard curve. 
Results were reported as gc per microgram of genomic DNA.
Immunohistochemistry on minipig prain tissues
PFA-fixed blocks were sliced in 20-25 coupes of approximately 5um (100-125 coupes/
brain). For immunostaining analysis, the endogenous peroxidase activity was blocked 
with a solution of 0.3% of hydrogen peroxide in methanol for 20 min, and the brain 
sections were immunostained using the rabbit primary antibodies anti-GFP (1:1,000, 
ab6556; Abcam). Sections were then treated with a biotinylated donkey anti-rabbit 
secondary antibody (1:400, RPN 1004V; GE Healthcare Life Sciences) followed by an 
avidin-peroxidase complex (1:400, A3151; Sigma-Aldrich). The avidin-peroxidase complex 
was visualized by incubation with solution containing a dissolved 3, 3 -diaminobenzidine 
tablet (4170; Kementec Diagnostics). The sections were dehydrated and mounted 
with DePeX (Sigma). Images were acquired using a histological scanner (Virtual Slide 
Microscope VS120-5 fluorescence; Olympus), and quantitative analysis of IHC-stained 
brain sections was performed using Fiji ImageJ distribution (https://fiji.sc/).
Statistical Analysis
Data were analyzed using the one-way ANOVA or Student’s t-test to determine statistically 
significances between control and treated cells. A two-way ANOVA was used to 
determine statistically significances between multiple treated groups. The p-values were 
either listed or represented by the following number of asterisks: *p < 0.05; **p < 0.01; 
***p < 0.001; ****p < 0.0001. 
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Supplementary material
Table S1. Treatment group design of the in vivo investigations. AAV5-miATXN3_7, -9 and -11 were 
tested in vivo and delivered to the SCA3 knock-in mice by 3 different routes of administration.
Groups Treatment Route of injection Number of animals (n) Amount of injection (µl)
1 AAV5-miATXN3_7 ICV 3 10
2 Cisterna magna 3 10
3 Bilateral DCN 3 4 = 2+2
4 AAV5-miATXN3_9 ICV 3 10
5 Cisterna magna 3 10
6 Bilateral DCN 3 4 = 2+2
7 AAV5-miATXN3_11 ICV 3 10
8 Cisterna magna 3 10
9 Bilateral DCN 3 4 = 2+2
10 AAV5-GFP Bilateral DCN 3 4 = 2+2
11 No treatment Not applicable 3 0
Table S2. Prediction of off-target genes based on BLAST search and RNA sequencing. BLAST search 
was performed with the guide sequences of miATXN3_7, miATXN3_9 and miATXN3_11. The blast 
results were then compared to RNA sequencing expression values obtained from human-derived frontal 
brain-like neurons treated with the AAV5-miATXN3 candidates or the formulation buffer. P-values 
>0.05 were excluded 
Treatment
Transcript
(Blast)
% coverage
(Blast)
Fold Change
(treatment vs PBS)
p-value
(treatment vs PBS)
miATXN3_7 ATXN3 100% -1.2 9.4E-03
miATXN3_7 GNPTAB 63% 1.1 4.2E-03
miATXN3_7 SOX5 63% -1.1 2.6E-02
miATXN3_7 GNPTAB 63% 1.1 4.2E-03
miATXN3_7 CTSC 63% 1.3 2.2E-16
miATXN3_9 ATXN3 100% -1.5 3.4E-16
miATXN3_9 TNFRSF6B 59% 1.3 4.4E-02
miATXN3_9 FGD6 59% -1.2 9.1E-03
miATXN3_11 ATXN3 100% -1.3 1.0E-06
miATXN3_11 ICA1 68% 1.3 4.8E-03
miATXN3_11 CACNA1D 63% 1.5 2.9E-02
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Table S3. Prediction of off-target genes in human by siSPOTR and RNA sequencing after AAV5-
miATXN3_7 treatment. A search was performed on siSPOTR with the seed sequence of miATXN3_7 
to check for binding within 3’UTR of human transcripts. The top 20 genes with highest tPOTS were 
compared to RNA sequencing expression values in human-derived frontal brain-like neurons. RNA 
sequencing was performed on RNA isolated from human-derived frontal brain-like neurons treated with 
AAV5-miATXN3_7 or the formulation buffer for 7 days. The genes with p-value < 0.05 were excluded.
Gene name
TPOTS
value 8mer 7mer-M8 7mer-1A 6mer
Fold Change
(mi7 vs PBS)
p-value
(mi7 vs PBS)
WDR72 0.816 1 1 9 1 -1.4 9.5E-03
SCAI 0.615 1 0 7 0 -1.3 3.4E-05
GDA 0.547 3 0 1 2 -2.3 6.9E-03
FOXP2 0.526 2 2 1 1 -1.3 2.9E-02
DNAL1 0.525 0 1 7 0 -1.3 1.5E-02
AAK1 0.522 2 0 3 7 1.1 3.3E-02
KCNMA1 0.488 1 0 5 3 1.3 1.8E-03
ONECUT2 0.487 1 0 5 2 -1.2 6.9E-04
FBXL20 0.428 1 1 3 3 -1.2 3.6E-03
IKZF2 0.426 1 1 3 1 -1.4 3.2E-02
BMPR1B 0.426 1 1 3 1 -1.3 1.6E-04
CSRNP3 0.403 0 2 4 3 -1.3 1.4E-02
LIFR 0.367 1 2 1 2 -1.4 1.5E-03
ZNF652 0.36 1 1 2 0 -1.1 3.1E-03
LONRF2 0.36 1 0 3 5 1.2 8.9E-05
CPNE3 0.36 1 1 2 0 -1.2 7.7E-03
PHF6 0.357 1 0 3 2 -1.2 1.3E-02
C21orf91 0.357 1 0 3 2 -1.2 1.2E-02
TMEM47 0.356 1 0 3 1 -1.3 1.3E-02
ARL3 0.355 1 0 3 0 -1.1 2.0E-03
ATXN3 0.295 1 1 1 0 -1.2 9.4E-03
Development of an AAV-based microRNA gene therapy to treat Machado-Joseph disease 
161
4
Table S4. Prediction of off-target genes in human by siSPOTR and RNA sequencing for AAV5-miATXN3_9 
treatment. Performed as described in table S3 for AAV5-miATXN3_9.
Gene name
TPOTS
value 8mer 7mer-M8 7mer-1A 6mer
Fold Change
(mi9 vs PBS)
p-value
(mi9 vs PBS)
PHC3 0.651 2 1 4 1 -1.3 1.2E-03
HIF3A 0.617 3 1 1 2 -1.4 3.1E-02
ONECUT2 0.606 0 3 6 6 -1.2 3.4E-13
UBE2R2 0.515 2 0 3 0 -1.1 1.5E-04
H6PD 0.493 1 1 4 3 -1.2 6.0E-16
RAB3B 0.43 1 1 3 5 -1.3 6.3E-10
PTGS1 0.427 1 1 3 2 -3.4 1.3E-121
KSR2 0.412 0 4 2 2 1.4 2.1E-04
TTC14 0.391 2 1 0 1 -1.1 1.9E-05
BBX 0.391 2 1 0 1 -1.2 3.2E-04
ZNF286B 0.385 2 0 1 0 -1.2 3.4E-03
SYT2 0.385 2 0 1 0 -1.2 2.2E-05
SYP 0.385 2 0 1 0 1.3 0.0E+00
THY1 0.365 1 2 1 0 1.3 7.2E-03
TFDP2 0.365 1 2 1 0 -1.4 1.3E-17
PRLR 0.357 1 0 3 2 -1.2 8.0E-03
FMN1 0.328 0 0 5 3 2.1 2.6E-05
PRX 0.326 0 0 5 1 -1.2 1.1E-02
NCALD 0.326 0 0 5 1 -1.1 1.9E-05
ATXN3 0.001 0 0 0 1 -1.5 3.4E-16
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Table S5. Prediction of off-target genes in human by siSPOTR and RNA sequencing for AAV5-miATXN3_11 
treatment. Performed as described in table S3 for AAV5-miATXN3_11.
Gene name
TPOTS
value 8mer 7mer-M8 7mer-1A 6mer
Fold Change
(mi11 vs PBS)
p-value
(mi11 vs PBS)
SPTY2D1 0.615 3 1 1 0 -1.1 9.3E-05
ENAH 0.586 2 1 3 1 1.2 3.0E-08
TDRD6 0.55 3 1 0 0 -1.6 2.8E-02
PRKAB2 0.546 3 0 1 1 1.1 9.2E-05
TAB3 0.525 2 2 1 0 -1.2 5.4E-04
C1orf21 0.518 2 0 3 3 -1.3 4.7E-57
SMAD2 0.517 2 0 3 2 -1.1 2.4E-03
BRWD1 0.515 2 0 3 0 -1.1 4.0E-17
EXD2 0.498 1 2 3 3 -1.2 4.1E-05
NFYA 0.497 1 2 3 2 -1.3 1.0E-35
AAK1 0.484 0 5 2 4 1.2 8.7E-06
RRAGD 0.456 2 1 1 1 -1.2 6.7E-03
RBM43 0.455 2 1 1 0 -1.4 2.3E-07
ATRNL1 0.455 2 1 1 0 -1.1 8.8E-04
ZFHX3 0.451 2 0 2 1 1.1 1.5E-02
LYSMD3 0.451 2 0 2 1 -1.2 3.6E-02
LOX 0.451 2 0 2 1 1.8 1.6E-12
LPP 0.446 1 4 0 6 1.2 1.1E-02
PAPOLG 0.432 1 2 2 2 -1.1 2.9E-02
C21orf91 0.426 1 1 3 1 -1.2 4.9E-02
ATXN3 0 0 0 0 0 -1.3 9.96E-07
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Table S6. Prediction of off-target genes in mice by siSPOTR and RNA sequencing for AAV5-miATXN3_9 
treatment. Performed as described in table S3. siSPOTR search was performed against mouse transcripts. 
RNA sequencing was performed on RNA isolated from brain stem of SCA3 knock-in mice treated with 
AAV5-miATXN3_9 or control (untreated) by injection in the cisterna magna. 
Gene name
TPOTS
value 8mer 7mer-M8 7mer-1A 6mer
Fold Change
(mi9 vs untreated)
p-value
(mi9 vs untreated)
Ncl 0.657 2 2 3 2 1.3 8.3E-03
Aak1 0.51 1 4 1 5 -1.6 5.0E-05
Onecut2 0.497 1 2 3 2 -1.2 1.3E-03
Nhsl2 0.461 0 1 6 1 -1.5 1.5E-04
Cacna1e 0.458 2 1 1 3 -1.0 5.0E-05
Nav1 0.435 1 2 2 5 -1.4 5.0E-05
Ttc14 0.422 1 0 4 2 -1.6 5.0E-05
Fzd3 0.408 0 3 3 3 -1.3 5.0E-05
Srgap3 0.396 0 1 5 1 -0.8 3.0E-04
Pde5a 0.391 2 1 0 1 -1.0 2.0E-03
Lonrf2 0.385 2 0 1 0 -1.3 5.0E-05
Zfp704 0.37 1 2 1 5 -1.1 5.0E-05
Mecp2 0.368 1 2 1 3 -1.5 5.0E-05
Cldn12 0.362 1 1 2 2 -1.3 5.0E-05
Dnajc18 0.361 1 1 2 1 -0.6 1.2E-02
0610030E20Rik 0.361 1 1 2 1 -1.2 2.0E-04
Dhx33 0.36 1 1 2 0 -0.7 5.8E-03
Pdzd2 0.356 1 0 3 1 -1.2 5.0E-05
D430041D05Rik 0.355 1 0 3 0 -1.4 5.0E-05
Atxn3 0.16 1 0 0 0 -1.7 5.0E-05
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Abstract
Various administration routes of adeno-associated virus (AAV)-based gene therapy 
have been examined to target the central nervous system. In this study, we evaluated 
a recently improved AAV5 vector system for its capability to target the central nervous 
system via intrastriatal, intrathalamic or intracerebroventricular delivery routes. AAV5 
is an ideal candidate for gene therapy because of its relatively low level of existing 
neutralizing antibodies compared to other serotypes, and its broad tissue and cell 
tropism. Intrastriatal administration of AAV5-GFP resulted in centralized localized vector 
distribution and expression in the frontal part of the brain. Intrathalamic injection showed 
transduction and gradient expression from the rostral brain into lumbar spinal cord, while 
intracerebroventricular administration led to a more evenly, albeit relatively superficially 
distributed, transduction and expression throughout the central nervous system. To 
visualize the differences between localized and intra-cerebral spinal fluid administration 
routes, we compared intrastriatal to intracerebroventricular and intrathecal administration 
of AAV5-GFP. Together, our results demonstrate that for efficient transgene expression 
in neuronal cell bodies of deeper brain structures local administration is necessary and 
that, depending on the desired AAV transduction pattern and transgene expression level, 
various administration routes can be applied.
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Introduction 
Since the first clinical protocol was published for the treatment of Canavan’s disease (CD) 
in 2002 1, great progress has been made in the field of adeno-associated virus (AAV)-based 
gene therapy for neurological diseases. Long-term follow-up studies have shown that 
although intra-cortical administration of AAV2-based therapy was safe, no clear benefit 
of the therapy has been observed, most likely due to insufficient delivery and hence 
inadequate expression of the therapeutic gene at the correct location 1. The 2002 clinical 
study has illustrated the importance of effective delivery to all affected sites. Cortical 
delivery of AAV2 resulted in relatively low transduction of tissue beyond the injection 
site. Therefore, other areas affected in CD, such as the brainstem and cerebellum, were 
not transduced. Additionally, in the brain the substrate of the mutated enzyme is found 
mostly in oligodendrocytes and their progenitor cells with smaller amounts in microglia 
and brainstem neurons. As AAV2 predominantly transduces neurons, the affected cells 
are not targeted by this serotype.
AAV5 is an ideal candidate for gene therapy as it has relatively low seroprevalence, 
i.e. antibodies against the capsid, compared to other serotypes 2 and a broad tropism 
for muscle, liver and CNS 3, 4. Intrastriatal (IStr) delivery of AAV5 to the murine brain 
has resulted in the highest degree of transduction of the striatum when compared to 
AAV serotypes 1,2,4,6,8 and 9 3. IStr administration of AAV5 to rats 5 and primates 6, 7 
showed improvement in transgene expression with regards to expression levels and scope 
of target cell population for AAV5 compared to other serotypes tested. Furthermore, 
following IStr administration AAV5 is transduced into neurons, astrocytes, microglia and 
oligodendrocytes 3 and into distant nuclei such as substantia nigra (SN) reticulata, globus 
pallidus, cortex and thalamus 8. Thus, AAV5 is a promising vector for disease indications 
that require a global transduction of the brain.
AAV can be administered through various routes, e.g. directly into the parenchyma 
(brain or spinal cord), into the cerebral spinal fluid (CSF) or intravenously (IV), in an effort 
to specifically target affected sites, whereby each route has its characteristics with specific 
advantages and disadvantages. In human subjects, intrathecal (IT) delivery is a relatively 
non-invasive procedure consisting of a lumbar puncture. Schuster and colleagues 9 
have shown that at the lumbar site IT administration of AAV5-GFP in rats led to GFP 
expression throughout the spinal cord and in discrete regions of the CNS throughout 
the rostro-caudal extent of the neuroaxis 9, 8. Broader transduction of the rostral part of 
the brain may be achieved with an intracerebroventricular (ICV) injection into the lateral 
ventricle. These studies have also shown that AAV5 does not cross the blood-brain barrier 
after IV transduction and hence this delivery route was not taken into consideration in 
the current study.
Different transduction patterns are desirable in order to target various diseases. For 
instance, in Parkinson’s Disease (PD) neurodegeneration mainly occurs in dopaminergic 
cells of the SN 10, while prominent neuropathology in Huntington Disease (HD) occurs within 
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the striatal part of the basal ganglia, and secondary marked neuronal loss and shrinkage 
is observed in the deep layers of the cerebral cortex 11. Parenchymal administration of 
AAV could result in significant transduction for production of therapeutic protein in these 
areas. In the monogenetic disease Niemann Pick Type C, a progressive loss of Purkinje 
cells is observed 12, the cerebellum and brainstem is the genesis of neuropathology in 
spinocerebellar ataxias (SCAs), and the hippocampus is the earliest brain region affected 
in Alzheimer’s Disease (AD). Direct administration of therapeutic-encoding AAV2/5 to 
the hippocampus in an AD model has been shown to ameliorate disease progression 13. 
These studies make hippocampal and cerebellar transduction of interest for transgene 
delivery. In order to develop a therapy for these disorders, it is essential to characterize to 
what extent a transgene is delivered by AAV to the brain or spinal cord.  In some cases, 
a broader delivery spectrum may be needed, such as in patients with Amyotrophic Lateral 
Sclerosis (ALS) where both the upper and lower motor neurons of the brain and spinal 
cord are affected. Another example is the neurological phenotype of infantile Pompe´s 
disease where the brain stem motor and sensory neurons, spinal cord motor-, sensory- and 
interneurons are affected 14. For these indications, a broader transduction pattern seems 
necessary, e.g. via an intrathecal approach. Recently, a phase-1 trial for San Filippo B disease 
has shown that 16 intraparenchymal injections of AAV2/5 encoding the deficient enzyme 
alpha-N-acetylglucosaminidase (NaGlu) into white matter of the cortex were well tolerated 
14. Theoretically, by infusing into a more central area in the brain, it might be possible 
to reach the affected areas with one bilateral IStr or intrathalamic (ITH) administration. 
Both sites have multiple anterograde and retrograde projections throughout the brain. 
These projections can be used to predict the distribution of the transgene product. 
Moreover, the choice of serotype can also influence the expression pattern, expanding 
the possibilities and necessities of a so-called AAV toolbox even further.
In this study, we explored the transduction pattern of AAV5 following IStr, ITH, 
ICV or IT administration. Predictable transduction patterns will aid the design of new 
therapeutic strategies.
Results
IStr, ICV and ITH administration of AAV5 leads to distinct vector DNA 
distributions and transgene RNA expression patterns in rats
To evaluate the capability of AAV5 to transduce the brain after parenchymal or CSF-
mediated administration, AAV5 was administered to rats  IStr, ICV or ITH (fig 1). IStr 
injection of AAV5-GFP resulted in vector DNA and GFP RNA expression in the cortex, 
striatum, thalamus, and hippocampus (fig. 2a brain). Vector DNA was not detected above 
background levels (1x103 genome copies(gc)/µg genomic DNA) in the cerebellum, brain 
stem, spinal cord or peripheral organs (fig. 2a).
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Figure 1. Overview of injection routes Intrastriatal (IStr), intrathalamic(ITH), 
intracerebroventricular (ICV) and intrathecal (IT) injections in the rat have been performed 
in this study. Green areas indicate the site of injection and the predicted spread of the fluid 
containing the vector.
Thalamic administration of AAV5-GFP led to the transduction (both presence of vector 
and GFP RNA expression) in the cortical-, striatal-, thalamic-, hippocampal-, cerebellar 
area, and brainstem (fig. 2b, brain). Furthermore, we also observed vector DNA and GFP 
RNA presence in the spinal cord, albeit at a lower level than in the brain (fig. 2b, spinal 
cord). Surprisingly, vector DNA was detected in the spleen. However, this did not result in 
GFP relative expression above background levels. (fig. 2b peripheral organs). 
ICV-administered rats showed a more even distribution pattern with similar amounts 
of vector DNA, and GFP RNA expression throughout the brain and spinal cord (fig. 2c 
brain and spinal cord). Vector DNA was also retrieved in liver, kidney, and spleen (fig. 2c 
peripheral organs). However, in the peripheral organs there was no GFP RNA detected 
above background levels, even though the CAG promoter is classified as a ubiquitous 
expression promoter 14.
Distinct protein expression pattern observed at macro level when 
comparing IStr administration of AAV5-GFP to ICV and IT in rats
We delved further into the potential use of AAV5 for diseases affecting the brain and spinal 
cord by aiming for a larger area of transduction. As shown in the previous experiment, 
ICV administration in rats leads to broad transduction of the cerebral areas and spinal 
cord on DNA and RNA level. To assess the maximum capability of AAV5, the vector 
was administered ICV and IT (fig. 1) at the highest titer available, 1x1014 GC/ml, and 
compared to IStr administration (as local administration method) at the same high titer, 
but the volume was adjusted depending on the administration method.
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Figure 2. Vector distribution and GFP expression following various cerebral administration 
routes of AAV5-GFP in rats. Rats(n=3) received a total of 5E10 genomic copies (GC) of AAV5-CAG-
GFP bilaterally by intrastriatal (IS) (a), intrathalamic (ITH) (b), or 5E11GC total via Intracerebroventricular 
(ICV) (c) administration. Tissues were collected eight weeks post surgery, and DNA and RNA were 
isolated to determine the vector distribution and GFP expression. IS-administration resulted into 
distribution and expression in the frontal areas, basal ganglia, and midbrain. ITH-administration les 
to a more spread gene expression compared to IS-administration. Black triangles represent GC/µg 
genomic DNA, whereas grey circles represent relative GFP expression (RNA). Sp: spinal cord.
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Figure 3 gives an overview of the results following the three administration routes in rat 
brain. In the frontal area, both IStr (fig. 3a) and ICV (fig. 3b) administration of AAV5-GFP 
resulted in GFP expression in the striatum and the cortex. At this magnification level, 
staining was only observed in the cortex of IT-administered rats (fig. 3c). In the striatal area 
of IStr-injected rats, the complete caudate putamen was transduced. In comparison, GFP 
staining was concentrated around the ventricles surrounding the striatum and the cortex 
in the brains of ICV-administered rats. 
In the hippocampal structure of IStr-administered rats, only the Cornu Ammonis 
(CA)1 area showed moderate GFP expression. In ICV-administered rats, the complete 
hippocampal structure appeared to be transduced. IT-administration showed propensity 
towards a low degree of GFP expression in the molecular layer of the hippocampus. In 
the midbrain area, both ICV- and IStr-administered rats displayed GFP staining in the SN, 
while this area was negative in IT rats. The hypothalamus shows some GFP-positive 
staining in both the ICV and IT administered rats. At the occipital end of the cerebral 
area, the cerebellum of ICV- and IT-injected  rats appeared to have some GFP-positive 
areas (Fig3C)
IT, IS and ICV administration of AAV5 leads to different GFP expression 
profiles in the frontal area 
Upon taking a closer look at the frontal brain area, we observed a striking difference 
between the three injection routes. In the striatum of IStr-injected rats, neurons and 
surrounding matter were GFP positive (fig.4a, ST). In the cortical area of these rats, GFP-
positive neurons were observed, yet the intensity of staining in the surrounding area 
was less intense compared to that in rats injected in the ICV or IT (fig 4a, CR). In ICV-
administered rats, the frontal area showed GFP expression in neurons and surrounding 
matter in the striatum and cortex (fig. 4b). In contrast to the pattern seen in ICV- and 
IStr-administered rats, in the striatum of IT- administered rats GFP-positive neurons 
and axons were observed, however surrounding striatal white matter showed no GFP 
expression (fig. 4c).
ICV administration of AAV5-GFP leads to GFP expression in the 
hippocampal structure of rat
IStr administration of AAV5-GFP in rats led to GFP staining of the hippocampal layers 
within the CA1 area, such as the pyramidal cell, lacunosum molecular and oriens layers. 
Some sparse neurons of the CA2 showed positive staining, but most of this area was 
negative. Neurons of the CA3 pyramidal cell layer were GFP positive as well as neurons 
and dendrites in the Dentate Gyrus (DG), but the surrounding matter and layers of the DG 
were negative for GFP expression (fig. 5a).  
In the ICV-administered rats, the core area of the hippocampus was thoroughly 
transduced, aiding in clear visualization of its structural architecture. For instance, at 
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Figure 3. GFP expression throughout the rat brain following intrastriatal (IStr), 
intracerebroventricular (ICV) or intrathecal (IT) administration of AAV5-GFP. Rats(n=3) were 
administered with AAV5-GFP at 1x1014 GC/ml, respectively 1, 50 and 50 µl and sacrificed after one 
month. Brains were extracted, fixed in 4% paraformaldehyde, embedded in gelatin and serially cut 
with a vibratome to 50 µm sections. a) IS-administered rats show GFP staining (shown in brown) 
in the striatum, neocortex, and upper septum region. Beyond the injection site, also the Cornu 
Ammonis 1 field of the hippocampus, rostral part of the thalamus and the substantia nigra were 
positive for GFP signal. b) ICV-administered rats showed partial GFP IR in the striatal area and 
neocortex, rostral part of the thalamus, the complete hippocampus and the substantia nigra. c) 
IT-administered rats showed primarily transduction of the neocortex and hypothalamus, and some 
layers of the cerebellum. At this magnification level, staining was not observed in the basal ganglia 
or thalamus. Areas of interest indicated by white arrows. Figure is representative from 3 animals. 
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Figure 4. GFP expression in cortex and striatum in rat brain following intrastriatal (IStr), 
intracerebroventricular (ICV) or intrathecal (IT) administration of AAV5-GFP Overview 
of striatal (ST) and cortical (CR) area from a) IS administered rat, b) ICV administered rats, c) 
IT administered rats. Both IS- and ICV-administration in rats result in GFP stained neurons and 
the surrounding fibers in the ST area. Striatal area of IT administered rats displayed GFP staining 
neurons and neurites. However, no GFP staining was observed in the surrounding area. In the cortical 
area a similar transduction pattern is seen in IT- and ICV-administered rats. In the cortical area of 
IS-administered rats, the matter staining is less intense compared to the other routes of injection. 
Black bar represents 1 mm and white bar represents 100µm for scale.  
the transition from CA1 to CA2 there was a difference in the intensity of GFP staining. 
Also, a clear distinction could be made in the morphology of the pyramidal layer of 
CA2 versus CA1. In the DG neurons of the granular layer were GFP positive as well as 
surrounding matter and molecular layers (fig. 5b). 
In IT-administered rats, strong GFP staining of middle and outer molecular layer 
of the DG was observed. Positive neurons, dendrites, and axons could be observed in 
the granular layer of the DG. The morphology of stained cells in the granular layer differs 
from that of ICV injected rats. In the ICV DG, a tightly packed layer of neurons was seen, 
whilst the IT neurons were spaced with longer neurites Therefore, it seems that these 
neurons are in the subgranular zone rather than the granular layer itself.  In the CA2 
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Figure 5. GFP expression in the hippocampal area in rat brain intrastriatal (IStr), 
intracerebroventricular (ICV) or intrathecal (IT) administration of AAV5-GFP. a) IS-administered 
rat, b) ICV-administered rats, c) IT-administered rats. Dentate gyrus (DG) of ICV-administered rats 
showed GFP staining in the Hilus area which was not seen in the other administration routes. 
The IStr-administrated animals show GFP stained neurons in the inner molecular area compared to 
the ICV where the complete CA2 showed GFP staining. Intrathecal (IT)-administered rats had sparse 
transduction of neurons. In the Thalamic (Th) area, both IStr- and ICV-administered rats showed GFP 
staining in the thalamic area of neurons and surrounding area. IT administration resulted in GFP 
stained neurons, however not in the surrounding area. Black bar represents 1mm scale and white 
bar represents 100 µm scale
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layer multipolar neurons were seen with branching dendrites. However, the layers were 
negative for GFP staining (fig. 5c).
Altogether, the results suggest that depending on the injection route AAV-mediated 
transduction patterns involve different neuronal pathways.
IT, IStr and ICV administration of AAV5 results in different  
GFP- expression profiles in SNpc hypothalamus and cerebellum of rats
In the midbrain area, the SN pars compacta (SNpc) and pars recticulata (SNrc) as well 
as in the Ventral Tegmental Area (VTA) neurons were positive for GFP in brains of IStr-
administered rats. All other areas of the midbrain were negative (fig 6a). After ICV injection, 
the SNrc and VTA are positive for GFP but not the SNpc. In the medial mammillary body 
of the hypothalamus GFP positive neurons are perceived (fig 6b). 
In brains from IT-administered rats, predominantly neurons of the mammillary body were 
positive for GFP (fig. 6c). In the cerebellum of IStr-administered rats, no positive neurons 
could be discerned (fig. 6d). ICV injection led to sparse transduction of the cerebellum, 
but positive Purkinje and Golgi cells were identified (fig. 6e). In the cerebellum of IT-
administered rats, more layers with positive cells were identified, for example in Purkinje 
cells, Bergman Glia and Golgi cells based on morphology and location (fig. 6f).
ICV- and IT-administration of AAV5-GFP results in GFP expression in 
spinal cord and dorsal root ganglia of rats
Along the entire length of the spinal cord (SC) and aligned Dorsal Root Ganglia (DRG) 
of IStr-administered rats, no GFP-positive cells were observed (fig. 7a). The cervical SC of 
ICV-injected rats did also not show staining for GFP. However, positive cells were observed 
in the cervical DRG. In the thoracic area, sporadic positive neurites in the dorsal root entry 
zone could be observed in the dorsal horn. Also, GFP-positive neurons in the DRG were 
observed. At the lowest part of the spinal cord at the lumbar section, GFP-stained neurons 
were visualized in the SC and DRG (fig. 7b). IT administration led to positive neurons 
at the injection site in the lumbar spinal cord and attached DRG, moving upwards to 
the thoracic section positive cells can also be observed in both SC and DRG. In the cervical 
SC and DRG, no GFP-positive cells were observed (fig. 7c).
Discussion
In this study we demonstrated that the distribution profile of AAV in the CNS is highly 
dependent on its delivery method. Thus, depending on the disease for which therapy 
is being developed each method has its own merits. IStr and ITH are more suited for 
diseases in which a high concentration of therapeutic compound is needed in the frontal 
to mid brain areas, such as PD and HD. ICV is suited for low to mid-range transgene 
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Figure 6. GFP staining in the midbrain area and cerebellum in rat brain following intrastriatal 
(IS), intracerebroventricular (ICV) or intrathecal (IT) administration of AAV5-GFP. a-c) overview 
of midbrain area. 20X magnification of the substantia nigra of IS administrated rats showed GFP 
stained neurons in the substantia nigra pars compacta and pars reticulata, ICV administered rats 
showed GFP staining in the pars reticulata but not in the pars compacta. In the hypothalamus (hyp) 
GFP IR neurons were observed in ICV- and IT administered rats for which IStr administered rats are 
negative. d-f) In the cerebellum of IT-administered rats, show GFP staining in Purkinje cells and 
Bergman cells. Neuronal staining also found in ICV-administered rats. However, transduced cells 
are more sporadic as compared to IT administration. No staining observed in IStr- administered rats. 
Black bar represents 500 µm, white bar 100µm and brown bar 50 µm for scale.
delivery in a broad distribution throughout the CNS with somewhat less penetration into 
deeper brain structures but could be useful for e.g. lysosomal storage diseases.
In brains of IStr-administered rats, vector and transgene expression were detected in 
the thalamus, cortex, and hippocampus, and thus outside the injected nucleus. There 
are strong indications that AAV travels beyond the injection site by axonal transport 12. 
Following IStr administration of AAV5 in NHP, AAV5 transduced the SNpc, cortex 
and thalamus by retrograde transduction and SNpr by anterograde transduction 8. 
Anterograde transport is characterized by transduction of vector distal to the injection 
site after cell body-mediated uptake. Retrograde transport involves the uptake of viral 
particles by nerve terminals at the site of injection, which are then transported to the cell 
body of the neuron. Samaranch et al 8 showed the same pattern of GFP-positive nuclei 
in NHP as we observed in rats. Therefore, in rats as well as NHP AAV5 may well use 
the same anterograde and retrograde mode of transport. This has great implications for 
the capability to predict the transduction patterns across species.
ICV administration only targets the SNpr and not the SNpc. In an earlier study 
comparing IStr- to ITH-delivery in NHP, it was also observed that ITH delivery does not 
result in the transduction of the SNpc whilst IStr administration does. 8. These results 
suggest that of the delivery methods studied for PD, IStr administration of AAV5-based 
therapy is currently the best option to deliver meaningful amounts of therapeutic to 
the SNpc.
Our distribution analysis showed that vector copies were detected evenly across 
all tissues analyzed following ICV infusion of AAV5. In contrast to direct infusion into 
the striatum, where almost the complete nucleus was GFP positive, only the nuclei in 
the vicinity of the lateral ventricle were positive for GFP after ICV administration. However, 
ICV injection led to complete transduction of the hippocampus making this a feasible 
alternative to direct administration into the hippocampal formation. This knowledge is 
crucial for the development of AAV-based therapies for AD. 
The SNpr, cerebellum and spinal cord could be transduced via the subarachnoid space. 
During the systolic phase, CSF flows from the ventricles into the subarachnoid space 
and spinal cord via the foramen located below the cerebellum. The SNpr projects to 
the thalamus, resulting in retrograde transduction of the thalamus. The thalamus has 
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an afferent projection to the mammillary body which could explain the positive cells 
observed in this region. Based on the transduction pattern it seems that ICV-based-AAV5 
transduction of the brain is a mixture of transependymal CSF flow of structures close 
to the ventricles and subsequent axonal transport to deeper areas. The transependymal 
CSF flow describes the progress of CSF across the ependymal layer that surrounds 
the ventricles into the brain parenchyma and adjacent structures. This flow is pushed by 
a pressure gradient which is driven by the production of CSF in the lateral ventricles. CSF 
flows in the direction of the venous sinuses into which it is eventually absorbed 15.
Lumbar IT delivery of AAV5-GFP resulted in GFP-positive cells in SC & DRG. Some 
GFP-positive neurons were also observed in the cerebrum, the cerebellum and frontal 
brain. There are indications that after IT administration AAV9 and AAVrh10 transduce 
the parenchyma via perivascular transport of CSF 13, 16. Guo et al., 2014 26 observed distinct 
GFP patches in the vicinity of vascular cavities in rat brains following IT administration 
of AAVrh10 26 and double staining with aquaporin 4, a marker for perivascular space, 
showed colocalization with GFP expression. We did not observe an obvious pattern of 
colocalization of vascular cavities and GFP staining. Both AAV9 and AAVrh10 are known 
to cross the blood-brain barrier after IV administration, while AAV5 does not 9, indicating 
that AAV5 employs a different method to cross pia mater.
Even though in both IT and ICV the same amount of vector is administered to the CSF, 
a different expression pattern was observed that could be explained by the flow of 
CSF. ICV-administered vector moves with the natural flow of the fluid, from the lateral 
ventricle, where it is produced, to ventricles beyond. AAV5 injected into the lumbar 
subarachnoid space has to populate and transduce the tissue against the flow and has no 
gradient push towards the parenchyma of the cerebrum. The GFP-positive areas observed 
in the cerebrum after IT administration are most likely due to axonal transport and not 
transport of the vector via the CSF. 
Surprisingly, ITH- and ICV-administered vector was observed outside the CNS, however 
this did not result in GFP-RNA expression. Possibly, the CAG promoter was not active in 
rats in these organs. In a study using the CAG promoter in a non-human primate (NHP) 
vector, the distribution in the periphery also did not lead to expression in the spleen, 
kidney and liver 17. Surprisingly, the CAG promoter is active in mouse liver 18, pointing 
towards species specificity of the promoter in peripheral organs. Presence of vector copies 
in unwanted locations may lead to side effects. Our results indicate that ICV delivery is 
promising when a CNS-specific promoter is used. 
Figure 7. GFP staining in the spinal cord and the dorsal root ganglion of intrastriatal (IS), 
intracerebroventricular (ICV) or intrathecal (IT) administered AAV5 rats. a) No staining was 
observed throughout the spinal cord (SC) and Dorsal Root Ganglia (DRG) of IS-administered rats. 
b) ICV-administered rats showed staining of cervical DRG, thoracic and lumbar SC and DRG. c) IT-
administered rats show GFP positive cells and matter in lumbar and thoracic SC&DRG. GFP stained 
cells marked by Arrow. White bar represents 100µm and brown bar 50 µm for scale.
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On the other hand, the delivery methods targeting all tissues equally are advantageous 
for lysosomal diseases such as Mucopolysaccharidoses IIA, where both the organs of 
the periphery and the CNS are affected. Both IT-and ICV-delivery routes can be considered 
for the treatment of such diseases that need a widespread transduction. Furthermore, 
lysosomal enzymes are capable of cross-correction as they are secreted to the extracellular 
space and taken up by neighboring cells which were not transduced, and have the capacity 
to travel across axonal projections 19. Due to these properties, the IT- and ICV-induced 
transduction to distal areas may give a therapeutic effect.
To allow translation to humans, the delivery methods should be tested in larger animal 
models. IStr administration of AAV5 has been tested in numerous NHP studies 6, 8, 20. IT 
delivery of AAV5 was tested in NHP at the same dose as in the current study and a similar 
transduction pattern was observed 8. Of the delivery methods, ICV is the least tested 
in larger animal models, but in dogs resulted in efficient transduction of the brain and 
spinal cord, and,  importantly, no adverse effects were seen 21. In a more recent study, ICV 
administration to the lateral ventricle of dogs resulted in encephalitis in one animal 25. As 
ventriculostomy is a common procedure in humans, one would not suspect the procedure 
to be high risk. However, both represent small studies and more research on large-animal 
pre-clinical models for ICV administration is necessary to carefully assess this delivery 
method and compare it to alternative methods.
Based on our current data and data from others, IStr and ITH could be used for gene-
delivery therapy for more localized diseases such as PD and HD. ICV could be employed 
for a disease like AD targeting the hippocampus and due to its broader reach also AAV5-
based therapy for lysosomal storage disease could be developed using ICV delivery. Both 
ICV and IT could be used for diseases where the cerebellum is the main target, although 
the transgene expression levels are relatively low. Moreover, IT delivery of AAV5-mediated 
therapy transduces the complete spinal cord and most of the cortical area, and  could 
thus be used for diseases affecting the spinal cord.
This study was performed in rodents and therefore the delivery methods need to 
be studied in larger animal models prior to application in the clinic. Ongoing studies in 
both wild-type and transgenic HD minipigs show promising results for IStr- and/or ITH-
administration to HD-patients 22. Especially when degeneration of the striatum is advanced, 
thalamic infusion may be an attractive alternate option. Our current data constitute a solid 
base for further development of AAV5-based gene therapy for neurological diseases. 
Material and methods
Production of vectors
Vectors were produced using uniQure’s patented insect cell-based system as previously 
described 23. Briefly, Spodoptera Frugiperda (SF) + cells were infected with recombinant 
baculovirus encoding for the capsid AAV5, REP gene and insert. The expression cassette 
of the insert consisted of the nucleotides encoding for CAG promoter, a combination 
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of the cytomegalovirus (CMV) early enhancer element and chicken beta-actin promoter. 
The transgene GFP is preceded by a Kozak sequence and followed by the bovine growth 
hormone polyadenylation (BGHpA) signal. At 72 hours post infection, cells were lysed 
and clarified lysate was purified on the AKTA explorer (FPLC chromatography system, GE 
healthcare) using AVB sepharose (GE healthcare). The vectors were titrated by Sybergreen 
Q-PCR using a primer pair binding to the promoter region (forward primer; GAG CCG 
CAG CCA TTG C, reverse primer; CAC AGA TTT GGG ACA AAG GAA GT) expressed as 
genome copies per ml (GC/ml). 
Animal study 
All animal studies described were approved by the local animal experimentation ethical 
committee.  Female Wistar rats (Janvier labs) were used for all experiments. Rats were 
anesthetized before surgery, by intramuscular administration of Hypnorm/Dormicum. 
A small hole is drilled in the skull, and the striatum or lateral ventricle are stereotactically 
approached. Coordinates for intrastriatal infusion were A/P 1.3, L +/- 2.5 and D 3.5; for 
intrathalamic A/P -2.5, +/- 3 and D 4.5; for intracerebroventricular A/P -1.5, L 2.5 and 
D 3.5. For the intrathecal administration, an incision was made in the skin on the back 
of the animal, muscle layers are split and a laminectomy performed at the lumbar 
vertebral level L3. The animal is placed into the spinal cord fixator and using a pulled 
glass needle the vector is infused. Volumes and dosage are described in table 1. After 
surgery, animals are given Temgesic for pain relief and returned to their cage. Depending 
on experiment, 4 or 6 weeks after experiments animals were sacrificed by decapitation 
under isoflurane anesthesia. Organs used for distribution analysis were snap frozen in 
liquid nitrogen and stored at -80 °C until analysis. Brains used for histology were fixed in 
4% paraformaldehyde for 24-48 hours. 
Vector distribution and GFP expression 
Organs were retrieved from -80 °C and pulverized to a powder using the Cryoprep 
system (Covaris, Woburn, MA, USA), from ±10 mg powder DNA was extracted using 
the DNeasy 96 Blood and Tissue kit (QIAGEN, Germany). Vector DNA was detected by 
Table 1. Overview of volume and dosages used in study
Study Injection route Volume (µl) Total dose(gc/rat) Titer (gc/ml)
Injection routes 1st study IStr 2 (per hemisphere) 5x1010 1.25x1013
ITH 2 (per hemisphere)
ICV 40 5x1011 1.25x1013
Injection routes 2nd study IStr 1 (per hemisphere) 1x1011 1x1014 
ICV 50 5x1012 1x1014 
IT 50 5x1012 1x1014 
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Q-PCR using TaqMan primers and probe binding to CAG promoter (forward primer: GAG 
CCG CAG CCA TTG C, reverse primer: CAC AGA TTT GGG ACA AAG GAA GT, probe: 
ATG GTA ATC GTG CGA GAG GGC GC). Vector DNA gc per µg DNA were quantified by 
interpolating from a standard line prepared from the plasmid of the expression cassette. 
RNA was isolated from powder using the RNeasy kit from Qiagen. Total RNA was reverse 
transcribed to cDNA using Maxima strand kit. RNA expression was quantified by using 
primers binding to GFP (forward primer: AGC AAA GAC CCC AAC GAG AA, reverse 
primer: GCG GCG GTC ACG AAC TC probe: CGC GAT CAC ATG GTC CTG CT) and GAPDH 
(Taqman expression array from Thermo Fisher) as housekeeping gene for reference. RNA 
expression was calculated using the ∆CT method normalized to the housekeeping gene.
Histology
24-48 hours after immersion fixation in 4% paraformaldehyde brains were embedded 
in 10% gelatin (Difco) in PBS as described previously 24. Embedded tissue was sectioned 
on a vibratome. Coronal sections were collected in PBS in series at a thickness of 50 µM. 
Immunohistochemistry was performed on free-floating sections. Endogenous peroxidase 
block was performed by incubating sections for 1 hour in 1% H2O2/30% ethanol in 
PBS. Sections were washed 3 times with washing buffer (PBS/0,05% tween). A-specific 
blocking was performed by incubating sections for 1 hour in PBS supplemented with 
4% BSA (Bovine Serum Albumin) and 5% Normal Goat Serum (NGS). Subsequently, 
sections were incubated overnight with primary antibody against GFP (Abcam ab290), 
diluted 1:1000 in PBS/1%BSA/1.25%NGS/0,5% Tween and incubated for one hour 
with horse radish peroxidase (HRP)-conjugated anti-rabbit before detection with 
3,3’-Diaminobenzidine (DAB) according to manufacturer’s instructions (Dako envision kit 
K4009). Sections of the spinal cord were counterstained with haematoxylin and eosin 
stain  (H&E). Subsequently, they were dehydrated through ethanol series, Xylene and 
embedded in Entellan before microscopical analysis. 
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Abstract
Gene therapy is being developed for the treatment of inherited diseases, whereby 
a therapeutic gene is continuously expressed in patients after delivery via viral vectors 
such as Adeno-associated virus (AAV). Depending on the transgene there could be 
a limited therapeutic window and regulating timing and levels of transgene expression is 
advantageous. To control transgene transcription, the regulatory system GeneSwitch was 
evaluated in detail both in vitro and in vivo. The classical two plasmid mifepristone (MFP)-
inducible GeneSwitch system was put into one plasmid or a single AAV5 vector. Our data 
demonstrate inducibility of multiple transgenes and the importance of promoter and 
regulatory elements within the GeneSwitch system. Mice injected with AAV5 containing 
the GeneSwitch system transiently expressed mRNA and protein after MFP induction. 
The inducer MFP could be measured in plasma and liver tissue, and assessment of MFP 
and its metabolites showed rapid clearance from murine plasma. In a head-to-head 
comparison, our single vector outclassed the classical two vector GeneSwitch system. 
Finally, we show repeated inducibility of the transgene that also translated into a dynamic 
phenotypic change in mice. Taken together, this in-depth analysis of the GeneSwitch 
system shows its applicability for regulated gene therapy. 
Keywords
Regulated gene expression, mifepristone inducible GeneSwitch system, 
AAV5 gene therapy
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Introduction
Several metabolic and inherited diseases are clinically targeted using gene therapeutic 
approaches1,2, which offer the prospect of a long-term causal correction of diseases that 
currently only have supportive treatments. One of the main gene therapy challenges is 
reaching sufficient concentrations of the therapeutic gene to correct disease symptoms, 
and for approaches based on growth factors or master regulators, fine-tuning of 
the protein expression is essential. Inducible protein expression also may improve 
the safety of approaches that have limited therapeutic windows, or that require temporal 
protein expression.
An efficient inducible system should be able to switch a gene on by delivering a clinically 
approved and safe small molecule and should switch off upon withdrawal of the drug, 
without any background expression. The inducer drug should be easy to deliver and have 
rapid on-off dynamics. Several regulatory systems have been engineered to control gene 
transcription, for example Tet-on/off and GeneSwitch. Both systems are based on binding 
of a transactivator protein to a specific DNA sequence in the promoter of the transgene 
and on ligand dependent activation of the system. In the presence of a small molecule-
inducing compound the transactivator protein is activated and can subsequently bind to 
sequences in the promoter of the transgene, which is then being transcribed.
The well-known Tet-on/off system gene transcription is modulated through 
the transactivator-protein (rtTA) which is sensitive to doxycycline. Although the Tet-system 
has been optimized for usage at doxycycline concentrations acceptable in the clinic3, 
long-term use of antibiotics is not preferred. Moreover the rtTA is potentially immunogenic4, 
because it contains domains of bacterial origin. This would limit the clinical use of the Tet-
system to immune privileged areas such as the brain.
The GeneSwitch system, addresses several limitations of the Tet-on/off system, 
because it is of mainly human origin and activated by the synthetic steroidal anti-
progesterone drug, mifepristone (MFP), a clinically approved drug. MFP acts as an agonist 
to activate gene transcription by binding to a subunit of the GeneSwitch protein, this 
interaction has been described by others previously.5–8 GeneSwitch, can induce regulated 
gene expression in rat brain at an MFP concentration that is in range of clinical use9. 
The GeneSwitch system has been successfully used in an animal model for Parkinson’s 
disease, where Glial cell-derived neurotrophic factor (GDNF) was regulated in rat brain 
and had neuroprotective and neurorestorative effects10,11. Moreover, the GeneSwitch 
system was able to modulate interferon (IFN) in the periphery, however in that study 
a CMV promoter was used which could elicit an immune response due to expression in 
antigen presenting cells12–14. Besides, in the periphery IFN has been modulated, however 
in that study GeneSwitch was behind a CMV promoter which could elicit an immune 
response due to expression in antigen presenting cells12–14. 
The GeneSwitch system consists of two expression cassettes: one constitutively 
expressing the GeneSwitch protein, the chimeric trans-activator protein. The other cassette 
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contains a transgene transcribed from an inducible promoter. GeneSwitch is a fusion 
protein of two human domains and a 97 amino acid yeast-derived sequence. The N-terminal 
domain is the DNA-binding domain of yeast transcription factor Gal4 that binds to a 17 
nucleotide long sequence in the regulatable promoter of the transgene. GeneSwitch 
binds to this sequence after dimerization, which is triggered by a conformational change 
of the ligand binding domain (LBD) in the presence of MFP. The LBD is a domain from 
the human progesterone receptor, hence that MFP is an inducer. The C-terminal part of 
GeneSwitch is the activation domain of NFkappaB p65 and is responsible for the initiation 
of transgene transcription (Figure 1). 
In the current study we performed an in-depth optimization of the GeneSwitch system 
for AAV gene therapy in the liver. Different promoters and regulatory elements were 
tested. A detailed head-to-head comparison of a single- and two-vector system were 
performed both in vitro and in vivo. Moreover, the kinetics of the GeneSwitch system 
transgene induction was investigated systematically. The inducer MFP and its metabolites 
were measured in vivo to gain insight in plasma kinetics and liver tissue concentrations. 
Insulin-like growth factor (IGF) and erythropoietin (EPO) were chosen as transgenes, 
due to the easy plasma read out and having a suitable size to fit into AAV vectors in 
combination with the GeneSwitch system. By using several transgenes, proof of concept 
and wide applicability of the single GeneSwitch system for AAV gene therapy in the liver 
was explored. Besides expression of the transgenes IGF and EPO upon MFP treatment, 
we have demonstrated that the single GeneSwitch-EPO vector induction translates into 
a reversible increase in hematocrit levels; a hallmark phenotypic effect of EPO expression. 
Results
Mifepristone induces a dose dependent regulation of luciferase 
expression by a single vector GeneSwitch system
In our initial experiments to develop regulated gene therapy, the expression of 
the GeneSwitch protein was placed under the control of the cytomegalovirus (CMV)-
promoter and firefly-luciferase was used as read-out reporter transgene for MFP inducibility. 
The two expression cassettes containing GeneSwitch (GS) and firefly-luciferase (FL) were 
cloned in a single vector in the head-to-tail configuration (CMV-GS-FL), as shown in 
Figure 2a. 
This plasmid CMV-GS-FL and a control plasmid expressing GFP from a CMV promoter 
(CMV-GFP) were transfected into HEK293T cells. Cells introduced with CMV-GFP showed 
GFP expression indicating successful transfection (data not shown). Exposure of cells 
transfected with CMV-GS-FL to MFP caused a concentration-dependent increase of 
luminescence, indicating MFP-dependent GeneSwitch activation (Figure 2b). 
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Figure 1. Schematic for the regulation of transgene expression by mifepristone inducible GeneSwitch 
system. Within the GeneSwitch system there are two protein expression cassettes, one for 
the inducible transgene of interest and another for GeneSwitch protein. The regulatory vector 
(Vector GS) contains the GeneSwitch gene and a promoter that is driving constant expression of 
GeneSwitch protein. In this example the promoter is a liver specific promoter, which is only active in 
hepatic tissue. GeneSwitch protein is a fusion protein of three domains: human NF-kB transcription 
activation subunit named p65, human progesterone receptor ligand binding domain (PR) and 
yeast Gal4 DNA binding domain (Gal4). After binding of the steroid inducer mifepristone (MFP) 
to the PR domain, GeneSwitch protein gets activated and changes conformation. An active dimer 
is formed that can bind via the Gal4 domain to the four Gal4 binding sites within the inducible 
promoter of the transgene vector. Then the p65 subunit of GeneSwitch protein facilitates the start 
of transcription of the regulated transgene (here EPO). EPO protein on its turn stimulates production 
of erythrocytes, resulting in increased hematocrit levels.
Induction rate of the single vector GeneSwitch system is promoter 
dependent
For many clinical indications it is preferred to restrict therapeutic gene expression to 
a single organ by using tissue specific promoters. To investigate the influence of different 
promoters on the GeneSwitch system for liver application, the universal CMV-promoter 
was compared with the liver specific human alpha1-antitrypsin (AAT)-promoter. Rat 
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insulin like growth factor-1 (IGF1) was used as a transgene, as it is an endocrine hormone 
mainly produced by hepatocytes. Plasmids with GS-IGF1 were cloned under control of 
the AAT-promoter and the CMV-promoter, respectively, in front of GeneSwitch (Figure 
3a). The expression cassettes of GeneSwitch and IGF1 were in opposite transcription 
directions based on results from Szymanski et al12. and in order to avoid close proximity 
of the promoters to the AAV inverted terminal repeats. 
MFP induced expression of IGF1 by the hepatocyte cell line Huh7 transfected 
with the AAT- or CMV-driven plasmids. The AAT promoter construct resulted in much 
higher IGF1 protein induction than the CMV promoter, 1,6 and 12 times over baseline 
respectively (Figure 3b). In the non-induced state, cells with the AAT-promoter plasmid 
secreted only 6 ng/ml IGF1 in contrast to 28 ng/ml IGF1 with the CMV-promoter, 
revealing low basal expression of the AAT-promoter compared to the high background 
expression of the CMV promoter.  The difference in IGF1 basal expression levels between 
the AAT- and CMV-promoters was unexpected as both promoters are strong and have 
been widely used to drive gene expression in hepatocellular cells. Additionally, the MFP-
induced IGF1 expression was higher with the AAT-promoter (76 ng/ml IGF1) than with 
the CMV promoter (45 ng/ml IGF1). Consequently, the AAT promoter resulted in low 
Figure 2. Mifepristone dose dependent expression of luciferase by a single-vector GeneSwitch 
system. A. Schematic of the two expression cassettes of the GeneSwitch system within a single 
vector. The cassettes are put into a tail to head configuration, where transcription is in the same 
direction. GeneSwitch protein expression is driven by a CMV-promoter and the inducible promoter 
of luciferase contains four Gal4 binding sites (4G). B. HEK293T cells were transfected with the CMV-
GS-Luc plasmid shown in A or a control plasmid (N.C.). The next day cells were incubated with 
different concentrations of MFP ranging from 0 to 10nM for 48h. Firefly luciferase activity was 
measured from three independent samples and averages are shown.
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background expression and a high dynamic range of MFP-dependent induction. Because 
of the superior characteristics of the AAT-promoter it was selected for further testing 
in vivo.
In vitro expression kinetics of the single vector GeneSwitch system
We next investigated the expression kinetics of the GeneSwitch system in vitro, using 
EPO as a reporter, to gain more insight into the GeneSwitch system. A single vector 
(GS-EPO) was constructed containing the AAT-promoter in front of GeneSwitch and an 
EPO expression cassette with the inducible promoter in opposite direction (Figure 4a). 
Huh7 cells were transfected with GS-EPO, incubated with 0, 1 or 10nM MFP and 
harvested 6, 16, 24 or 48 hours after induction. EPO mRNA levels were measured by 
RT-qPCR and ELISA was performed to determine EPO protein concentrations in the culture 
supernatant. Both EPO mRNA and protein levels increased in the presence of MFP 
(Figure 4b and 4c). EPO mRNA levels increased to reach a maximum at 16h, followed by 
Figure 3. Single-vector GeneSwitch system promoter optimization and applicability to different 
transgenes. A. Configuration of head-to-head single vector GeneSwitch system in which 
the transgene is insulin like growth factor 1(IGF1) and the promoter in the GeneSwitch expression 
cassette is either CMV or AAT. B. Huh7 cells were mock transfected (negative control, n.c) or 
transfected with AAT-GS-IGF1 or CMV-GS-IGF1. The next day culture medium was replenished by 
medium without (no MFP, black bars) or with 10nM MFP (gray bars). After 48h, IGF1 secretion into 
the culture supernatant was measured by ELISA. Data were evaluated using student’s t test for 
the treatment with MFP versus without MFP. The significant difference of p < 0.05 between the AAT-
GS-IGF1 groups is indicated with (*). There was only a positive trend for the difference between no 
MFP and 10 nM MFP of the CMV promotor containing construct.
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Figure 4. In vitro expression kinetics of EPO mRNA, protein and GeneSwitch protein after MFP 
induction of the single-vector GeneSwitch system. A. Configuration of head-to-head single vector 
GS-EPO in which the transgene is erythropoietin (EPO) and with the AAT-promoter in the GeneSwitch 
expression cassette. B. EPO mRNA kinetics. Huh7 cells were transfected with single vector GS-EPO 
or no plasmid (n.c.). The next day they were incubated with 0 to 10nM MFP for 6 to 48h hours. 
Then EPO mRNA expression in the cells was determined by reverse transcription qPCR. Data were 
analyzed with a two-way ANOVA and the most significant induction rate was at 16h after 1nM and 
10 nM MFP (p < 0.0001).  At 24 and 48h induction was also significant (p < 0.05). Full statistical 
analysis can be found in supplemental table 1. C. EPO protein kinetics.  EPO protein expression 
and secretion into the culture medium was measured by ELISA. Two-way ANOVA at 6h revealed 
p < 0.05 for no MFP versus 1 nm MFP and p < 0.0001 for no MFP versus 10 nm MFP. At 16, 24, 
and 48h, p values were < 0.0001 for no MFP versus both 1 nM and 10 nM MFP. D. Detection of 
GeneSwitch protein. Presence of GeneSwitch protein in cells was assessed by SDS-PAGE followed by 
western blotting using a p65-antibody. Arrows indicate endogenous p65 and GeneSwitch protein. 
Relative GeneSwitch protein levels were quantified by normalizing the GeneSwitch protein signal 
to endogenous p65 signal and set relative to 0nM MFP of each timepoint. The values are indicated 
above each lane.
protein expression that reached its maximum at 24h to 48h. GeneSwitch protein kinetics 
were monitored by western blot using an antibody against its p65-domain and quantified 
relative to endogenous NF-kappaB p65 signal. In the absence of MFP, the amount of 
GeneSwitch protein increases from 6h to 48h, due to constitutive production of 
GeneSwitch from the AAT-promoter (Figure 4d). After addition of 10nM MFP the signal 
for GeneSwitch protein on the western blot was constant. However, in comparison to 
non-induced cells GeneSwitch protein declined over time, to two-thirds the amount at 
24h and half the amount at 48h post MFP. This difference could either be due to lack of 
antibody recognition, as activated GeneSwitch changes conformation to form a dimer, 
or due to degradation of GeneSwitch after activation. Hence, induction by MFP results in 
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transgene mRNA expression followed by protein expression, after which all components 
including the GeneSwitch protein reach an equilibrium from 24 hours to at least 48h.
In vitro induction and comparison of the single- and two-vector 
GeneSwitch system
The original GeneSwitch system is based on two plasmids, but we have put all GeneSwitch 
components into a single plasmid and kept within the maximal packaging capacity of 
the AAV vector. We compared the characteristics of the single and two-vector GeneSwitch 
system in vitro and in vivo using four constructs (Figure 5a). In addition to the single vector 
GS-EPO, described in the previous section, two combinations of the two vector system 
were designed: A two vector system containing GeneSwitch on one plasmid (GS) and 
the EPO transgene together with the regulated promoter having either four or eight Gal4 
binding sites (GS-EPO, 4G-EPO or  8G-EPO) on the second plasmid. GS-EPO, GS together 
with 4G-EPO and GS with 8G-EPO were investigated for inducibility and the effect of 
the number of GeneSwitch protein binding sites on (basal) expression levels. 
The hepatocyte cell lines Huh7 and Hepa1-6 were transfected with these plasmids and 
after two days of incubation with MFP, EPO was measured in the culture supernatant. In 
both cell lines, addition of MFP induced the expression of EPO from the single and two 
vector systems (Figure 5b and c). In Huh7 cells induction rates for all three conditions tested 
were just above 6 times (6,2 times for GS and 4G-EPO; 6,4 times for GS and 8G-EPO and 
6,3 times for GS-EPO), indicating that in these cells the single and two vector GeneSwitch 
systems perform similarly (Figure 5b).  The measured induction levels were higher and 
more distinctive in Hepa1-6 cells than in Huh7 cells (Figure 5b and c), mostly because 
in Huh7 cells the constructs have to overcome endogenous EPO expression. In Hepa1-6 
cells the single vector outperformed the two-vector system. Whereas the induction ratio 
in cells transfected with GS and 4G-EPO was 4 times and 14 times using GS and 8G-EPO, 
with the GS-EPO construct this was more than 500-fold (Figure 5c). These Induction 
differences were in large part due to the different levels of background expression of 
the GeneSwitch systems tested. With the single vector GS-EPO expression of EPO was not 
detectable without MFP. This was in contrast to the two-vector systems which triggered 
EPO expression in the absence of MFP. A higher leakiness was observed with the 4G-EPO 
plasmid compared to the 8G-EPO plasmid, but only in Hepa1-6 cells and not in Huh7 
cells. These results showed an impact of the number of Gal4-binding sites on the activity 
of the inducible promotor and indicated that an increased number of those sites could 
result in less background expression. 
Measurement of Mifepristone concentrations in biological matrices 
such as plasma and liver tissue
Because the GeneSwitch system is regulated by MFP, it is important to know the MFP 
concentrations necessary for gene induction in plasma and in liver. MFP is metabolized 
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and then excreted from the body, hence its pharmacokinetics are important for the timing 
of GeneSwitch activation.
In rats, maximal MFP plasma levels are reached one to two hours after MFP 
administration15. Mice were injected intraperitoneally during four consecutive days with 
20mg/kg MFP and sacrificed 2h after the last injection. MFP was extracted from plasma 
and liver tissue and measured quantitatively by HPLC followed by quadrupole time of 
flight-mass spectrometry. In Figure 6a a positive and negative chromatogram are shown. 
A peak with a retention time consistent with MFP (2,73 min) was exclusively present in 
the plasma sample from the MFP injected mice. Applying the same method MFP levels 
could also be measured in liver tissue (Table in Figure 6b). The average concentration of 
MFP from six mice was 677 ng/ml in the plasma and 3835 ng/g in the liver. Hence, MFP 
seems to be a suitable inducer for liver-directed gene therapy.
MFP can be C-hydroxylated, mono- and di-demethylated and in the liver. These MFP 
metabolites retain binding affinity to the human progesterone receptor and could induce 
the GeneSwich system16,17 . To follow MFP and MFP metabolite concentrations in plasma 
in time, mice were injected three consecutive days with MFP and plasma was recovered 
at 1h, 4h, 8h, 16h and 24h post last MFP injection. Each MFP metabolite has a different 
retention time and to compare MFP to its metabolite concentrations deuterated MFP 
was used as an internal standard.   MFP, mono- and di-demethylated MFP levels peaked 
at 1h post last MFP injection in the plasma samples, while hydroxylated MFP reached 
a maximum at 4h (Figure 6c).  Mono-demethylated MFP was more prevalent than di-
demethylated MFP in plasma, as the demethylations occur successively. At 16h post MFP 
the concentration of each compound reached the detection limit of 10ng/ml and at 24h 
post injection no MFP or metabolite could be detected. The half-lives were calculated to 
be around 3,5h for MFP and hydroxylated MFP, 1h for mono-demethylated MFP and 2,5h 
for di-demethylated MFP. Although the half-life of MFP measured in mice was slightly 
longer than the 2 hours reported previously in rats15 , MFP and its metabolites are rapidly 
cleared in rodents.
In vivo expression kinetics of the single vector GeneSwitch system
For testing kinetic expression of the components of the GeneSwitch system in mice, 
the single vector construct GS-IGF1 and constitutive expression construct IGF1 both with 
the AAT-promoter were encapsulated into AAV5 (AAV5-GS-IGF1 and AAV5-IGF1). IGF1 
was chosen as transgene, because protein-bound IGF1 has a longer half-life than EPO18, 
and the rat IGF1 sequence was used, to distinguish between endogenous murine IGF1 
and vector-expressed IGF1. 
The AAV5-vectors were injected intravenously at a dose of 10e13 genome copies (gc) 
per animal. One group of mice received the constitutive expression vector AAV5-IGF1 
(Figure 7a). The other groups were transduced with AAV5-GS-IGF1 and 4 weeks later 
injected with MFP for three consecutive days. Blood was drawn at 1h, 4h, 8h, 16h or 
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Figure 5. Mifepristone inducible expression of EPO by single- and two-vector GeneSwitch system in 
vitro. A. Within the two-vector system the GeneSwitch protein expression cassette is in one vector 
(GS) and the transgene expression cassette with EPO is in the second vector. The latter contains either 
four Gal4 (4G-EPO) or eight Gal4 (8G-EPO) binding sites in their inducible promoter. The single-
vector system comprises both the GeneSwitch protein and erythropoietin (EPO) expression cassettes 
in one vector (GS-EPO), here in tail-to-tail orientation with transcription in opposing directions. B. 
The different plasmids illustrated in A. were transfected into Huh7 cells. The next day, they were 
incubated with 0 or 10nM MFP for 48h. Then ELISA was performed on culture supernatant, to 
measure the concentration of secreted EPO. C. Same as B, except in Hepa1-6 cells. Mock transfected 
cells are indicated with negative control (n.c.). In the GS-EPO treated cells, the background levels of 
EPO without MFP were too low to visualize in the graph. Data were evaluated using student’s t test 
to compare with MFP versus without MFP. MFP treatment significantly induced EPO expression in 
both cell lines. (**p < 0.01; ***p < 0.001; ****p < 0.0001)
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24h after each MFP injection (Figure 7a). Following the third MFP injection the mice 
were sacrificed and vector DNA and rat IGF1 mRNA levels were quantitated in the liver. 
The average transduction efficiency of the AAV5-vector was similar for the groups, 
however there was high variance within each group (Figure 7a and b). Four animals 
seemed to have been miss-injected and had very low liver vector DNA levels (less than 
10e6 gc/ug DNA), were excluded from the subsequent mRNA and protein analyses. 
Rat IGF1 mRNA levels were quantified using rat specific IGF1 primers and compared to 
the AAV5-GS-IGF group that did not receive MFP. AAV5-IGF1 injected animals constitutively 
express IGF1 and around 60 times over the non-induced AAV5-GS-IGF1 transduced 
animals. After induction of the AAV5-GS-IGF1 groups, IGF1 mRNA concentrations 
increased up to 4 hours after administration MFP, and subsequently gradually decreased 
to non-induced levels at 24h post MFP. Concordantly, a time dependent increase in IGF1 
mRNA levels after induction with MFP using the GeneSwitch system was detected in vivo 
(Figure 7c).
Finally, IGF1 protein levels were determined in murine plasma upon MFP induction 
at three consecutive days. The plasma concentrations of IGF1 varied between 100 and 
400 ng/ml for all groups over these three days (Supplemental Figure 1). Higher steady 
state IGF1 levels were detected in mice injected with the constitutive AAV5-IGF1 vector 
compared to the uninduced AAV5-GS-IGF1 injected group. IGF1 protein induction was 
determined at 1, 4, 8, 16 and 24h after the last induction. A clear time-dependent increase 
was observed in all animals (Fig7D), demonstrating a tight regulation of the transgene 
expression over time. Taken together these results indicate MFP and time dependent 
regulated transgene mRNA and protein expression by the GeneSwitch system in vivo.
In vivo induction and comparison of the single- and two-vector 
GeneSwitch system
After evaluating the kinetics of MFP and the GeneSwitch system in mice, we compared 
the characteristics of the single and the two vector GeneSwitch system encapsulated in 
AAV5. Instead of IGF1, EPO was as the reporter gene because it can be easily measured 
in blood and increases hematocrit, providing a simple measurable functional effect.
Mice were transduced with 10e12 gc of the constitutive expressing AAV5-EPO or 
the single vector virus AAV5-GS-EPO. In addition, two groups of mice were injected 
intravenously with AAV5-GS either in combination with AAV5-4G-EPO or AAV5-8G-EPO, 
each virus at 10e12 gc per animal (Table in Figure 8a). To investigate repeated inducibility 
of the GeneSwitch system, the mice received two rounds of MFP at 4- and 8-weeks 
post transduction. Blood was taken regularly from the mice to measure EPO plasma 
concentrations and hematocrit (Figure 8b). 
After the second round of MFP injections the mice were sacrificed and vector DNA 
was measured with EPO or GeneSwitch specific primers (Table in Figure 8a). The liver-
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specific transduction of the different AAV5-delivered constructs was similar for all groups 
(Figure 8c).
AAV5-EPO caused continuous transgene expression resulting in plasma EPO levels 
of approximately 600 mIU/ml (Figure 8d, panel i). This caused a high hematocrit and 
after a month it was decided to sacrifice the mice. (Figure 8e). The groups injected with 
either the single or the two vector GeneSwitch system, all had increased EPO plasma 
levels after induction with MFP. The EPO levels dropped to background at four days post 
last MFP injection (data not shown) and remained at basal levels till the week before 
the next MFP-induction round (Figure 8d, panels ii, iii, iv). The induction ratio of the single 
vector was more than 200 times, while the ratios with two-vector system with 4G-EPO 
or 8G-EPO were 60 and 20 times, respectively. The difference of the induction ratios was 
mainly a consequence of the low background expression levels and not the amplitude 
of expression observed with the single vector system. Although the two-vector system 
GS and 4G-EPO showed high levels of EPO after induction, they were considerably more 
basal expression than the single vector system. As had been observed in vitro, the addition 
of four additional Gal4 binding sites, to a total of eight, reduced background levels as 
well as the induced expression levels, resulting in a lower induction ratio. The induced 
EPO production in mice injected with the single-vector system had functional effects 
and increased red blood cell volume (Figure 8e). Hematocrit levels were above normal 
in mice injected with either of the two-vector systems in the absence of MFP, due to 
background EPO expression. In summary, in vivo the single vector GeneSwitch system had 
low background expression and a high induction rate, two requirements that are essential 
for developing regulated AAV gene therapy. Mice injected with the single vector system 
had a normal hematocrit in the non-induced state, and hemoglobin levels increased upon 
MFP injection, returning to baseline in the absence of the inducer (Figure 8f). Hence, 
the GeneSwitch system can be adapted to cause background free repeated induction of 
a therapeutic transgene, resulting in an inducible phenotype. 
Discussion
Gene therapy offers the potential of a long-term solution for many chronic diseases, 
whereby the transgene is continuously expressed following a single vector administration. 
However, in some cases it would be desirable to regulate transgene expression within 
a well-defined therapeutic window in time, or to regulate the rate of expression of 
a therapeutic transgene. The present report describes a series of in vitro and in vivo 
proof-of-concept studies to explore the MFP-inducible GeneSwitch system in regard of 
timing and transgene expression levels and carrying out an in depth characterization of 
the regulated gene expression system. Our data support the rationale that the GeneSwitch 
system could be applied in future clinical development programs.
The classical GeneSwitch system consists of two vectors with separate GeneSwitch 
and transgene expression cassettes. We chose to develop a single vector system, because 
Chapter 6
200
6
Figure 6. Assay development for detection of mifepristone and its metabolites in biological matrices. 
A. Mice received intraperitoneal MFP injections (20mg/kg) for four consecutive days. Then plasma 
and liver samples were taken 2 hours after the last MFP injection and measured by UPLC-QTOF-MS. 
Mass spectrometry chromatograms for mifepristone at 2.73 min in murine plasma samples from 
mice without (no MFP) or with MFP injections (+MFP) are shown in A. The table in B. contains 
the average MFP concentration in plasma and liver samples of six mice. The standard deviation is 
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in brackets. C. Mice were treated with MFP for three consecutive days, blood samples on the third 
day were taken at indicated hours post injection, followed by measurement on UPLC MSMS to 
determine concentrations of MFP (i) and three MFP metabolites C-hydroxylated MFP (ii), mono-
demethylated MFP (iii) and di-demethylated MFP (iv).
it circumvents the hurdle of delivery of both cassettes at a predefined ratio in the same 
target cell in vivo.  Furthermore, a single product would simplify AAV manufacturing. 
Based on the relative large size of GeneSwitch (2,5kb), the additional cargo size is limited 
to approximately 2 kb to not exceed the AAV packaging limit of approximately 4,7kb. 
With suitable sized transgenes such as luciferase, EPO and IGF we were able to show 
inducibility of the single vector system for all three genes. Albeit in a different expression 
cassette orientation, others have used a single vector AAV with transgenes GFP, GDNF and 
IFN9,10,12 . Collectively, this demonstrates wide applicability of the single vector GeneSwitch 
system to multiple transgenes. Besides transgene size, other discriminating points in 
the development of a single vector are the orientation of both expression cassettes and 
the promoter for the GeneSwitch protein, as described by Szymanski et al12. In addition, 
we showed that the promoter can affect the inducibility of the system, as the use of 
the AAT-promoter improved induction ratios compared to the CMV-promoter because it 
has lower non-induced expression and higher transgene expression after MFP addition. 
The use of the liver specific AAT-promoter adds additional value to the GS system because 
expression will be limited to hepatocytes, hence increase the safety of the approach.
The GS system is designed to be silent in a non-induced state and active after 
the addition of MFP. The advantage of a positively induced system is that it requires 
the administration of the inducer MFP only when necessary, increasing the safety profile 
of the regulated expression system. The need-on-demand principle for MFP would allow 
discontinuation of therapy in case of adverse effects or when treatment is no longer 
required, by simply stop taking the inducer drug. In mice we observed a rapid (16-24 
hour) clearance of MFP and metabolites after the last injection with the inducer. Moreover, 
transgene levels increased at first and then decreased, showing that the GeneSwitch 
system can be switched off by the removal of MFP. It should be noted that the half-life of 
MFP in humans is around 25 to 30 hours, and it therefore is expected that the induced 
transgene expression in humans would last longer than in rodents19 . 
One requirement for a regulated expression planned for clinical use would be to turn it 
on and off repeatedly. Previous data showed effective usage of the GeneSwitch system in 
a murine model of experimental allergic encephalomyelitis, with one plasmid containing 
the inducible system that regulated interferon expression20. This single vector system 
was packaged into AAV1 and injected intramuscularly into mice and interferon was 
induced over nearly a year20. We carried out a similar in vivo study using AAV5 to target 
hepatocytes in the liver. The Gene switch system was induced twice with MFP resulting 
both times in high EPO plasma levels with a meaningful impact on hematocrit levels 
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Figure7. In vivo expression kinetics of IGF mRNA and protein after MFP induction in murine liver 
by the single-vector GeneSwitch system. Mice were transduced with AAV5 expressing rat IGF 
constitutively (AAV5-IGF, group 1) or regulated through the GeneSwitch system (AAV5-GS-IGF, 
group 2 to 7). Four weeks later, groups 3 to 7 were given MFP on three consecutive days and blood 
was taken at the indicated hours after each injection (+1h, +4h, etc). Group 1 and group 2 did not 
receive MFP (no MFP). On the third day the animals were sacrificed, and the livers dissected. One 
animal of the 16h group died before MFP injections for unknown reasons. A. Table indicates with 
which AAV5 the groups were injected, treatment of MFP and time post MFP for blood sampling. 
The average transduction efficiency of vector DNA was determined in liver tissue 5 weeks after 
virus injection by qPCR. B. Transduction efficiency of vector DNA of each mouse from each group. 
The small lines indicate the average per group. Four animals seemed to be miss-injected and had 
below 10e6 genome copies per ug DNA, they were excluded from the subsequent mRNA and 
protein analyses. C. Liver samples were analyzed for rat IGF mRNA levels by reverse transcription and 
qPCR. Levels were normalized to GAPDH and put relative to mRNA levels in mice transduced with 
GS-IGF without induction (group 2). A one-way ANOVA revealed a significant change in IGF mRNA 
levels over time post MFP induction. Full statistical analysis can be found in supplemental table 1. D. 
IGF plasma concentrations were determined in the blood samples after three days of MFP injections 
by ELISA against mouse and rat IGF. There was a significant increase in plasma concentration post 
MFP induction (one-way ANOVA). 
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that increased temporarily. Both studies demonstrate the broad and robust versatility of 
the Gene Switch system.  
A critical feature in optimizing a regulation system for gene expression is to avoid 
background expression of the system. Our study has identified several factors that are 
involved in non-induced transgene expression:  promoter choice, regulatory elements and 
the application as a single or two-vector system. The use of the liver-specific AAT promoter 
in conjunction with GeneSwitch resulted in a higher induction ratio, mainly due to low 
basal transgene expression in the absence of MFP. Increasing the number of Gal4-binding 
sites from four to eight to more tightly regulate transcription, also resulted in reduced 
basal expression levels. However, whilst this approach reduced background expression, 
both in vitro and in vivo, it also lowered maximal expression, resulting in a lower induction 
ratio in mice. The lowest background expression levels were observed using a single 
vector system: Mice transduced with the single vector GS-EPO and not injected with MFP 
had EPO plasma levels that were similar to the control group. Therefore, the single vector 
with the AAT-promoter meets the safety criteria of reducing basal expression levels of 
the transgene.
The transgene induction rate provides an estimate of the dynamic range of protein 
expression using the GeneSwitch system. In vivo with the single vector AAV5-GS-EPO 
a more than 200 times increased transgene expression was observed compared to the basal 
state in the presence of MFP, indicating a two-log range regulated EPO expression. To 
compare the induction rate of GeneSwitch to other inducible systems in vivo, multiple 
variables need to be taken into account, including the promoter, vector architecture, 
the transgene, a single or two-vector, the target cell and the inducer. We preferred 
the AAT-promoter over the CMV-promoter, with a 7,5-times induction rate difference 
and with the additional benefit of restricting transgene expression to the liver. It has 
been reported that the transthyretin promoter can drive GeneSwitch protein to regulate 
IL12 expression. Mice injected with the inducible adenoviral vector showed two to three 
log increased IL12 levels, depending on viral load and MFP dose21. Other tissue specific 
promoters that were used in combination with the GeneSwitch system were selective 
for brain and muscle and had 24 and 500 times induction ratios respectively10,22. Hence, 
the performance of the AAT-promoter as part of the GeneSwitch system is comparable to 
the previously reported results. 
The single vector architecture of the GeneSwitch system as well as the type of 
transgene, can make a difference for inducibility12. The orientation of the expression 
cassettes determined the induction rates for SEAP between 4 to 900 times, while 
the rates from vectors with EPO were between 19 and 34 times, which is significantly 
lower than the AAV5-GS-EPO we have tested. The Tet-on system has been incorporated 
into a single AAV vector with a liver specific albumin promoter and expressing luciferase 
as transgene23. Injection of the vector into mice, gave similarly to the AAV5-GS-EPO 
vector, a dynamic range of 250 times. In contrast, an in vivo study using the Tet-on 
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Figure 8. Mifepristone inducible expression of EPO in murine liver by the single- and two-vector 
GeneSwitch system. A. Table indicating the groups, the name and concentration of the AAV5 injected 
and the MFP treatment. The average vector DNA level of each vector per group determined in 
murine liver tissue using qPCR. B. Illustration of experimental set up. Arrows above timeline indicate 
the day of AAV5 transduction and the days of intraperitoneal injections with MFP. Arrows below 
the timeline specify when blood samples were taken and at day 58 when the animals were sacrificed. 
C. Individual values of vector DNA levels in liver tissue of each AAV5, determined in mice 9 weeks 
post vector injection using qPCR. Specific primers were used to quantify GeneSwitch sequences (GS, 
squares) and EPO sequences (EPO, circles). D. EPO concentrations in the plasma of mice injected 
with different AAV5 vectors. In panel i animals were transduced with AAV5-EPO and EPO plasma 
concentration was measured at day 13, 29 and 33. The mice of panel ii received the single vector 
AAV5-GS-EPO. In panel iii and iv the animals were co-injected with AAV5-GS and AAV5-4G-EPO or 
AAV5_8G-EPO. EPO plasma levels were measured at day 13, 29, 48 and 57. Animals subjected to 
two rounds of four days of MFP injections are indicated with circles, the non-MFP injected animals 
with triangles. Each panel contains the EPO plasma concentration of animals without vector and MFP 
injections (Ctrl). Data were evaluated using student’s t test to determine the significance between 
groups treated with and without MFP. Some measurements are also indicated with n.s to show 
they are not significantly different. E. All ghemoloups were subjected to hematocrit measurement 
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at day 33. The hematocrit levels between the dotted lines at 6,3 and 10,3 mmol/l are considered 
normal or healthy. Basal expression levels between groups were analyzed by a two-way ANOVA 
(see table S1). A second comparison was done with a t-test to determine the effect of MFP on Hb 
levels. F. Average hematocrit levels from animals transduced with the single vector AAV5-GS-EPO 
at day 13, 33 and 48. Triangles represent the mice without MFP and circles is the group injected 
with MFP. Gray bar indicates when MFP was injected and dotted lines are the borders of normal 
hematocrit levels. (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001).
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system, controlling EPO expression in a single vector with both cassettes facing inward 
the induction rate reported was 15 times above baselines. This relatively low increase 
after administration of doxycycline was mainly due to the high basal expression levels 
that already were sufficient to increase the hematocrit in mice24 . In contrast, a two-vector 
AAV Rapamycin system expressing EPO did not elevate hematocrit levels in the absence 
of the inducer, and similar to our experiments, rapamycin administration resulted in an 
induction rate of 200 times25,26. A main advantage of the two-vector rapamycin system 
is its tight regulation compared to other systems27 . We here report that using a single 
vector, a similar tight control of gene regulation and predictable repeated induction, 
leading to an induced phenotype, can be achieved.
The kinetics and orchestration of transgene expression has not been studied extensively 
for GeneSwitch, nor for other regulated gene expression systems, and was therefore 
investigated by us in vitro and in vivo. In vivo we observed that the highest plasma levels 
of MFP and metabolites were measured at 1 to 4 hours post injection, followed by 
a peak expression of mRNA at 4 to 8 hours. Transgene protein levels could be measured 
the same day and the next day; a timeframe confirmed with our two vector system 
and by others21,22. The rise of transgene mRNA followed by increasing levels of protein 
correlated with the in vitro results. We also managed to detect GeneSwitch protein by 
western blot in liver tissue, albeit weakly, showing that after MFP induction GeneSwitch 
protein decreased, confirming our in vitro data (data not shown). We´d expect similar 
kinetics for other regulated gene expression systems, however how long it takes before 
expression can be switched off will depend on the pharmacodynamics of the inducer 
and the stability of the mRNA and protein. Here we used EPO as transgene, which has 
a half-life of around 5 hours and could not be measured four days post the last MFP 
injection (data not shown). On the other hand, using GDNF as transgene with a half-life 
of 37 hours resulted in longer expression, as GDNF was still detectable one week post 
MFP injections10. Doxycycline is cleared from the body in 15-25 hours, which is shorter 
than MFP (25-30 hours), but is around twice as long for rapamycin (60 hours). Expression 
from the GeneSwitch system might therefore, due to MFP inducibility, be switched off 
relatively quickly.
One of the advantages of using MFP as an inducer in the GeneSwitch system is 
the fact that it is licensed for clinical use. The GeneSwitch inducer MFP and its safety has 
been studied only short term and in females. However, the drug is currently investigated 
for long term use in psychiatric disorders with male and female participants28. Moreover, 
the MFP concentration inducing expression in our in vivo experiments has been safely 
tested in psychiatric patients29–31. Besides progesterone-antagonizing effects MFP has 
anti-glucocorticoid properties. Although, the IC50 of the latter effects is a 100-fold 
lower, and low-dose MFP is not expected to have an effect on the glucocorticoid 
receptor. In the current experiments, using a single vector GeneSwitch system MFP 
induced the transgene at a concentration between 0,2 nM and 1 nM. This is as low as 
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demonstrated previously32. Alternative regulated systems use rapamycin or tetracyclins 
as inducer. Rapamycin is an immunosuppressant and clinical application would require 
development of non-toxic rapamycin orthologs. Tetracyclins have short-term side effects 
and long-term use of tetracyclins could increase antibiotic resistance in microorganisms. 
Recently, a Tet-on system was optimized to be inducible at low enough concentrations to 
have the potential to not invoke resistance3. 
Gene therapy should be restricted to the organ where the gene product is required. 
The delivery to the target organ is achieved by the choice of the AAV variant, by the route 
of administration and by a promoter that is restricting the expression to the area of 
choice. In case of a regulated gene expression system it is also necessary to ensure 
that the inducer is reaching the target cells. We found that sufficient concentrations of 
MFP reach the liver in vivo. Rapamycin and doxycyclin have difficulty reaching the brain 
and CSF levels are 30% and 25% of the plasma concentration, respectively33,34 . MFP 
does cross the blood brain barrier, and the GeneSwitch system has been successfully 
utilized in rat brain9. Additionally, it is possible to induce expression from the GeneSwitch 
system which is injected in mice muscle or when expressed in lung cells22,35 . Hence, 
the Gene Switch system is applicable to multiple organs and can be controlled by 
tissue-specific promoters. 
The ongoing successes for clinical trials for hemophilia A and hemophilia B have 
led to increasing enthusiasm for AAV gene therapy targeting liver diseases36. Preclinical 
studies in animal models have demonstrated proof of concept for several other types 
of liver disorders36.  Many of these disorders such as glycogen storage disease type Ia, 
citrullinemia type I, ornithine transcarbamylase deficiency, phenylketonuria, Wilson 
disease, methylmalonic acideamia and Crigler-Najjar syndrome are currently under 
investigation by several pharmaceutical companies36,37.  As more disease indications for 
the liver are moving closer to the clinic, inducible systems will inevitable be needed in 
the future to allow a more controlled regulation of transgenes that may induce transgene-
specific immune responses or cause other unwanted effect at sustained expression and/
or high doses. The data presented in this study supports the applicability of regulatable 
GeneSwitch system delivered by AAV for future clinical application in the liver.
Material and Methods
Plasmid construction
Erythropoietin (EPO) coding sequence is from M18189.1, Insulin like growth factor 1 
(IGF1) coding sequence from M15480.1 (rat) and human growth hormone polyA tail (pA) 
sequence from NM_022560, these were synthesized and digested from shuttle vectors 
prepared by BaseClear (Leiden, The Netherlands). The alpha1 anti-trypsin promoter 
combined with the mouse albumin gene enhancer (AAT-promoter) was taken from 
a plasmid described before38 . pIF1683 (Inovio, San Diego, CA) contained minimal pol II 
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promoter with four upstream activation elements (4xGal4) and IVS8 that was cloned in 
front of the transgene. The GeneSwitch sequence (GS) was from pGS1694 (Inovio, San 
Diego, CA). The specific order of elements within the expression cassettes designed in 
this study will be summed up here: CMV-GS-luciferase has CMV-GS-pA-4xGal4-IVS8-
luciferase-pA, CMV-GS-IGF has pA-IGF-IVS8-4xGal4-CMV-IVS8-GS-pA,  AAT-GS-IGF has 
pA-IGF-IVS8-4xGal4-AAT-IVS8-GS-pA, EPO has AAT-EPO-pA, GS has 4xGal4-AAT-IVS8-
GS-pA, 4G-EPO has 4xGal4-IVS8-EPO-pA, 8G-EPO has 4xGal4-4xGal4-IVS8-EPO-pA and 
GS-EPO has pA-EPO-4xGal4-AAT-IVS8-GS-pA. 
Cell culture, transfection and MFP induction
Huh7, Hepa1-6 and HEK293 cells were cultured in DMEM medium (Gibco), supplemented 
with 10% fetal bovine serum with or without penicillin/streptomycin at 37C, 5% CO2. 
Trypsin 0,25% EDTA (Gibco) was utilized for cell detachment and cells were seeded one 
day prior to transfection. HEK293 cells were transfected using Lipofectamine 2000, 
according to manufacturer’s protocol. Lipofectamine 3000 at a ratio of 1: 0,75 for P3000: 
Lipofectamine 3000 was used to transfect Huh7 and Hepa1-6 cells. The following day 
culture supernatant was replaced by medium with the appropriate MFP concentration. 
MFP was diluted from a 1mM MFP-ethanol stock solution into medium.
Luciferase assay
To measure luciferase activity, culture medium was removed and cells were washed ones 
in PBS, followed by lysis with 1x passive lysis buffer (Promega). Plates were incubated on 
an orbit-shaker at 450 rpm at room temperature for 20 min. Firefly luciferase activity of 
10ul samples was measured with the dual-luciferase reporter assay system (Promega) 
according to manufacturer’s protocol. An average of luciferase counts was taken from 
triplicate transfections. 
ELISA
For EPO and IGF1 ELISA murine plasma or cell culture supernatant was collected. 
The samples were diluted in specimen diluent buffer for EPO measurements and in 
calibrator diluent buffer for IGF1 measurements to range within the standard curve values. 
After that manufacturer’s protocol was followed (R&D systems; DEP00 and MG100). EPO 
or IGF1 concentrations were calculated using a trend line derived from the standard curve 
samples in Excel.
RNA and DNA isolation, cDNA synthesis and qPCR
Genomic DNA (gDNA) was isolated from murine liver using the DNeasy Blood & Tissue 
Kit (QIAGEN Inc., Chatsworth, CA) according to the manufacturer’s protocol. Total RNA 
was isolated from liver sections or from Huh7 cells using Trizol (Invitrogen, Carlsbad, CA) 
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according to the manufacturer’s protocol. gDNA was removed by double stranded DNase 
treatment using engineered shrimp DNase (Thermo Scientific, EN0771). First strand cDNA 
was reverse transcribed using random hexamer primers with DyNAmo cDNA synthesis kit 
(Thermo Scientific, F-470L) and 500 ng of total RNA. 
Real time PCR amplification was performed with 10 time diluted cDNA or 250 
ng gDNA, Fast SYBR Green Master Mix (Thermo Scientific, 4385612) and primers 
specific for EPO (ATATCACCGTCCCAGACACC and CAGGACAGCTTCTGAGAGCA), 
IGF (TCACAGGGATGCCAAGAT and GTCAACATGAGCGCACC), GeneSwitch 
(AGCATGCGATATTTGCCGAC and AGAGTAGCGACACTCCCAGT), AAT 
(AGGCCAACTTGTCTACGTTTAGTATG and CAGCGTCCTGTGTCCAAGGT), beta-Actin 
(ACGGCCAGGTCATCACTATTG and CAAGAAGGAAGGCTGGAAAAGA) and/or GAPDH 
(TCCACCCATGGCAAATTCC and GGGATTTCCATTGATGACAAGCT). PCR reaction 
conditions were: 95°C for 20 sec, followed by 40 cycles of 3 sec at 95°C and 30 sec 
at 60°C. The assays were performed on ABI 7500 Fast (Applied Biosystems, Foster City, 
CA). EPO and IGF mRNA expression levels were normalized to GAPDH or beta-Actin and 
the relative gene expression 2-DeltaDeltaCt method was used for analysis of PCR data. AAV5 
titers were determined using a standard curve, made with plasmid containing the AAT-
promoter and EPO coding sequence.
SDS-PAGE, transfer and western blot
Cells were washed in PBS and lysed in 1x NuPAGE LDS Sample Buffer (Life Technologies). 
NuPAGE Reducing Agent was added to the samples prior to heating at 95C. Proteins 
were separated on a NuPAGE Novex Tris-bis, 4-12% gel in a Biorad system with MOPS 
SDS Running buffer (Life Technologies). To transfer proteins from the gel onto Immun-Blot 
PVDF Membrane (Biorad) a wet blotting system (Biorad) was used with NuPAGE transfer 
buffer containing 10% methanol. The membrane was blocked with 5% semiskimmed milk 
(Sigma), 0,1% Tween-20 (Calbiochem) in PBS (Gibco). This was followed by incubation 
with the primary antibody against NF-kappaB p65 (abcam ab7970) in blocking buffer. 
After washing the membrane, the antibody swine-anti-rabbit with HRP conjugate (Dako) 
was added. Subsequent to washing the membrane, HRP was visualized by ECL Lumilight 
plus (Roche) and the signal was captured with the ImageQuant LAS4000 (GE Healthcare). 
Quantification of the protein bands in the images was done with ImageJ Fiji. 
AAV5 vector production
AAV5 vectors used in this study were produced by a baculovirus-based AAV production 
system. Briefly, the expression cassettes of interest were cloned into a uniQure transfer 
plasmid in order to generate an entry plasmid. The presence of the two inverted terminal 
repeats (ITRs) was confirmed. The ITR-expression cassette was inserted in a recombinant 
baculovirus vector by homologous recombination in Sf9 cells and clones were selected by 
plaque purification. The recombinant baculoviruses containing the ITR-expression cassette 
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were further amplified and screened for the best production and stability by PCR and 
qPCR. To generate AAV5, cells were infected with recombinant baculoviruses expressing 
the ITRs-expression cassette, the replicon enzyme and the capsid protein. The cells 
were lysed and crude lysate was treated with Benzonase (50U/ml) (Merck, Darmstadt, 
Germany) for 1 hour at 37 °C. AAV5 was purified on an AVB Sepharose column (GE 
Healthcare, Little Chalfont, UK) using an AKTA purification system (GE Healthcare) and 
the final concentration was determined by quantitative PCR.
In vivo
C57BL6 mice were maintained under a 12-hour light: 12-hour dark cycle in a clean facility 
with free access to food and water. Experiments were performed with the approval of 
the Animal Ethics Committee (DEC) in the Netherlands. Three-month-old animals were 
intravenously injected with AAV5; EPO expressing viruses at 1e12 and IGF expressing 
viruses at 1e13 vector genome copies per animal. Four weeks after, mice injected with 
AAV5-GS-IGF were treated with 20mg/kg MFP three days in a row, except for the non-
induced group of mice. In the experiment concerning EPO expression, four- and eight-
weeks post-transduction several groups of mice were injected intraperitoneally with 
20mg/kg MFP for four consecutive days. Blood was taken at the indicated days of 
the experiment; in general before transduction, before and after induction with MFP. All 
blood samples were collected in tubes with heparin and after centrifugation at 1500rpm 
for 15min plasma was stored at -80C and used for ELISA or MFP measurement at a later 
stage. Hematocrit was analyzed in a HemoCue 201+ (HemoCue AB, Ängelholm, Sweden) 
with a drop of blood immediately collected on a microcuvette. When the animals were 
sacrificed their liver was dissected.
MFP quantification
MFP was quantified at Eurofins | PROXY Laboratories the Netherlands according to 
company’s SOPs. In brief, after addition of internal standard D3-Mifepristone, MFP 
was extracted from 50ul of plasma or approximately 10 mg of liver tissue. The MFP 
standard curve was prepared in the appropriate matrix. Chromatographic separation 
of the samples was performed on a UPLC (Ultra Performance Liquid Chromatography) 
column, followed by positive electrospray ionization at QTOF-MS (Quadrupole 
Time of Flight-Mass Spectrometry). Then MFP concentrations were calculated from 
the recorded chromatograms.
Statistical Analysis
Data were analyzed using either the one-way ANOVA, two-way ANOVA or Student’s 
t-test with a predefined significance level of α=0.05 to determine statistically significances 
between two groups. The p values are represented by the following number of asterisks: 
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*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. Table S1 shows the full statistical 
analysis for the one-way ANOVA and two-way ANOVA.
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Supplemental data
Supplemental figure 1. In vivo expression of IGF protein after MFP induction in murine liver by 
the single-vector GeneSwitch system. Mice were transduced with AAV5 expressing rat IGF 
constitutively (AAV5-IGF) or regulated through the GeneSwitch system (AAV5-GS-IGF). Four weeks 
later, MFP was given three consecutive days (1st, 2nd, 3rd) and blood was taken at the indicated hours 
after each injection (+1h, +4h, etc). One group of the AAV5-GS-IGF injected mice and the AAV5-IGF1 
group did not receive MFP (no MFP), from them blood was collected at a convenient time on day 1, 
2 and 3 when the other groups received MFP. The IGF plasma concentrations were determined by 
ELISA against mouse and rat IGF.
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Supplemental Table 1. Statistical analysis using either the one-way or two-way ANOVA. Statistical 
analysis was performed using Graphpad Prism 8.0.0.
Figure Test Alpha
Source of 
Variation
% of total 
variation P value
P value 
summary F (DFn, DFd)
4b Two-way 
ANOVA, 
Dunnett’s 
multiple 
comparisons 
test
0.05 Interaction: 11.36 0.0671 ns F (9, 40) = 1,984
Time: 9.693 0.0045 ** F (3, 40) = 5.076
MFP 
treatment
49.33 <0.0001 **** F (3, 40) = 25.83
4c Two-way 
ANOVA, 
Dunnett’s 
multiple 
comparisons 
test
0.05 Interaction 14,86 <0,0001 **** Yes
Time 37,92 <0,0001 **** Yes
MFP 
treatment
47,17 <0,0001 **** Yes
7c One-way 
ANOVA
0.05 NA NA 0.0246 * F (5, 19) = 3,347
7d One-way 
ANOVA
0.05 NA NA 0,0019 ** F (5, 19) = 5,907
8e Two-way 
ANOVA, 
Bonferroni’s 
multiple 
comparisons 
test
0.05 Interaction 5,688 0,0098 ** Yes
MFP 
treatment
0,7851 0,1548 ns No
AAV5 vector 74,25 <0,0001 **** Yes


Chapte r 7General discussion and 
future perspectives

General discussion and future perspectives
221
7
Main findings of this thesis
In this thesis we demonstrated the development and characterization of miRNA-based 
gene therapies for two common neurogenerative diseases, ALS and SCA3, each with 
a different pathology. We used the novel miQURE™ silencing technology developed by 
uniQure to design several therapeutic miRNAs to target different regions in C9orf72 and 
ATXN3 gene. The miRNAs were incorporated in AAV5 and evaluated for efficacy and 
safety using several in vitro and in vivo model systems. The main goal was to reduce 
the gain of toxicity caused by mutations in these genes. In addition, we studied two key 
aspect for a successful gene therapy which is the route of delivery to reach the affected 
cells in the CNS and regulation of transgene expression using an inducible system. 
Therapeutic approaches for C9orf72-ALS/FTD: 
unanswered questions and the road ahead
Targeting C9orf72 RNA
An efficient way to reduce the negative effects caused by both the repeat-containing 
transcripts and DPR proteins is by therapeutically targeting the RNA transcripts containing 
the mutation. The two most common approaches that have been extensively studied 
in preclinical studies are based on RNAi and ASOs. Several targeting methods have 
been tested herein and each have their own advantages and disadvantages. Targeting 
the coding region of the C9orf72 gene is highly efficient and specific and we confirmed 
with RNAseq data (chapter 1) that the exons are well conserved between patients. 
However, this approach would further reduce C9orf72 expression in patients. Targeting 
the G4C2 repeat directly would spare the “healthy” transcripts but the probability to 
bind to off-target genes is high, as GC rich sequences are widespread within the human 
genome. In addition, sequence variations have been found between patients in the region 
around the repeat and screening of patients may be required if non-conserved regions 
are targeted.1 The presence of sense and antisense transcripts adds to the complexity and 
two products would be needed to target both strands. Thus, an important unanswered 
question remains what the roles of the sense versus the antisense strand of C9orf72 are, 
and what is their individual contribution to the disease pathology. 
Liu et al reported on a C9BAC mouse model for C9orf72 ALS/FTD with decreased 
survival, paralysis, muscle denervation, motor neuron loss, anxiety-like behavior, and 
cortical and hippocampal neurodegeneration.2 Interestingly, they reported that antisense 
transcripts were upregulated in these mice and mainly expressed in regions that tend 
to degenerate such as in spinal interneurons. The authors suggested that the antisense 
transcripts and/or the corresponding antisense DPR proteins may be critical drivers of 
the disease.2 Attempts to determine expression of the sense and antisense transcripts in 
patient-derived iPSC-neurons and brain tissue have yielded controversial data, with some 
studies reporting a trend towards upregulated antisense transcripts or its corresponding 
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DPRs, while others observed more sense transcript products.2–6 Some data suggest that 
targeting only one of the two strands could potentially rescue G4C2 repeat-related cellular 
defects. ASOs targeting the repeat-containing sense transcripts significantly reduced 
the accumulation of sense RNA foci and its DPR proteins in a C9BAC mouse model.7 
In addition, the development of behavioral deficits was also significantly attenuated.8 
Consistently, mislocalization of proteins was rescued in motor neurons treated with 
ASOs against either the sense or antisense transcripts (Hayes et al, unpublished results 
presented at AAN2018). Thus, it seems that targeting either the sense or antisense 
transcripts of C9orf72, may reduce motor neuron toxicity in ALS. These findings suggest 
that accumulation of both sense and antisense repeat-containing transcripts could have 
a combined threshold at which they become toxic. Reducing either one of these strands 
could sufficiently decrease the threshold at which they become toxic. We demonstrated 
in chapters 1 and 2 the design of miRNAs to target the sense and/or antisense transcripts 
of C9orf72. Two candidates that are targeting coding regions for a total knockdown of 
C9orf72 were selected for a proof of concept in vivo study.  A total knockdown approach 
was preferred in this study because currently the repeat-containing transcripts are poorly 
characterized, and little is known about their sequence conservation among patients. 
We demonstrated significant reduction of C9orf72 and its repeat-containing sense 
transcripts and sense RNA foci in a C9BAC mouse model. Thus, despite that the antisense 
transcripts were not targeted, targeting coding regions can contribute in reduction of 
the toxicity threshold. 
Another aspect to consider is the tolerability of C9orf72 silencing. C9orf72 expression 
is already reduced in patients due to repressive epigenetic marks, such as DNA 
hypermethylation within CpG islands in the G4C2 repeat. Therefore, it is arguable whether 
further reduction of C9orf72 is safe for the patients. RNAi or ASOs can be designed 
to selectively target the mutant allele or to target both healthy and mutant allele. An 
allele specific targeting approach is theoretically attractive, but difficult to implement, 
as the therapeutic molecule should bind to the poorly conserved GC sequences. On 
the other hand, a total silencing approach can be highly specific, but will result in further 
reduction of the C9orf72 protein in patients. 
There is currently no in vivo evidence to link C9orf72 reduction to the pathology seen 
in patients. Complete reduction of C9orf72 in mice was not linked to neurodegeneration 
but these mice developed immune-related problems, most likely due to C9orf72 
depletion in the peripheral organs.9 Heterozygous mice with 50% less C9orf72 expression 
compared to wildtype mice are healthy. Notably, reduction of C9orf72 levels due to DNA 
hypermethylation of the G4C2 repeat seems to occur in at least ~30% patients and this has 
been reported to have neuroprotective properties due the decrease of repeat-containing 
C9orf72 transcripts.10–14 This suggests that therapeutic silencing of C9orf72 transcription 
may have neuroprotective benefits in patients. Taken together, we believe that both 
selective and non-selective approaches with either RNAi or ASOs could have the potential 
to modify the course of the disease as long as the G4C2 repeat-containing transcripts 
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are being reduced. Both approaches would not only target the RNA-mediated toxicity 
but will also reduce DPRs as less transcripts are available to undergo RAN translation. 
The advantage of our AAV-based miRNA approach is that a single administration would 
be enough for a long-lived silencing of C9orf72 without the need for re-administration. 
Currently, a phase I clinical trial run by Biogen and IONIS is ongoing using ASOs targeting 
only the sense transcript. The outcome of this study could provide better understanding 
whether targeting only one of the toxic strands is indeed beneficial to the patients. 
Targeting DPRs
The repeat-containing transcripts of C9orf72 are translated into five DPR proteins 
through an unconventional translation, known as RAN translation.15–21  DPR proteins 
are considered typical pathological hallmark in C9orf72-ALS/FTD patients and form 
cytoplasmic aggregates.22,23 While most current therapeutic strategies are targeting 
the RNA, it is assumable that targeting RAN translation or DPRs directly could also lower 
the toxicity threshold of the C9orf72 expansion. 
Although our understanding on the occurrence of RAN translation from the C9orf72 
repeat-containing transcripts is poor, some crucial evidence were found suggesting that 
they follow a canonical mechanism of translation.24 Canonical translation of mRNAs requires 
several complex processes and recruitment of numerous eukaryotic initiation factors. 
These factors can form complex with the 40S ribosomal subunit, which subsequently 
binds to the 5’ cap of a mRNA to start scanning for a start codon.  The translation 
regulation in eukaryotes almost always initiates at a methionine (AUG) start codon that 
once recognized by the 40S ribosomal subunit is decoded by the methionyl-tRNA.25 
The production of DPR proteins from the G4C2 repeat-containing transcripts also requires 
a 5’ cap insertion and follow a 5’ to 3’ canonical scanning mechanism to start translation 
at a near-cognate CUG codon.24 Interestingly, it was demonstrated that ASOs targeting 
the region immediately upstream of the repeats can block the ribosomal scanning 
and prevent RAN translation, resulting in efficient reduction of DPR proteins without 
inducing RNAse-H-dependent RNA degradation.24 Thus, blocking the ribosomal scanning 
mechanism could be considered a therapeutic intervention. The advantage of this 
approach is that the healthy C9orf72 transcripts are not affected. However, the specificity 
and therapeutic efficacy was not addressed in this study.
 Another promising method to achieve reduction of DPR protein is by immunotherapy. 
For example,  Anti‐GA antibodies showed efficient reduction of poly‐GA DPR protein 
levels and prevented aggregate formation in cell lines over-expressing DPR proteins.26 
Currently, Neurimmune in collaboration with three other research institutes (University of 
Florida, University of Zurich and Massachusetts General Hospital) won the target discovery 
and development funding for the development immunotherapies targeting DPR proteins 
in ALS and FTD. Preliminary data was presented during the 2019 Gordon Research 
Conference on CAG Triplet Repeat Disorders, showing that targeting only the poly-GA 
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from all 5 DPR proteins is sufficient to improve gait and cage behavior and increase 
survival in the progressive C9BAC ALS mouse model (Ranum et al, data unpublished). Their 
findings support our earlier mentioned hypothesis that by removing only one component 
from the bulk of toxic products could be enough to lower the toxicity threshold and 
improve symptoms. Ultimately targeting more pathways could lead in better reverse of 
the disease phenotype. 
One advantage of our AAV-based miRNA approach is that besides targeting RNA 
toxicity, it is likely to also reduce DPR proteins because less transcripts will be available 
to undergo RAN translation. Crucial evidence for this was shown by another group 
using ASOs targeting either intronic or coding regions of C9orf72.8 Both strategies led 
to a significant reduction of RNA toxicity and DPR-mediated toxicity in vitro and in vivo.
Targeting nucleocytoplasmic transport in C9orf72-ALS/FTD
It was recently discovered that nucleocytoplasmic transport pathways are highly affected 
in C9orf72-ALS/FTD.27–29 For example, cytoplasmic mislocalization and aggregation of 
TDP-43 is observed in nearly all C9orf72 related ALS and FTD cases and is also often seen 
in other ALS cases caused by other mutations. Other proteins that are less commonly 
found mislocalized in the cytoplasm are the RNA-binding proteins FUS and hnRNPs.30,31 
Cytoplasmic mislocalization of proteins results in depletion of these proteins in the nucleus, 
leading to loss of function and accumulation of cytoplasmic aggregates leads to gain of 
toxicity in the cytoplasm. 
As disruption of nucleocytoplasmic trafficking plays a critical role in the pathogenesis 
of C9orf72-ALS/FTD, some attention has turned on strategies to restore nucleocytoplasmic 
trafficking function. Using a forward genetic screen of putative G4C2 repeat RNA-binding 
proteins in Drosophila, RanGAP (RanGTPase activating protein A) was found to be a major 
regulator of nucleocytoplasmic trafficking.27,32 RanGAP is an  nuclear pore protein that is 
normally localized on the cytoplasmic surface of the nuclear pore complex that stimulates 
the hydrolysis of RanGTPase in the cytoplasm and plays a key role in importin-mediated 
nuclear import of proteins. It has been found in Drosophila models and in patients 
derived iPSC-neurons that the G4C2 repeat of C9orf72 inhibits RanGAP, leading to 
mislocalization of proteins to the cytoplasm.27 Consistently, overexpression of RanGAP or 
a single copy of a gain of function allele of RanGAP (RanGAP[SD]) significantly suppressed 
neurodegeneration and rescued certain phenotypic traits due to the G4C2 repeat in flies.
27 
Thus, RanGAP is considered an effective suppressor of the G4C2 repeat mediated toxicity 
by preventing mislocalization of proteins in the cytoplasm and is an interesting target 
for therapeutics.
There has been also some interest in compounds that block nuclear export to prevent 
cytoplasmic mislocalization of nuclear proteins.  Karyopharm Therapeutics developed 
several selective inhibitors of nuclear export (SINE) compounds that specifically inhibit 
exportin-1 (XPO1) aiming to treat different types of cancer.  These compounds have been 
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also tested in preclinical studies for several neurodegenerative diseases such as ALS and 
HD and showed neuroprotective features. in C9orf72-related ALS/FTD, the efficacies of 
these compounds are still unclear as increased toxicity was observed in some preclinical 
models, while mitigated toxicity was observed in others.27,28,33 Interestingly, neuron 
survival and motor neuron function was improved in rats overexpressing TDP-43 when 
treated with SINE compounds.34 The SINE compound Selinexor (KPT-330), has been 
tested in clinical trials for different types of cancers and some studies reported promising 
results.35 Biogen has acquired KPT-350 in 2018 and is planned to initiate a phase I trial for 
C9orf72-ALS using this compound.36 Overall, it seems that SINE compounds could have 
mild neuroprotective properties but several challenges remain to be solved. Completely 
blocking nuclear export with SINE compounds have been linked to significant neurotoxicity 
and finding the right balance seems challenging. In preclinical studies, these compounds 
were often not effective at low doses that are considered safe to humans.34 A main 
advantage of our RNAi approach over SINE compounds is that no safety concerns was 
observed thus far in preclinical studies and multiple toxicity pathways can be targeted, 
increasing the probability for therapeutic efficacy.
Current advances and therapeutic strategies for SCA3:  
implications for AAV5-miATXN3 gene therapy
Gene silencing in SCA3
RNAi and ASOs can be designed to selectively target the mutant ATXN3 transcripts or 
to non-selectively silence both mutant and healthy alleles. Both strategies have been 
tested in preclinical studies and resulted into successful reduction of the mutant ATXN3 
transcripts and protein. In chapter 4 we described a non-selective approach to target 
both healthy and mutant ATXN3 using miRNAs delivered by AAV5. The advantage of our 
approach is that it is highly specific because we are targeting a well conserved coding 
region. Besides, our approach can treat the whole SCA3 patient population and several 
crucial steps has been taken to ensure minimal risk for off-target effects. Despite that our 
approach led to a reduction of the healthy ataxin-3 protein in mice, this was well tolerable 
without major alterations in gene expression. A very similar approach was performed 
by Rodríguez-Lebrón et al.37 Their strategy was to silence  mutant  ATXN3  expression 
using miRNA mimics designed to target the 3’UTR  region  of  human  ATXN3. The lead 
miRNA mimic was tested in vivo by delivery in the DCN using rAAV1. They demonstrated 
clearance of mutant ataxin-3  from  neuronal  nuclei and improved phenotype in  the 
cerebellum  of  a SCA3/MJD84.2  transgenic  mice  expressing the full human ATXN3 
disease gene.  Rodríguez-Lebrón et al also hypothesized that targeting the 3’UTR of 
ATXN3 could be more efficient because this region could be more accessible for the RNAi 
machinery due to limited translational activity in this region of the transcript. They further 
argued that targeting the 3’UTR  of  ATXN3  would  guide  AGO2-mediated cleavage of 
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most ATXN3 isoforms leading to a  robust  reduction  in  ataxin-3  levels.  We have shown 
that targeting coding regions using artificial miRNA can achieve similar silencing efficacy, 
thus both the coding region and the 3’-UTR can be effective targets. More importantly, 
we believe that a proper miRNA design would ensure targeting of all transcript isoform. 
One important question remains whether the silencing specificity is the same when 
targeting 3’UTRs or coding regions of mRNAs. Interestingly, one study investigated this 
using siRNA with introduced mismatches to target 3’UTR and coding regions of reporter 
genes.38 it was found that the silencing activity of siRNA on mismatched sites was 
universally much higher in the 3’-UTR compared to the silencing in mismatched coding 
region. On perfectly-matches sites, the potency was only slightly better in the 3’-UTR. 
They further tested the effect on AGO2 ablation on the silencing activity of siRNA on 
matched and mismatched sites placed in the 3’-UTR and coding regions. The absence 
of AGO2 resulted in only a slight decrease in silencing potency of siRNA targeting both 
matched and mismatched sites in the 3’-UTR. In contrast, the activity of siRNAs targeting 
matched and mismatches sites of coding regions were greatly diminished in AGO2 knock-
down cells. Thus, clearly suggesting the existence of an AGO2 independent translational 
repression activity in the 3’-UTR. Another aspect to consider is that sequence variation 
in 3’-UTRs between patients is common.39 Taken together, these finding may implicate 
that targeting 3’UTR is less specific and although this approach still seems promising 
in the study of Rodríguez-Lebrón et al., it may be less suitable in allele-specific RNAi 
approaches to discriminate SNPs from wildtype alleles. Nevertheless, targeting 3’UTRs 
could be useful to facilitate the design of RNAi approaches that would target multiple 
genes in a large gene family. 
Non-allele-specific targeting of ATXN3 using ASOs also proofed promising in different 
preclinical studies.40 A study conducted by Alves et al. showed that silencing wildtype 
ATXN3 do not increase SCA3/MJD pathology, and silencing both wildtype and mutant 
allele mitigated neuropathology in a rat model of SCA3/MJD.41 All together the studies 
performed by us and others strongly suggest that an non-allele-specific therapy is 
probably safe and as effective as allele-specific approaches to treat SCA3/MJD. Ataxin-3 
is a deubiquitinating enzyme and other deubiquitinating enzymes might compensate for 
the loss of normal ataxin-3 function.42
The RNAi approach investigated by us rely on delivery to the CNS using viral vectors. 
Conceiçao et al investigated the delivery of siRNA targeting the mutant ATXN3 allele 
using nucleic acid lipid particles (SNALPs) aiming to a systemic administration. They 
demonstrated that intravenous administration of SNALPs can successfully cross the BBB 
and reduce mutant ataxin-3 levels, resulting in alleviation of motor performance defects 
and improved striatal and cerebellar-associated neuropathology in a lentiviral SCA3 mouse 
model.  This RNAi-delivery strategy is less invasive and overcomes the main disadvantages 
of other non-viral approaches, such as electrostatic interaction leading to inflammatory 
toxicity. One major concern of this approach is that ATXN3-lowering is not restricted to 
the CNS. In fact, they found high siRNA expression in the brain, heart, lungs, liver, spleen 
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and kidney. Thus, expression of gene silencing molecules in these organs and their off-
target effects should be carefully investigated. Allele specific silencing of mutant ATXN3 
has been widely studied by different other groups. For example, siRNA targeting SNPs 
resulted in silencing of only the mutant ATXN3 and not the wildtype ATXN3.43 Similar 
results was obtained with shRNAs targeting SNPs.44,45 Evers et al demonstrated that ASO-
mediated exon skipping targeting exon 9 and 10 of ATXN3 can also efficiently reduce 
the mutant ATXN3 while maintaining normal ATXN3 function.46 
Notably, despite the extensive preclinical studies on ATXN3 gene silencing for nearly 2 
decades, none of these studies have reached clinical trial yet. This is expected to change 
in the coming years as more gene silencing approaches for other neurodegenerative 
diseases is entering human trials and the safety concerns of these therapeutic approaches 
are being tackled. Our RNAi approach for SCA3 have been designed based on several 
years of experience gained by the HD program that is currently moving to clinical trial. 
The strong lowering of mutant ATNX3 observed in cell and mouse model increases our 
confidence to continue investigating this program for clinical applications.
Clearance of mutant ataxin-3 by inducing autophagy
The autophagy and the ubiquitin–proteasome system (UPS) are crucial for the degradation 
of misfolded, oligomerized, and aggregated mutant proteins in cells. Therefore, 
enhancing autophagy using therapeutic compounds or by long term fasting is proposed 
to have beneficial effects. In SCA3 patients, autophagy dysfunction is regarded to be 
one of the mechanisms involved in the SCA3 phenotype and reversing this dysfunction 
could be therapeutically relevant.47,48 A common classical method to induce autophagy 
in mammalian cells is by inhibition of the mammalian target of rapamycin  (mTOR) 
pathway. This can be achieved by administration of rapamycin, a macrolide compound 
known to cross the BBB and a well-known inducer of autophagy.49 Indeed, preclinical 
studies in SCA3 cell models and in SCA3 transgenic mice showed that rapamycin and 
a rapamycin ester can induce clearance of mutant ataxin-3 and reduce its toxicity.50,51 
Several compounds to induce autophagy in a mTOR-independent manner have also been 
tested in SCA3 models, some showing clearance of mutant ataxin-3 and others showing 
only limited effect.52–58 Thus, it seems uncertain whether induction of autophagy could 
reduce toxic mutant ataxin-3 to therapeutically relevant levels. The advantage is that most 
of these compounds can be administered orally without complicated delivery methods. 
However, it is important to bear in mind that autophagy dysfunction is only one aspect of 
the disease within the bulk of cellular disturbances that was described earlier in chapter 
1. Other dysfunctional pathways that are caused for instance by RNA toxicity is not being 
targeted. Thus, whether enhancing autophagy alone is sufficient to modify the course of 
the disease in patients is yet to be discovered in clinical trials. Alternatively, combination 
therapies to rescue normal function of multiple dysfunction pathways in SCA3 could be 
more potent.
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Clearance of mutant ataxin-3 by targeting proteolytic cleavage
Ataxin-3 can be cleaved by proteolytic enzymes such as caspases and calcium-dependent 
calpains, yielding short ataxin-3 fragments containing the polyQ stretch. These short 
ataxin-3 fragments have increased toxicity profile and are prone to accumulate nuclear 
aggregates as they lack the N-terminal nuclear export signal (NES).59–64 inhibition of 
proteolytic cleavage have been proposed to reduce the formation of the toxic ataxin-3 
short fragments and could potentially have therapeutic benefit for treatment of SCA3 
patients. Indeed several inhibitors of caspases and calpains have been tested in preclinical 
models for SCA3 and showed attenuation of the short ataxin-3 fragments, reduced 
levels of nuclear ataxin-3 levels and reduction of its aggregates.48,60–62,65,66 In a lentiviral 
SCA3 mouse model of SCA3/MJD, inhibition of calpain  resulted in improvement 
of neuropathology and alleviation of motor deficits.66 Thus, inhibition of proteolytic 
enzymes could potentially be considered as a therapeutic intervention. However, the side 
effects due to inhibition of caspases and calpains should be carefully investigated as 
these enzymes play key roles in several crucial cellular processes including apoptosis, 
synaptic plasticity, dendritic development, and learning ability.48,63,67,68 Thus, inhibition of 
their normal functions is less favorable. An alternative approach that are currently being 
investigated is removal and/or modification of cleavage sites for caspases and calpains 
on mutant ataxin-3. This approach could be safer because it does not interfere with 
the activity of proteolytic enzymes.
7.4 Safety and delivery of RNAi gene therapy in ALS 
and SCA3 patients
The use of AAV vectors as transgene delivery has become one of the safest and most 
reliable method to obtain sustained expression of a therapeutic transgene. Non-viral 
delivery methods using nanoparticles or ASOs can also deliver therapeutic agents but 
the need for recurrent injections can become overwhelming and increase the risk for 
infections in patients. Nevertheless, ASOs have shown to be efficient and safe in animal 
models and have led to the initiation of several clinical trials for SOD1-ALS, C9orf72-ALS 
and SMN2 for SMA.69–71 
The delivery of RNAi to the affected cells in ALS and SCA3 patients is currently 
a challenge that is still not completely answered in this thesis. We demonstrated 
the potential of different routes of administration for AAV5 in rodent models and studies 
in larger animal models is still required to see how our findings in rodent models translate 
to larger animal models. Several studies have implicated that the utility of AAV vectors 
for gene transfer is mainly determined by the capsid. We believe that this statement is 
partly true as the capsid is involved in several key cell entry steps. However, in chapter 
5 we also showed crucial evidence that the route of administration is equally important 
as capsids behave differently upon different administration routes due to different 
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microenvironments. For example, we demonstrated that intraparenchymal injection of 
AAV5 resulted in high transduction of the rat brain. This finding was later confirmed by 
us in a transgenic minipig model showing successful transduction at the injection site 
(striatum) and its surrounding area.72 In addition, both anterograde (e.g., to caudate) and 
retrograde (to cortex) AAV5 viral transport was observed, suggesting that the vector can 
travel along axons and transduce distance areas. While this route is promising for diseases 
with a more localized pathology, such as HD, it is unlikely to be sufficient in multifocal 
neurological pathologies such as in ALS because anterograde and retrograde transport to 
cerebellum, brain stem and spinal cord was not observed. Intrathecal administration led 
to a more even distribution of the vector within the CNS and is potentially more relevant 
in ALS and potentially also SCA3. The feasibility to deliver therapeutically relevant dose 
still needs to be addressed in larger animal models. Another crucial aspect for AAV 
delivered RNAi is safety. Especially, due to the irreversible nature of current gene therapies, 
evaluation of short term and long-term toxicity is critical. Other crucial parameters that 
needs to be addressed during preclinical studies are prediction of on- and off-target 
effects, immunogenicity, dose finding, timing of treatment and the ability to modulate 
gene expression.
Prediction of safety, on- and off-target effect
The most important aspects for drug development are safety and tolerability in patients. 
In the case of RNAi-based gene therapies, both RNAi and the delivery vector could lead to 
toxicity. Several clinical studies have demonstrated that administration of AAV in human 
CNS is safe, but immune responses should still be investigated during preclinical and 
clinical studies. The RNAi products that are delivered could induce on- and off-target 
effects. Prediction of these unwanted side effects can be evaluated early in preclinical 
studies using the currently available tools such as iPSC-technology, animal models and 
bioinformatics to increase safety and tolerability in patients. 
Timing of treatment
The success of RNAi based gene therapy is likely to be determined by the timing. Most of 
the adult onset neurodegenerative diseases have a pre-symptomatic stage and it may take 
several years to gradually progress into a severe state with progressive neuronal death. 
While neuronal death cannot be reversed, emerging evidence suggests that neurons in 
atrophic state can regenerated their normal functions.73 Thus, early treatment before 
neuron death occur is likely to provide better protection and could decelerate neuronal 
death. Currently all gene therapy clinical trials are performed during the manifest state in 
patient while treatment during pre-manifest could be more beneficial. With the current 
knowledge and technologies, neurodegenerative diseases with a family history can 
be diagnosed prenatal or later in life during the pre-symptomatic phase using genetic 
screening. The discovery and characterization of more clinically validated biomarkers that 
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correlate with disease progression will also contribute to early diagnosis of both familial 
and sporadic neurodegenerative diseases. Biomarkers that track disease progression and 
correlate predictably in response to a therapeutic intervention can also greatly support 
future clinical trials by reducing the duration of the studies and number of patients that 
need to be followed. This is especially important in pre-manifest subjects when no clinical 
measures of disease progression can be applied. Another good predictor of disease onset 
could be the brain volume. For example, in HD, changes in striatal and brain volume 
seems to occur more than 10 years prior symptom onset. 74 However due to the lack of 
effective treatments, diagnoses during premanifest also raises many ethical concerns and 
even patients at high risk to develop these diseases are fearful to do a genetic screening. 
Patients who test positive are currently faced with difficult decisions that can have mayor 
psychological and financial impacts on the patients themselves and their families. For 
example, a positive genetic test could have implications on the daily life of the persons, 
on their health insurance, on their ability to find a job and on making decisions in 
their lives that may affect their family.75,76 Ultimately, a positive genetic test may have 
consequences on the ability of the person to get a mortgage and integrate into  society.77 
This is a phenomenon known as “genetic discrimination” and needs further attention. 
The success of new therapeutics will hopefully extend to trials in premanifest carriers and 
could make it easier for patients at risk to make the decision to do a genetic screening.
Modulation of gene expression
Besides from constitutively active promotors to drive transgene expression, the ability to 
“turn on” expression of a therapeutic molecule when it is needed and to “turn off” its 
expression in case of unwanted effects would also add considerably to the safety profile 
of any genetic therapy. In chapter 6 we demonstrated the feasibility of the GeneSwitch 
inducible transgene expression system to use in combination with gene therapy. 
Furthermore, we optimize this system to fit into a single vector with enhanced inducibility 
and less leakage compared to the classical duo vector system. The incorporation of 
this system to regulated RNAi gene therapy would add to the safety by preventing 
accumulation of high RNAi concentrations that could result in a gene knockdown outside 
the therapeutic window or adjustments on individual basis. For example, for the ALS 
and SCA3, we are aiming for approximately 50% endogenous knockdown of the mRNA 
for in case they are still needed to maintain normal cellular processes. The GeneSwitch 
system would make it possible to modulate expression of our therapeutic genes. A second 
example is the long-term shRNA-mediated apolipoprotein B100 knockdown that resulted 
in a dramatic cholesterol decrease in mice associated with fat accumulation in the liver 
as a side effect.78 In such cases a inducible transgene expression system would be highly 
desired. However, there are still room for improvement to make inducible systems suitable 
for clinical applications. One drawback is the basal activity of these systems in the “off-
state”. Especially small transgenes such as non-coding RNAs tend to be leaky when using 
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inducible systems and further optimizations are needed. Another aspect that needs more 
attention is to obtain sufficient expression of the transgene once in the on-state. Especially 
for CNS diseases, the inducer drug needs to efficiently cross the BBB and reach the target 
tissue at concentrations that are high enough for therapeutically relevant expression of 
the transgene. Possible immune responses to element inherent to the GeneSwitch system 
and side effects of the inducer drug should also be considered for clinical development. 
The co-development of two different products (GeneSwitch and transgene) in either 
a single or duo vector also add more parameters to the safety concerns of gene therapies, 
but these systems also offer notable advantages. Being able to modulate transgene 
expression will at least reduce safety concerns of the permanency expressed transgene. 
Thus, making further investigation and optimization of these systems highly attractive for 
application in gene therapy.
Future perspectives
Gene therapy holds great promise to deliver therapeutic genes to treat neurological 
disorders. AAV vectors are currently considered one of safest vehicles to deliver therapeutic 
genes to treat CNS disorders. Several serotypes are available and as the potential of gene 
therapy is becoming more recognized, there is emerging need for new AAV serotypes. 
for multi-focal neurological disorders, there is an enormous desire for new AAV vectors 
with improved transduction profile and better distribution in the target organs upon 
less invasive administration routes. Although direct administration of AAV vectors into 
the parenchyma is invasive, the advantages over injections into the venous system or 
other fluid-filled compartments are clear. Intra-parenchymal administration provides high 
concentration of the transgene in the target cells, high local transduction, less distribution 
to other organs and lower risk for immune responses or toxicities due to AAV particles 
or ectopic expression of the transgene. There is also much room for improvement at 
the transgene level. For example, generation of new tissue-specific promotors and efficient 
transgene design could improve efficacy in the desired cell populations and restrict 
unwanted transgene expression in other cell types. In chapter 1, several clinical trials on 
AAV-based gene therapies for CNS disorders was discusses. Although all studies showed 
that AAV is safe and well tolerable in the human CNS, few of these studies have been 
efficacious in demonstrating therapeutic outcomes. Too low transduction of the target 
organs could have played important role but one of the major problems is the lack of 
good predictive animal models for better translation of favorable preclinical outcomes to 
the clinic. another important aspect that are often overlooked is the potential of immune 
responses, both against the vector and expressed transgene, as the CNS is considered 
immune privileged. Recent studies have demonstrated that neutralizing antibodies against 
some capsids can be generated in the CNS, and transduction of antigen-presenting cells 
can trigger neurotoxic immune response.79,80 Addressing these concerns early during 
preclinical studies could increase the success of next generation CNS gene therapy clinical 
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trials. Furthermore, the discovery of biomarkers for early detection of the diseases will be 
important to identify new patients and to better predict clinical outcome. More importantly, 
delivering therapies prior to onset of neurodegeneration will be key to improving efficacy 
of gene therapies for neurodegenerative diseases. Finally, we should also acknowledge 
and give credit to all the efforts ongoing using different cell and animal models to better 
understand the pathways leading to neurodegenerative diseases. Good understanding of 
the genetic factors and mechanisms involved in neurodegenerative diseases is crucial to 
develop new and effective therapies. A better understanding of factors leading to these 
diseases will also allow development of better pre-clinical models to better predict clinical 
success.  uniQure is preparing to initiate the first ever gene therapy trial using the miQure 
technology with AMT-130 for the treatment of early-stage HD patients. Investigational 
New Drug Application (IND) has been accepted by FDA in January 2019. This trial will 
provide uniQure with additional knowledge and experience and a better understanding 
of the translation from preclinical to clinical studies. Such knowledge is critical to improve 
study designs for better vector and transgene design, more effective dose setting, more 
rational patient-selecting criteria and more directed clinical measurements. Accordingly, 
these lessons will be highly valuable to apply on other programs in the pipeline such as 
SCA3, ALS and other neurodegenerative diseases.
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English Summary
Neurodegenerative diseases are a group of disorders caused by degeneration of nerve 
cells (also called neurons) in the central nervous system (CNS). The occurrence of these 
diseases is increasing while no effective treatments are available. It is well established 
that some neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS) 
and spinocerebellar ataxia type 3 (SCA3) are caused by genetic mutations leading to 
a toxic gain of function. Artificial microRNAs designed to reduce the expression of these 
defective genes are a promising therapeutic strategy to slow down the toxicity caused 
by these genes. microRNAs are small non-coding RNAs that can bind to complementary 
sequences of mRNAs, leading to mRNA degradation and/or supress the translation of 
mRNA into protein (gene silencing). For therapeutic applications, gene therapy can be 
used to deliver therapeutic microRNAs to the target cells in patients and silence the genes 
responsible for the diseases. This can be done by packaging a transgene (in this case, 
the precursor microRNA) into recombinant adeno-associated virus (AAV) vectors for 
delivery to the affected cells. Once inside the cell, the AAV vector is unpackaged to 
deliver the precursor microRNA to the cell. The precursor microRNA remains in the cell for 
life and uses the cell’s own RNA interference (RNAi) machinery for further processing into 
a mature microRNA molecule that can bind and silence the expression of the defective 
target gene to provide long-lived benefit to the patient. 
This thesis describes the development of microRNA-based gene therapies for ALS and 
SCA3. Other aspects of a successful gene therapy including the administration routes to 
reach the target organs and regulation of the transgene expression were also investigated. 
Due to the permanent nature of gene therapy, a method to modulate the transgene 
expression is desirable.
Chapter 1 is a general introduction reviewing the past, current and future perspectives 
of gene therapy for neurodegenerative diseases. The mechanisms leading to the pathology 
of ALS and SCA3 are discussed as well as the therapeutic strategies that are currently 
being investigated. The challenges facing the currently available preclinical models are 
discussed and an overview is provided on the outcome of gene therapy clinical trials 
for neurodegenerative diseases.  In chapter 2 we describe the design, characterization 
and selection of therapeutic microRNAs targeting the C9orf72 gene. A GGGGCC 
repeat expansion in this gene is responsible for most ALS cases. Based on several in 
vitro experiments, we demonstrated the feasibility to silence different types of C9orf72 
transcripts in both nucleus and cytoplasm of cells. In chapter 3 we further investigated 
the potential of AAV5-delivered microRNAs targeting C9orf72 (AAV5-miC) in neurons 
derived from human induced pluripotent stem cells (iPSC) and in an C9orf72-ALS mouse 
model. We showed that C9orf72 silencing results in reduction of toxic nuclear RNA foci 
in the brain of ALS-mice. These RNA foci are one of the contributors to the ALS disease 
pathology. This study demonstrated a functional efficacy of AAV5-miC to reduce toxicity 
caused by the mutated C9orf72 gene. In chapter 4 we applied our microRNA technology 
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and designed microRNAs to target the ATXN3 gene (AAV5-miATXN3). A polyglutamine 
expansion in the ATXN3 gene is responsible for SCA3. We showed efficient silencing of 
ATXN3 in vitro on human-derived iPSC-neurons and in vivo in the SCA3 mouse model. In 
addition, different routes of delivery were investigated to target the affected brain regions. 
We found therapeutically relevant reduction of the mutant ataxin-3 protein in the brain 
stem and cerebellum after a single injection with AAV5-miATXN3 in the cisterna magna. 
These brain regions are also the most affected in SCA3 patients. Using a minipig model, 
the transduction of these brain regions was confirmed in a model with a larger brain size. 
This proof of concept study shows the potential of our approach to reduce toxicity by 
the mutant ataxin-3 protein in the affected brain regions of SCA3 patients. In chapter 
5 we further investigated the administration of AAV-based gene therapy in rodents for 
delivery of therapeutic transgenes in neurodegenerative diseases. We demonstrated that 
local injection of AAV to the brain leads to efficient transduction of neuronal cell bodies 
of the deeper brain structures and is promising for diseases with a localized pathology 
such as Huntington’s disease. Intrathecal administration led to a more even distribution 
within the CNS and is potentially more relevant in diseases with a spread pathology 
throughout the CNS such as ALS. In chapter 6, the feasibility to modulate the expression 
of gene therapy using the mifepristone-inducible GeneSwitch system was investigated in 
vitro and in vivo. We showed repeated inducibility of the transgene that also translated 
into a dynamic phenotypic change in mice. Chapter 7 Is a general discussion about our 
findings compared to others. Different target strategies are described and compared to 
our AAV-microRNA strategy. We further discuss the safety preclinical measures and future 
perspectives for a successful gene therapy to treat neurodegeneratative diseases.
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Nederlandse samenvatting
Neurodegeneratieve ziektes behoren tot een groep aandoeningen die veroorzaakt wordt 
door degeneratie van zenuwcellen (ook wel bekend als neuronen). Hoewel deze ziektes 
steeds vaker voorkomen, is er nog geen effectieve behandeling voor gevonden. Het is 
bekend dat sommige neurodegeneratieve aandoendingen zoals amyotrofische laterale 
sclerose (ALS) en spinocerebellaire ataxie type 3 (SCA3) veroorzaakt worden door 
een mutatie in bepaalde genen dat leidt tot een toxische functie. Een veelbelovende 
therapeutische strategie is om de expressie van deze defecte genen te reduceren 
door middel van artificiële microRNAs om de bijbehorende toxische effecten van deze 
genen te verminderen. MicroRNAs zijn korte niet-coderende RNA moleculen die aan 
complementaire stuk messenger RNA (mRNA) kan binden om vervolgens de mRNA 
te degraderen en/of om de translatie tot eiwit stop te zetten (ofwel uitschakelen van 
een gen). Door middel van gentherapie kan therapeutische microRNAs aan de cellen 
 van patiënten worden geleverd om zo de expressie van de genen die betrokken zijn bij 
de ziektes uit te schakelen. Dit wordt gedaan door een transgen (in dit geval de voorloper 
van de microRNA (ofwel microRNA precursor)) te verpakken in een recombinant virus 
genaamd “adeno-associated virus” (AAV). Eenmaal in de cel, wordt de AAV uitgepakt 
en de precursor microRNA geleverd aan de cel. De precursor microRNA kan gedurende 
een hele leven stabiel blijven in de cel en wordt verder verwerkt door de cellulaire 
RNA interferentie (RNAi) mechanisme tot een gematureerde microRNA molecuul. 
De gematureerde microRNA molecuul kan vervolgens binden aan een complementair 
stukje mRNA en zo blijft de expressie van de defecte gen langdurig uitgeschakeld in 
de patiënt.
Dit proefschrift beschrijft de ontwikkeling van een microRNA gentherapie voor ALS en 
SCA3. Andere cruciale aspecten voor een succesvolle gentherapie komen ook ter sprake, 
zoals de methodes waarop de gentherapie toegediend kan worden en een methode om 
gentherapie naar eigen wens te moduleren. Omdat de huidige gentherapieen permanent 
en omkeerbaar zijn, is een methode die expressie van de transgen kan moduleren 
zeer gewenst.
Hoofdstuk 1 is een algemene introductie waar onder andere de huidige en 
toekomstige perspectieven van gentherapie wordt samengevat. Daarnaast worden 
de ziekte veroorzakende mechanismen, die leiden tot ALS en SCA3 beschreven. Ook 
komen de behandelingsstrategieën die tot nu werden onderzocht aan orde. Verder worden 
de uitdagingen van de huidige preklinische modellen, en de toepassing van gentherapie 
in klinische studies voor neurodegeneratieve ziekten beschreven. In hoofdstuk 2 wordt 
het ontwerp, karakterisering en selectie van microRNAs beschreven die resulteren in het 
uitschakelen van het C9orf72 gen. Een expansie bestaande uit GGGGC nucleotides in 
deze gen is de meest voorkomende oorzaak van ALS. Door middel van verschillende 
in vitro experimenten lieten we zien dat het mogelijk is om de expressie van verschillende 
types C9orf72 mRNA moleculen zowel in de celkern als in het cytoplasma te verlagen. 
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In hoofdstuk 3 hebben we de microRNAs tegen C9orf72 in AAV verpakt (AAV5-mic) 
en vervolgens getest in een ALS muismodel en op humane neuronen gedifferentieerd 
vanuit geïnduceerde pluripotente stamcellen (iPS-cellen). Dit resulteerde tot een sterke 
vermindering van een soort toxische precipitaat genaamd RNA-foci in de brein van 
de ALS muismodel. Deze RNA foci worden geproduceerd door de mutante C9orf72 
mRNA en zijn deels verantwoordelijk voor de ALS-pathologie. Onze bevindingen dienen 
als een mechanistische bewijs dat AAV5-miC de toxische effecten van de mutante C9orf72 
gen kan verminderen in het brein van een ALS-muismodel. In hoofdstuk 4 hebben we 
onze microRNA technologie toegepast voor de ontwikkeling van een gentherapie die 
de ATXN3 gen kan uitschakelen (AAV5-miATXN3). SCA3 wordt veroorzaakt door een 
zogenaamde polyglutamine expansie in de ATXN3 gen. We hebben een sterke reductie 
van de ATXN3 mRNA aangetoond na behandeling met AAV5-miATXN3, zowel in vitro 
op iPS-neuronen en in vivo in een SCA3 muismodel. Daarnaast hebben we uitgebreid 
onderzocht op welke manieren onze AAV5-miATXN3 toegediend kan worden om de 
aangetaste gebieden in de hersenen te bereiken. Het beste methode van toediening 
was door te injecteren in de cisterna magna. Eén  enkele injectie in de cisterna manga 
leidde tot een sterke vermindering van de mutante ataxin-3 eiwit in de cerebellum en 
hersenstam van de muizen. Deze gebieden zijn ook het meest aangetast in SCA3 patiënten. 
Vervolgens lieten we zien dat deze gebieden van de hersenen ook bereikt kunnen worden 
in een varkensmodel met een veel grotere hersensvolume. Deze proof-of-concept studie 
liet zien dat onze strategie mogelijk tot reductie van de mutante ataxin-3 eiwit kan leiden 
in SCA3 patiënten. In hoofdstuk 5 werd de verschillende type methodes om gentherapie 
toe te dienen uitgebreid onderzocht in ratten. Lokale injectie van AAV in de hersenen, 
bijvoorbeeld in de striatum leidde tot efficiënte transductie van neuronen in de diepere 
structuren van de brein. Dus, deze methode is vooral interessant voor ziektes waar de 
pathologie op een bepaalde gebied van de hersenen is geconcentreerd, bijvoorbeeld 
de ziekte van Huntington. Intrathecale toediening resulteerde in een meer verspreide 
transductie in de CNS en kan een uitkomst bieden voor ziektes waar de pathologie 
verspreid ligt tussen meerdere gebieden in de CNS, bijvoorbeeld in ALS. In hoofdstuk 
6 wordt een zogenaamd mifrepristone-induceerbare GeneSwitch systeem beschreven 
om de expressie van gentherapieën te moduleren. Door deze systeem toe te passen in 
gentherapie kan de expressie van de transgen aan- of uitgezet worden door wel of niet 
toedienen van de medicijn mifrepristone. We lieten zowel in celculturen en in muizen 
zien dat dit systeem gebruikt kan worden om expressie van de transgen te moduleren. 
Tot slot, in hoofdstuk 7 wordt onze AAV-microRNA strategie vergeleken met andere 
therapeutische strategieën die momenteel worden onderzocht voor behandeling van 
ALS en SCA3. Verder worden veschillende parameters besproken die belangrijk zijn om 
te onderzoeken om zo de veiligheid en succes van gentherapie voor neurodegeneratieve 
ziektes te garanderen.
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Resúmen na Papiamentu
Enfermedat neurodegenerativo ta un grupo di trastorno kousá pa degenerashon di sèl 
di sistema nèrvioso (konosí tambe komo neurona). E enfermedatnan akí ta birando mas 
frekuente i ainda no tin tratamentu efektivo pa nan. Ta bon konosí ku sierto enfermedat 
neurodegenerativo, manera por ehèmpel sklerósis lateral amiotrófiko (abreviá na ingles 
komo ALS) i ataksia spinoserebeloso tipo 3 (SCA3) ta surgi debí na sierto mutashon 
genétiko ku ta okashoná toksisidat. Un strategia terapéutiko prometedor pa baha 
e toksisidat okashoná pa e gènnan akí ta mikroRNA artifisial diseñá pa limitá ekspreshon 
di e gènnan defektuoso. MikroRNA ta un tipo di RNA chikitu ku no ta kontené kódigo di 
proteina i ku por mara na un sekuensia di RNA mensahero (mRNA) komplementario pa 
asina silensiá e gèn dor di degradá e mRNA i/òf blòkia e proseso di traha proteina a base 
di e mRNA. Por usa terapia di gèn pa hiba mikroRNA na e sèlnan konserní di un pashènt 
i silensiá e gènnan ku ta okashoná e enfermedat. Pa hasi esaki, ta paketá e transgèn (den 
e kaso akí, e prekursor di e mikroRNA) den un vírùs rekombinante di e tipo “adeno-
asosiá” (abreviá na ingles komo AAV) pa e vírùs hiba e  mikroRNA prekursor na e sèlnan 
afektá. Unabes den e sèl, e AAV ta wordu desempaketá i e mikroRNA prekursor ta ser 
entregá na e sèl. E mikroRNA prekursor por keda stabil den e sèl permanentemente i usa 
e sèl su mekanismo di interferensia di RNA (RNAi) mes pa sigui madurá i bira un molékula 
di mikroRNA ku por mara na e gèn defektuoso i silensi’é, di e manera ei silensiando e gèn 
defektuoso di e pashènt pa bida largu. 
E tesina akí ta deskribí desaroyo di un terapia genétiko basá riba mikroRNA pa ALS 
i SCA3. A investigá tambe algun otro aspekto krusial pa éksito di un terapia genétiko, 
entre otro, ki método ta usa pa atministrá e terapia genétiko i kon por regulá e terapia. 
Debí ku terapia genétiko ta di karakter permanente, un método pa regulá ekspreshon di 
e transgèn ta algu sumamente deseabel.
Kapítulo 1 ta sirbi komo un introdukshon general. E ta resumí e perspektivanan di 
terapia genétiko aktual i pa futuro pa enfermedat neurodegenerativo. E kapítulo akí 
ta papia tambe riba e mekanismonan ku ta okashoná e patologia di ALS i SCA3, i 
e strategianan terapéutiko ku ta siendo studiá te asina leu. Ta menshoná e desafionan 
relashoná ku e modelonan preklíniko ku tin disponibel aktualmente i ta duna un 
resúmen di e resultadonan di terapia genétiko optení den tèst klíniko pa enfermedat 
neurodegenerativo. Na Kapítulo 2, nos ta splika diseño, karakterisashon i selekshon di 
mikroRNA terapéutiko pa silensiá e gèn C9orf72. Mayoria di kaso di ALS ta debí na un 
ekspanshon di nukleotido GGGGCC den e gèn akí. A base di diferente eksperimento in 
vitro, nos a demostrá ku ta faktibel pa redusí ekspreshon di diferente tipo di C9orf72 
tantu den núkleo komo den sitoplasma di sèl. Den Kapítulo 3, nos a sigui investigá uso 
di mikroRNA ku ta silensiá C9orf72, empaketá den AAV (AAV5-miC). A tèst esaki riba 
neurona derivá for di sèl mama (stamcel) humano pluripotente indusí (iPSC) i tambe riba 
raton ku ta sirbi komo modelo pa studia ALS. E resultado tabata un redukshon supstansial 
di e presipitashon tóksiko konosí komo RNA-foci den serebro di e raton ku ALS. RNA-foci 
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ta ser produsí pa C9orf72 mRNA mutante i ta un di e faktornan ku ta kontribuí na 
patologia di e enfermedat ALS. E investigashon akí a demostrá efektividat funshonal 
di AAV5-miC pa redusí e toksisidat kousá pa gèn C9orf72 mutante. Na Kapítulo 4, nos 
a pone nos teknologia di mikroRNA na práktika i a diseñá un terapia genétiko (AAV5-
miATXN3) pa silensiá e gèn ATXN3. Un ekspanshon di poliglutamina den e gèn ATXN3 
ta loke ta okashoná SCA3. Nos a silensiá ATXN3 supstansialmente, tantu in vitro den 
neurona iPSC derivá di tehido humano, komo in vivo serka raton ku ta sirbi komo modelo 
pa studia SCA3. Ademas, nos a investigá diferente manera pa atministrá e terapia pa 
trata e regionnan afektá di serebro. E mihó método di atministrashon a resultá di ta via 
inyekshon den cisterna magna. Serka raton, nos a konstatá un redukshon supstansial di 
e proteina ataksina-3 mutante den tronkon di serebro i den serebro chikitu despues di un 
solo inyekshon di AAV5-miATXN3 den cisterna magna. E regionnan akí di serebro ta tambe 
esunnan mas afektá serka pashènt di SCA3. A usa un porko miniatura komo modelo, 
konfirmando di e manera ei ku serka modelo ku serebro mas grandi tambe e terapia por 
alkansá e regionnan ei di serebro. E estudio akí ta un ‘proof of concept’ ku ta demostrá 
e potensial di nos strategia pa redusí nivel di e proteina ataksina-3 mutante serka pashènt 
di SCA3. Den Kapítulo 5, nos ta sigui investigá diferente método pa atministrá terapia 
genétiko serka djaka. A base di e estudio aki por concluí ku inyekshon lokal di AAV den 
serebro ta produsí transdukshon efisiente di neurona den e strukturanan mas profundo di 
serebro, loke ta hasié un método di inyekshon prometedor, prinsipalmente pa enfermedat 
kaminda e patologia ta konsentrá den sierto area di serebro, manera enfermedat di 
Huntington. Via angua den wes’i lomba, tabatin transdukshon den un área mas amplio 
di sistema nèrvioso sentral, loke ta nifiká ku esaki por ta un bon opshon ora ta trata di 
enfermedat kaminda e patologia ta plama den diferente region di e sistema nèrvioso 
sentral, por ehèmpel ALS. Kapítulo 6 ta deskribí kon por usa e sistema ‘mifepristone-
inducible GeneSwitch’ pa regulá ekspreshon di terapia genétiko. Ku e sistema akí, por sea 
aktivá òf desaktivá ekspreshon di e transgèn. Pa hasi esei, ta sea atministrá òf keda sin 
atministrá e remedi mifrepristona. Nos a demostrá tantu in vitro komo serka raton bibu 
ku por usa e sistema akí pa regulá ekspreshon di e transgèn. Finalmente, na Kapítulo 7 
nos ta kompará nos strategia di AAV-mikroRNA ku algun otro strategia terapéutiko ku 
ta siendo studiá aktualmente komo tratamentu pa ALS i SCA3. Ademas, nos ta papia 
riba diferente parameter ku ta importante pa investigá, pa garantisá ku tratamentu di 
enfermedat neurodegenerativo por ta eksitoso i tambe safe.
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List of abbreviations
AAT    alpha1-antitrypsin 
AAV    adeno-associated virus 
AD    Alzheimer’s disease
AGO   argonaute 
ALS   amyotrophic lateral sclerosis
ASOs    antisense oligonucleotides
ATXN    ataxin gene
BAC    bacterial artificial chromosome
BBB    blood brain barrier
C9orf72   chromosome 9 open reading frame 72
CA    Cornu Ammonis
CAG    cytomegalovirus immediate-early enhancer fused to chicken 
   β-actin promoter
Cas9    CRISPR-associated system 9
CMV    cytomegalovirus 
CRISPR    clustered regulatory interspaced short palindromic repeats 
CSF    cerebrospinal fluid
DCN    deep cerebellar nuclei 
DG   Dentate Gyrus
DM1   myotonic dystrophy type 1
DMD   Duchenne muscular dystrophy
DPRs   dipeptide repeat proteins 
DRG    dorsal Root Ganglia 
DSBs    DNA double strand breaks 
EPO    erythropoietin
FISH    fluorescence in situ hybridization 
FTD    frontotemporal dementia
FUS    fused in sarcoma
GA    glycine-alanine
gc    genome copies
GDNF    glial cell-derived neurotrophic factor 
GFP    green fluorescent protein
GP    glycine-proline
GR    glycine-arginine
GS    GeneSwitch
HD    Huntington’s disease
HDR    homology-directed repair
HP1α    heterochromatin protein 1α
HSV    herpes simplex virus 
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HTT    huntingtin gene
ICV    intracerebroventricular
IFN    interferon 
IGF    Insulin-like growth factor 
iPSC    induced-pluripotent stem cells 
Istr    Intrastriatal 
IT    intrathecal
ITH    intrathalamic
ITRs    inverted terminal repeats 
IV    intravenously
Kb   kilobase
Luc   luciferase
MBNL1    muscleblind-like 1
MFP    mifepristone
miATXN3   ATXN3 targeting microRNA
miC    C9orf72 targeting microRNA
miR-451a or miR-451 microRNA-451a 
miRNA    microRNA
MJD    Machado-Joseph disease
mRNA    messenger RNA 
NGS    next generation sequencing 
NHEJ    nonhomologous end-joining
NHP   nonhuman primate 
Nt    nucleotide
PA    proline-alanine
PARN    poly(A)-specific ribonuclease
PD    Parkinson’s disease
piRNAs    piwi-interacting RNAs
polyA    polyalanine
PolyQ    polyglutamine
PR    proline-arginine
pre-miRNA   precursor microRNA
pri-miRNA   primary microRNA
rAAV    recombinant adeno-associated virus 
RAN    translation repeat-associated non-ATG translation
RISC    RNAi-induced silencing complex 
RNAi    RNA interference 
RNAse H   ribonuclease H
RT-PCR    real-time polymerase chain reaction
RT-qPCR   quantitative real-time polymerase chain reaction
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rtTA    transactivator-protein 
SCA    spinocerebellar ataxia
shRNA   short hairpin RNA
siRNA    small interfering RNA
SMA    spinal muscular atrophy 
SMN   survival motor neuron 
SN    substantia nigra
SNP    single nucleotide polymorphism
SNpc    SN pars compacta 
SNrc    pars recticulata 
SOD1    superoxide dismutase1 
TALENs    transcription activator-like effector nucleases 
TARDBP   transactive response DNA-binding protein of 43 kDa 
TDP-43    transactive response DNA-binding protein 43
UIM    ubiquitin-interacting motifs 
UTR    untranslated region 
VTA    Ventral Tegmental Area
ZFNs    zinc-finger nucleases
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